<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE chapter PUBLIC "-//ES//DTD book DTD version 5.5.0//EN//XML" "book550.dtd" [<!ENTITY b023-025-9780702070280 SYSTEM "b023-025-9780702070280" NDATA IMAGE><!ENTITY f023-001-9780702070280 SYSTEM "f023-001-9780702070280" NDATA IMAGE><!ENTITY f023-002-9780702070280 SYSTEM "f023-002-9780702070280" NDATA IMAGE><!ENTITY f023-003-9780702070280 SYSTEM "f023-003-9780702070280" NDATA IMAGE><!ENTITY f023-004-9780702070280 SYSTEM "f023-004-9780702070280" NDATA IMAGE><!ENTITY f023-005-9780702070280 SYSTEM "f023-005-9780702070280" NDATA IMAGE><!ENTITY f023-006abc-9780702070280 SYSTEM "f023-006abc-9780702070280" NDATA IMAGE><!ENTITY f023-006def-9780702070280 SYSTEM "f023-006def-9780702070280" NDATA IMAGE><!ENTITY f023-007-9780702070280 SYSTEM "f023-007-9780702070280" NDATA IMAGE><!ENTITY f023-008ai-9780702070280 SYSTEM "f023-008ai-9780702070280" NDATA IMAGE><!ENTITY f023-009ad-9780702070280 SYSTEM "f023-009ad-9780702070280" NDATA IMAGE><!ENTITY f023-010-9780702070280 SYSTEM "f023-010-9780702070280" NDATA IMAGE><!ENTITY f023-011-9780702070280 SYSTEM "f023-011-9780702070280" NDATA IMAGE><!ENTITY f023-012a-9780702070280 SYSTEM "f023-012a-9780702070280" NDATA IMAGE><!ENTITY f023-012b-9780702070280 SYSTEM "f023-012b-9780702070280" NDATA IMAGE><!ENTITY f023-012c-9780702070280 SYSTEM "f023-012c-9780702070280" NDATA IMAGE><!ENTITY f023-012d-9780702070280 SYSTEM "f023-012d-9780702070280" NDATA IMAGE><!ENTITY f023-012e-9780702070280 SYSTEM "f023-012e-9780702070280" NDATA IMAGE><!ENTITY f023-013-9780702070280 SYSTEM "f023-013-9780702070280" NDATA IMAGE><!ENTITY f023-014-9780702070280 SYSTEM "f023-014-9780702070280" NDATA IMAGE><!ENTITY f023-015-9780702070280 SYSTEM "f023-015-9780702070280" NDATA IMAGE><!ENTITY f023-016-9780702070280 SYSTEM "f023-016-9780702070280" NDATA IMAGE><!ENTITY f023-017-9780702070280 SYSTEM "f023-017-9780702070280" NDATA IMAGE><!ENTITY f023-018-9780702070280 SYSTEM "f023-018-9780702070280" NDATA IMAGE><!ENTITY f023-019-9780702070280 SYSTEM "f023-019-9780702070280" NDATA IMAGE><!ENTITY f023-020ab-9780702070280 SYSTEM "f023-020ab-9780702070280" NDATA IMAGE><!ENTITY f023-021-9780702070280 SYSTEM "f023-021-9780702070280" NDATA IMAGE><!ENTITY f023-022-9780702070280 SYSTEM "f023-022-9780702070280" NDATA IMAGE><!ENTITY f023-023-9780702070280 SYSTEM "f023-023-9780702070280" NDATA IMAGE><!ENTITY f023-024a-9780702070280 SYSTEM "f023-024a-9780702070280" NDATA IMAGE><!ENTITY f023-024b-9780702070280 SYSTEM "f023-024b-9780702070280" NDATA IMAGE><!ENTITY f023-025-9780702070280 SYSTEM "f023-025-9780702070280" NDATA IMAGE><!ENTITY f023-026-9780702070280 SYSTEM "f023-026-9780702070280" NDATA IMAGE><!ENTITY f023-027a-9780702070280 SYSTEM "f023-027a-9780702070280" NDATA IMAGE><!ENTITY f023-027b-9780702070280 SYSTEM "f023-027b-9780702070280" NDATA IMAGE><!ENTITY f023-027c-9780702070280 SYSTEM "f023-027c-9780702070280" NDATA IMAGE><!ENTITY f023-028-9780702070280 SYSTEM "f023-028-9780702070280" NDATA IMAGE><!ENTITY f023-029a-9780702070280 SYSTEM "f023-029a-9780702070280" NDATA IMAGE><!ENTITY f023-029b-9780702070280 SYSTEM "f023-029b-9780702070280" NDATA IMAGE><!ENTITY f023-030-9780702070280 SYSTEM "f023-030-9780702070280" NDATA IMAGE><!ENTITY f023-031-9780702070280 SYSTEM "f023-031-9780702070280" NDATA IMAGE><!ENTITY f023-032-9780702070280 SYSTEM "f023-032-9780702070280" NDATA IMAGE><!ENTITY f023-033-9780702070280 SYSTEM "f023-033-9780702070280" NDATA IMAGE><!ENTITY icon01-9780702070280 SYSTEM "icon01-9780702070280" NDATA IMAGE><!ENTITY icon02-9780702070280 SYSTEM "icon02-9780702070280" NDATA IMAGE><!ENTITY icon03-9780702070280 SYSTEM "icon03-9780702070280" NDATA IMAGE><!ENTITY icon04-9780702070280 SYSTEM "icon04-9780702070280" NDATA IMAGE><!ENTITY icon05-9780702070280 SYSTEM "icon05-9780702070280" NDATA IMAGE><!ENTITY icon06-9780702070280 SYSTEM "icon06-9780702070280" NDATA IMAGE><!ENTITY u023-001-9780702070280 SYSTEM "u023-001-9780702070280" NDATA IMAGE><!ENTITY u023-002-9780702070280 SYSTEM "u023-002-9780702070280" NDATA IMAGE><!ENTITY u023-003-9780702070280 SYSTEM "u023-003-9780702070280" NDATA IMAGE>]><chapter docsubtype="chp" id="c00023" version="5.5" xml:lang="en" xmlns="http://www.elsevier.com/xml/bk/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:xlink="http://www.w3.org/1999/xlink"><info><ce:pii>B978-0-7020-7028-0.00023-8</ce:pii><ce:doi>10.1016/B978-0-7020-7028-0.00023-8</ce:doi><ce:isbn>978-0-7020-7028-0</ce:isbn><ce:copyright type="full-transfer" year="2018">Elsevier Ltd</ce:copyright></info><ce:floats><ce:figure id="f0025"><ce:label>Fig. 23.1</ce:label><ce:caption id="ca0010"><ce:simple-para id="sp0010" role="title">Structural organisation of normal bone marrow.</ce:simple-para></ce:caption><ce:alt-text id="atte0010" role="short">Fig. 23.1</ce:alt-text><ce:link id="ln0025" locator="f023-001-9780702070280" xlink:href="pii:B9780702070280000238/f023-001-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0030"><ce:label>Fig. 23.2</ce:label><ce:caption id="ca0015"><ce:simple-para id="sp0015" role="title">Stem cells and growth factors in haematopoietic cell development.</ce:simple-para><ce:simple-para id="sp0020" role="caption">(BFU–E = burst-forming unit – erythroid; CFU–E = colony-forming unit – erythroid; CFU–GM = colony-forming unit – granulocyte, monocyte; CFU–Meg = colony-forming unit – megakaryocyte; Epo = erythropoietin; G–CSF = granulocyte–colony-stimulating factor; GM–CSF = granulocyte, macrophage–colony-stimulating factor; IL = interleukin; M–CSF = macrophage–colony-stimulating factor; SCF = stem cell factor; Tpo = thrombopoietin)</ce:simple-para></ce:caption><ce:alt-text id="atte0015" role="short">Fig. 23.2</ce:alt-text><ce:link id="ln0030" locator="f023-002-9780702070280" xlink:href="pii:B9780702070280000238/f023-002-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0035"><ce:label>Fig. 23.3</ce:label><ce:caption id="ca0020"><ce:simple-para id="sp0025" role="title">Maturation pathway of red cells, granulocytes and platelets.</ce:simple-para><ce:simple-para id="sp0030" role="caption">The image on the right is a normal blood film.</ce:simple-para></ce:caption><ce:alt-text id="atte0020" role="short">Fig. 23.3</ce:alt-text><ce:link id="ln0035" locator="f023-003-9780702070280" xlink:href="pii:B9780702070280000238/f023-003-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0040"><ce:label>Fig. 23.4</ce:label><ce:caption id="ca0025"><ce:simple-para id="sp0035" role="title">Normal structure of red cell membrane.</ce:simple-para><ce:simple-para id="sp0040" role="caption">Red cell membrane flexibility is conferred by attachment of cytoskeletal proteins. Important transmembrane proteins include band 3 (an ion transport channel) and glycophorin C (involved in cytoskeletal attachment and gas exchange, and a receptor for <ce:italic>Plasmodium falciparum</ce:italic> in malaria). Antigens on the red blood cell determine an individual's blood group. There are about 22 blood group systems (groups of carbohydrate or protein antigens controlled by a single gene or by multiple closely linked loci); the most important clinically are the ABO and Rhesus (Rh) systems (p. 931). The ABO genetic locus has three main allelic forms: A, B and O. The A and B alleles encode glycosyltransferases that introduce <ce:italic>N</ce:italic>-acetylgalactosamine (open circle) and <ce:italic>D</ce:italic>-galactose (blue circle), respectively, on to antigenic carbohydrate molecules on the membrane surface. People with the O allele produce an O antigen, which lacks either of these added sugar groups. Rh antigens are transmembrane proteins.</ce:simple-para></ce:caption><ce:alt-text id="atte0025" role="short">Fig. 23.4</ce:alt-text><ce:link id="ln0040" locator="f023-004-9780702070280" xlink:href="pii:B9780702070280000238/f023-004-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0045"><ce:label>Fig. 23.5</ce:label><ce:caption id="ca0030"><ce:simple-para id="sp0045" role="title">The haemoglobin–oxygen dissociation curve.</ce:simple-para><ce:simple-para id="sp0050" role="caption">Factors are listed that shift the curve to the right (more oxygen released from blood) and to the left (less oxygen released) at given <ce:italic>P</ce:italic>O<ce:inf loc="post">2</ce:inf>. To convert kPa to mmHg, multiply by 7.5. (2,3-BPG = 2,3-bisphosphoglycerate)</ce:simple-para></ce:caption><ce:alt-text id="atte0030" role="short">Fig. 23.5</ce:alt-text><ce:link id="ln0045" locator="f023-005-9780702070280" xlink:href="pii:B9780702070280000238/f023-005-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0050"><ce:label>Fig. 23.6</ce:label><ce:caption id="ca0035"><ce:simple-para id="sp0055" role="title">The stages of normal haemostasis.</ce:simple-para><ce:simple-para id="sp0060" role="caption"><ce:bold>A</ce:bold> <ce:italic>Stage 1. Pre-injury conditions encourage flow</ce:italic>. The vascular endothelium produces substances (including nitric oxide, prostacyclin and heparans) to prevent adhesion of platelets and white cells to the vessel wall. Platelets and coagulation factors circulate in a non-activated state. <ce:bold>B</ce:bold> <ce:italic>Stage 2. Early haemostatic response: platelets adhere; coagulation is activated.</ce:italic> At the site of injury, the endothelium is breached, exposing subendothelial collagen. Small amounts of tissue factor (TF) are released. Platelets bind to collagen via a specific receptor, glycoprotein Ia (GPIa), causing a change in platelet shape and its adhesion to the area of damage by the binding of other receptors (GPIb and GPIIb/IIIa) to von Willebrand factor and fibrinogen, respectively. Coagulation is activated by the tissue factor (extrinsic) pathway, generating small amounts of thrombin. <ce:bold>C</ce:bold> and <ce:bold>D</ce:bold> <ce:italic>Stage 3. Fibrin clot formation: platelets become activated and aggregate; fibrin formation is supported by the platelet membrane; stable fibrin clot forms.</ce:italic> The adherent platelets are activated by many pathways, including binding of adenosine diphosphate (ADP), collagen, thrombin and adrenaline (epinephrine) to surface receptors. The cyclo-oxygenase pathway converts arachidonic acid from the platelet membrane into thromboxane A<ce:inf loc="post">2</ce:inf>, which causes aggregation of platelets. Activation of the platelets results in release of the platelet granule contents, enhancing coagulation further (see <ce:cross-ref id="crf0295" refid="f0055">Fig. 23.7</ce:cross-ref>). Thrombin plays a key role in the control of coagulation: the small amount generated via the TF pathway massively amplifies its own production; the ‘intrinsic’ pathway becomes activated and large amounts of thrombin are generated. Thrombin directly causes clot formation by cleaving fibrinopeptides (FPs) from fibrinogen to produce fibrin. Fibrin monomers are cross-linked by factor XIII, which is also activated by thrombin. Having had a key role in clot formation and stabilisation, thrombin then starts to regulate clot formation in two main ways: (a) activation of the protein C (PC) pathway (a natural anticoagulant), which reduces further coagulation; (b) activation of thrombin-activatable fibrinolysis inhibitor (TAFI), which inhibits fibrinolysis (see E and F). <ce:bold>E</ce:bold> <ce:italic>Stage 4. Limiting clot formation: natural anticoagulants reverse activation of coagulation factors.</ce:italic> Once haemostasis has been secured, the propagation of clot is curtailed by anticoagulants. Antithrombin is a serine protease inhibitor synthesised by the liver, which destroys activated factors such as XIa, Xa and thrombin (IIa). Its major activity against thrombin and Xa is enhanced by heparin and fondaparinux, explaining their anticoagulant effect. Tissue factor pathway inhibitor (TFPI) binds to and inactivates VIIa and Xa. Activation of PC occurs following binding of thrombin to membrane-bound thrombomodulin; activated protein C (aPC) binds to its co-factor, protein S (PS), and cleaves Va and VIIIa. PC and PS are vitamin K-dependent and are depleted by coumarin anticoagulants such as warfarin. <ce:bold>F</ce:bold> <ce:italic>Stage 5. Fibrinolysis: plasmin degrades fibrin to allow vessel recanalisation and tissue repair.</ce:italic> The insoluble clot needs to be broken down for vessel recanalisation. Plasmin, the main fibrinolytic enzyme, is produced when plasminogen is activated, e.g. by tissue plasminogen activator (t-PA) or urokinase in the clot. Plasmin hydrolyses the fibrin clot, producing fibrin degradation products, including the D-dimer. This process is highly regulated; the plasminogen activators are controlled by an inhibitor called plasminogen activator inhibitor (PAI), the activity of plasmin is inhibited by α<ce:inf loc="post">2</ce:inf>-antiplasmin and α<ce:inf loc="post">2</ce:inf>-macroglobulin, and fibrinolysis is further inhibited by the thrombin-activated TAFI.</ce:simple-para></ce:caption><ce:alt-text id="atte0035" role="short">Fig. 23.6</ce:alt-text><ce:link id="ln0050" locator="f023-006abc-9780702070280" xlink:href="pii:B9780702070280000238/f023-006abc-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:link id="ln0055" locator="f023-006def-9780702070280" xlink:href="pii:B9780702070280000238/f023-006def-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0055"><ce:label>Fig. 23.7</ce:label><ce:caption id="ca0040"><ce:simple-para id="sp0065" role="title">Normal platelet structure.</ce:simple-para><ce:simple-para id="sp0070" role="caption">The platelet surface is populated by glycoproteins, which bind to key structures including fibrinogen, collagen and von Willebrand factor and cell surface receptors for thrombin, ADP and adrenaline (epinephrine). Through internal signalling pathways, platelet activation causes degranulation of alpha and dense granules, which ultimately results in platelet aggregation. Blockade of these pathways by drugs such as aspirin, clopidogrel, ticagrelor, tirofiban and abcixamab forms the basis of antiplatelet therapy. (ADP = adenosine diphosphate; GP = glycoprotein)</ce:simple-para></ce:caption><ce:alt-text id="atte0040" role="short">Fig. 23.7</ce:alt-text><ce:link id="ln0060" locator="f023-007-9780702070280" xlink:href="pii:B9780702070280000238/f023-007-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0065"><ce:label>Fig. 23.9</ce:label><ce:caption id="ca0050"><ce:simple-para id="sp0085" role="title">Bone marrow aspirate and trephine.</ce:simple-para><ce:simple-para id="sp0090" role="caption"><ce:bold>A</ce:bold> Trephine biopsy needle. <ce:bold>B</ce:bold> Macroscopic appearance of a trephine biopsy. <ce:bold>C</ce:bold> Microscopic appearance of stained section of trephine. <ce:bold>D</ce:bold> Bone marrow aspirate needle. <ce:bold>E</ce:bold> Stained macroscopic appearance of marrow aspirate: smear (left) and squash (right). <ce:bold>F</ce:bold> Microscopic appearance of stained marrow particles and trails of haematopoietic cells.</ce:simple-para></ce:caption><ce:alt-text id="atte0045" role="short">Fig. 23.9</ce:alt-text><ce:link id="ln0080" locator="f023-009ad-9780702070280" xlink:href="pii:B9780702070280000238/f023-009ad-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0070"><ce:label>Fig. 23.10</ce:label><ce:caption id="ca0055"><ce:simple-para id="sp0100" role="title">Investigation of anaemia with normal or low mean cell volume (MCV).</ce:simple-para><ce:simple-para id="sp0105" role="caption">(Hb = haemoglobin; MCH = mean cell haemoglobin)</ce:simple-para></ce:caption><ce:alt-text id="atte0050" role="short">Fig. 23.10</ce:alt-text><ce:link id="ln0110" locator="f023-010-9780702070280" xlink:href="pii:B9780702070280000238/f023-010-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0075"><ce:label>Fig. 23.11</ce:label><ce:caption id="ca0060"><ce:simple-para id="sp0110" role="title">Investigation of anaemia with high mean cell volume (MCV).</ce:simple-para><ce:simple-para id="sp0115" role="caption">(LDH = lactate dehydrogenase)</ce:simple-para></ce:caption><ce:alt-text id="atte0055" role="short">Fig. 23.11</ce:alt-text><ce:link id="ln0115" locator="f023-011-9780702070280" xlink:href="pii:B9780702070280000238/f023-011-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0085"><ce:label>Fig. 23.13</ce:label><ce:caption id="ca0070"><ce:simple-para id="sp0130" role="title">Petechial purpura.</ce:simple-para></ce:caption><ce:alt-text id="atte0060" role="short">Fig. 23.13</ce:alt-text><ce:link id="ln0175" locator="f023-013-9780702070280" xlink:href="pii:B9780702070280000238/f023-013-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0090"><ce:label>Fig. 23.14</ce:label><ce:caption id="ca0075"><ce:simple-para id="sp0140" role="title">Blood donation, processing and storage.</ce:simple-para><ce:simple-para id="sp0145" role="caption"><ce:sup loc="post">1</ce:sup>Platelet apheresis involves circulating the donor's blood through a cell separator to remove platelets before returning other blood components to the donor. <ce:sup loc="post">2</ce:sup>In the UK, plasma for fractionation is imported as a precautionary measure against vCJD. (vCJD = variant Creutzfeldt–Jakob disease; HIV = human immunodeficiency virus; HTLV = human T-cell lymphotropic virus)</ce:simple-para></ce:caption><ce:alt-text id="atte0065" role="short">Fig. 23.14</ce:alt-text><ce:link id="ln0205" locator="f023-014-9780702070280" xlink:href="pii:B9780702070280000238/f023-014-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0095"><ce:label>Fig. 23.15</ce:label><ce:caption id="ca0080"><ce:simple-para id="sp0150" role="title">Bedside procedures for safe blood transfusion.</ce:simple-para><ce:simple-para id="sp0155" role="caption">The patient's safety depends on adherence to standard procedures for taking samples for compatibility testing, administering blood, record-keeping and observations.</ce:simple-para></ce:caption><ce:alt-text id="atte0070" role="short">Fig. 23.15</ce:alt-text><ce:link id="ln0220" locator="f023-015-9780702070280" xlink:href="pii:B9780702070280000238/f023-015-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0100"><ce:label>Fig. 23.16</ce:label><ce:caption id="ca0085"><ce:simple-para id="sp0160" role="title">Investigation and management of acute transfusion reactions.</ce:simple-para><ce:simple-para id="sp0165" role="caption">*Use size-appropriate dose in children. (ARDS = acute respiratory distress syndrome; BP = blood pressure; CVP = central venous pressure; DIC = disseminated intravascular coagulation; FBC = full blood count; IV = intravenous)</ce:simple-para></ce:caption><ce:alt-text id="atte0075" role="short">Fig. 23.16</ce:alt-text><ce:link id="ln0225" locator="f023-016-9780702070280" xlink:href="pii:B9780702070280000238/f023-016-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0110"><ce:label>Fig. 23.17</ce:label><ce:caption id="ca0090"><ce:simple-para id="sp0175" role="title">Factors that influence the size of red cells in anaemia.</ce:simple-para><ce:simple-para id="sp0180" role="caption">In microcytosis, the MCV is &#x003C; 76 fL. In macrocytosis, the MCV is &#x003E; 100 fL. (MCV = mean cell volume; RBC = red blood cell)</ce:simple-para></ce:caption><ce:alt-text id="atte0080" role="short">Fig. 23.17</ce:alt-text><ce:link id="ln0280" locator="f023-017-9780702070280" xlink:href="pii:B9780702070280000238/f023-017-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0115"><ce:label>Fig. 23.18</ce:label><ce:caption id="ca0095"><ce:simple-para id="sp0185" role="title">The regulation of iron absorption, uptake and distribution in the body.</ce:simple-para><ce:simple-para id="sp0190" role="caption">The transport of iron is regulated in a similar fashion to enterocytes in other iron-transporting cells such as macrophages.</ce:simple-para></ce:caption><ce:alt-text id="atte0085" role="short">Fig. 23.18</ce:alt-text><ce:link id="ln0285" locator="f023-018-9780702070280" xlink:href="pii:B9780702070280000238/f023-018-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0120"><ce:label>Fig. 23.19</ce:label><ce:caption id="ca0100"><ce:simple-para id="sp0200" role="title">Causes and classification of haemolysis.</ce:simple-para><ce:simple-para id="sp0205" role="caption"><ce:bold>A</ce:bold> Inherited causes. <ce:bold>B</ce:bold> Acquired causes. (CLL = chronic lymphocytic leukaemia; DIC = disseminated intravascular coagulation; EBV = Epstein–Barr virus; G6PD = glucose-6-phosphate dehydrogenase; HUS = haemolytic uraemic syndrome; PK = pyruvate kinase; RA = rheumatoid arthritis; SLE = systemic lupus erythematosus; TTP = thrombotic thrombocytopenic purpura)</ce:simple-para></ce:caption><ce:alt-text id="atte0090" role="short">Fig. 23.19</ce:alt-text><ce:link id="ln0325" locator="f023-019-9780702070280" xlink:href="pii:B9780702070280000238/f023-019-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0125"><ce:label>Fig. 23.20</ce:label><ce:caption id="ca0105"><ce:simple-para id="sp0210" role="title">Direct and indirect antiglobulin tests.</ce:simple-para></ce:caption><ce:alt-text id="atte0095" role="short">Fig. 23.20</ce:alt-text><ce:link id="ln0345" locator="f023-020ab-9780702070280" xlink:href="pii:B9780702070280000238/f023-020ab-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0130"><ce:label>Fig. 23.21</ce:label><ce:caption id="ca0110"><ce:simple-para id="sp0215" role="title">The geographical distribution of the haemoglobinopathies.</ce:simple-para></ce:caption><ce:alt-text id="atte0100" role="short">Fig. 23.21</ce:alt-text><ce:source>From Hoffbrand AV, Pettit JE. Essential haematology, 3rd edn. Edinburgh: Blackwell Science; 1992.</ce:source><ce:link id="ln0350" locator="f023-021-9780702070280" xlink:href="pii:B9780702070280000238/f023-021-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0135"><ce:label>Fig. 23.22</ce:label><ce:caption id="ca0115"><ce:simple-para id="sp0220" role="title">Clinical and laboratory features of sickle-cell disease.</ce:simple-para></ce:caption><ce:alt-text id="atte0105" role="short">Fig. 23.22</ce:alt-text><ce:link id="ln0355" locator="f023-022-9780702070280" xlink:href="pii:B9780702070280000238/f023-022-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0140"><ce:label>Fig. 23.23</ce:label><ce:caption id="ca0120"><ce:simple-para id="sp0230" role="title">Acute myeloid leukaemia.</ce:simple-para><ce:simple-para id="sp0235" role="caption">Bone marrow aspirate showing infiltration with large blast cells, which display nuclear folding and prominent nucleoli.</ce:simple-para></ce:caption><ce:alt-text id="atte0110" role="short">Fig. 23.23</ce:alt-text><ce:link id="ln0395" locator="f023-023-9780702070280" xlink:href="pii:B9780702070280000238/f023-023-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0145"><ce:label>Fig. 23.24</ce:label><ce:caption id="ca0125"><ce:simple-para id="sp0240" role="title">Investigation of acute lymphoblastic leukaemia (ALL).</ce:simple-para><ce:simple-para id="sp0245" role="caption"><ce:bold>A</ce:bold> Flow cytometric analysis of blasts labelled with the fluorescent antibodies anti-CD19 (y axis) and anti-CD10 (x axis). ALL blasts are positive for both CD19 and CD10 (arrow). <ce:bold>B</ce:bold> Chromosome analysis (karyotype) of blasts showing additional chromosomes X, 4, 6, 7, 14, 18 and 21.</ce:simple-para></ce:caption><ce:alt-text id="atte0115" role="short">Fig. 23.24</ce:alt-text><ce:link id="ln0400" locator="f023-024a-9780702070280" xlink:href="pii:B9780702070280000238/f023-024a-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:link id="ln0405" locator="f023-024b-9780702070280" xlink:href="pii:B9780702070280000238/f023-024b-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0150"><ce:label>Fig. 23.25</ce:label><ce:caption id="ca0130"><ce:simple-para id="sp0250" role="title">Schema of lymph node architecture.</ce:simple-para><ce:simple-para id="sp0255" role="caption">Different lymphocyte populations reside in different areas of the node: B cells in the follicles, T cells in the paracortex and plasma cells in the medulla. B cells are selected for antigen in the follicle centre. Errors during this process result in B-cell lymphomas, which are by far the most common type.</ce:simple-para></ce:caption><ce:alt-text id="atte0120" role="short">Fig. 23.25</ce:alt-text><ce:link id="ln0445" locator="f023-025-9780702070280" xlink:href="pii:B9780702070280000238/f023-025-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0155"><ce:label>Fig. 23.26</ce:label><ce:caption id="ca0135"><ce:simple-para id="sp0260" role="title">Hodgkin lymphoma.</ce:simple-para><ce:simple-para id="sp0265" role="caption">In the centre of this lymph node biopsy is a large typical Reed–Sternberg cell with two nuclei containing a prominent eosinophilic nucleolus.</ce:simple-para></ce:caption><ce:alt-text id="atte0125" role="short">Fig. 23.26</ce:alt-text><ce:link id="ln0450" locator="f023-026-9780702070280" xlink:href="pii:B9780702070280000238/f023-026-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0160"><ce:label>Fig. 23.27</ce:label><ce:caption id="ca0140"><ce:simple-para id="sp0270" role="title">Positron emission tomography (PET) scans in Hodgkin lymphoma, demonstrating response to treatment.</ce:simple-para><ce:simple-para id="sp0275" role="caption"><ce:bold>A</ce:bold> Chest X-ray from a young man with Hodgkin lymphoma at presentation, showing a left-sided anterior–superior mediastinal mass with tracheal deviation to the right. <ce:bold>B</ce:bold> Fused PET-CT image showing intense fluorodeoxyglucose (FDG) uptake (avidity) in the mass at presentation. <ce:bold>C</ce:bold> Fused PET-CT image showing no FDG uptake (PET negativity), representing complete response at the end of treatment.</ce:simple-para></ce:caption><ce:alt-text id="atte0130" role="short">Fig. 23.27</ce:alt-text><ce:link id="ln0470" locator="f023-027a-9780702070280" xlink:href="pii:B9780702070280000238/f023-027a-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:link id="ln0475" locator="f023-027b-9780702070280" xlink:href="pii:B9780702070280000238/f023-027b-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:link id="ln0480" locator="f023-027c-9780702070280" xlink:href="pii:B9780702070280000238/f023-027c-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0165"><ce:label>Fig. 23.28</ce:label><ce:caption id="ca0145"><ce:simple-para id="sp0280" role="title">CT-guided percutaneous needle biopsy of retroperitoneal nodes involved by lymphoma.</ce:simple-para></ce:caption><ce:alt-text id="atte0135" role="short">Fig. 23.28</ce:alt-text><ce:link id="ln0485" locator="f023-028-9780702070280" xlink:href="pii:B9780702070280000238/f023-028-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0170"><ce:label>Fig. 23.29</ce:label><ce:caption id="ca0150"><ce:simple-para id="sp0285" role="title">Histology of non-Hodgkin lymphoma.</ce:simple-para><ce:simple-para id="sp0290" role="caption"><ce:bold>A</ce:bold> (Low-grade) follicular or nodular pattern. <ce:bold>B</ce:bold> (High-grade) diffuse pattern.</ce:simple-para></ce:caption><ce:alt-text id="atte0140" role="short">Fig. 23.29</ce:alt-text><ce:link id="ln0500" locator="f023-029a-9780702070280" xlink:href="pii:B9780702070280000238/f023-029a-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:link id="ln0505" locator="f023-029b-9780702070280" xlink:href="pii:B9780702070280000238/f023-029b-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0175"><ce:label>Fig. 23.30</ce:label><ce:caption id="ca0155"><ce:simple-para id="sp0295" role="title">Bulky axillary lymphadenopathy with distended superficial veins in a patient presenting with high-grade lymphoma.</ce:simple-para></ce:caption><ce:alt-text id="atte0145" role="short">Fig. 23.30</ce:alt-text><ce:source>From Howard MR, Hamilton PJ. Haematology: An illustrated colour text, 4th edn. Edinburgh: Elsevier Ltd; 2013.</ce:source><ce:link id="ln0510" locator="f023-030-9780702070280" xlink:href="pii:B9780702070280000238/f023-030-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0180"><ce:label>Fig. 23.31</ce:label><ce:caption id="ca0160"><ce:simple-para id="sp0300" role="title">Clinical and laboratory features of multiple myeloma.</ce:simple-para><ce:simple-para id="sp0305" role="caption">(ESR = erythrocyte sedimentation rate; NSAIDs = non-steroidal anti-inflammatory drugs)</ce:simple-para></ce:caption><ce:alt-text id="atte0150" role="short">Fig. 23.31</ce:alt-text><ce:link id="ln0520" locator="f023-031-9780702070280" xlink:href="pii:B9780702070280000238/f023-031-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0185"><ce:label>Fig. 23.32</ce:label><ce:caption id="ca0165"><ce:simple-para id="sp0315" role="title">Clinical manifestations of haemophilia.</ce:simple-para><ce:simple-para id="sp0320" role="caption">On the knee X-ray, repeated bleeds have led to broadening of the femoral epicondyles, and there is no cartilage present, as evidenced by the close proximity of the femur and tibia (A); sclerosis (B), osteophyte (C) and bony cysts (D) are present. (HCV = hepatitis C virus)</ce:simple-para></ce:caption><ce:alt-text id="atte0155" role="short">Fig. 23.32</ce:alt-text><ce:source><ce:italic>Inset (Massive bruising)</ce:italic> From Hoffbrand VA. Color atlas of clinical hematology, 3rd edn. Philadelphia: Mosby, Elsevier Inc.; 2000.</ce:source><ce:link id="ln0550" locator="f023-032-9780702070280" xlink:href="pii:B9780702070280000238/f023-032-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0190"><ce:label>Fig. 23.33</ce:label><ce:caption id="ca0170"><ce:simple-para id="sp0330" role="title">Causes and consequences of venous thromboembolic disease and its treatment.</ce:simple-para><ce:simple-para id="sp0335" role="caption">(DVT = deep vein thrombosis; IVC = inferior vena cava)</ce:simple-para></ce:caption><ce:alt-text id="atte0160" role="short">Fig. 23.33</ce:alt-text><ce:link id="ln0565" locator="f023-033-9780702070280" xlink:href="pii:B9780702070280000238/f023-033-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:textbox id="b0040" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0065" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0165" role="short">Image 1</ce:alt-text></ce:inline-figure>23.1</ce:label><ce:alt-text id="atte0170" role="short">23.1</ce:alt-text><ce:textbox-head><ce:title id="tit0045">Spurious full blood count results from autoanalysers</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0710"><ce:display><ce:table frame="topbot" id="t0010"><ce:alt-text id="atte0175" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Result</entry><entry align="left">Explanation</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Increased haemoglobin</ce:bold></entry><entry align="left">Lipaemia, jaundice, very high white cell count</entry></row><row rowsep="1"><entry align="left"><ce:bold>Reduced haemoglobin</ce:bold></entry><entry align="left">Improper sample mixing, blood taken from vein into which an infusion is flowing</entry></row><row rowsep="1"><entry align="left"><ce:bold>Increased red cell volume (mean cell volume, MCV)</ce:bold></entry><entry align="left">Cold agglutinins, non-ketotic hyperosmolarity</entry></row><row rowsep="1"><entry align="left"><ce:bold>Increased white cell count</ce:bold></entry><entry align="left">Nucleated red cells present</entry></row><row><entry align="left"><ce:bold>Reduced platelet count</ce:bold></entry><entry align="left">Clot in sample, platelet clumping</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0045" role="alt3"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0070" locator="icon03-9780702070280" xlink:href="pii:B9780702070280000238/icon03-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0180" role="short">Image 2</ce:alt-text></ce:inline-figure>23.2</ce:label><ce:alt-text id="atte0185" role="short">23.2</ce:alt-text><ce:textbox-head><ce:title id="tit0050">How to interpret red cell appearances</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0720"><ce:display><ce:table frame="topbot" id="t0015"><ce:alt-text id="atte0190" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Microcytosis (reduced average cell size, MCV &#x003C; 76 fL) A</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0115"><ce:list-item id="u0505"><ce:label>•</ce:label><ce:para id="p0725">Iron deficiency</ce:para></ce:list-item><ce:list-item id="u0510"><ce:label>•</ce:label><ce:para id="p0730">Thalassaemia</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0120"><ce:list-item id="u0515"><ce:label>•</ce:label><ce:para id="p0735">Sideroblastic anaemia</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Macrocytosis (increased average cell size, MCV &#x003E; 100 fL) B</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0125"><ce:list-item id="u0520"><ce:label>•</ce:label><ce:para id="p0740">Vitamin B<ce:inf loc="post">12</ce:inf> or folate deficiency</ce:para></ce:list-item><ce:list-item id="u0525"><ce:label>•</ce:label><ce:para id="p0745">Liver disease, alcohol</ce:para></ce:list-item><ce:list-item id="u0530"><ce:label>•</ce:label><ce:para id="p0750">Hypothyroidism</ce:para></ce:list-item><ce:list-item id="u0540"><ce:label>•</ce:label><ce:para id="p0760">Myelodysplastic syndromes</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0130"><ce:list-item id="u0535"><ce:label>•</ce:label><ce:para id="p0755">Drugs (e.g. zidovudine, trimethoprim, phenytoin, methotrexate, hydroxycarbamide)</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Target cells (central area of haemoglobinisation) C</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0135"><ce:list-item id="u0545"><ce:label>•</ce:label><ce:para id="p0765">Liver disease</ce:para></ce:list-item><ce:list-item id="u0550"><ce:label>•</ce:label><ce:para id="p0770">Thalassaemia</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0140"><ce:list-item id="u0555"><ce:label>•</ce:label><ce:para id="p0775">Post-splenectomy</ce:para></ce:list-item><ce:list-item id="u0560"><ce:label>•</ce:label><ce:para id="p0780">Haemoglobin C disease</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Spherocytes (dense cells, no area of central pallor) D</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0145"><ce:list-item id="u0565"><ce:label>•</ce:label><ce:para id="p0785">Autoimmune haemolytic anaemia</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0150"><ce:list-item id="u0570"><ce:label>•</ce:label><ce:para id="p0790">Post-splenectomy</ce:para></ce:list-item><ce:list-item id="u0575"><ce:label>•</ce:label><ce:para id="p0795">Hereditary spherocytosis</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Red cell fragments (intravascular haemolysis) E</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0155"><ce:list-item id="u0580"><ce:label>•</ce:label><ce:para id="p0800">Microangiopathic haemolysis, e.g. haemolytic uraemic syndrome (HUS), thrombotic thrombocytopenic purpura (TTP)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0160"><ce:list-item id="u0585"><ce:label>•</ce:label><ce:para id="p0805">Disseminated intravascular coagulation (DIC)</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Nucleated red blood cells (normoblasts) F</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0165"><ce:list-item id="u0590"><ce:label>•</ce:label><ce:para id="p0810">Marrow infiltration</ce:para></ce:list-item><ce:list-item id="u0595"><ce:label>•</ce:label><ce:para id="p0815">Severe haemolysis</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0170"><ce:list-item id="u0600"><ce:label>•</ce:label><ce:para id="p0820">Myelofibrosis</ce:para></ce:list-item><ce:list-item id="u0605"><ce:label>•</ce:label><ce:para id="p0825">Acute haemorrhage</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Howell–Jolly bodies (small round nuclear remnants) G</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0175"><ce:list-item id="u0610"><ce:label>•</ce:label><ce:para id="p0830">Hyposplenism</ce:para></ce:list-item><ce:list-item id="u0615"><ce:label>•</ce:label><ce:para id="p0835">Post-splenectomy</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0180"><ce:list-item id="u0620"><ce:label>•</ce:label><ce:para id="p0840">Dyshaematopoiesis</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Polychromasia (young red cells – reticulocytes present) H</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0185"><ce:list-item id="u0625"><ce:label>•</ce:label><ce:para id="p0845">Haemolysis, acute haemorrhage</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0190"><ce:list-item id="u0630"><ce:label>•</ce:label><ce:para id="p0850">Increased red cell turnover</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Basophilic stippling (abnormal ribosomal RNA appears as blue dots) I</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist0195"><ce:list-item id="u0635"><ce:label>•</ce:label><ce:para id="p0855">Dyshaematopoiesis</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0200"><ce:list-item id="u0640"><ce:label>•</ce:label><ce:para id="p0860">Lead poisoning</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display><ce:display><ce:figure id="f0060"><ce:label>Fig. 23.8</ce:label><ce:caption id="ca0045"><ce:simple-para id="sp0075" role="title">Appearance of red blood cells.</ce:simple-para><ce:simple-para id="sp0080" role="caption"><ce:bold>A</ce:bold> Microcytosis. <ce:bold>B</ce:bold> Macrocytosis. <ce:bold>C</ce:bold> Target cells. <ce:bold>D</ce:bold> Spherocytes. <ce:bold>E</ce:bold> Red cell fragments. <ce:bold>F</ce:bold> Nucleated red blood cells. <ce:bold>G</ce:bold> Howell–Jolly bodies. <ce:bold>H</ce:bold> Polychromasia. <ce:bold>I</ce:bold> Basophilic stippling.</ce:simple-para></ce:caption><ce:alt-text id="atte0195" role="short">Fig. 23.8</ce:alt-text><ce:link id="ln0075" locator="f023-008ai-9780702070280" xlink:href="pii:B9780702070280000238/f023-008ai-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0050" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0085" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0200" role="short">Image 3</ce:alt-text></ce:inline-figure>23.3</ce:label><ce:alt-text id="atte0205" role="short">23.3</ce:alt-text><ce:textbox-head><ce:title id="tit0055">Coagulation screening tests<ce:cross-ref id="crf9005" refid="tn9000"><ce:sup loc="post">1</ce:sup></ce:cross-ref></ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0875"><ce:display><ce:table frame="topbot" id="t0020"><ce:alt-text id="atte0210" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Investigation</entry><entry align="left">Reference range<ce:cross-ref id="crf0335" refid="tn9100">2</ce:cross-ref></entry><entry align="left">Situations in which tests may be abnormal</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Platelet count</ce:bold></entry><entry align="left">150–400 × 10<ce:sup loc="post">9</ce:sup>/L</entry><entry align="left">Thrombocytopenia</entry></row><row><entry morerows="1" rowsep="1" align="left"><ce:bold>Prothrombin time (PT)</ce:bold></entry><entry morerows="1" rowsep="1" align="left">9–12 secs</entry><entry rowsep="0" align="left">Deficiencies of factors II, V, VII or X</entry></row><row rowsep="1"><entry align="left">Severe fibrinogen deficiency</entry></row><row><entry morerows="4" rowsep="1" align="left"><ce:bold>Activated partial thromboplastin time (APTT)</ce:bold></entry><entry morerows="4" rowsep="1" align="left">26–36 secs</entry><entry rowsep="0" align="left">Deficiencies of factors II, V, VIII, IX, X, XI, XII</entry></row><row rowsep="0"><entry align="left">Severe fibrinogen deficiency</entry></row><row rowsep="0"><entry align="left">Unfractionated heparin therapy</entry></row><row rowsep="0"><entry align="left">Antibodies against clotting factors</entry></row><row rowsep="1"><entry align="left">Lupus anticoagulant<ce:br/>Multiple factor deficiency (e.g. DIC)</entry></row><row><entry align="left"><ce:bold>Fibrinogen concentration</ce:bold></entry><entry align="left">1.5–4.0 g/L</entry><entry align="left">Hypofibrinogenaemia, e.g. liver failure, DIC</entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp9000">(DIC = disseminated intravascular coagulation)</ce:simple-para></ce:legend><ce:table-footnote id="tn9000"><ce:label>1</ce:label><ce:note-para id="np9000"><ce:bold>N.B.</ce:bold> International normalised ratio (INR) is used only to monitor coumarin therapy and is not a coagulation screening test.</ce:note-para></ce:table-footnote><ce:table-footnote id="tn9100"><ce:label>2</ce:label><ce:note-para id="np0010">Ranges are approximate and may vary between laboratories.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0055" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0090" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0215" role="short">Image 4</ce:alt-text></ce:inline-figure>23.4</ce:label><ce:alt-text id="atte0220" role="short">23.4</ce:alt-text><ce:textbox-head><ce:title id="tit0060">Investigation of possible thrombophilia</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0180"><ce:section id="s0185"><ce:section-title id="st0175">Full blood count</ce:section-title><ce:para id="p0915">Plasma levels</ce:para><ce:para id="p0920"><ce:list id="ulist0205"><ce:list-item id="u0645"><ce:label>•</ce:label><ce:para id="p0925">Antithrombin</ce:para></ce:list-item><ce:list-item id="u0650"><ce:label>•</ce:label><ce:para id="p0930">Protein C</ce:para></ce:list-item><ce:list-item id="u0655"><ce:label>•</ce:label><ce:para id="p0935">Protein S (free)</ce:para></ce:list-item><ce:list-item id="u0660"><ce:label>•</ce:label><ce:para id="p0940">Antiphospholipid antibodies, lupus anticoagulant, anticardiolipin antibody/anti-β<ce:inf loc="post">2</ce:inf>GP1</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0190"><ce:section-title id="st0180">Thrombin/reptilase time (for dysfibrinogenaemia)</ce:section-title><ce:para id="p0945">Genetic testing</ce:para><ce:para id="p0950"><ce:list id="ulist0210"><ce:list-item id="u0665"><ce:label>•</ce:label><ce:para id="p0955">Factor V Leiden</ce:para></ce:list-item><ce:list-item id="u0670"><ce:label>•</ce:label><ce:para id="p0960">Prothrombin G20210A</ce:para></ce:list-item><ce:list-item id="u0675"><ce:label>•</ce:label><ce:para id="p0965"><ce:italic>JAK-2 V617F</ce:italic> mutation</ce:para></ce:list-item><ce:list-item id="u0680"><ce:label>•</ce:label><ce:para id="p0970"><ce:italic>CALR</ce:italic> mutations</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0195"><ce:section-title id="st0185">Flow cytometry</ce:section-title><ce:para id="p0975"><ce:list id="ulist0215"><ce:list-item id="u0685"><ce:label>•</ce:label><ce:para id="p0980">Screen for GPI-linked cell surface proteins (CD14, 16, 55, 59), deficient in paroxysmal nocturnal haemoglobinuria</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p0985">(CD = cluster of differentiation; GP1 = glycoprotein 1; GPI = glycerol phosphatidyl inositol)</ce:para></ce:section></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0060" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0095" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0225" role="short">Image 5</ce:alt-text></ce:inline-figure>23.5</ce:label><ce:alt-text id="atte0230" role="short">23.5</ce:alt-text><ce:textbox-head><ce:title id="tit0065">Possible indications for thrombophilia testing<ce:cross-ref id="crf0365" refid="fn0010">*</ce:cross-ref><ce:footnote id="fn0010"><ce:label>*</ce:label><ce:note-para id="np0015">Antiphospholipid antibodies should be sought where clinical criteria for antiphospholipid syndrome (APS) are fulfilled (p. 977). Thrombophilia testing may explain the diagnosis without necessarily affecting management and this limits the clinical value of such an approach.</ce:note-para></ce:footnote></ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0990"><ce:display><ce:table frame="topbot" id="t0025"><ce:alt-text id="atte0235" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row><entry align="left"><ce:list id="ulist0220"><ce:list-item id="u0690"><ce:label>•</ce:label><ce:para id="p0995">Venous thrombosis &#x003C; 45 years</ce:para></ce:list-item><ce:list-item id="u0695"><ce:label>•</ce:label><ce:para id="p1000">Recurrent venous thrombosis</ce:para></ce:list-item><ce:list-item id="u0700"><ce:label>•</ce:label><ce:para id="p1005">Family history of unprovoked or recurrent thrombosis</ce:para></ce:list-item><ce:list-item id="u0705"><ce:label>•</ce:label><ce:para id="p1010">Combined arterial and venous thrombosis</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0225"><ce:list-item id="u0710"><ce:label>•</ce:label><ce:para id="p1015">Venous thrombosis at an unusual site:<ce:list id="ulist0230"><ce:list-item id="u0715"><ce:para id="p1020">Cerebral venous thrombosis</ce:para></ce:list-item><ce:list-item id="u0720"><ce:para id="p1025">Hepatic vein (Budd–Chiari syndrome)</ce:para></ce:list-item><ce:list-item id="u0725"><ce:para id="p1030">Portal vein, mesenteric vein</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0065" role="alt2"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0100" locator="icon02-9780702070280" xlink:href="pii:B9780702070280000238/icon02-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0240" role="short">Image 6</ce:alt-text></ce:inline-figure>23.6</ce:label><ce:alt-text id="atte0245" role="short">23.6</ce:alt-text><ce:textbox-head><ce:title id="tit0070">Haematological investigations in old age</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1040"><ce:list id="ulist0235"><ce:list-item id="u0730"><ce:label>•</ce:label><ce:para id="p1045"><ce:bold>Blood cell counts and film components</ce:bold>: not altered in general by ageing alone, although haemoglobin concentrations fall with increasing age.</ce:para></ce:list-item><ce:list-item id="u0735"><ce:label>•</ce:label><ce:para id="p1050"><ce:bold>Ratio of bone marrow cells to marrow fat</ce:bold>: falls.</ce:para></ce:list-item><ce:list-item id="u0740"><ce:label>•</ce:label><ce:para id="p1055"><ce:bold>Neutrophils</ce:bold>: maintained throughout life, although leucocytes may be less readily mobilised by bacterial invasion in old age.</ce:para></ce:list-item><ce:list-item id="u0745"><ce:label>•</ce:label><ce:para id="p1060"><ce:bold>Lymphocytes</ce:bold>: functionally compromised by age due to a T-cell-related defect in cell-mediated immunity.</ce:para></ce:list-item><ce:list-item id="u0750"><ce:label>•</ce:label><ce:para id="p1065"><ce:bold>Clotting factors</ce:bold>: no major changes, although mild congenital deficiencies may be first noticed in old age.</ce:para></ce:list-item><ce:list-item id="u0755"><ce:label>•</ce:label><ce:para id="p1070"><ce:bold>Erythrocyte sedimentation rate (ESR)</ce:bold>: raised above the reference range but usually in association with chronic or subacute disease. In truly healthy older people, the ESR range is very similar to that in younger people.</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0070" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0105" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0250" role="short">Image 7</ce:alt-text></ce:inline-figure>23.7</ce:label><ce:alt-text id="atte0255" role="short">23.7</ce:alt-text><ce:textbox-head><ce:title id="tit0075">Causes of anaemia</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1085"><ce:display><ce:table frame="topbot" id="t0030"><ce:alt-text id="atte0260" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Decreased or ineffective marrow production</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0240"><ce:list-item id="u0760"><ce:label>•</ce:label><ce:para id="p1090">Lack of iron, vitamin B<ce:inf loc="post">12</ce:inf> or folate</ce:para></ce:list-item><ce:list-item id="u0765"><ce:label>•</ce:label><ce:para id="p1095">Hypoplasia/myelodysplasia</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0245"><ce:list-item id="u0770"><ce:label>•</ce:label><ce:para id="p1100">Invasion by malignant cells</ce:para></ce:list-item><ce:list-item id="u0775"><ce:label>•</ce:label><ce:para id="p1105">Renal failure</ce:para></ce:list-item><ce:list-item id="u0780"><ce:label>•</ce:label><ce:para id="p1110">Anaemia of chronic disease</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Normal marrow production but increased removal of cells</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist0250"><ce:list-item id="u0785"><ce:label>•</ce:label><ce:para id="p1115">Blood loss</ce:para></ce:list-item><ce:list-item id="u0790"><ce:label>•</ce:label><ce:para id="p1120">Haemolysis</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0255"><ce:list-item id="u0795"><ce:label>•</ce:label><ce:para id="p1125">Hypersplenism</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0075" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0120" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0265" role="short">Image 8</ce:alt-text></ce:inline-figure>23.8</ce:label><ce:alt-text id="atte0270" role="short">23.8</ce:alt-text><ce:textbox-head><ce:title id="tit0080">Classification and causes of erythrocytosis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1195"><ce:display><ce:table frame="topbot" id="t0035"><ce:alt-text id="atte0275" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left"/><entry align="left">Absolute erythrocytosis</entry><entry align="left">Relative (low-volume) erythrocytosis</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Haematocrit</ce:bold></entry><entry align="left">High</entry><entry align="left">High</entry></row><row rowsep="1"><entry align="left"><ce:bold>Red cell mass</ce:bold></entry><entry align="left">High</entry><entry align="left">Normal</entry></row><row rowsep="1"><entry align="left"><ce:bold>Plasma volume</ce:bold></entry><entry align="left">Normal</entry><entry align="left">Low</entry></row><row><entry align="left"><ce:bold>Causes</ce:bold></entry><entry align="left"><ce:list id="ulist0270"><ce:list-item id="u0840"><ce:para id="p1200"><ce:italic>Primary</ce:italic></ce:para></ce:list-item><ce:list-item id="u0845"><ce:para id="p1205">Myeloproliferative disorder<ce:list id="ulist0275"><ce:list-item id="u0850"><ce:para id="p1210">Polycythaemia rubra vera (primary proliferative polycythaemia)</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0855"><ce:para id="p1215"><ce:italic>Secondary</ce:italic></ce:para></ce:list-item><ce:list-item id="u0860"><ce:para id="p1220">High erythropoietin due to tissue hypoxia:<ce:list id="ulist0280"><ce:list-item id="u0865"><ce:para id="p1225">High altitude</ce:para></ce:list-item><ce:list-item id="u0870"><ce:para id="p1230">Cardiorespiratory disease</ce:para></ce:list-item><ce:list-item id="u0875"><ce:para id="p1235">High-affinity haemoglobins</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0880"><ce:para id="p1240">Inappropriately increased erythropoietin:<ce:list id="ulist0285"><ce:list-item id="u0885"><ce:para id="p1245">Renal disease (hydronephrosis, cysts, carcinoma)</ce:para></ce:list-item><ce:list-item id="u0890"><ce:para id="p1250">Other tumours (hepatoma, bronchogenic carcinoma, uterine fibroids, phaeochromocytoma, cerebellar haemangioblastoma)</ce:para></ce:list-item><ce:list-item id="u0895"><ce:para id="p1255">Exogenous testosterone therapy</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0900"><ce:para id="p1260">Exogenous erythropoietin administration:<ce:list id="olist9000"><ce:list-item id="u0905"><ce:para id="p1265">Performance-enhancing drug-taking in athletes</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0290"><ce:list-item id="u0910"><ce:para id="p1270">Diuretics</ce:para></ce:list-item><ce:list-item id="u0915"><ce:para id="p1275">Smoking</ce:para></ce:list-item><ce:list-item id="u0920"><ce:para id="p1280">Obesity</ce:para></ce:list-item><ce:list-item id="u0925"><ce:para id="p1285">Alcohol excess</ce:para></ce:list-item><ce:list-item id="u0930"><ce:para id="p1290">Gaisböck's syndrome</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0080" role="alt3"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0125" locator="icon03-9780702070280" xlink:href="pii:B9780702070280000238/icon03-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0280" role="short">Image 9</ce:alt-text></ce:inline-figure>23.9</ce:label><ce:alt-text id="atte0285" role="short">23.9</ce:alt-text><ce:textbox-head><ce:title id="tit0085">How to interpret white blood cell results</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0250"><ce:section-title id="st0230">Neutrophils <ce:bold>A</ce:bold></ce:section-title><ce:section id="s0255"><ce:section-title id="st0235">Neutrophilia</ce:section-title><ce:para id="p1320"><ce:list id="ulist0295"><ce:list-item id="u0935"><ce:label>•</ce:label><ce:para id="p1325">Infection: bacterial, fungal</ce:para></ce:list-item><ce:list-item id="u0940"><ce:label>•</ce:label><ce:para id="p1330">Trauma: surgery, burns</ce:para></ce:list-item><ce:list-item id="u0945"><ce:label>•</ce:label><ce:para id="p1335">Infarction: myocardial infarct, pulmonary embolus, sickle-cell crisis</ce:para></ce:list-item><ce:list-item id="u0950"><ce:label>•</ce:label><ce:para id="p1340">Inflammation: gout, rheumatoid arthritis, ulcerative colitis, Crohn's disease</ce:para></ce:list-item><ce:list-item id="u0955"><ce:label>•</ce:label><ce:para id="p1345">Malignancy: solid tumours, Hodgkin lymphoma</ce:para></ce:list-item><ce:list-item id="u0960"><ce:label>•</ce:label><ce:para id="p1350">Myeloproliferative disease: polycythaemia, chronic myeloid leukaemia</ce:para></ce:list-item><ce:list-item id="u0965"><ce:label>•</ce:label><ce:para id="p1355">Physiological: exercise, pregnancy</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0260"><ce:section-title id="st0240">Neutropenia</ce:section-title><ce:para id="p1360"><ce:list id="ulist0300"><ce:list-item id="u0970"><ce:label>•</ce:label><ce:para id="p1365">Infection: viral, bacterial (e.g. <ce:italic>Salmonella</ce:italic>), protozoal (e.g. malaria)</ce:para></ce:list-item><ce:list-item id="u0975"><ce:label>•</ce:label><ce:para id="p1370">Drugs: see <ce:cross-ref id="crf0400" refid="b0085">Box 23.10</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0980"><ce:label>•</ce:label><ce:para id="p1375">Autoimmune: connective tissue disease</ce:para></ce:list-item><ce:list-item id="u0985"><ce:label>•</ce:label><ce:para id="p1380">Alcohol</ce:para></ce:list-item><ce:list-item id="u0990"><ce:label>•</ce:label><ce:para id="p1385">Bone marrow infiltration: leukaemia, myelodysplasia</ce:para></ce:list-item><ce:list-item id="u0995"><ce:label>•</ce:label><ce:para id="p1390">Congenital: Kostmann's syndrome</ce:para></ce:list-item><ce:list-item id="u1000"><ce:label>•</ce:label><ce:para id="p1395">Constitutional: Afro-Caribbean and Middle Eastern descent</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:section><ce:section id="s0265"><ce:section-title id="st0245">Eosinophils <ce:bold>B</ce:bold></ce:section-title><ce:section id="s0270"><ce:section-title id="st0250">Eosinophilia</ce:section-title><ce:para id="p1400"><ce:list id="ulist0305"><ce:list-item id="u1005"><ce:label>•</ce:label><ce:para id="p1405">Allergy: hay fever, asthma, eczema</ce:para></ce:list-item><ce:list-item id="u1010"><ce:label>•</ce:label><ce:para id="p1410">Infection: parasitic</ce:para></ce:list-item><ce:list-item id="u1015"><ce:label>•</ce:label><ce:para id="p1415">Drug hypersensitivity: e.g. gold, sulphonamides</ce:para></ce:list-item><ce:list-item id="u1020"><ce:label>•</ce:label><ce:para id="p1420">Vasculitis: e.g. eosinophilic granulomatosis with polyangiitis (Churg–Strauss), granulomatosis with polyangiitis (Wegener's)</ce:para></ce:list-item><ce:list-item id="u1025"><ce:label>•</ce:label><ce:para id="p1425">Connective tissue disease: polyarteritis nodosa</ce:para></ce:list-item><ce:list-item id="u1030"><ce:label>•</ce:label><ce:para id="p1430">Malignancy: solid tumours, lymphomas</ce:para></ce:list-item><ce:list-item id="u1035"><ce:label>•</ce:label><ce:para id="p1435">Primary bone marrow disorders: myeloproliferative disorders, hypereosinophilic syndrome (HES), acute myeloid leukaemia</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:section><ce:section id="s0275"><ce:section-title id="st0255">Basophils <ce:bold>C</ce:bold></ce:section-title><ce:section id="s0280"><ce:section-title id="st0260">Basophilia</ce:section-title><ce:para id="p1440"><ce:list id="ulist0310"><ce:list-item id="u1040"><ce:label>•</ce:label><ce:para id="p1445">Myeloproliferative disease: polycythaemia, chronic myeloid leukaemia</ce:para></ce:list-item><ce:list-item id="u1045"><ce:label>•</ce:label><ce:para id="p1450">Inflammation: acute hypersensitivity, ulcerative colitis, Crohn's disease</ce:para></ce:list-item><ce:list-item id="u1050"><ce:label>•</ce:label><ce:para id="p1455">Iron deficiency</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:section><ce:section id="s0285"><ce:section-title id="st0265">Monocytes <ce:bold>D</ce:bold></ce:section-title><ce:section id="s0290"><ce:section-title id="st0270">Monocytosis</ce:section-title><ce:para id="p1460"><ce:list id="ulist0315"><ce:list-item id="u1055"><ce:label>•</ce:label><ce:para id="p1465">Infection: bacterial (e.g. tuberculosis)</ce:para></ce:list-item><ce:list-item id="u1060"><ce:label>•</ce:label><ce:para id="p1470">Inflammation: connective tissue disease, ulcerative colitis, Crohn's disease</ce:para></ce:list-item><ce:list-item id="u1065"><ce:label>•</ce:label><ce:para id="p1475">Malignancy: solid tumours, chronic myelomonocytic leukaemia</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:section><ce:section id="s0295"><ce:section-title id="st0275">Lymphocytes <ce:bold>E</ce:bold></ce:section-title><ce:section id="s0300"><ce:section-title id="st0280">Lymphocytosis</ce:section-title><ce:para id="p1480"><ce:list id="ulist0320"><ce:list-item id="u1070"><ce:label>•</ce:label><ce:para id="p1485">Infection: viral, bacterial (e.g. <ce:italic>Bordetella pertussis</ce:italic>)</ce:para></ce:list-item><ce:list-item id="u1075"><ce:label>•</ce:label><ce:para id="p1490">Lymphoproliferative disease: chronic lymphocytic leukaemia, lymphoma</ce:para></ce:list-item><ce:list-item id="u1080"><ce:label>•</ce:label><ce:para id="p1495">Post-splenectomy</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0305"><ce:section-title id="st0285">Lymphopenia</ce:section-title><ce:para id="p1500"><ce:list id="ulist0325"><ce:list-item id="u1085"><ce:label>•</ce:label><ce:para id="p1505">Inflammation: connective tissue disease</ce:para></ce:list-item><ce:list-item id="u1090"><ce:label>•</ce:label><ce:para id="p1510">Lymphoma</ce:para></ce:list-item><ce:list-item id="u1095"><ce:label>•</ce:label><ce:para id="p1515">Renal failure</ce:para></ce:list-item><ce:list-item id="u1100"><ce:label>•</ce:label><ce:para id="p1520">Sarcoidosis</ce:para></ce:list-item><ce:list-item id="u1105"><ce:label>•</ce:label><ce:para id="p1525">Drugs: glucocorticoids, cytotoxics</ce:para></ce:list-item><ce:list-item id="u1110"><ce:label>•</ce:label><ce:para id="p1530">Congenital: severe combined immunodeficiency</ce:para></ce:list-item><ce:list-item id="u1115"><ce:label>•</ce:label><ce:para id="p1535">HIV infection</ce:para></ce:list-item></ce:list><ce:display><ce:figure id="f0080"><ce:label>Fig. 23.12</ce:label><ce:caption id="ca0065"><ce:simple-para id="sp0120" role="title">Appearance of white blood cells.</ce:simple-para><ce:simple-para id="sp0125" role="caption"><ce:bold>A</ce:bold> Neutrophil. <ce:bold>B</ce:bold> Eosinophil. <ce:bold>C</ce:bold> Basophil. <ce:bold>D</ce:bold> Monocyte. <ce:bold>E</ce:bold> Lymphocyte.</ce:simple-para></ce:caption><ce:alt-text id="atte0290" role="short">Fig. 23.12</ce:alt-text><ce:link id="ln0130" locator="f023-012a-9780702070280" xlink:href="pii:B9780702070280000238/f023-012a-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:link id="ln0135" locator="f023-012b-9780702070280" xlink:href="pii:B9780702070280000238/f023-012b-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:link id="ln0140" locator="f023-012c-9780702070280" xlink:href="pii:B9780702070280000238/f023-012c-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:link id="ln0145" locator="f023-012d-9780702070280" xlink:href="pii:B9780702070280000238/f023-012d-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:link id="ln0150" locator="f023-012e-9780702070280" xlink:href="pii:B9780702070280000238/f023-012e-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure></ce:display></ce:para></ce:section></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0085" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0155" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0295" role="short">Image 10</ce:alt-text></ce:inline-figure>23.10</ce:label><ce:alt-text id="atte0300" role="short">23.10</ce:alt-text><ce:textbox-head><ce:title id="tit0090">Drugs that can induce neutropenia<ce:cross-ref id="crf0415" refid="fn0015">*</ce:cross-ref><ce:footnote id="fn0015"><ce:label>*</ce:label><ce:note-para id="np0020">Many drugs can induce cytopenias. In suspected cases check drug summary of product characteristics.</ce:note-para></ce:footnote></ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1540"><ce:display><ce:table frame="topbot" id="t0040"><ce:alt-text id="atte0305" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Group</entry><entry align="left">Examples</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Analgesics/anti-inflammatory agents</ce:bold></entry><entry align="left">Gold, penicillamine, naproxen</entry></row><row rowsep="1"><entry align="left"><ce:bold>Antithyroid drugs</ce:bold></entry><entry align="left">Carbimazole, propylthiouracil</entry></row><row rowsep="1"><entry align="left"><ce:bold>Anti-arrhythmics</ce:bold></entry><entry align="left">Quinidine, procainamide</entry></row><row rowsep="1"><entry align="left"><ce:bold>Antihypertensives</ce:bold></entry><entry align="left">Captopril, enalapril, nifedipine</entry></row><row rowsep="1"><entry align="left"><ce:bold>Antidepressants/psychotropics</ce:bold></entry><entry align="left">Amitriptyline, dosulepin, mianserin</entry></row><row rowsep="1"><entry align="left"><ce:bold>Antimalarials</ce:bold></entry><entry align="left">Pyrimethamine, dapsone, sulfadoxine, chloroquine</entry></row><row rowsep="1"><entry align="left"><ce:bold>Anticonvulsants</ce:bold></entry><entry align="left">Phenytoin, sodium valproate, carbamazepine</entry></row><row rowsep="1"><entry align="left"><ce:bold>Antibiotics</ce:bold></entry><entry align="left">Sulphonamides, penicillins, cephalosporins</entry></row><row><entry align="left"><ce:bold>Miscellaneous</ce:bold></entry><entry align="left">Cimetidine, ranitidine, chlorpropamide, zidovudine</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0090" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0160" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0310" role="short">Image 11</ce:alt-text></ce:inline-figure>23.11</ce:label><ce:alt-text id="atte0315" role="short">23.11</ce:alt-text><ce:textbox-head><ce:title id="tit0095">Causes of lymphadenopathy</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0340"><ce:section id="s0345"><ce:section-title id="st0320">Infective</ce:section-title><ce:para id="p1585"><ce:list id="ulist0330"><ce:list-item id="u1120"><ce:label>•</ce:label><ce:para id="p1590">Bacterial: streptococcal, tuberculosis, brucellosis</ce:para></ce:list-item><ce:list-item id="u1125"><ce:label>•</ce:label><ce:para id="p1595">Viral: Epstein–Barr virus (EBV), human immunodeficiency virus (HIV)</ce:para></ce:list-item><ce:list-item id="u1130"><ce:label>•</ce:label><ce:para id="p1600">Protozoal: toxoplasmosis</ce:para></ce:list-item><ce:list-item id="u1135"><ce:label>•</ce:label><ce:para id="p1605">Fungal: histoplasmosis, coccidioidomycosis</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0350"><ce:section-title id="st0325">Neoplastic</ce:section-title><ce:para id="p1610"><ce:list id="ulist0335"><ce:list-item id="u1140"><ce:label>•</ce:label><ce:para id="p1615">Primary: lymphomas, leukaemias</ce:para></ce:list-item><ce:list-item id="u1145"><ce:label>•</ce:label><ce:para id="p1620">Secondary: lung, breast, thyroid, stomach, melanoma</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0355"><ce:section-title id="st0330">Connective tissue disorders</ce:section-title><ce:para id="p1625"><ce:list id="ulist0340"><ce:list-item id="u1150"><ce:label>•</ce:label><ce:para id="p1630">Rheumatoid arthritis</ce:para></ce:list-item><ce:list-item id="u1155"><ce:label>•</ce:label><ce:para id="p1635">Systemic lupus erythematosus (SLE)</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0360"><ce:section-title id="st0335">Sarcoidosis</ce:section-title><ce:para id="p1640">Amyloidosis</ce:para><ce:para id="p1645">Drugs</ce:para><ce:para id="p1650"><ce:list id="ulist0345"><ce:list-item id="u1160"><ce:label>•</ce:label><ce:para id="p1655">Phenytoin</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0095" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0165" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0320" role="short">Image 12</ce:alt-text></ce:inline-figure>23.12</ce:label><ce:alt-text id="atte0325" role="short">23.12</ce:alt-text><ce:textbox-head><ce:title id="tit0100">Causes of splenomegaly</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1690"><ce:display><ce:table frame="topbot" id="t0045"><ce:alt-text id="atte0330" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Congestive</ce:bold></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Portal hypertension</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0355"><ce:list-item id="u1180"><ce:label>•</ce:label><ce:para id="p1695">Cirrhosis</ce:para></ce:list-item><ce:list-item id="u1185"><ce:label>•</ce:label><ce:para id="p1700">Hepatic vein occlusion</ce:para></ce:list-item><ce:list-item id="u1190"><ce:label>•</ce:label><ce:para id="p1705">Portal vein thrombosis</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0360"><ce:list-item id="u1195"><ce:label>•</ce:label><ce:para id="p1710">Stenosis or malformation of portal or splenic vein</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Cardiac</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0365"><ce:list-item id="u1200"><ce:label>•</ce:label><ce:para id="p1715">Chronic congestive cardiac failure</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0370"><ce:list-item id="u1205"><ce:label>•</ce:label><ce:para id="p1720">Constrictive pericarditis</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Infective</ce:bold></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Bacterial</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0375"><ce:list-item id="u1210"><ce:label>•</ce:label><ce:para id="p1725">Endocarditis</ce:para></ce:list-item><ce:list-item id="u1215"><ce:label>•</ce:label><ce:para id="p9080">Sepsis</ce:para></ce:list-item><ce:list-item id="u1220"><ce:label>•</ce:label><ce:para id="p1735">Tuberculosis</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0380"><ce:list-item id="u1225"><ce:label>•</ce:label><ce:para id="p1740">Brucellosis</ce:para></ce:list-item><ce:list-item id="u1230"><ce:label>•</ce:label><ce:para id="p1745"><ce:italic>Salmonella</ce:italic></ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Viral</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0385"><ce:list-item id="u1235"><ce:label>•</ce:label><ce:para id="p1750">Hepatitis</ce:para></ce:list-item><ce:list-item id="u1240"><ce:label>•</ce:label><ce:para id="p1755">Epstein–Barr</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0390"><ce:list-item id="u1245"><ce:label>•</ce:label><ce:para id="p1760">Cytomegalovirus</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Protozoal</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0395"><ce:list-item id="u1250"><ce:label>•</ce:label><ce:para id="p1765">Malaria<ce:cross-ref id="crf0455" refid="tn0015">*</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u1255"><ce:label>•</ce:label><ce:para id="p1770">Leishmaniasis (kala-azar)<ce:cross-ref id="crf0460" refid="tn0015">*</ce:cross-ref></ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0400"><ce:list-item id="u1260"><ce:label>•</ce:label><ce:para id="p1775">Trypanosomiasis</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Fungal</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0405"><ce:list-item id="u1265"><ce:label>•</ce:label><ce:para id="p1780">Histoplasmosis</ce:para></ce:list-item></ce:list></entry><entry align="left"/></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Inflammatory/granulomatous disorders</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0410"><ce:list-item id="u1270"><ce:label>•</ce:label><ce:para id="p1785">Felty's syndrome in rheumatoid arthritis</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0415"><ce:list-item id="u1275"><ce:label>•</ce:label><ce:para id="p1790">Sarcoidosis</ce:para></ce:list-item><ce:list-item id="u1280"><ce:label>•</ce:label><ce:para id="p1795">Systemic lupus erythematosus</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Haematological</ce:bold></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Red cell disorders</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0420"><ce:list-item id="u1285"><ce:label>•</ce:label><ce:para id="p1800">Megaloblastic anaemia</ce:para></ce:list-item><ce:list-item id="u1290"><ce:label>•</ce:label><ce:para id="p1805">Haemoglobinopathies</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0425"><ce:list-item id="u1295"><ce:label>•</ce:label><ce:para id="p1810">Hereditary spherocytosis</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Autoimmune haemolytic anaemias</ce:bold></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Myeloproliferative disorders</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0430"><ce:list-item id="u1300"><ce:label>•</ce:label><ce:para id="p1815">Chronic myeloid leukaemia<ce:cross-ref id="crf0465" refid="tn0015">*</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u1305"><ce:label>•</ce:label><ce:para id="p1820">Myelofibrosis<ce:cross-ref id="crf0470" refid="tn0015">*</ce:cross-ref></ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0435"><ce:list-item id="u1310"><ce:label>•</ce:label><ce:para id="p1825">Polycythaemia rubra vera</ce:para></ce:list-item><ce:list-item id="u1315"><ce:label>•</ce:label><ce:para id="p1830">Essential thrombocythaemia</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Neoplastic</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0440"><ce:list-item id="u1320"><ce:label>•</ce:label><ce:para id="p1835">Leukaemias, including chronic myeloid leukaemia<ce:cross-ref id="crf0475" refid="tn0015">*</ce:cross-ref></ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0445"><ce:list-item id="u1325"><ce:label>•</ce:label><ce:para id="p1840">Lymphomas</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Other malignancies</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0450"><ce:list-item id="u1330"><ce:label>•</ce:label><ce:para id="p1845">Metastatic cancer – rare</ce:para></ce:list-item></ce:list></entry><entry align="left"/></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Lysosomal storage diseases</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0455"><ce:list-item id="u1335"><ce:label>•</ce:label><ce:para id="p1850">Gaucher's disease</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0460"><ce:list-item id="u1340"><ce:label>•</ce:label><ce:para id="p1855">Niemann–Pick disease</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Miscellaneous</ce:bold></entry></row><row><entry namest="col1" nameend="col2" align="left"><ce:list id="ulist0465"><ce:list-item id="u1345"><ce:label>•</ce:label><ce:para id="p1860">Cysts, amyloid, thyrotoxicosis, haemophagocytic syndromes</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup><ce:table-footnote id="tn0015"><ce:label>*</ce:label><ce:note-para id="np0025">Causes of massive splenomegaly.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0100" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0170" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0335" role="short">Image 13</ce:alt-text></ce:inline-figure>23.13</ce:label><ce:alt-text id="atte0340" role="short">23.13</ce:alt-text><ce:textbox-head><ce:title id="tit0105">Causes of non-thrombocytopenic purpura</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1880"><ce:display><ce:table frame="topbot" id="t0050"><ce:alt-text id="atte0345" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row><entry align="left"><ce:list id="ulist0470"><ce:list-item id="u1350"><ce:label>•</ce:label><ce:para id="p1885">Senile purpura</ce:para></ce:list-item><ce:list-item id="u1355"><ce:label>•</ce:label><ce:para id="p1890">Factitious purpura</ce:para></ce:list-item><ce:list-item id="u1360"><ce:label>•</ce:label><ce:para id="p1895">Henoch–Schönlein purpura (<ce:intra-ref id="ii0230" xlink:href="pii:B978-0-7020-7028-0.00024-X#s1580">p. 1043</ce:intra-ref>)</ce:para></ce:list-item><ce:list-item id="u1365"><ce:label>•</ce:label><ce:para id="p1900">Vasculitis (<ce:intra-ref id="ii0235" xlink:href="pii:B978-0-7020-7028-0.00024-X#p5220">p. 1040</ce:intra-ref>)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0475"><ce:list-item id="u1370"><ce:label>•</ce:label><ce:para id="p1905">Paraproteinaemias</ce:para></ce:list-item><ce:list-item id="u1375"><ce:label>•</ce:label><ce:para id="p1910">Purpura fulminans, e.g. in disseminated intravascular coagulation secondary to sepsis</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0105" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0180" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0350" role="short">Image 14</ce:alt-text></ce:inline-figure>23.14</ce:label><ce:alt-text id="atte0355" role="short">23.14</ce:alt-text><ce:textbox-head><ce:title id="tit0110">Causes of thrombocytopenia</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1980"><ce:display><ce:table frame="topbot" id="t0055"><ce:alt-text id="atte0360" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Decreased production</ce:bold></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Marrow hypoplasia</ce:bold></entry></row><row rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:list id="ulist0490"><ce:list-item id="u1420"><ce:label>•</ce:label><ce:para id="p1985">Childhood bone marrow failure syndromes, e.g. Fanconi's anaemia, dyskeratosis congenita, amegakaryocytic thrombocytopenia</ce:para></ce:list-item><ce:list-item id="u1425"><ce:label>•</ce:label><ce:para id="p1990">Idiopathic aplastic anaemia</ce:para></ce:list-item><ce:list-item id="u1430"><ce:label>•</ce:label><ce:para id="p1995">Drug-induced: cytotoxics, antimetabolites</ce:para></ce:list-item><ce:list-item id="u1435"><ce:label>•</ce:label><ce:para id="p2000">Transfusion-associated graft-versus-host disease</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Marrow infiltration</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0495"><ce:list-item id="u1440"><ce:label>•</ce:label><ce:para id="p2005">Leukaemia</ce:para></ce:list-item><ce:list-item id="u1445"><ce:label>•</ce:label><ce:para id="p2010">Myeloma</ce:para></ce:list-item><ce:list-item id="u1450"><ce:label>•</ce:label><ce:para id="p2015">Carcinoma (rare)</ce:para></ce:list-item><ce:list-item id="u1455"><ce:label>•</ce:label><ce:para id="p2020">Myelofibrosis</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0500"><ce:list-item id="u1460"><ce:label>•</ce:label><ce:para id="p2025">Osteopetrosis</ce:para></ce:list-item><ce:list-item id="u1465"><ce:label>•</ce:label><ce:para id="p2030">Lysosomal storage disorders, e.g. Gaucher's disease</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Haematinic deficiency</ce:bold></entry></row><row rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:list id="ulist0505"><ce:list-item id="u1470"><ce:label>•</ce:label><ce:para id="p2035">Vitamin B<ce:inf loc="post">12</ce:inf> and/or folate deficiency</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Familial (macro-)thrombocytopathies</ce:bold></entry></row><row rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:list id="ulist0510"><ce:list-item id="u1475"><ce:label>•</ce:label><ce:para id="p2040">Myosin heavy chain abnormalities, e.g. Alport's syndrome, Fechtner's syndrome, May–Hegglin anomaly</ce:para></ce:list-item><ce:list-item id="u1480"><ce:label>•</ce:label><ce:para id="p2045">Bernard–Soulier syndrome</ce:para></ce:list-item><ce:list-item id="u1485"><ce:label>•</ce:label><ce:para id="p2050">Montreal platelet syndrome</ce:para></ce:list-item><ce:list-item id="u1490"><ce:label>•</ce:label><ce:para id="p2055">Wiskott–Aldrich syndrome (small platelets)</ce:para></ce:list-item><ce:list-item id="u1495"><ce:label>•</ce:label><ce:para id="p2060">Mediterranean macrothrombocytopathy</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Increased consumption</ce:bold></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Immune mechanisms</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0515"><ce:list-item id="u1500"><ce:label>•</ce:label><ce:para id="p2065">Idiopathic thrombocytopenic purpura<ce:cross-ref id="crf0500" refid="tn0020">*</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u1505"><ce:label>•</ce:label><ce:para id="p2070">Neonatal alloimmune thrombocytopenia</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0520"><ce:list-item id="u1510"><ce:label>•</ce:label><ce:para id="p2075">Post-transfusion purpura</ce:para></ce:list-item><ce:list-item id="u1515"><ce:label>•</ce:label><ce:para id="p2080">Drug-associated, especially quinine, vancomycin and heparin</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Coagulation activation</ce:bold></entry></row><row rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:list id="ulist0525"><ce:list-item id="u1520"><ce:label>•</ce:label><ce:para id="p2085">Disseminated intravascular coagulation (see <ce:cross-ref id="crf0505" refid="b0110">Box 23.68</ce:cross-ref>, <ce:cross-ref id="crf9030" refid="u4055">p. 978</ce:cross-ref>)</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Mechanical pooling</ce:bold></entry></row><row rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:list id="ulist0535"><ce:list-item id="u1565"><ce:label>•</ce:label><ce:para id="p2140">Hypersplenism</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Thrombotic microangiopathies</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0540"><ce:list-item id="u1570"><ce:label>•</ce:label><ce:para id="p2145">Haemolytic uraemic syndrome (HUS) and atypical HUS</ce:para></ce:list-item><ce:list-item id="u1575"><ce:label>•</ce:label><ce:para id="p2150">Liver disease</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0545"><ce:list-item id="u1580"><ce:label>•</ce:label><ce:para id="p2155">Thrombotic thrombocytopenic purpura</ce:para></ce:list-item><ce:list-item id="u1585"><ce:label>•</ce:label><ce:para id="p2160">Pre-eclampsia</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Others</ce:bold></entry></row><row><entry namest="col1" nameend="col2" align="left"><ce:list id="ulist0550"><ce:list-item id="u1590"><ce:label>•</ce:label><ce:para id="p2165">Gestational thrombocytopenia</ce:para></ce:list-item><ce:list-item id="u1595"><ce:label>•</ce:label><ce:para id="p2170">Type 2B von Willebrand disease</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup><ce:table-footnote id="tn0020"><ce:label>*</ce:label><ce:note-para id="np0030">Associated conditions include collagen vascular diseases (particularly systemic lupus erythematosus), B-cell malignancy, HIV infection and antiphospholipid syndrome.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0115" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0190" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0365" role="short">Image 15</ce:alt-text></ce:inline-figure>23.15</ce:label><ce:alt-text id="atte0370" role="short">23.15</ce:alt-text><ce:textbox-head><ce:title id="tit0120">Causes of a raised platelet count</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2185"><ce:display><ce:table frame="topbot" id="t0065"><ce:alt-text id="atte0375" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Reactive thrombocytosis</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0555"><ce:list-item id="u1600"><ce:label>•</ce:label><ce:para id="p2190">Acute and chronic inflammatory disorders</ce:para></ce:list-item><ce:list-item id="u1605"><ce:label>•</ce:label><ce:para id="p2195">Infection</ce:para></ce:list-item><ce:list-item id="u1610"><ce:label>•</ce:label><ce:para id="p2200">Malignant disease</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0560"><ce:list-item id="u1615"><ce:label>•</ce:label><ce:para id="p2205">Tissue damage</ce:para></ce:list-item><ce:list-item id="u1620"><ce:label>•</ce:label><ce:para id="p2210">Haemolytic anaemias</ce:para></ce:list-item><ce:list-item id="u1625"><ce:label>•</ce:label><ce:para id="p2215">Post-splenectomy</ce:para></ce:list-item><ce:list-item id="u1630"><ce:label>•</ce:label><ce:para id="p2220">Post-haemorrhage</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Clonal thrombocytosis</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist0565"><ce:list-item id="u1635"><ce:label>•</ce:label><ce:para id="p2225">Primary thrombocythaemia</ce:para></ce:list-item><ce:list-item id="u1640"><ce:label>•</ce:label><ce:para id="p2230">Polycythaemia rubra vera</ce:para></ce:list-item><ce:list-item id="u1645"><ce:label>•</ce:label><ce:para id="p2235">Chronic myeloid leukaemia</ce:para></ce:list-item><ce:list-item id="u1650"><ce:label>•</ce:label><ce:para id="p2240">Myelofibrosis</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0570"><ce:list-item id="u1655"><ce:label>•</ce:label><ce:para id="p2245">Myelodysplastic syndromes (MDSs; refractory anaemia with ring sideroblasts and thrombocytosis (RARS-T), MDS with isolated deletion of 5q)</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0120" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0195" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0380" role="short">Image 16</ce:alt-text></ce:inline-figure>23.16</ce:label><ce:alt-text id="atte0385" role="short">23.16</ce:alt-text><ce:textbox-head><ce:title id="tit0125">Causes of pancytopenia</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0405"><ce:section-title id="st0375">Bone marrow failure</ce:section-title><ce:para id="p2260"><ce:list id="ulist0575"><ce:list-item id="u1660"><ce:label>•</ce:label><ce:para id="p2265">Hypoplastic/aplastic anaemia (p. 968): inherited, idiopathic, viral, drugs</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0410"><ce:section-title id="st0380">Bone marrow infiltration</ce:section-title><ce:para id="p2270"><ce:list id="ulist0580"><ce:list-item id="u1665"><ce:label>•</ce:label><ce:para id="p2275">Acute leukaemia</ce:para></ce:list-item><ce:list-item id="u1670"><ce:label>•</ce:label><ce:para id="p2280">Myeloma</ce:para></ce:list-item><ce:list-item id="u1675"><ce:label>•</ce:label><ce:para id="p2285">Lymphoma</ce:para></ce:list-item><ce:list-item id="u1680"><ce:label>•</ce:label><ce:para id="p2290">Carcinoma</ce:para></ce:list-item><ce:list-item id="u1685"><ce:label>•</ce:label><ce:para id="p2295">Haemophagocytic syndrome</ce:para></ce:list-item><ce:list-item id="u1690"><ce:label>•</ce:label><ce:para id="p2300">Myelodysplastic syndromes</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0415"><ce:section-title id="st0385">Ineffective haematopoiesis</ce:section-title><ce:para id="p2305"><ce:list id="ulist0585"><ce:list-item id="u1695"><ce:label>•</ce:label><ce:para id="p2310">Megaloblastic anaemia</ce:para></ce:list-item><ce:list-item id="u1700"><ce:label>•</ce:label><ce:para id="p2315">Acquired immunodeficiency syndrome (AIDS)</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0420"><ce:section-title id="st0390">Peripheral pooling/destruction</ce:section-title><ce:para id="p2320"><ce:list id="ulist0590"><ce:list-item id="u1705"><ce:label>•</ce:label><ce:para id="p2325">Hypersplenism: portal hypertension, Felty's syndrome, malaria, myelofibrosis</ce:para></ce:list-item><ce:list-item id="u1710"><ce:label>•</ce:label><ce:para id="p2330">Systemic lupus erythematosus</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0125" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0200" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0390" role="short">Image 17</ce:alt-text></ce:inline-figure>23.17</ce:label><ce:alt-text id="atte0395" role="short">23.17</ce:alt-text><ce:textbox-head><ce:title id="tit0130">Blood components and their use</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2350"><ce:display><ce:table frame="topbot" id="t0070"><ce:alt-text id="atte0400" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Component</entry><entry align="left">Major haemorrhage</entry><entry align="left">Other indications</entry></row></thead><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col3" align="left"><ce:bold>Red cell concentrate</ce:bold><ce:cross-ref id="crf0525" refid="tn0025"><ce:bold><ce:sup loc="post">1</ce:sup></ce:bold></ce:cross-ref></entry></row><row rowsep="1"><entry align="left">Most of the plasma is removed and replaced with a solution of glucose and adenine in saline to maintain viability of red cells<ce:br/>ABO compatibility with recipient essential</entry><entry align="left">Replace acute blood loss: increase circulating red cell mass to relieve clinical features caused by insufficient oxygen delivery. Order 4–6 U initially to allow high red cell to FFP transfusion ratios of (at least) 2 : 1</entry><entry align="left"><ce:italic>Severe anaemia</ce:italic><ce:br/>If no cardiovascular disease, transfuse to maintain Hb at 70 g/L<ce:br/>If known or likely to have cardiovascular disease, maintain Hb at 90 g/L</entry></row><row rowsep="0"><entry align="left"><ce:bold>Platelet concentrate</ce:bold></entry><entry align="left"/><entry align="left"/></row><row rowsep="1"><entry align="left">One adult dose is made from four donations of whole blood, or from a single platelet apheresis donation<ce:br/>ABO compatibility with recipient preferable</entry><entry align="left">Maintain platelet count &#x003E; 50 × 10<ce:sup loc="post">9</ce:sup>/L, or in multiple or central nervous system trauma &#x003E; 100 × 10<ce:sup loc="post">9</ce:sup>/L<ce:br/>If ongoing bleeding, order when platelets &#x003C; 100 × 10<ce:sup loc="post">9</ce:sup>/L to allow for delivery time<ce:br/>Each adult dose has a minimum of 2.4 × 10<ce:sup loc="post">11</ce:sup> platelets, which raises platelet count by 40 × 10<ce:sup loc="post">9</ce:sup>/L unless there is consumptive coagulopathy, e.g. disseminated intravascular coagulation</entry><entry align="left"><ce:italic>Thrombocytopenia</ce:italic>, e.g. in acute leukaemia<ce:br/>Maintain platelet count &#x003E; 10 × 10<ce:sup loc="post">9</ce:sup>/L if not bleeding<ce:br/>Maintain platelet count &#x003E; 20 × 10<ce:sup loc="post">9</ce:sup>/L if minor bleeding or at risk (sepsis, concurrent use of antibiotics, abnormal coagulation)<ce:br/>Increase platelet count &#x003E; 50 × 10<ce:sup loc="post">9</ce:sup>/L for minor invasive procedure (e.g. lumbar puncture, gastroscopy and biopsy, insertion of indwelling lines, liver biopsy, laparotomy) or in acute, major blood loss<ce:br/>Increase platelet count &#x003E; 100 × 10<ce:sup loc="post">9</ce:sup>/L for operations in critical sites such as brain or eyes</entry></row><row rowsep="0"><entry align="left"><ce:bold>Fresh frozen plasma</ce:bold><ce:cross-ref id="crf0530" refid="tn0030"><ce:sup loc="post">2</ce:sup></ce:cross-ref></entry><entry align="left"/><entry align="left"/></row><row rowsep="1"><entry align="left">150–300 mL plasma from one donation of whole blood<ce:br/>ABO compatibility with recipient recommended</entry><entry align="left">Dilutional coagulopathy with a PT prolonged &#x003E; 50% is likely after replacement of 1–1.5 blood volumes with red cell concentrate<ce:br/>Give initially in (at least) a ratio of 1 FFP:2 red cell concentrate; order 15–20 mL/kg and allow for thawing time. Further doses only if bleeding continues and guided by PT and APTT</entry><entry align="left"><ce:italic>Replacement of coagulation factor deficiency</ce:italic><ce:br/>If no virally inactivated or recombinant product is available<ce:br/><ce:italic>Thrombotic thrombocytopenic purpura</ce:italic><ce:br/>Plasma exchange (using virus-inactivated plasma if available) is frequently effective</entry></row><row rowsep="0"><entry align="left"><ce:bold>Cryoprecipitate</ce:bold><ce:cross-ref id="crf0535" refid="tn0030"><ce:sup loc="post">2</ce:sup></ce:cross-ref></entry><entry align="left"/><entry align="left"/></row><row><entry align="left"><ce:list id="ulist0595"><ce:list-item id="u1715"><ce:para id="p2355">Fibrinogen and coagulation factor concentrated from plasma by controlled thawing</ce:para></ce:list-item><ce:list-item id="u1720"><ce:para id="p2360">10–20 mL pack contains:<ce:list id="ulist0600"><ce:list-item id="u1725"><ce:para id="p2365">Fibrinogen 150–300 mg</ce:para></ce:list-item><ce:list-item id="u1730"><ce:para id="p2370">Factor VIII 80–120 U</ce:para></ce:list-item><ce:list-item id="u1735"><ce:para id="p2375">von Willebrand factor 80–120 U</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u1740"><ce:para id="p2380">In UK supplied as pools of 5 U</ce:para></ce:list-item></ce:list></entry><entry align="left">Aim to keep fibrinogen &#x003E; 1.5 g/L. Pooled units (of 10 donations) will raise fibrinogen by 1 g/L</entry><entry align="left"><ce:italic>von Willebrand disease and haemophilia</ce:italic><ce:br/>If virus-inactivated or recombinant products are not available</entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0135">(APTT = activated partial thromboplastin time; FFP = fresh frozen plasma; Hb = haemoglobin; PT = prothrombin time)</ce:simple-para></ce:legend><ce:table-footnote id="tn0025"><ce:label>1</ce:label><ce:note-para id="np0035">Whole blood is an alternative to red cell concentrate. ABO compatibility with recipient essential.</ce:note-para></ce:table-footnote><ce:table-footnote id="tn0030"><ce:label>2</ce:label><ce:note-para id="np0040">Pooled plasma can be treated with solvent and detergent or single units treated with methylene blue as an additional viral inactivation step. Virus-inactivated plasma is indicated for large-volume exposure, as in treatment of thrombotic thrombocytopenic purpura, and for treatment of children in the UK born after 1995.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0130" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0210" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0405" role="short">Image 18</ce:alt-text></ce:inline-figure>23.18</ce:label><ce:alt-text id="atte0410" role="short">23.18</ce:alt-text><ce:textbox-head><ce:title id="tit0135">ABO blood group antigens and antibodies</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2430"><ce:display><ce:table frame="topbot" id="t0075"><ce:alt-text id="atte0415" role="short">Unlabelled table</ce:alt-text><tgroup cols="4"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><colspec colname="col4" colnum="4"/><thead><row rowsep="1"><entry align="left">ABO blood group</entry><entry align="left">Red cell A or B antigens</entry><entry align="left">Antibodies in plasma</entry><entry align="left">UK frequency (%)</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>O</ce:bold></entry><entry align="left">None</entry><entry align="left">Anti-A and anti-B</entry><entry align="left">46</entry></row><row rowsep="1"><entry align="left"><ce:bold>A</ce:bold></entry><entry align="left">A</entry><entry align="left">Anti-B</entry><entry align="left">42</entry></row><row rowsep="1"><entry align="left"><ce:bold>B</ce:bold></entry><entry align="left">B</entry><entry align="left">Anti-A</entry><entry align="left">9</entry></row><row><entry align="left"><ce:bold>AB</ce:bold></entry><entry align="left">A and B</entry><entry align="left">None</entry><entry align="left">3</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0135" role="alt5"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0215" locator="icon05-9780702070280" xlink:href="pii:B9780702070280000238/icon05-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0420" role="short">Image 19</ce:alt-text></ce:inline-figure>23.19</ce:label><ce:alt-text id="atte0425" role="short">23.19</ce:alt-text><ce:textbox-head><ce:title id="tit0140">Rhesus D blood groups in pregnancy</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2450"><ce:list id="ulist0610"><ce:list-item id="u1760"><ce:label>•</ce:label><ce:para id="p2455"><ce:bold>Haemolytic disease of the newborn (HDN)</ce:bold>: occurs when the mother has anti-red cell immunoglobulin G (IgG) antibodies that cross the placenta and haemolyse fetal red cells.</ce:para></ce:list-item><ce:list-item id="u1765"><ce:label>•</ce:label><ce:para id="p2460"><ce:bold>Screening for HDN in pregnancy</ce:bold>: at the time of booking (12–16 weeks) and again at 28–34 weeks' gestation, every pregnant woman should have a blood sample sent for determination of ABO and Rhesus D (RhD) group and testing for red cell alloantibodies that may be directed against paternal blood group antigens present on fetal red cells.</ce:para></ce:list-item><ce:list-item id="u1770"><ce:label>•</ce:label><ce:para id="p2465"><ce:bold>Anti-D immunoglobulin prophylaxis in a pregnant woman who is RhD-negative</ce:bold>: antenatal anti-D prophylaxis is offered at 28–34 weeks to RhD-negative pregnant women who have no evidence of immune anti-D. This prevents the formation of antibodies that could cause HDN. Following delivery of an RhD-positive baby, the mother is given further anti-D within 72 hours; a maternal sample is checked for remaining fetal red cells and additional anti-D is given if indicated. Additional anti-D is also given after potential sensitising events antenatally (e.g. early bleeding). Doses vary according to national recommendations.</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0140" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0230" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0430" role="short">Image 20</ce:alt-text></ce:inline-figure>23.20</ce:label><ce:alt-text id="atte0435" role="short">23.20</ce:alt-text><ce:textbox-head><ce:title id="tit0145">Key points in transfusion medicine</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2520"><ce:list id="ulist0615"><ce:list-item id="u1775"><ce:label>•</ce:label><ce:para id="p2525">A restrictive strategy for red cell transfusion (Hb &#x003C; 70 g/L) is at least as effective as a liberal strategy (&#x003C; 100 g/L).</ce:para></ce:list-item><ce:list-item id="u1780"><ce:label>•</ce:label><ce:para id="p2530">The majority of reports in haemovigilance schemes such as SHOT relate to errors in the process of transfusion.</ce:para></ce:list-item><ce:list-item id="u1785"><ce:label>•</ce:label><ce:para id="p2535">Although transfusion-transmitted infection is a major concern for patients receiving transfusion, it is rare.</ce:para></ce:list-item><ce:list-item id="u1790"><ce:label>•</ce:label><ce:para id="p2540">In patients with trauma or burns or those who have had surgery, there is no evidence that resuscitation with albumin or other colloid solutions reduces the risk of death compared to resuscitation with crystalloid solutions.</ce:para></ce:list-item><ce:list-item id="u1795"><ce:label>•</ce:label><ce:para id="p2545">It is recommended that transfusion should be carried out at night time only in unavoidable circumstances.</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p2550">(SHOT = Serious Hazards of Transfusion)</ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0145" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0235" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0440" role="short">Image 21</ce:alt-text></ce:inline-figure>23.21</ce:label><ce:alt-text id="atte0445" role="short">23.21</ce:alt-text><ce:textbox-head><ce:title id="tit0150">Examples of commonly used groups of cancer drugs in haematology</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0510"><ce:section-title id="st0480">Alkylating agents</ce:section-title><ce:para id="p2560"><ce:list id="ulist0620"><ce:list-item id="u1800"><ce:label>•</ce:label><ce:para id="p2565">Cross-link double-stranded DNA by adding an alkyl group, e.g. cyclophosphamide, melphalan, chlorambucil</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0515"><ce:section-title id="st0485">Anthracyclines</ce:section-title><ce:para id="p2570"><ce:list id="ulist0625"><ce:list-item id="u1805"><ce:label>•</ce:label><ce:para id="p2575">Intercalate between base pairs in the DNA molecule, e.g. daunorubicin, doxorubicin, idarubicin</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0520"><ce:section-title id="st0490">Antimetabolites</ce:section-title><ce:para id="p2580"><ce:list id="ulist0630"><ce:list-item id="u1810"><ce:label>•</ce:label><ce:para id="p2585">Inhibit DNA and RNA synthesis, e.g. cytosine arabinoside, fludarabine, methotrexate</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0525"><ce:section-title id="st0495">Vinca alkaloids</ce:section-title><ce:para id="p2590"><ce:list id="ulist0635"><ce:list-item id="u1815"><ce:label>•</ce:label><ce:para id="p2595">Cause disruption of tubulin, e.g. vincristine, vinblastine</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0530"><ce:section-title id="st0500">Topoisomerase II inhibitors</ce:section-title><ce:para id="p2600"><ce:list id="ulist0640"><ce:list-item id="u1820"><ce:label>•</ce:label><ce:para id="p2605">Prevent DNA repair, e.g. etoposide, daunorubicin, mitoxantrone</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p2610">An example of a common combination regimen is CHOP, used in lymphoma: <ce:bold>c</ce:bold>yclophosphamide, <ce:bold>h</ce:bold>ydroxydaunorubicin (doxorubicin), <ce:bold>o</ce:bold>ncovin (vincristine) and <ce:bold>p</ce:bold>rednisolone, given every 21 days for six cycles</ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0150" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0240" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0450" role="short">Image 22</ce:alt-text></ce:inline-figure>23.22</ce:label><ce:alt-text id="atte0455" role="short">23.22</ce:alt-text><ce:textbox-head><ce:title id="tit0155">Indications for allogeneic haematopoietic stem cell transplantation</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2630"><ce:list id="ulist0645"><ce:list-item id="u1825"><ce:label>•</ce:label><ce:para id="p2635">Neoplastic disorders affecting stem cell compartments (e.g. leukaemias)</ce:para></ce:list-item><ce:list-item id="u1830"><ce:label>•</ce:label><ce:para id="p2640">Failure of haematopoiesis (e.g. aplastic anaemia)</ce:para></ce:list-item><ce:list-item id="u1835"><ce:label>•</ce:label><ce:para id="p2645">Major inherited defects in blood cell production (e.g. thalassaemia, immunodeficiency diseases)</ce:para></ce:list-item><ce:list-item id="u1840"><ce:label>•</ce:label><ce:para id="p2650">Inborn errors of metabolism with missing enzymes or cell lines</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0155" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0245" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0460" role="short">Image 23</ce:alt-text></ce:inline-figure>23.23</ce:label><ce:alt-text id="atte0465" role="short">23.23</ce:alt-text><ce:textbox-head><ce:title id="tit0160">Complications of allogeneic haematopoietic stem cell transplantation</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2685"><ce:display><ce:table frame="topbot" id="t0080"><ce:alt-text id="atte0470" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Early</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0655"><ce:list-item id="u1855"><ce:label>•</ce:label><ce:para id="p2690">Anaemia</ce:para></ce:list-item><ce:list-item id="u1860"><ce:label>•</ce:label><ce:para id="p2695">Infections</ce:para></ce:list-item><ce:list-item id="u1865"><ce:label>•</ce:label><ce:para id="p2700">Bleeding</ce:para></ce:list-item><ce:list-item id="u1870"><ce:label>•</ce:label><ce:para id="p2705">Acute GVHD</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0660"><ce:list-item id="u1875"><ce:label>•</ce:label><ce:para id="p2710">Mucositis – pain, nausea, diarrhoea</ce:para></ce:list-item><ce:list-item id="u1880"><ce:label>•</ce:label><ce:para id="p2715">Liver veno-occlusive disease</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Late</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist0665"><ce:list-item id="u1885"><ce:label>•</ce:label><ce:para id="p2720">Chronic GVHD</ce:para></ce:list-item><ce:list-item id="u1890"><ce:label>•</ce:label><ce:para id="p2725">Infertility</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0670"><ce:list-item id="u1895"><ce:label>•</ce:label><ce:para id="p2730">Cataracts</ce:para></ce:list-item><ce:list-item id="u1900"><ce:label>•</ce:label><ce:para id="p2735">Second malignancy</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para><ce:para id="p2740">(GVHD = graft-versus-host disease)</ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0160" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0250" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0475" role="short">Image 24</ce:alt-text></ce:inline-figure>23.24</ce:label><ce:alt-text id="atte0480" role="short">23.24</ce:alt-text><ce:textbox-head><ce:title id="tit0165">Infections during recovery from haematopoietic stem cell transplantation (HSCT)</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2745"><ce:display><ce:table frame="topbot" id="t0085"><ce:alt-text id="atte0485" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Infection</entry><entry align="left">Time after HSCT</entry><entry align="left">Management</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Herpes simplex</ce:bold> (<ce:intra-ref id="ii0350" xlink:href="pii:B978-0-7020-7028-0.00011-1#s0895">p. 247</ce:intra-ref>)</entry><entry align="left">0–4 weeks (aplastic phase)</entry><entry align="left">Aciclovir prophylaxis and therapy</entry></row><row rowsep="1"><entry align="left"><ce:bold>Bacterial, fungal</ce:bold></entry><entry align="left">0–4 weeks (aplastic phase)</entry><entry align="left">As for acute leukaemia (p. 956) – antibiotic and antifungal prophylaxis and therapy</entry></row><row rowsep="1"><entry align="left"><ce:bold>Cytomegalovirus</ce:bold> (<ce:intra-ref id="ii0360" xlink:href="pii:B978-0-7020-7028-0.00011-1#s0730">p. 242</ce:intra-ref>)</entry><entry align="left">5–21 weeks (cell-mediated immune deficiency)</entry><entry align="left">Antigen screening in blood (PCR) and pre-emptive therapy (e.g. ganciclovir)</entry></row><row rowsep="1"><entry align="left"><ce:bold>Varicella zoster</ce:bold> (<ce:intra-ref id="ii0365" xlink:href="pii:B978-0-7020-7028-0.00011-1#s0590">p. 238</ce:intra-ref>)</entry><entry align="left">After 13 weeks</entry><entry align="left">Aciclovir prophylaxis and therapy</entry></row><row rowsep="1"><entry align="left"><ce:bold><ce:italic>Pneumocystis jirovecii</ce:italic></ce:bold> (<ce:intra-ref id="ii0370" xlink:href="pii:B978-0-7020-7028-0.00012-3#s0220">p. 318</ce:intra-ref>)</entry><entry align="left">8–26 weeks</entry><entry align="left">Co-trimoxazole</entry></row><row><entry align="left"><ce:bold>Encapsulated bacteria</ce:bold></entry><entry align="left">8 weeks to years (immunoglobulin deficiency, prolonged with GVHD)</entry><entry align="left">Prophylaxis and revaccination</entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0170">(GVHD = graft-versus-host disease; PCR = polymerase chain reaction)</ce:simple-para></ce:legend></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0165" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0255" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0490" role="short">Image 25</ce:alt-text></ce:inline-figure>23.25</ce:label><ce:alt-text id="atte0495" role="short">23.25</ce:alt-text><ce:textbox-head><ce:title id="tit0170">Indications for anticoagulation</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2775"><ce:display><ce:figure id="f0105"><ce:alt-text id="atte0500" role="short">Unlabelled image</ce:alt-text><ce:link id="ln0260" locator="b023-025-9780702070280" xlink:href="pii:B9780702070280000238/b023-025-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure></ce:display></ce:para><ce:para id="p2780">(INR = international normalised ratio; LMWH = low-molecular-weight heparin; MI = myocardial infarction; VTE = venous thromboembolism)</ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0170" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0265" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0505" role="short">Image 26</ce:alt-text></ce:inline-figure>23.26</ce:label><ce:alt-text id="atte0510" role="short">23.26</ce:alt-text><ce:textbox-head><ce:title id="tit0175">Modes of action of anticoagulant and antithrombotic drugs</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2790"><ce:display><ce:table frame="topbot" id="t0090"><ce:alt-text id="atte0515" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Mode of action</entry><entry align="left">Drug</entry></row></thead><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Antiplatelet drugs</ce:bold></entry></row><row rowsep="0"><entry align="left">Cyclo-oxygenase (COX) inhibition</entry><entry align="left">Aspirin</entry></row><row rowsep="0"><entry align="left">Adenosine diphosphate (ADP) receptor inhibition</entry><entry align="left">Clopidogrel<ce:br/>Prasugrel<ce:br/>Ticagrelor</entry></row><row rowsep="0"><entry align="left">Glycoprotein IIb/IIIa inhibition</entry><entry align="left">Abciximab<ce:br/>Tirofiban<ce:br/>Eptifibatide</entry></row><row rowsep="1"><entry align="left">Phosphodiesterase inhibition</entry><entry align="left">Dipyridamole</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Oral anticoagulants</ce:bold></entry></row><row rowsep="0"><entry align="left">Vitamin K antagonism</entry><entry align="left">Warfarin/coumarins</entry></row><row rowsep="0"><entry align="left">Direct thrombin inhibition</entry><entry align="left">Dabigatran</entry></row><row rowsep="1"><entry align="left">Direct Xa inhibition</entry><entry align="left">Rivaroxaban<ce:br/>Apixaban<ce:br/>Edoxaban</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Injectable anticoagulants</ce:bold></entry></row><row rowsep="0"><entry align="left">Antithrombin-dependent inhibition of thrombin and Xa</entry><entry align="left">Heparin<ce:br/>LMWH</entry></row><row rowsep="0"><entry align="left">Antithrombin-dependent inhibition of Xa</entry><entry align="left">Fondaparinux<ce:br/>Danaparoid</entry></row><row><entry align="left">Direct thrombin inhibition</entry><entry align="left">Argatroban<ce:br/>Bivalirudin</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0175" role="alt6"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0270" locator="icon06-9780702070280" xlink:href="pii:B9780702070280000238/icon06-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0520" role="short">Image 27</ce:alt-text></ce:inline-figure>23.27</ce:label><ce:alt-text id="atte0525" role="short">23.27</ce:alt-text><ce:textbox-head><ce:title id="tit0180">Treatments for emergencies in haematological practice</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2825"><ce:list id="ulist0680"><ce:list-item id="u1925"><ce:label>•</ce:label><ce:para id="p2830">Reversal of life- and limb-threatening haemorrhage in anticoagulated patients:<ce:list id="ulist0685"><ce:list-item id="u1930"><ce:para id="p2835">Warfarin: prothrombin complex concentrate and IV vitamin K<ce:inf loc="post">1</ce:inf></ce:para></ce:list-item><ce:list-item id="u1935"><ce:para id="p2840">Unfractionated heparin: protamine sulphate</ce:para></ce:list-item><ce:list-item id="u1940"><ce:para id="p2845">Dabigatran: idarucizumab</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u1955"><ce:label>•</ce:label><ce:para id="p2860">Recognition of thrombotic thrombocytopenic purpura and treatment with plasma exchange</ce:para></ce:list-item><ce:list-item id="u1960"><ce:label>•</ce:label><ce:para id="p2865">Recognition of coagulopathy associated with acute promyelocytic leukaemia and treatment with all-trans-retinoic acid and fibrinogen replacement</ce:para></ce:list-item><ce:list-item id="u1965"><ce:label>•</ce:label><ce:para id="p2870">Recognition of chest syndrome and stroke in patients with sickle-cell anaemia and red cell transfusion or exchange transfusion</ce:para></ce:list-item><ce:list-item id="u1970"><ce:label>•</ce:label><ce:para id="p2875">Recognition of neutropenic sepsis in patients receiving chemotherapy and early treatment with empirical broad-spectrum antibiotics</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0180" role="alt3"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0275" locator="icon03-9780702070280" xlink:href="pii:B9780702070280000238/icon03-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0530" role="short">Image 28</ce:alt-text></ce:inline-figure>23.28</ce:label><ce:alt-text id="atte0535" role="short">23.28</ce:alt-text><ce:textbox-head><ce:title id="tit0185">How to assess risks of anticoagulation</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0595"><ce:section-title id="st0565">Contraindications</ce:section-title><ce:para id="p2975"><ce:list id="ulist0700"><ce:list-item id="u2010"><ce:label>•</ce:label><ce:para id="p2980">Recent surgery, especially to eye or central nervous system</ce:para></ce:list-item><ce:list-item id="u2015"><ce:label>•</ce:label><ce:para id="p2985">Pre-existing haemorrhagic state, e.g. advanced liver disease, haemophilia, thrombocytopenia</ce:para></ce:list-item><ce:list-item id="u2020"><ce:label>•</ce:label><ce:para id="p2990">Pre-existing structural lesions, e.g. peptic ulcer</ce:para></ce:list-item><ce:list-item id="u2025"><ce:label>•</ce:label><ce:para id="p2995">Recent cerebral or gastrointestinal haemorrhage</ce:para></ce:list-item><ce:list-item id="u2030"><ce:label>•</ce:label><ce:para id="p3000">Uncontrolled hypertension</ce:para></ce:list-item><ce:list-item id="u2035"><ce:label>•</ce:label><ce:para id="p3005">Cognitive impairment</ce:para></ce:list-item><ce:list-item id="u2040"><ce:label>•</ce:label><ce:para id="p3010">Frequent falls</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0600"><ce:section-title id="st0570">Bleeding risk score</ce:section-title><ce:para id="p3015"><ce:list id="ulist0705"><ce:list-item id="u2045"><ce:label>•</ce:label><ce:para id="p3020">Several bleeding risk scores exist for different indications for anticoagulation</ce:para></ce:list-item><ce:list-item id="u2050"><ce:label>•</ce:label><ce:para id="p3025">The validation of most bleeding risk scores has been poor</ce:para></ce:list-item><ce:list-item id="u2055"><ce:label>•</ce:label><ce:para id="p3030">Many risk factors for thrombosis are also risk factors for bleeding</ce:para></ce:list-item><ce:list-item id="u2060"><ce:label>•</ce:label><ce:para id="p3035">Following anticoagulant-related bleeding, reassessment of bleeding and thrombosis risk is indicated</ce:para></ce:list-item><ce:list-item id="u2065"><ce:label>•</ce:label><ce:para id="p3040">In many cases, patients benefit from recommencing anticoagulants after bleeding</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0185" role="alt5"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0290" locator="icon05-9780702070280" xlink:href="pii:B9780702070280000238/icon05-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0540" role="short">Image 29</ce:alt-text></ce:inline-figure>23.29</ce:label><ce:alt-text id="atte0545" role="short">23.29</ce:alt-text><ce:textbox-head><ce:title id="tit0190">Haematological physiology in pregnancy</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3100"><ce:list id="ulist0715"><ce:list-item id="u2080"><ce:label>•</ce:label><ce:para id="p3105"><ce:bold>Full blood count</ce:bold>: increased plasma volume (40%) lowers normal haemoglobin (reference range reduced to &#x003E; 105 g/L at 28 weeks). The mean cell volume (MCV) may increase by 5 fL. A progressive neutrophilia occurs. Gestational thrombocytopenia (rarely &#x003C; 60 × 10<ce:sup loc="post">9</ce:sup>/L) is a benign phenomenon.</ce:para></ce:list-item><ce:list-item id="u2085"><ce:label>•</ce:label><ce:para id="p3110"><ce:bold>Depletion of iron stores</ce:bold>: iron deficiency is a common cause of anaemia in pregnancy and, if present, should be treated with oral iron supplement.</ce:para></ce:list-item><ce:list-item id="u2090"><ce:label>•</ce:label><ce:para id="p3115"><ce:bold>Vitamin B<ce:inf loc="post">12</ce:inf></ce:bold>: serum levels are physiologically low in pregnancy but deficiency is uncommon.</ce:para></ce:list-item><ce:list-item id="u2095"><ce:label>•</ce:label><ce:para id="p3120"><ce:bold>Folate</ce:bold>: tissue stores may become depleted, and folate supplementation is recommended in all pregnancies (see <ce:intra-ref id="ii0420" xlink:href="pii:B978-0-7020-7028-0.00019-6#b0165">Box 19.29</ce:intra-ref>, <ce:intra-ref id="ii0425" xlink:href="pii:B978-0-7020-7028-0.00019-6#p1945">p. 712</ce:intra-ref>).</ce:para></ce:list-item><ce:list-item id="u2100"><ce:label>•</ce:label><ce:para id="p3125"><ce:bold>Coagulation factors</ce:bold>: from the second trimester, procoagulant factors increase approximately threefold, particularly fibrinogen, von Willebrand factor and factor VIII. This causes activated protein C resistance and a shortened activated partial thromboplastin time (APTT), and contributes to a prothrombotic state.</ce:para></ce:list-item><ce:list-item id="u2105"><ce:label>•</ce:label><ce:para id="p3130"><ce:bold>Anticoagulants</ce:bold>: levels of protein C increase from the second trimester, while levels of free protein S fall as C4b binding protein increases.</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0190" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0295" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0550" role="short">Image 30</ce:alt-text></ce:inline-figure>23.30</ce:label><ce:alt-text id="atte0555" role="short">23.30</ce:alt-text><ce:textbox-head><ce:title id="tit0195">Investigations to differentiate anaemia of chronic disease from iron deficiency anaemia</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3140"><ce:display><ce:table frame="topbot" id="t0095"><ce:alt-text id="atte0560" role="short">Unlabelled table</ce:alt-text><tgroup cols="6"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><colspec colname="col4" colnum="4"/><colspec colname="col5" colnum="5"/><colspec colname="col6" colnum="6"/><thead><row rowsep="1"><entry align="left"/><entry align="left">Ferritin</entry><entry align="left">Iron</entry><entry align="left">TIBC</entry><entry align="left">Transferrin saturation</entry><entry align="left">Soluble transferrin receptor</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Iron deficiency anaemia</ce:bold></entry><entry align="left">↓</entry><entry align="left">↓</entry><entry align="left">↑</entry><entry align="left">↓</entry><entry align="left">↑</entry></row><row><entry align="left"><ce:bold>Anaemia of chronic disease</ce:bold></entry><entry align="left">↑/Normal</entry><entry align="left">↓</entry><entry align="left">↓</entry><entry align="left">↓</entry><entry align="left">↓/Normal</entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0195">(TIBC = total iron binding capacity)</ce:simple-para></ce:legend></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0195" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0300" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0565" role="short">Image 31</ce:alt-text></ce:inline-figure>23.31</ce:label><ce:alt-text id="atte0570" role="short">23.31</ce:alt-text><ce:textbox-head><ce:title id="tit0200">Clinical features of megaloblastic anaemia</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3200"><ce:display><ce:table frame="topbot" id="t0100"><ce:alt-text id="atte0575" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Symptoms</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0720"><ce:list-item id="u2110"><ce:label>•</ce:label><ce:para id="p3205">Malaise (90%)</ce:para></ce:list-item><ce:list-item id="u2115"><ce:label>•</ce:label><ce:para id="p3210">Breathlessness (50%)</ce:para></ce:list-item><ce:list-item id="u2120"><ce:label>•</ce:label><ce:para id="p3215">Paraesthesiae (80%)</ce:para></ce:list-item><ce:list-item id="u2125"><ce:label>•</ce:label><ce:para id="p3220">Sore mouth (20%)</ce:para></ce:list-item><ce:list-item id="u2130"><ce:label>•</ce:label><ce:para id="p3225">Weight loss</ce:para></ce:list-item><ce:list-item id="u2135"><ce:label>•</ce:label><ce:para id="p3230">Impotence</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0725"><ce:list-item id="u2140"><ce:label>•</ce:label><ce:para id="p3235">Poor memory</ce:para></ce:list-item><ce:list-item id="u2145"><ce:label>•</ce:label><ce:para id="p3240">Depression</ce:para></ce:list-item><ce:list-item id="u2150"><ce:label>•</ce:label><ce:para id="p3245">Personality change</ce:para></ce:list-item><ce:list-item id="u2155"><ce:label>•</ce:label><ce:para id="p3250">Hallucinations</ce:para></ce:list-item><ce:list-item id="u2160"><ce:label>•</ce:label><ce:para id="p3255">Visual disturbance</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Signs</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist0730"><ce:list-item id="u2165"><ce:label>•</ce:label><ce:para id="p3260">Smooth tongue</ce:para></ce:list-item><ce:list-item id="u2170"><ce:label>•</ce:label><ce:para id="p3265">Angular cheilosis</ce:para></ce:list-item><ce:list-item id="u2175"><ce:label>•</ce:label><ce:para id="p3270">Vitiligo</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0735"><ce:list-item id="u2180"><ce:label>•</ce:label><ce:para id="p3275">Skin pigmentation</ce:para></ce:list-item><ce:list-item id="u2185"><ce:label>•</ce:label><ce:para id="p3280">Heart failure</ce:para></ce:list-item><ce:list-item id="u2190"><ce:label>•</ce:label><ce:para id="p3285">Pyrexia</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0200" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0305" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0580" role="short">Image 32</ce:alt-text></ce:inline-figure>23.32</ce:label><ce:alt-text id="atte0585" role="short">23.32</ce:alt-text><ce:textbox-head><ce:title id="tit0205">Investigations in megaloblastic anaemia</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3290"><ce:display><ce:table frame="topbot" id="t0105"><ce:alt-text id="atte0590" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Investigation</entry><entry align="left">Result</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Haemoglobin</ce:bold></entry><entry align="left">Often reduced, may be very low</entry></row><row rowsep="1"><entry align="left"><ce:bold>Mean cell volume</ce:bold></entry><entry align="left">Usually raised, commonly &#x003E; 120 fL</entry></row><row rowsep="1"><entry align="left"><ce:bold>Erythrocyte count</ce:bold></entry><entry align="left">Low for degree of anaemia</entry></row><row rowsep="1"><entry align="left"><ce:bold>Blood film</ce:bold></entry><entry align="left">Oval macrocytosis, poikilocytosis, red cell fragmentation, neutrophil hypersegmentation</entry></row><row rowsep="1"><entry align="left"><ce:bold>Reticulocyte count</ce:bold></entry><entry align="left">Low for degree of anaemia</entry></row><row rowsep="1"><entry align="left"><ce:bold>Leucocyte count</ce:bold></entry><entry align="left">Low or normal</entry></row><row rowsep="1"><entry align="left"><ce:bold>Platelet count</ce:bold></entry><entry align="left">Low or normal</entry></row><row rowsep="1"><entry align="left"><ce:bold>Bone marrow</ce:bold></entry><entry align="left">Increased cellularity, megaloblastic changes in erythroid series, giant metamyelocytes, dysplastic megakaryocytes, increased iron in stores, pathological non-ring sideroblasts</entry></row><row rowsep="1"><entry align="left"><ce:bold>Serum ferritin</ce:bold></entry><entry align="left">Elevated</entry></row><row><entry align="left"><ce:bold>Plasma lactate dehydrogenase</ce:bold></entry><entry align="left">Elevated, often markedly</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0205" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0310" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0595" role="short">Image 33</ce:alt-text></ce:inline-figure>23.33</ce:label><ce:alt-text id="atte0600" role="short">23.33</ce:alt-text><ce:textbox-head><ce:title id="tit0210">Neurological findings in B<ce:inf loc="post">12</ce:inf> deficiency</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0690"><ce:section id="s0695"><ce:section-title id="st0645">Peripheral nerves</ce:section-title><ce:para id="p3295"><ce:list id="ulist0740"><ce:list-item id="u2195"><ce:label>•</ce:label><ce:para id="p3300">Glove and stocking paraesthesiae</ce:para></ce:list-item><ce:list-item id="u2200"><ce:label>•</ce:label><ce:para id="p3305">Loss of ankle reflexes</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0700"><ce:section-title id="st0650">Spinal cord</ce:section-title><ce:para id="p3310"><ce:list id="ulist0745"><ce:list-item id="u2205"><ce:label>•</ce:label><ce:para id="p3315">Subacute combined degeneration of the cord<ce:list id="ulist0750"><ce:list-item id="u2210"><ce:para id="p3320">Posterior columns – diminished vibration sensation and proprioception</ce:para></ce:list-item><ce:list-item id="u2215"><ce:para id="p3325">Corticospinal tracts – upper motor neuron signs</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0705"><ce:section-title id="st0655">Cerebrum</ce:section-title><ce:para id="p3330"><ce:list id="ulist0755"><ce:list-item id="u2220"><ce:label>•</ce:label><ce:para id="p3335">Dementia</ce:para></ce:list-item><ce:list-item id="u2225"><ce:label>•</ce:label><ce:para id="p3340">Optic atrophy</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p3345">Autonomic neuropathy</ce:para></ce:section></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0210" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0315" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0605" role="short">Image 34</ce:alt-text></ce:inline-figure>23.34</ce:label><ce:alt-text id="atte0610" role="short">23.34</ce:alt-text><ce:textbox-head><ce:title id="tit0215">Causes of folate deficiency</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0760"><ce:section-title id="st0710">Diet</ce:section-title><ce:para id="p3405"><ce:list id="ulist0760"><ce:list-item id="u2230"><ce:label>•</ce:label><ce:para id="p3410">Poor intake of vegetables</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0765"><ce:section-title id="st0715">Malabsorption</ce:section-title><ce:para id="p3415"><ce:list id="ulist0765"><ce:list-item id="u2235"><ce:label>•</ce:label><ce:para id="p3420">e.g. Coeliac disease, small bowel surgery</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0770"><ce:section-title id="st0720">Increased demand</ce:section-title><ce:para id="p3425"><ce:list id="ulist0770"><ce:list-item id="u2240"><ce:label>•</ce:label><ce:para id="p3430">Cell proliferation, e.g. haemolysis</ce:para></ce:list-item><ce:list-item id="u2245"><ce:label>•</ce:label><ce:para id="p3435">Pregnancy</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0775"><ce:section-title id="st0725">Drugs<ce:cross-ref id="crf0735" refid="fn0020">*</ce:cross-ref><ce:footnote id="fn0020"><ce:label>*</ce:label><ce:note-para id="np0045">Usually only a problem in patients deficient in folate from another cause.</ce:note-para></ce:footnote></ce:section-title><ce:para id="p3440"><ce:list id="ulist0775"><ce:list-item id="u2250"><ce:label>•</ce:label><ce:para id="p3445">Certain anticonvulsants (e.g. phenytoin)</ce:para></ce:list-item><ce:list-item id="u2255"><ce:label>•</ce:label><ce:para id="p3450">Contraceptive pill</ce:para></ce:list-item><ce:list-item id="u2260"><ce:label>•</ce:label><ce:para id="p3455">Certain cytotoxic drugs (e.g. methotrexate)</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0215" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0320" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0615" role="short">Image 35</ce:alt-text></ce:inline-figure>23.35</ce:label><ce:alt-text id="atte0620" role="short">23.35</ce:alt-text><ce:textbox-head><ce:title id="tit0220">Investigation of folic acid deficiency</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0780"><ce:section-title id="st0730">Diagnostic findings</ce:section-title><ce:para id="p3460"><ce:list id="ulist0780"><ce:list-item id="u2265"><ce:label>•</ce:label><ce:para id="p3465">Serum folate levels may be low but are difficult to interpret</ce:para></ce:list-item><ce:list-item id="u2270"><ce:label>•</ce:label><ce:para id="p3470">Low red cell folate levels indicate prolonged folate deficiency and are probably the most relevant measure</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0785"><ce:section-title id="st0735">Corroborative findings</ce:section-title><ce:para id="p3475"><ce:list id="ulist0785"><ce:list-item id="u2275"><ce:label>•</ce:label><ce:para id="p3480">Macrocytic dysplastic blood picture</ce:para></ce:list-item><ce:list-item id="u2280"><ce:label>•</ce:label><ce:para id="p3485">Megaloblastic marrow</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0220" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0330" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0625" role="short">Image 36</ce:alt-text></ce:inline-figure>23.36</ce:label><ce:alt-text id="atte0630" role="short">23.36</ce:alt-text><ce:textbox-head><ce:title id="tit0225">Investigation results indicating active haemolysis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3615"><ce:display><ce:table frame="topbot" id="t0110"><ce:alt-text id="atte0635" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Hallmarks of haemolysis</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0805"><ce:list-item id="u2330"><ce:label>•</ce:label><ce:para id="p3620">↓Haemoglobin</ce:para></ce:list-item><ce:list-item id="u2335"><ce:label>•</ce:label><ce:para id="p3625">↑Unconjugated bilirubin</ce:para></ce:list-item><ce:list-item id="u2340"><ce:label>•</ce:label><ce:para id="p3630">↑Lactate dehydrogenase</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0810"><ce:list-item id="u2345"><ce:label>•</ce:label><ce:para id="p3635">↑Reticulocytes</ce:para></ce:list-item><ce:list-item id="u2350"><ce:label>•</ce:label><ce:para id="p3640">↑Urinary urobilinogen</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Additional features of intravascular haemolysis</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist0815"><ce:list-item id="u2355"><ce:label>•</ce:label><ce:para id="p3645">↓Haptoglobin</ce:para></ce:list-item><ce:list-item id="u2360"><ce:label>•</ce:label><ce:para id="p3650">↑Methaemalbumin</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0820"><ce:list-item id="u2365"><ce:label>•</ce:label><ce:para id="p3655">Positive urinary haemosiderin</ce:para></ce:list-item><ce:list-item id="u2370"><ce:label>•</ce:label><ce:para id="p3660">Haemoglobinuria</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0225" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0335" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0640" role="short">Image 37</ce:alt-text></ce:inline-figure>23.37</ce:label><ce:alt-text id="atte0645" role="short">23.37</ce:alt-text><ce:textbox-head><ce:title id="tit0230">Management of the splenectomised patient</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3670"><ce:list id="ulist0825"><ce:list-item id="u2375"><ce:label>•</ce:label><ce:para id="p3675">Vaccinate with pneumococcal, <ce:italic>Haemophilus influenzae</ce:italic> type B, meningococcal group C and influenza vaccines at least 2–3 weeks before elective splenectomy. Vaccination should be given after emergency surgery but may be less effective</ce:para></ce:list-item><ce:list-item id="u2380"><ce:label>•</ce:label><ce:para id="p3680">Pneumococcal re-immunisation should be given at least 5-yearly and influenza annually. Vaccination status must be documented</ce:para></ce:list-item><ce:list-item id="u2385"><ce:label>•</ce:label><ce:para id="p3685">Life-long prophylactic penicillin V (500 mg twice daily) is recommended. In penicillin-allergic patients, consider a macrolide</ce:para></ce:list-item><ce:list-item id="u2390"><ce:label>•</ce:label><ce:para id="p3690">Patients should be educated regarding the risks of infection and methods of prophylaxis</ce:para></ce:list-item><ce:list-item id="u2395"><ce:label>•</ce:label><ce:para id="p3695">A card or bracelet should be carried to alert health professionals to the risk of overwhelming sepsis</ce:para></ce:list-item><ce:list-item id="u2400"><ce:label>•</ce:label><ce:para id="p3700">In sepsis, patients should be resuscitated and given IV antibiotics to cover pneumococcus, <ce:italic>Haemophilus</ce:italic> and meningococcus, according to local resistance patterns</ce:para></ce:list-item><ce:list-item id="u2405"><ce:label>•</ce:label><ce:para id="p3705">The risk of cerebral malaria is increased in the event of infection</ce:para></ce:list-item><ce:list-item id="u2410"><ce:label>•</ce:label><ce:para id="p3710">Animal bites should be promptly treated with local disinfection and antibiotics, to prevent serious soft tissue infection and sepsis</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0230" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0340" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0650" role="short">Image 38</ce:alt-text></ce:inline-figure>23.38</ce:label><ce:alt-text id="atte0655" role="short">23.38</ce:alt-text><ce:textbox-head><ce:title id="tit0235">Glucose-6-phosphate dehydrogenase deficiency</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0870"><ce:section-title id="st0810">Clinical features</ce:section-title><ce:para id="p3750"><ce:list id="ulist0830"><ce:list-item id="u2415"><ce:label>•</ce:label><ce:para id="p3755">Acute drug-induced haemolysis to (e.g.):<ce:list id="ulist0835"><ce:list-item id="u2420"><ce:para id="p3760">Analgesics: aspirin, phenacetin</ce:para></ce:list-item><ce:list-item id="u2425"><ce:para id="p3765">Antimalarials: primaquine, quinine, chloroquine, pyrimethamine</ce:para></ce:list-item><ce:list-item id="u2430"><ce:para id="p3770">Antibiotics: sulphonamides, nitrofurantoin, ciprofloxacin</ce:para></ce:list-item><ce:list-item id="u2435"><ce:para id="p3775">Miscellaneous: quinidine, probenecid, vitamin K, dapsone</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u2440"><ce:label>•</ce:label><ce:para id="p3780">Chronic compensated haemolysis</ce:para></ce:list-item><ce:list-item id="u2445"><ce:label>•</ce:label><ce:para id="p3785">Infection or acute illness</ce:para></ce:list-item><ce:list-item id="u2450"><ce:label>•</ce:label><ce:para id="p3790">Neonatal jaundice: may be a feature of the B<ce:sup loc="post">−</ce:sup> enzyme</ce:para></ce:list-item><ce:list-item id="u2455"><ce:label>•</ce:label><ce:para id="p3795">Favism, i.e. acute haemolysis after ingestion of broad beans (<ce:italic>Vicia fava</ce:italic>)</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0875"><ce:section-title id="st0815">Laboratory features</ce:section-title><ce:section id="s0880"><ce:section-title id="st0820">Non-spherocytic intravascular haemolysis during an attack</ce:section-title><ce:para id="p3800">The blood film will show:<ce:list id="ulist0840"><ce:list-item id="u2460"><ce:label>•</ce:label><ce:para id="p3805">Bite cells (red cells with a ‘bite’ of membrane missing)</ce:para></ce:list-item><ce:list-item id="u2465"><ce:label>•</ce:label><ce:para id="p3810">Blister cells (red cells with surface blistering of the membrane)</ce:para></ce:list-item><ce:list-item id="u2470"><ce:label>•</ce:label><ce:para id="p3815">Irregularly shaped small cells</ce:para></ce:list-item><ce:list-item id="u2475"><ce:label>•</ce:label><ce:para id="p3820">Polychromasia reflecting the reticulocytosis</ce:para></ce:list-item><ce:list-item id="u2480"><ce:label>•</ce:label><ce:para id="p3825">Denatured haemoglobin visible as Heinz bodies within the red cell cytoplasm with a supravital stain such as methyl violet</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0885"><ce:section-title id="st0825">G6PD level</ce:section-title><ce:para id="p3830"><ce:list id="ulist0845"><ce:list-item id="u2485"><ce:label>•</ce:label><ce:para id="p3835">Can be indirectly assessed by screening methods that usually depend on the decreased ability to reduce dyes</ce:para></ce:list-item><ce:list-item id="u2490"><ce:label>•</ce:label><ce:para id="p3840">Direct assessment of G6PD is made in those with low screening values</ce:para></ce:list-item><ce:list-item id="u2495"><ce:label>•</ce:label><ce:para id="p3845">Care must be taken close to an acute haemolytic episode because reticulocytes may have higher enzyme levels and give rise to a false normal result</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0235" role="alt5"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0360" locator="icon05-9780702070280" xlink:href="pii:B9780702070280000238/icon05-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0660" role="short">Image 39</ce:alt-text></ce:inline-figure>23.39</ce:label><ce:alt-text id="atte0665" role="short">23.39</ce:alt-text><ce:textbox-head><ce:title id="tit0240">Sickle-cell disease in pregnancy</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4050"><ce:list id="ulist0870"><ce:list-item id="u2570"><ce:label>•</ce:label><ce:para id="p4055"><ce:bold>Pre-conceptual counselling</ce:bold>: advice on the effect of sickle-cell disease on pregnancy, and vice versa, should be offered.</ce:para></ce:list-item><ce:list-item id="u2575"><ce:label>•</ce:label><ce:para id="p4060"><ce:bold>Vaccination status</ce:bold>: should be updated before conception.</ce:para></ce:list-item><ce:list-item id="u2580"><ce:label>•</ce:label><ce:para id="p4065"><ce:bold>Testing of partner</ce:bold>: testing for haemoglobinopathy status is advised.</ce:para></ce:list-item><ce:list-item id="u2585"><ce:label>•</ce:label><ce:para id="p4070"><ce:bold>Folic acid</ce:bold>: should be taken in high dose (5 mg daily) prior to and throughout pregnancy.</ce:para></ce:list-item><ce:list-item id="u2590"><ce:label>•</ce:label><ce:para id="p4075"><ce:bold>Hydroxycarbamide</ce:bold>: should be discontinued 3 months prior to conception.</ce:para></ce:list-item><ce:list-item id="u2595"><ce:label>•</ce:label><ce:para id="p4080"><ce:bold>Angiotensin-converting enzyme (ACE) inhibitors</ce:bold>: should be discontinued prior to conception.</ce:para></ce:list-item><ce:list-item id="o9010"><ce:label>•</ce:label><ce:para id="p9010"><ce:bold>Pulmonary hypertension</ce:bold>: should be excluded prior to conception.</ce:para></ce:list-item><ce:list-item id="u2600"><ce:label>•</ce:label><ce:para id="p4085"><ce:bold>Placental failure</ce:bold>: women with sickle-cell disease have increased rates, resulting in pre-eclampsia and intrauterine growth retardation.</ce:para></ce:list-item><ce:list-item id="u2605"><ce:label>•</ce:label><ce:para id="p4090"><ce:bold>Aspirin 75</ce:bold> <ce:bold>mg</ce:bold>: should be given throughout pregnancy.</ce:para></ce:list-item><ce:list-item id="u2610"><ce:label>•</ce:label><ce:para id="p4095"><ce:bold>Thromboprophylaxis after delivery</ce:bold>: all women with sickle-cell disease should receive thromboprophylaxis with low-molecular-weight heparin for at least 10 days post vaginal delivery and for 6 weeks post caesarean section. Antenatal thromboprophylaxis should be considered for women with additional risk factors for venous thromboembolism (see <ce:cross-ref id="crf9020" refid="b0365">Box 23.65</ce:cross-ref>).</ce:para></ce:list-item><ce:list-item id="u2615"><ce:label>•</ce:label><ce:para id="p4100"><ce:bold>Transfusion</ce:bold>: extended cross-matched blood for Rhesus and Kell status should be provided. Blood should be cytomegalovirus-negative.</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0240" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0365" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0670" role="short">Image 40</ce:alt-text></ce:inline-figure>23.40</ce:label><ce:alt-text id="atte0675" role="short">23.40</ce:alt-text><ce:textbox-head><ce:title id="tit0245">Diagnostic features of beta-thalassaemia</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s1045"><ce:section-title id="st0970">Beta-thalassaemia major (homozygotes)</ce:section-title><ce:para id="p4150"><ce:list id="ulist0875"><ce:list-item id="u2620"><ce:label>•</ce:label><ce:para id="p4155">Profound hypochromic anaemia</ce:para></ce:list-item><ce:list-item id="u2625"><ce:label>•</ce:label><ce:para id="p4160">Evidence of severe red cell dysplasia</ce:para></ce:list-item><ce:list-item id="u2630"><ce:label>•</ce:label><ce:para id="p4165">Erythroblastosis</ce:para></ce:list-item><ce:list-item id="u2635"><ce:label>•</ce:label><ce:para id="p4170">Absence or gross reduction of the amount of haemoglobin A</ce:para></ce:list-item><ce:list-item id="u2640"><ce:label>•</ce:label><ce:para id="p4175">Raised levels of haemoglobin F</ce:para></ce:list-item><ce:list-item id="u2645"><ce:label>•</ce:label><ce:para id="p4180">Evidence that both parents have thalassaemia minor</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1050"><ce:section-title id="st0975">Beta-thalassaemia minor (heterozygotes)</ce:section-title><ce:para id="p4185"><ce:list id="ulist0880"><ce:list-item id="u2650"><ce:label>•</ce:label><ce:para id="p4190">Mild anaemia</ce:para></ce:list-item><ce:list-item id="u2655"><ce:label>•</ce:label><ce:para id="p4195">Microcytic hypochromic erythrocytes (not iron-deficient)</ce:para></ce:list-item><ce:list-item id="u2660"><ce:label>•</ce:label><ce:para id="p4200">Some target cells</ce:para></ce:list-item><ce:list-item id="u2665"><ce:label>•</ce:label><ce:para id="p4205">Punctate basophilia</ce:para></ce:list-item><ce:list-item id="u2670"><ce:label>•</ce:label><ce:para id="p4210">Raised haemoglobin A<ce:inf loc="post">2</ce:inf> fraction</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0245" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0370" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0680" role="short">Image 41</ce:alt-text></ce:inline-figure>23.41</ce:label><ce:alt-text id="atte0685" role="short">23.41</ce:alt-text><ce:textbox-head><ce:title id="tit0250">Treatment of beta-thalassaemia major</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4220"><ce:display><ce:table frame="topbot" id="t0115"><ce:alt-text id="atte0690" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Problem</entry><entry align="left">Management</entry></row></thead><tbody><row><entry morerows="2" rowsep="1" align="left"><ce:bold>Erythropoietic failure</ce:bold></entry><entry rowsep="0" align="left">Allogeneic HSCT from HLA-compatible sibling</entry></row><row rowsep="0"><entry align="left">Transfusion to maintain Hb &#x003E; 100 g/L</entry></row><row rowsep="1"><entry align="left">Folic acid 5 mg daily</entry></row><row><entry morerows="1" rowsep="1" align="left"><ce:bold>Iron overload</ce:bold></entry><entry rowsep="0" align="left">Iron therapy contraindicated</entry></row><row rowsep="1"><entry align="left">Iron chelation therapy</entry></row><row><entry align="left"><ce:bold>Splenomegaly causing mechanical problems, excessive transfusion needs</ce:bold></entry><entry align="left">Splenectomy; see <ce:cross-ref id="crf0870" refid="b0225">Box 23.37</ce:cross-ref></entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0225">(Hb = haemoglobin; HLA = human leucocyte antigen; HSCT = haematopoietic stem cell transplantation)</ce:simple-para></ce:legend></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0250" role="alt2"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0375" locator="icon02-9780702070280" xlink:href="pii:B9780702070280000238/icon02-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0695" role="short">Image 42</ce:alt-text></ce:inline-figure>23.42</ce:label><ce:alt-text id="atte0700" role="short">23.42</ce:alt-text><ce:textbox-head><ce:title id="tit0255">Anaemia in old age</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4265"><ce:list id="ulist0890"><ce:list-item id="u2695"><ce:label>•</ce:label><ce:para id="p4270"><ce:bold>Mean haemoglobin</ce:bold>: falls with age in both sexes but remains well within the reference range. When a low haemoglobin does occur, it is generally due to disease.</ce:para></ce:list-item><ce:list-item id="u2700"><ce:label>•</ce:label><ce:para id="p4275"><ce:bold>Anaemia can never be considered ‘normal’ in old age</ce:bold>.</ce:para></ce:list-item><ce:list-item id="u2705"><ce:label>•</ce:label><ce:para id="p4280"><ce:bold>Symptoms</ce:bold>: may be subtle and insidious. Cardiovascular features such as dyspnoea and oedema, and cerebral features such as dizziness and apathy, tend to predominate.</ce:para></ce:list-item><ce:list-item id="u2710"><ce:label>•</ce:label><ce:para id="p4285"><ce:bold>Ferritin</ce:bold>: if lower than 45 µg/L in older people, is highly predictive of iron deficiency. Conversely, ferritin may be raised by chronic disease and so a normal ferritin does not exclude iron deficiency.</ce:para></ce:list-item><ce:list-item id="u2715"><ce:label>•</ce:label><ce:para id="p4290"><ce:bold>Serum iron and transferrin</ce:bold>: fall with age because of the prevalence of other disorders, and are not reliable indicators of deficiency.</ce:para></ce:list-item><ce:list-item id="u2720"><ce:label>•</ce:label><ce:para id="p4295"><ce:bold>Most common cause of iron deficiency</ce:bold>: gastrointestinal blood loss.</ce:para></ce:list-item><ce:list-item id="u2725"><ce:label>•</ce:label><ce:para id="p4300"><ce:bold>Most common cause of vitamin B<ce:inf loc="post">12</ce:inf> deficiency</ce:bold>: pernicious anaemia, as the prevalence of chronic atrophic gastritis rises in old age.</ce:para></ce:list-item><ce:list-item id="u2730"><ce:label>•</ce:label><ce:para id="p4305"><ce:bold>Neuropsychiatric symptoms associated with vitamin B<ce:inf loc="post">12</ce:inf> deficiency</ce:bold>: well-established association but a causal relationship has not been clearly shown. Dementia associated with vitamin B<ce:inf loc="post">12</ce:inf> deficiency in the absence of haematological abnormalities is rare.</ce:para></ce:list-item><ce:list-item id="u2735"><ce:label>•</ce:label><ce:para id="p4310"><ce:bold>Anaemia of chronic disease</ce:bold>: frequent in old age because of the rising prevalence of diseases that inhibit iron transport.</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0255" role="alt4"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0380" locator="icon04-9780702070280" xlink:href="pii:B9780702070280000238/icon04-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0705" role="short">Image 43</ce:alt-text></ce:inline-figure>23.43</ce:label><ce:alt-text id="atte0710" role="short">23.43</ce:alt-text><ce:textbox-head><ce:title id="tit0260">Consequences of haematological malignancy in adolescence</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4320"><ce:list id="ulist0895"><ce:list-item id="u2740"><ce:label>•</ce:label><ce:para id="p4325"><ce:bold>Tailored management protocols</ce:bold>: the most effective treatment schedules for leukaemia and lymphoma differ between children and adults. Adolescent patients may be most appropriately managed in specialist centres.</ce:para></ce:list-item><ce:list-item id="u2745"><ce:label>•</ce:label><ce:para id="p4330"><ce:bold>Psychosocial effects</ce:bold>: adolescents undergoing treatment for haematological malignancy may suffer significant consequences for their schooling and social development, and require support from a multidisciplinary team.</ce:para></ce:list-item><ce:list-item id="u2750"><ce:label>•</ce:label><ce:para id="p4335"><ce:bold>‘Late effects’</ce:bold>: adolescents who have been treated with chemotherapy and/or radiotherapy in childhood may be at risk of a wide range of complications, depending on the region irradiated, radiation dose and the drugs used. Particularly relevant complications in this age group include short stature, growth hormone deficiency, delayed puberty, and cognitive dysfunction affecting schooling (after cranial irradiation). Life-long follow-up is often undertaken to detect and manage these late effects and to deal with consequences such as infertility and second malignancy.</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0260" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0385" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0715" role="short">Image 44</ce:alt-text></ce:inline-figure>23.44</ce:label><ce:alt-text id="atte0720" role="short">23.44</ce:alt-text><ce:textbox-head><ce:title id="tit0265">Risk factors for leukaemia</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s1085"><ce:section-title id="st1005">Ionising radiation</ce:section-title><ce:para id="p4355"><ce:list id="ulist0900"><ce:list-item id="u2755"><ce:label>•</ce:label><ce:para id="p4360">After atomic bombing of Japanese cities (myeloid leukaemia)</ce:para></ce:list-item><ce:list-item id="u2760"><ce:label>•</ce:label><ce:para id="p4365">Radiotherapy</ce:para></ce:list-item><ce:list-item id="u2765"><ce:label>•</ce:label><ce:para id="p4370">Diagnostic X-rays of the fetus in pregnancy</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1090"><ce:section-title id="st1010">Cytotoxic drugs</ce:section-title><ce:para id="p4375"><ce:list id="ulist0905"><ce:list-item id="u2770"><ce:label>•</ce:label><ce:para id="p4380">Especially alkylating agents (myeloid leukaemia, usually after a latent period of several years)</ce:para></ce:list-item><ce:list-item id="u2775"><ce:label>•</ce:label><ce:para id="p4385">Industrial exposure to benzene</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1095"><ce:section-title id="st1015">Retroviruses</ce:section-title><ce:para id="p4390"><ce:list id="ulist0910"><ce:list-item id="u2780"><ce:label>•</ce:label><ce:para id="p4395">Adult T-cell leukaemia/lymphoma (ATLL) caused by human T-cell lymphotropic virus 1(HTLV-1), most prevalent in Japan, the Caribbean and some areas of Central and South America and Africa</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1100"><ce:section-title id="st1020">Genetic</ce:section-title><ce:para id="p4400"><ce:list id="ulist0915"><ce:list-item id="u2785"><ce:label>•</ce:label><ce:para id="p4405">Identical twin of patients with leukaemia</ce:para></ce:list-item><ce:list-item id="u2790"><ce:label>•</ce:label><ce:para id="p4410">Down's syndrome and certain other genetic disorders</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1105"><ce:section-title id="st1025">Immunological</ce:section-title><ce:para id="p4415"><ce:list id="ulist0920"><ce:list-item id="u2795"><ce:label>•</ce:label><ce:para id="p4420">Immune deficiency states (e.g. hypogammaglobulinaemia)</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0265" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0390" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0725" role="short">Image 45</ce:alt-text></ce:inline-figure>23.45</ce:label><ce:alt-text id="atte0730" role="short">23.45</ce:alt-text><ce:textbox-head><ce:title id="tit0270">WHO classification of acute leukaemia<ce:cross-ref id="crf9015" refid="fn9005">*</ce:cross-ref></ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s1115"><ce:section id="s1120"><ce:section-title id="st1035">Acute myeloid leukaemia (AML) with recurrent genetic abnormalities</ce:section-title><ce:para id="p4460"><ce:list id="ulist0930"><ce:list-item id="u2820"><ce:label>•</ce:label><ce:para id="p4465">AML with t(8;21)(q22;q22.1), gene product RUNX1-RUNX1T1</ce:para></ce:list-item><ce:list-item id="u2825"><ce:label>•</ce:label><ce:para id="p4470">AML with inv(16)(p13.1;q22), gene product CBFB-MYHL1</ce:para></ce:list-item><ce:list-item id="u2830"><ce:label>•</ce:label><ce:para id="p4475">Acute promyelocytic leukaemia t(15;17), gene product PML-RARA</ce:para></ce:list-item><ce:list-item id="u2835"><ce:label>•</ce:label><ce:para id="p4480">AML with t(9;11)(p21.3;q23.3), gene product MLLT3-KMT2A</ce:para></ce:list-item><ce:list-item id="u2840"><ce:label>•</ce:label><ce:para id="p4485">AML with t(6;9)(p23;q34), gene product DEK-NUP214</ce:para></ce:list-item><ce:list-item id="u2845"><ce:label>•</ce:label><ce:para id="p4490">AML with inv(3)(q21.3;q26.2) or t(3;3)(q21.3;q26.2), gene products GATA2, MECOM</ce:para></ce:list-item><ce:list-item id="o9020"><ce:label>•</ce:label><ce:para id="p9085">AML (megakaryoblastic) with t(1;22)(p13.3;q13.3), gene product RBM15-MKL1</ce:para></ce:list-item><ce:list-item id="o9025"><ce:label>•</ce:label><ce:para id="p9090">AML with mutated NPM1</ce:para></ce:list-item><ce:list-item id="o9030"><ce:label>•</ce:label><ce:para id="p9095">AML with biallelic mutations of CEBPA</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1125"><ce:section-title id="st1040">Acute myeloid leukaemia with myelodysplasia-related changes</ce:section-title><ce:para id="p4495"><ce:list id="ulist0935"><ce:list-item id="u2850"><ce:label>•</ce:label><ce:para id="p4500">e.g. Following a myelodysplastic syndrome</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1130"><ce:section-title id="st1045">Therapy-related myeloid neoplasms</ce:section-title><ce:para id="p4505"><ce:list id="ulist0940"><ce:list-item id="u2855"><ce:label>•</ce:label><ce:para id="p4510">e.g. Alkylating agent or topoisomerase II inhibitor</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1135"><ce:section-title id="st1050">Myeloid sarcoma</ce:section-title><ce:para id="p4515"><ce:bold>Myeloid proliferations related to Down's syndrome</ce:bold></ce:para><ce:para id="p4520"><ce:bold>Acute myeloid leukaemia not otherwise specified</ce:bold></ce:para><ce:para id="p4525"><ce:list id="ulist0945"><ce:list-item id="u2860"><ce:label>•</ce:label><ce:para id="p4530">e.g. AML with or without differentiation, acute myelomonocytic leukaemia, erythroleukaemia, megakaryoblastic leukaemia</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1140"><ce:section-title id="st1055">Acute lymphoblastic leukaemia (ALL)<ce:footnote id="fn9005"><ce:label>*</ce:label><ce:note-para id="np9005">Updated 2016; major subtypes.</ce:note-para></ce:footnote></ce:section-title><ce:para id="p4535"><ce:list id="ulist0950"><ce:list-item id="u2865"><ce:label>•</ce:label><ce:para id="p4540">B-lymphoblastic leukaemia/lymphoma</ce:para></ce:list-item><ce:list-item id="u2870"><ce:label>•</ce:label><ce:para id="p4545">T-lymphoblastic leukaemia/lymphoma</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0270" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0410" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0735" role="short">Image 46</ce:alt-text></ce:inline-figure>23.46</ce:label><ce:alt-text id="atte0740" role="short">23.46</ce:alt-text><ce:textbox-head><ce:title id="tit0275">Preparation for specific therapy in acute leukaemia</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4570"><ce:list id="ulist0955"><ce:list-item id="u2875"><ce:label>•</ce:label><ce:para id="p4575">Existing infections identified and treated (e.g. urinary tract infection, oral candidiasis, dental, gingival and skin infections)</ce:para></ce:list-item><ce:list-item id="u2880"><ce:label>•</ce:label><ce:para id="p4580">Anaemia corrected by red cell concentrate transfusion</ce:para></ce:list-item><ce:list-item id="u2885"><ce:label>•</ce:label><ce:para id="p4585">Thrombocytopenic bleeding controlled by platelet transfusions</ce:para></ce:list-item><ce:list-item id="u2890"><ce:label>•</ce:label><ce:para id="p4590">If possible, central venous catheter (e.g. Hickman line) inserted to facilitate access to the circulation for delivery of chemotherapy, fluids, blood products and other supportive drugs</ce:para></ce:list-item><ce:list-item id="u2895"><ce:label>•</ce:label><ce:para id="p4595">Tumour lysis risk assessed and prevention started: fluids with allopurinol or rasburicase</ce:para></ce:list-item><ce:list-item id="u2900"><ce:label>•</ce:label><ce:para id="p4600">Therapeutic regimen carefully explained to the patient and informed consent obtained</ce:para></ce:list-item><ce:list-item id="u2905"><ce:label>•</ce:label><ce:para id="p4605">Consideration of entry into clinical trial</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0275" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0415" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0745" role="short">Image 47</ce:alt-text></ce:inline-figure>23.47</ce:label><ce:alt-text id="atte0750" role="short">23.47</ce:alt-text><ce:textbox-head><ce:title id="tit0280">Drugs commonly used in the treatment of acute leukaemia</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4645"><ce:display><ce:table frame="topbot" id="t0120"><ce:alt-text id="atte0755" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Phase</entry><entry align="left">Acute lymphoblastic leukaemia</entry><entry align="left">Acute myeloid leukaemia</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Induction</ce:bold></entry><entry align="left"><ce:list id="ulist0965"><ce:list-item id="u2925"><ce:para id="p4650">Vincristine (IV)</ce:para></ce:list-item><ce:list-item id="u2930"><ce:para id="p4655">Prednisolone (oral)</ce:para></ce:list-item><ce:list-item id="u2935"><ce:para id="p4660">L-Asparaginase (IM)</ce:para></ce:list-item><ce:list-item id="u2940"><ce:para id="p4665">Daunorubicin (IV)</ce:para></ce:list-item><ce:list-item id="u2945"><ce:para id="p4670">Methotrexate (intrathecal)</ce:para></ce:list-item><ce:list-item id="u2950"><ce:para id="p4675">Imatinib (oral)<ce:cross-ref id="crf0915" refid="tn0035">*</ce:cross-ref></ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0970"><ce:list-item id="u2955"><ce:para id="p4680">Daunorubicin (IV)</ce:para></ce:list-item><ce:list-item id="u2960"><ce:para id="p4685">Cytarabine (IV)</ce:para></ce:list-item><ce:list-item id="u2965"><ce:para id="p4690">Etoposide (IV and oral)</ce:para></ce:list-item><ce:list-item id="u2970"><ce:para id="p4695">Gentuzumab ozogamicin (IV)</ce:para></ce:list-item><ce:list-item id="u2975"><ce:para id="p4700">All-<ce:italic>trans</ce:italic> retinoic acid (ATRA) (oral)</ce:para></ce:list-item><ce:list-item id="o9035"><ce:para id="p9100">Arsenic trioxide (ATO)</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left"><ce:bold>Consolidation</ce:bold></entry><entry align="left"><ce:list id="ulist0975"><ce:list-item id="u2980"><ce:para id="p4705">Daunorubicin (IV)</ce:para></ce:list-item><ce:list-item id="u2985"><ce:para id="p4710">Cytarabine (IV)</ce:para></ce:list-item><ce:list-item id="u2990"><ce:para id="p4715">Etoposide (IV)</ce:para></ce:list-item><ce:list-item id="u2995"><ce:para id="p4720">Methotrexate (IV)</ce:para></ce:list-item><ce:list-item id="u3000"><ce:para id="p4725">Imatinib (oral)<ce:cross-ref id="crf0920" refid="tn0035">*</ce:cross-ref></ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0980"><ce:list-item id="u3005"><ce:para id="p4730">Cytarabine (IV)</ce:para></ce:list-item><ce:list-item id="u3010"><ce:para id="p4735">Amsacrine (IV)</ce:para></ce:list-item><ce:list-item id="u3015"><ce:para id="p4740">Mitoxantrone (IV)</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left"><ce:bold>Maintenance</ce:bold></entry><entry align="left"><ce:list id="ulist0985"><ce:list-item id="u3020"><ce:para id="p4745">Prednisolone (oral)</ce:para></ce:list-item><ce:list-item id="u3025"><ce:para id="p4750">Vincristine (IV)</ce:para></ce:list-item><ce:list-item id="u3030"><ce:para id="p4755">Mercaptopurine (oral)</ce:para></ce:list-item><ce:list-item id="u3035"><ce:para id="p4760">Methotrexate (oral)</ce:para></ce:list-item><ce:list-item id="u3040"><ce:para id="p4765">Imatinib (oral)<ce:cross-ref id="crf0925" refid="tn0035">*</ce:cross-ref></ce:para></ce:list-item></ce:list></entry><entry align="left"/></row><row><entry align="left"><ce:bold>Relapse</ce:bold></entry><entry align="left"><ce:list id="ulist0990"><ce:list-item id="u3045"><ce:para id="p4770">Fludarabine</ce:para></ce:list-item><ce:list-item id="u3050"><ce:para id="p4775">Cytarabine</ce:para></ce:list-item><ce:list-item id="u3065"><ce:para id="p4790">Idarubicin</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0995"><ce:list-item id="u3055"><ce:para id="p4780">Fludarabine</ce:para></ce:list-item><ce:list-item id="u3060"><ce:para id="p4785">Cytarabine</ce:para></ce:list-item><ce:list-item id="o9040"><ce:para id="p9105">Arsenic trioxide (ATO)</ce:para></ce:list-item><ce:list-item id="u3070"><ce:para id="p4795">Idarubicin</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup><ce:table-footnote id="tn0035"><ce:label>*</ce:label><ce:note-para id="np0050">If Philadelphia chromosome-positive.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0280" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0420" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0760" role="short">Image 48</ce:alt-text></ce:inline-figure>23.48</ce:label><ce:alt-text id="atte0765" role="short">23.48</ce:alt-text><ce:textbox-head><ce:title id="tit0285">Outcome in adult acute leukaemia</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4870"><ce:display><ce:table frame="topbot" id="t0125"><ce:alt-text id="atte0770" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Disease/risk</entry><entry align="left">Risk factors</entry><entry align="left">5-year overall survival</entry></row></thead><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col3" align="left"><ce:bold>Acute myeloid leukaemia (AML)</ce:bold></entry></row><row rowsep="0"><entry morerows="2" align="left">Good risk</entry><entry align="left">Promyelocytic leukaemia t(15;17)</entry><entry align="left">90%</entry></row><row rowsep="0"><entry align="left">t(8;21)</entry><entry align="left">65%</entry></row><row rowsep="0"><entry align="left">inv 16 or t(16;16)</entry><entry align="left">70%</entry></row><row rowsep="0"><entry morerows="2" align="left">Poor risk</entry><entry align="left">Cytogenetic abnormalities</entry><entry morerows="2" align="left">21%</entry></row><row rowsep="0"><entry align="left">−5, −7, del</entry></row><row rowsep="0"><entry align="left">5q, abn(3q), complex (&#x003E; 5)</entry></row><row rowsep="1"><entry align="left">Intermediate risk</entry><entry align="left">AML with none of the above</entry><entry align="left">48%</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col3" align="left"><ce:bold>Acute lymphoblastic leukaemia (ALL)</ce:bold></entry></row><row rowsep="0"><entry morerows="3" align="left">Poor risk</entry><entry align="left">Philadelphia chromosome</entry><entry morerows="3" align="left">20%</entry></row><row rowsep="0"><entry align="left">High white count &#x003E; 100 × 10<ce:sup loc="post">9</ce:sup>/L</entry></row><row rowsep="0"><entry align="left">Abnormal short arm of chromosome</entry></row><row rowsep="0"><entry align="left">11 t(1;19)</entry></row><row><entry align="left">Standard</entry><entry align="left">ALL with none of the above</entry><entry align="left">37%</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0285" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9020" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0775" role="short">Image 49</ce:alt-text></ce:inline-figure>23.49</ce:label><ce:alt-text id="atte0780" role="short">23.49</ce:alt-text><ce:textbox-head><ce:title id="tit9005">Tyrosine kinase inhibition in chronic myeloid leukaemia</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p9015"><ce:display><ce:table frame="topbot" id="t9000"><ce:alt-text id="atte0785" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Agents</ce:bold></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>First-line</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist9000"><ce:list-item id="u9010"><ce:label>•</ce:label><ce:para id="p9110">Imatinib</ce:para></ce:list-item><ce:list-item id="u9015"><ce:label>•</ce:label><ce:para id="p9115">Nilotinib</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist9005"><ce:list-item id="u9020"><ce:label>•</ce:label><ce:para id="p9120">Dasatinib</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Second-line</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist9010"><ce:list-item id="u9025"><ce:label>•</ce:label><ce:para id="p9035">Imatinib</ce:para></ce:list-item><ce:list-item id="u9030"><ce:label>•</ce:label><ce:para id="p9040">Nilotinib</ce:para></ce:list-item><ce:list-item id="u9035"><ce:label>•</ce:label><ce:para id="p9045">Dasatinib</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist9015"><ce:list-item id="u9040"><ce:label>•</ce:label><ce:para id="p9050">Bosutinib</ce:para></ce:list-item><ce:list-item id="u9045"><ce:label>•</ce:label><ce:para id="p9055">Ponatinib<ce:cross-ref id="crf9025" refid="tn9010">*</ce:cross-ref></ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Outcomes</ce:bold></entry></row><row><entry namest="col1" nameend="col2" align="left"><ce:list id="ulist9020"><ce:list-item id="u9050"><ce:label>•</ce:label><ce:para id="p9060">90% achieve complete cytogenetic response</ce:para></ce:list-item><ce:list-item id="u9055"><ce:label>•</ce:label><ce:para id="p9065">Responses faster with nilotinib and dasatinib</ce:para></ce:list-item><ce:list-item id="u9060"><ce:label>•</ce:label><ce:para id="p9070">Median survival comparable to normal population</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup><ce:table-footnote id="tn9010"><ce:label>*</ce:label><ce:note-para id="np9010">For patients with T315I kinase domain mutations use ponatinib.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0290" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0430" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0790" role="short">Image 50</ce:alt-text></ce:inline-figure>23.50</ce:label><ce:alt-text id="atte0795" role="short">23.50</ce:alt-text><ce:textbox-head><ce:title id="tit0295">Staging of chronic lymphocytic leukaemia</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s1255"><ce:section-title id="st1170">Clinical stage A (60% patients)</ce:section-title><ce:para id="p4960"><ce:list id="ulist1015"><ce:list-item id="u3090"><ce:label>•</ce:label><ce:para id="p4965">No anaemia or thrombocytopenia and fewer than three areas of lymphoid enlargement</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1260"><ce:section-title id="st1175">Clinical stage B (30% patients)</ce:section-title><ce:para id="p4970"><ce:list id="ulist1020"><ce:list-item id="u3095"><ce:label>•</ce:label><ce:para id="p4975">No anaemia or thrombocytopenia, with three or more involved areas of lymphoid enlargement</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1265"><ce:section-title id="st1180">Clinical stage C (10% patients)</ce:section-title><ce:para id="p4980"><ce:list id="ulist1025"><ce:list-item id="u3100"><ce:label>•</ce:label><ce:para id="p4985">Anaemia and/or thrombocytopenia, regardless of the number of areas of lymphoid enlargement</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0295" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9025" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0800" role="short">Image 51</ce:alt-text></ce:inline-figure>23.51</ce:label><ce:alt-text id="atte0805" role="short">23.51</ce:alt-text><ce:textbox-head><ce:title id="tit9010">WHO classification of myelodysplastic syndromes (MDSs)</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p9075"><ce:display><ce:table frame="topbot" id="t9005"><ce:alt-text id="atte0810" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="0"><entry align="left">Disease</entry><entry align="left">Bone marrow findings</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>MDS with single-lineage dysplasia</ce:bold></entry><entry align="left">&#x003C; 5% blasts and single-lineage dysplasia only</entry></row><row rowsep="1"><entry align="left"><ce:bold>MDS with ring sideroblasts (MDS-RS)</ce:bold></entry><entry align="left">&#x003E; 15% ring sideroblasts, or 6–14% and presence of <ce:italic>SF3B1</ce:italic> gene mutation</entry></row><row rowsep="1"><entry align="left"><ce:bold>MDS with multilineage dysplasia</ce:bold></entry><entry align="left">&#x003C; 5% blasts and dysplasia in 2 or more lineages</entry></row><row rowsep="1"><entry align="left"><ce:bold>MDS with excess blasts</ce:bold></entry><entry align="left">5–19% blasts</entry></row><row><entry morerows="2" rowsep="1" align="left"><ce:bold>MDS with isolated del(5q)</ce:bold></entry><entry rowsep="0" align="left">Myelodysplastic syndrome associated with a del(5q) cytogenetic abnormality</entry></row><row rowsep="0"><entry align="left">&#x003C; 5% blasts</entry></row><row rowsep="1"><entry align="left">Often normal or increased blood platelet count</entry></row><row><entry align="left"><ce:bold>MDS, unclassifiable</ce:bold></entry><entry align="left">None of the above or inadequate material</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0300" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0440" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0815" role="short">Image 52</ce:alt-text></ce:inline-figure>23.52</ce:label><ce:alt-text id="atte0820" role="short">23.52</ce:alt-text><ce:textbox-head><ce:title id="tit0305">Revised International Prognostic Scoring System and outcomes in myelodysplasia<ce:cross-ref id="crf0975" refid="fn0025">*</ce:cross-ref><ce:footnote id="fn0025"><ce:label>*</ce:label><ce:note-para id="np0060">The IPSS-R is based on three prognostic factors: the blast percentage in bone marrow; karyotype; and number and degree of blood cytopenias. A score is derived from which patients can be stratified into five risk categories for survival and leukaemic transformation.</ce:note-para></ce:footnote></ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5050"><ce:display><ce:table frame="topbot" id="t0140"><ce:alt-text id="atte0825" role="short">Unlabelled table</ce:alt-text><tgroup cols="4"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><colspec colname="col4" colnum="4"/><thead><row rowsep="1"><entry align="left">Risk category</entry><entry align="left">Overall score</entry><entry align="left">Median survival (years)</entry><entry align="left">25% progression to acute myeloid leukaemia (years)</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Very low</ce:bold></entry><entry align="left">≤ 1.5</entry><entry align="left">8.8</entry><entry align="left">Not reached</entry></row><row rowsep="1"><entry align="left"><ce:bold>Low</ce:bold></entry><entry align="left">&#x003E; 1.5–3</entry><entry align="left">5.3</entry><entry align="left">10.8</entry></row><row rowsep="1"><entry align="left"><ce:bold>Intermediate</ce:bold></entry><entry align="left">&#x003E; 3–4.5</entry><entry align="left">3.0</entry><entry align="left">3.2</entry></row><row rowsep="1"><entry align="left"><ce:bold>High</ce:bold></entry><entry align="left">&#x003E; 4.5–6</entry><entry align="left">1.6</entry><entry align="left">1.4</entry></row><row><entry align="left"><ce:bold>Very high</ce:bold></entry><entry align="left">&#x003E; 6</entry><entry align="left">0.8</entry><entry align="left">0.73</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0305" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0455" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0830" role="short">Image 53</ce:alt-text></ce:inline-figure>23.53</ce:label><ce:alt-text id="atte0835" role="short">23.53</ce:alt-text><ce:textbox-head><ce:title id="tit0310">Epidemiology and aetiology of Hodgkin lymphoma</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s1315"><ce:section-title id="st1230">Incidence</ce:section-title><ce:para id="p5085"><ce:list id="ulist1035"><ce:list-item id="u3115"><ce:label>•</ce:label><ce:para id="p5090">Approximately 4 new cases/100 000 population/year</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1320"><ce:section-title id="st1235">Sex ratio</ce:section-title><ce:para id="p5095"><ce:list id="ulist1040"><ce:list-item id="u3120"><ce:label>•</ce:label><ce:para id="p5100">Slight male excess (1.5 : 1)</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1325"><ce:section-title id="st1240">Age</ce:section-title><ce:para id="p5105"><ce:list id="ulist1045"><ce:list-item id="u3125"><ce:label>•</ce:label><ce:para id="p5110">Median age 31 years; first peak at 20–35 years and second at 50–70 years</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1330"><ce:section-title id="st1245">Aetiology</ce:section-title><ce:para id="p5115"><ce:list id="ulist1050"><ce:list-item id="u3130"><ce:label>•</ce:label><ce:para id="p5120">Unknown</ce:para></ce:list-item><ce:list-item id="u3135"><ce:label>•</ce:label><ce:para id="p5125">More common in patients from well-educated backgrounds and small families</ce:para></ce:list-item><ce:list-item id="u3140"><ce:label>•</ce:label><ce:para id="p5130">Three times more likely with a past history of infectious mononucleosis but no definitive causal link to Epstein–Barr virus infection proven</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0310" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0460" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0840" role="short">Image 54</ce:alt-text></ce:inline-figure>23.54</ce:label><ce:alt-text id="atte0845" role="short">23.54</ce:alt-text><ce:textbox-head><ce:title id="tit0315">WHO pathological classification of Hodgkin lymphoma (HL)</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5135"><ce:display><ce:table frame="topbot" id="t0145"><ce:alt-text id="atte0850" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Type</entry><entry align="left">Histology classification</entry><entry align="left">Proportion of HL</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Nodular lymphocyte-predominant HL</ce:bold></entry><entry align="left"/><entry align="left">5%</entry></row><row><entry morerows="3" align="left"><ce:bold>Classical HL</ce:bold></entry><entry rowsep="0" align="left">Nodular sclerosing</entry><entry rowsep="0" align="left">70%</entry></row><row rowsep="0"><entry align="left">Mixed cellularity</entry><entry align="left">20%</entry></row><row rowsep="0"><entry align="left">Lymphocyte-rich</entry><entry align="left">5%</entry></row><row><entry align="left">Lymphocyte-depleted</entry><entry align="left">Rare</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0315" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0465" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0855" role="short">Image 55</ce:alt-text></ce:inline-figure>23.55</ce:label><ce:alt-text id="atte0860" role="short">23.55</ce:alt-text><ce:textbox-head><ce:title id="tit0320">Clinical stages of Hodgkin lymphoma (Ann Arbor classification)</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5155"><ce:display><ce:table frame="topbot" id="t0150"><ce:alt-text id="atte0865" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Stage</entry><entry align="left">Definition</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>I</ce:bold></entry><entry align="left">Involvement of a single lymph node region (I) or extralymphatic<ce:cross-ref id="crf1005" refid="tn0045">*</ce:cross-ref> site (I<ce:inf loc="post">E</ce:inf>)</entry></row><row rowsep="1"><entry align="left"><ce:bold>II</ce:bold></entry><entry align="left">Involvement of two or more lymph node regions (II) or an extralymphatic site and lymph node regions on the same side of (above or below) the diaphragm (II<ce:inf loc="post">E</ce:inf>)</entry></row><row rowsep="1"><entry align="left"><ce:bold>III</ce:bold></entry><entry align="left">Involvement of lymph node regions on both sides of the diaphragm with (III<ce:inf loc="post">E</ce:inf>) or without (III) localised extralymphatic involvement or involvement of the spleen (III<ce:inf loc="post">s</ce:inf>), or both (III<ce:inf loc="post">SE</ce:inf>)</entry></row><row rowsep="1"><entry align="left"><ce:bold>IV</ce:bold></entry><entry align="left">Diffuse involvement of one or more extralymphatic tissues, e.g. liver or bone marrow</entry></row><row rowsep="0"><entry namest="col1" nameend="col2" align="left">Each stage is subclassified:</entry></row><row rowsep="0"><entry align="left"><ce:bold>A</ce:bold></entry><entry align="left">No systemic symptoms</entry></row><row><entry align="left"><ce:bold>B</ce:bold></entry><entry align="left">Weight loss &#x003E; 10%, drenching sweats, fever</entry></row></tbody></tgroup><ce:table-footnote id="tn0045"><ce:label>*</ce:label><ce:note-para id="np0065">The lymphatic structures are defined as the lymph nodes, spleen, thymus, Waldeyer's ring, appendix and Peyer's patches.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0320" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0490" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0870" role="short">Image 56</ce:alt-text></ce:inline-figure>23.56</ce:label><ce:alt-text id="atte0875" role="short">23.56</ce:alt-text><ce:textbox-head><ce:title id="tit0325">The Hasenclever prognostic index for advanced Hodgkin lymphoma</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5240"><ce:display><ce:table frame="topbot" id="t0155"><ce:alt-text id="atte0880" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><tbody><row rowsep="0"><entry namest="col1" nameend="col3" align="left">Score 1 for each of the following risk factors present at diagnosis:</entry></row><row rowsep="1"><entry namest="col1" nameend="col3" align="left"><ce:list id="ulist1060"><ce:list-item id="u3190"><ce:label>•</ce:label><ce:para id="p5245">Age &#x003E; 45 years</ce:para></ce:list-item><ce:list-item id="u3195"><ce:label>•</ce:label><ce:para id="p5250">Male gender</ce:para></ce:list-item><ce:list-item id="u3200"><ce:label>•</ce:label><ce:para id="p5255">Serum albumin &#x003C; 40 g/L</ce:para></ce:list-item><ce:list-item id="u3205"><ce:label>•</ce:label><ce:para id="p5260">Hb &#x003C; 105 g/L</ce:para></ce:list-item><ce:list-item id="u3210"><ce:label>•</ce:label><ce:para id="p5265">Stage IV disease</ce:para></ce:list-item><ce:list-item id="u3215"><ce:label>•</ce:label><ce:para id="p5270">White blood cell count &#x003E; 15 × 10<ce:sup loc="post">9</ce:sup>/L</ce:para></ce:list-item><ce:list-item id="u3220"><ce:label>•</ce:label><ce:para id="p5275">Lymphopenia &#x003C; 0.6 × 10<ce:sup loc="post">9</ce:sup>/L</ce:para></ce:list-item></ce:list></entry></row><row rowsep="0"><entry align="left"><ce:bold>Score</ce:bold></entry><entry align="left"><ce:bold>5-year rate of freedom from progression (%)</ce:bold></entry><entry align="left"><ce:bold>5-year rate of overall survival (%)</ce:bold></entry></row><row rowsep="0"><entry align="left">0–1</entry><entry align="left">79</entry><entry align="left">90</entry></row><row rowsep="0"><entry align="left">&#x003E; 2</entry><entry align="left">60</entry><entry align="left">74</entry></row><row rowsep="0"><entry align="left">&#x003E; 3</entry><entry align="left">55</entry><entry align="left">70</entry></row><row><entry align="left">&#x003E; 4</entry><entry align="left">47</entry><entry align="left">59</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0325" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0495" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0885" role="short">Image 57</ce:alt-text></ce:inline-figure>23.57</ce:label><ce:alt-text id="atte0890" role="short">23.57</ce:alt-text><ce:textbox-head><ce:title id="tit0330">Epidemiology and aetiology of non-Hodgkin lymphoma</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s1360"><ce:section-title id="st1275">Incidence</ce:section-title><ce:para id="p5290"><ce:list id="ulist1065"><ce:list-item id="u3225"><ce:label>•</ce:label><ce:para id="p5295">12 new cases/100 000 people/year</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1365"><ce:section-title id="st1280">Sex ratio</ce:section-title><ce:para id="p5300"><ce:list id="ulist1070"><ce:list-item id="u3230"><ce:label>•</ce:label><ce:para id="p5305">Slight male excess</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1370"><ce:section-title id="st1285">Age</ce:section-title><ce:para id="p5310"><ce:list id="ulist1075"><ce:list-item id="u3235"><ce:label>•</ce:label><ce:para id="p5315">Median age 65–70 years</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1375"><ce:section-title id="st1290">Aetiology</ce:section-title><ce:para id="p5320"><ce:list id="ulist1080"><ce:list-item id="u3240"><ce:label>•</ce:label><ce:para id="p5325">No single causative abnormality described</ce:para></ce:list-item><ce:list-item id="u3245"><ce:label>•</ce:label><ce:para id="p5330">Lymphoma is a late manifestation of HIV infection (<ce:intra-ref id="ii0620" xlink:href="pii:B978-0-7020-7028-0.00012-3#s0355">p. 322</ce:intra-ref>)</ce:para></ce:list-item><ce:list-item id="u3250"><ce:label>•</ce:label><ce:para id="p5335">Specific lymphoma types are associated with viruses: e.g. Epstein–Barr virus (EBV) with post-transplant NHL, human herpesvirus 8 (HHV8) with a primary effusion lymphoma, and human T-cell lymphotropic virus (HTLV-1) with adult T-cell leukaemia lymphoma</ce:para></ce:list-item><ce:list-item id="u3255"><ce:label>•</ce:label><ce:para id="p5340">Gastric lymphoma can be associated with <ce:italic>Helicobacter pylori</ce:italic> infection</ce:para></ce:list-item><ce:list-item id="u3260"><ce:label>•</ce:label><ce:para id="p5345">Some lymphomas are associated with specific chromosomal translocations:<ce:list id="ulist1085"><ce:list-item id="u3265"><ce:para id="p5350">The t(14;18) in follicular lymphoma results in the dysregulated expression of the BCL-2 gene product, which inhibits apoptotic cell death</ce:para></ce:list-item><ce:list-item id="u3270"><ce:para id="p5355">The t(8;14) found in Burkitt lymphoma and the t(11;14) in mantle cell lymphoma alter function of c-myc and cyclin D1, respectively, resulting in malignant proliferation</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u3275"><ce:label>•</ce:label><ce:para id="p5360">Lymphoma occurs in congenital immunodeficiency states and in immunosuppressed patients after organ transplantation</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0330" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0515" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0895" role="short">Image 58</ce:alt-text></ce:inline-figure>23.58</ce:label><ce:alt-text id="atte0900" role="short">23.58</ce:alt-text><ce:textbox-head><ce:title id="tit0335">Classification of multiple myeloma</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5525"><ce:display><ce:table frame="topbot" id="t0160"><ce:alt-text id="atte0905" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Type of monoclonal (M)-protein</entry><entry align="left">Relative frequency (%)</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>IgG</ce:bold></entry><entry align="left">55</entry></row><row rowsep="1"><entry align="left"><ce:bold>IgA</ce:bold></entry><entry align="left">21</entry></row><row rowsep="1"><entry align="left"><ce:bold>Light chain only</ce:bold></entry><entry align="left">22</entry></row><row><entry align="left"><ce:bold>Others (D, E, non-secretory)</ce:bold></entry><entry align="left">2</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0335" role="alt2"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0525" locator="icon02-9780702070280" xlink:href="pii:B9780702070280000238/icon02-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0910" role="short">Image 59</ce:alt-text></ce:inline-figure>23.59</ce:label><ce:alt-text id="atte0915" role="short">23.59</ce:alt-text><ce:textbox-head><ce:title id="tit0340">Haematological malignancy in old age</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5610"><ce:list id="ulist1115"><ce:list-item id="u3400"><ce:label>•</ce:label><ce:para id="p5615"><ce:bold>Median age</ce:bold>: approximately 70 years for most haematological malignancies.</ce:para></ce:list-item><ce:list-item id="u3405"><ce:label>•</ce:label><ce:para id="p5620"><ce:bold>Poor-risk biological features</ce:bold>: adverse cytogenetics or the presence of a multidrug resistance phenotype are more frequent.</ce:para></ce:list-item><ce:list-item id="u3410"><ce:label>•</ce:label><ce:para id="p5625"><ce:bold>Prognosis</ce:bold>: increasing age is an independent adverse variable in acute leukaemia and aggressive lymphoma.</ce:para></ce:list-item><ce:list-item id="u3415"><ce:label>•</ce:label><ce:para id="p5630"><ce:bold>Chemotherapy</ce:bold>: may be less well tolerated. Older people are more likely to have antecedent cardiac, pulmonary or metabolic problems, tolerate systemic infection less well and metabolise cytotoxic drugs differently.</ce:para></ce:list-item><ce:list-item id="u3420"><ce:label>•</ce:label><ce:para id="p5635"><ce:bold>Cure rates</ce:bold>: similar to those in younger patients, in those who do tolerate treatment.</ce:para></ce:list-item><ce:list-item id="u3425"><ce:label>•</ce:label><ce:para id="p5640"><ce:bold>Decision to treat</ce:bold>: should be based on the individual's biological status, the level of social support available, and the patient's wishes and those of the immediate family, but not on chronological age alone.</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0340" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0530" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0920" role="short">Image 60</ce:alt-text></ce:inline-figure>23.60</ce:label><ce:alt-text id="atte0925" role="short">23.60</ce:alt-text><ce:textbox-head><ce:title id="tit0345">Camitta criteria</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s1500"><ce:section-title id="st1410">Severe AA (SAA)</ce:section-title><ce:para id="p5680"><ce:list id="ulist1120"><ce:list-item id="u3430"><ce:label>•</ce:label><ce:para id="p5685">Marrow cellularity &#x003C; 25% (or 25–50% with &#x003C; 30% residual haematopoietic cells), plus at least two of:<ce:list id="ulist1125"><ce:list-item id="u3435"><ce:para id="p5690">Neutrophils &#x003C; 0.5 × 10<ce:sup loc="post">9</ce:sup>/L</ce:para></ce:list-item><ce:list-item id="u3440"><ce:para id="p5695">Platelets &#x003C; 20 × 10<ce:sup loc="post">9</ce:sup>/L</ce:para></ce:list-item><ce:list-item id="u3445"><ce:para id="p5700">Reticulocyte count &#x003C; 20 × 10<ce:sup loc="post">9</ce:sup>/L</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1505"><ce:section-title id="st1415">Very severe AA (VSAA)</ce:section-title><ce:para id="p5705"><ce:list id="ulist1130"><ce:list-item id="u3450"><ce:label>•</ce:label><ce:para id="p5710">As for SAA but neutrophils &#x003C; 0.2 × 10<ce:sup loc="post">9</ce:sup>/L</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1510"><ce:section-title id="st1420">Non-severe AA (NSAA)</ce:section-title><ce:para id="p5715"><ce:list id="ulist1135"><ce:list-item id="u3455"><ce:label>•</ce:label><ce:para id="p5720">AA not fulfilling the criteria for SAA or VSAA</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0345" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0535" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0930" role="short">Image 61</ce:alt-text></ce:inline-figure>23.61</ce:label><ce:alt-text id="atte0935" role="short">23.61</ce:alt-text><ce:textbox-head><ce:title id="tit0350">Causes of secondary aplastic anaemia</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5735"><ce:list id="ulist1140"><ce:list-item id="u3460"><ce:label>•</ce:label><ce:para id="p5740">Drugs:<ce:list id="ulist1145"><ce:list-item id="u3465"><ce:para id="p5745">Cytotoxic drugs</ce:para></ce:list-item><ce:list-item id="u3470"><ce:para id="p5750">Antibiotics – chloramphenicol, sulphonamides</ce:para></ce:list-item><ce:list-item id="u3475"><ce:para id="p5755">Antirheumatic agents – penicillamine, gold, phenylbutazone, indometacin</ce:para></ce:list-item><ce:list-item id="u3480"><ce:para id="p5760">Antithyroid drugs – carbimazole, propylthiouracil</ce:para></ce:list-item><ce:list-item id="u3485"><ce:para id="p5765">Anticonvulsants</ce:para></ce:list-item><ce:list-item id="u3490"><ce:para id="p5770">Immunosuppressants – azathioprine</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u3495"><ce:label>•</ce:label><ce:para id="p5775">Chemicals:<ce:list id="ulist1150"><ce:list-item id="u3500"><ce:para id="p5780">Benzene, toluene solvent misuse – glue-sniffing</ce:para></ce:list-item><ce:list-item id="u3505"><ce:para id="p5785">Insecticides – chlorinated hydrocarbons (DDT), organophosphates and carbamates (<ce:intra-ref id="ii0700" xlink:href="pii:B978-0-7020-7028-0.00007-X#p1740">pp. 145 and 146</ce:intra-ref>)</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u3510"><ce:label>•</ce:label><ce:para id="p5790">Radiation</ce:para></ce:list-item><ce:list-item id="u3515"><ce:label>•</ce:label><ce:para id="p5795">Viral hepatitis</ce:para></ce:list-item><ce:list-item id="u3520"><ce:label>•</ce:label><ce:para id="p5800">Pregnancy</ce:para></ce:list-item><ce:list-item id="u3525"><ce:label>•</ce:label><ce:para id="p5805">Paroxysmal nocturnal haemoglobinuria</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0350" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0540" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0940" role="short">Image 62</ce:alt-text></ce:inline-figure>23.62</ce:label><ce:alt-text id="atte0945" role="short">23.62</ce:alt-text><ce:textbox-head><ce:title id="tit0355">Causes of coagulopathy</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s1620"><ce:section-title id="st1525">Congenital</ce:section-title><ce:section id="s1625"><ce:section-title id="st1530">X-linked</ce:section-title><ce:para id="p5960"><ce:list id="ulist1160"><ce:list-item id="u3540"><ce:label>•</ce:label><ce:para id="p5965">Haemophilia A and B</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1630"><ce:section-title id="st1535">Autosomal</ce:section-title><ce:para id="p5970"><ce:list id="ulist1165"><ce:list-item id="u3545"><ce:label>•</ce:label><ce:para id="p5975">Von Willebrand disease</ce:para></ce:list-item><ce:list-item id="u3550"><ce:label>•</ce:label><ce:para id="p5980">Factor II, V, VII, X, XI and XIII deficiencies</ce:para></ce:list-item><ce:list-item id="u3555"><ce:label>•</ce:label><ce:para id="p5985">Combined II, VII, IX and X deficiency</ce:para></ce:list-item><ce:list-item id="u3560"><ce:label>•</ce:label><ce:para id="p5990">Combined V and VIII deficiency</ce:para></ce:list-item><ce:list-item id="u3565"><ce:label>•</ce:label><ce:para id="p5995">Hypofibrinogenaemia</ce:para></ce:list-item><ce:list-item id="u3570"><ce:label>•</ce:label><ce:para id="p6000">Dysfibrinogenaemia</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:section><ce:section id="s1635"><ce:section-title id="st1540">Acquired</ce:section-title><ce:section id="s1640"><ce:section-title id="st1545">Under-production</ce:section-title><ce:para id="p6005"><ce:list id="ulist1170"><ce:list-item id="u3575"><ce:label>•</ce:label><ce:para id="p6010">Liver failure</ce:para></ce:list-item><ce:list-item id="u3580"><ce:label>•</ce:label><ce:para id="p6015">Vitamin K deficiency</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1645"><ce:section-title id="st1550">Increased consumption</ce:section-title><ce:para id="p6020"><ce:list id="ulist1175"><ce:list-item id="u3585"><ce:label>•</ce:label><ce:para id="p6025">Coagulation activation:<ce:list id="ulist1180"><ce:list-item id="u3590"><ce:para id="p6030">Disseminated intravascular coagulation (DIC)</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u3595"><ce:label>•</ce:label><ce:para id="p6035">Immune-mediated:<ce:list id="ulist1185"><ce:list-item id="u3600"><ce:para id="p6040">Acquired haemophilia and von Willebrand disease</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u3605"><ce:label>•</ce:label><ce:para id="p6045">Others:<ce:list id="ulist1190"><ce:list-item id="u3610"><ce:para id="p6050">Acquired factor X deficiency (in amyloid)</ce:para></ce:list-item><ce:list-item id="u3615"><ce:para id="p6055">Acquired von Willebrand disease in Wilms' tumour</ce:para></ce:list-item><ce:list-item id="u3620"><ce:para id="p6060">Acquired factor VII deficiency in sepsis</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1650"><ce:section-title id="st1555">Drug-induced</ce:section-title><ce:para id="p6065"><ce:list id="ulist1195"><ce:list-item id="u3625"><ce:label>•</ce:label><ce:para id="p6070">Inhibition of function:<ce:list id="ulist1200"><ce:list-item id="u3630"><ce:para id="p6075">Heparins</ce:para></ce:list-item><ce:list-item id="u3635"><ce:para id="p6080">Argatroban</ce:para></ce:list-item><ce:list-item id="u3640"><ce:para id="p6085">Bivalirudin</ce:para></ce:list-item><ce:list-item id="u3645"><ce:para id="p6090">Fondaparinux</ce:para></ce:list-item><ce:list-item id="u3650"><ce:para id="p6095">Rivaroxaban</ce:para></ce:list-item><ce:list-item id="u3655"><ce:para id="p6100">Apixaban</ce:para></ce:list-item><ce:list-item id="u3660"><ce:para id="p6105">Dabigatran</ce:para></ce:list-item><ce:list-item id="u3665"><ce:para id="p6110">Edoxaban</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u3670"><ce:label>•</ce:label><ce:para id="p6115">Inhibition of post-translational modification:<ce:list id="ulist1205"><ce:list-item id="u3675"><ce:para id="p6120">Warfarin</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0355" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0545" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0950" role="short">Image 63</ce:alt-text></ce:inline-figure>23.63</ce:label><ce:alt-text id="atte0955" role="short">23.63</ce:alt-text><ce:textbox-head><ce:title id="tit0360">Severity of haemophilia (ISTH criteria)</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p6145"><ce:display><ce:table frame="topbot" id="t0165"><ce:alt-text id="atte0960" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Severity</entry><entry align="left">Factor VIII or IX level</entry><entry align="left">Clinical presentation</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Severe</ce:bold></entry><entry align="left">&#x003C; 0.01 U/mL</entry><entry align="left">Spontaneous haemarthroses and muscle haematomas</entry></row><row rowsep="1"><entry align="left"><ce:bold>Moderate</ce:bold></entry><entry align="left">0.01–0.05 U/mL</entry><entry align="left">Mild trauma or surgery causes bleeding</entry></row><row><entry align="left"><ce:bold>Mild</ce:bold></entry><entry align="left">&#x003E; 0.05–0.4 U/mL</entry><entry align="left">Major injury or surgery results in excess bleeding</entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0310">(ISTH = International Society on Thrombosis and Haemostasis)</ce:simple-para></ce:legend></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0360" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0555" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0965" role="short">Image 64</ce:alt-text></ce:inline-figure>23.64</ce:label><ce:alt-text id="atte0970" role="short">23.64</ce:alt-text><ce:textbox-head><ce:title id="tit0365">Classification of von Willebrand disease</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p6200"><ce:display><ce:table frame="topbot" id="t0170"><ce:alt-text id="atte0975" role="short">Unlabelled table</ce:alt-text><tgroup cols="4"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><colspec colname="col4" colnum="4"/><thead><row rowsep="1"><entry align="left">Type</entry><entry align="left">Defect</entry><entry align="left">Inheritance</entry><entry align="left">Investigations/patterns</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>1</ce:bold></entry><entry align="left">Partial quantitative</entry><entry align="left">AD</entry><entry align="left">Parallel decrease in vWF:Ag, RiCoF and Vlll:c</entry></row><row rowsep="1"><entry align="left"><ce:bold>2A</ce:bold></entry><entry align="left">Qualitative</entry><entry align="left">AD</entry><entry align="left">Absent HWM of vWF<ce:br/>Ratio of vWF activity to antigen &#x003C; 0.7</entry></row><row rowsep="1"><entry align="left"><ce:bold>2B</ce:bold></entry><entry align="left">Qualitative</entry><entry align="left">AD</entry><entry align="left">Reduced HWM of vWF<ce:br/>Enhanced platelet agglutination (RIPA)</entry></row><row rowsep="1"><entry align="left"><ce:bold>2M</ce:bold></entry><entry align="left">Qualitative</entry><entry align="left">AD</entry><entry align="left">Ratio of vWF activity to antigen ≪ 0.7<ce:br/>Normal multimers of vWF<ce:br/>Abnormal vWF/platelet interactions</entry></row><row rowsep="1"><entry align="left"><ce:bold>2N</ce:bold></entry><entry align="left">Qualitative</entry><entry align="left">AR</entry><entry align="left">Defective binding of vWF to VIII<ce:br/>Low VIII</entry></row><row><entry align="left"><ce:bold>3</ce:bold></entry><entry align="left">Severe quantitative</entry><entry align="left">AR or CH</entry><entry align="left">Very low vWF and VIII:c activity<ce:br/>Absent multimers</entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0325">(AD = autosomal dominant; AR = autosomal recessive; CH = compound heterozygote; HWM = high-weight multimers of vWF; RiCoF = ristocetin co-factor; RIPA = ristocetin-induced platelet agglutination; VIII:c = coagulation factor VIII activity in functional assay; vWF = von Willebrand factor; vWF:Ag = vWF antigen measured by ELISA)</ce:simple-para></ce:legend></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0365" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0560" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0980" role="short">Image 65</ce:alt-text></ce:inline-figure>23.65</ce:label><ce:alt-text id="atte0985" role="short">23.65</ce:alt-text><ce:textbox-head><ce:title id="tit0370">Factors predisposing to venous thrombosis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s1735"><ce:section id="s1740"><ce:section-title id="st1640">Patient factors</ce:section-title><ce:para id="p6255"><ce:list id="ulist1210"><ce:list-item id="u3680"><ce:label>•</ce:label><ce:para id="p6260">Increasing age</ce:para></ce:list-item><ce:list-item id="u3685"><ce:label>•</ce:label><ce:para id="p6265">Obesity</ce:para></ce:list-item><ce:list-item id="u3690"><ce:label>•</ce:label><ce:para id="p6270">Varicose veins</ce:para></ce:list-item><ce:list-item id="u3695"><ce:label>•</ce:label><ce:para id="p6275">Previous deep vein thrombosis</ce:para></ce:list-item><ce:list-item id="u3700"><ce:label>•</ce:label><ce:para id="p6280">Family history, especially of unprovoked venous thromboembolism when young</ce:para></ce:list-item><ce:list-item id="u3705"><ce:label>•</ce:label><ce:para id="p6285">Transient additional risk factors:<ce:list id="ulist1215"><ce:list-item id="u3710"><ce:para id="p6290">Pregnancy/puerperium</ce:para></ce:list-item><ce:list-item id="u3715"><ce:para id="p6295">Oestrogen-containing oral contraceptives and hormone replacement therapy</ce:para></ce:list-item><ce:list-item id="u3720"><ce:para id="p6300">Immobility, e.g. long-distance travel (&#x003E; 4 hrs)</ce:para></ce:list-item><ce:list-item id="u3725"><ce:para id="p6305">Intravenous drug use involving the femoral vein</ce:para></ce:list-item><ce:list-item id="u3730"><ce:para id="p6310">Surgery (see below)</ce:para></ce:list-item><ce:list-item id="u3735"><ce:para id="p6315">Medical illnesses (see below)</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1745"><ce:section-title id="st1645">Surgical conditions</ce:section-title><ce:para id="p6320"><ce:list id="ulist1220"><ce:list-item id="u3740"><ce:label>•</ce:label><ce:para id="p6325">Major surgery, especially if &#x003E; 30 mins' duration</ce:para></ce:list-item><ce:list-item id="u3745"><ce:label>•</ce:label><ce:para id="p6330">Abdominal or pelvic surgery, especially for cancer</ce:para></ce:list-item><ce:list-item id="u3750"><ce:label>•</ce:label><ce:para id="p6335">Major lower limb orthopaedic surgery, e.g. joint replacement and hip fracture surgery</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1750"><ce:section-title id="st1650">Medical conditions</ce:section-title><ce:para id="p6340"><ce:list id="ulist1225"><ce:list-item id="u3755"><ce:label>•</ce:label><ce:para id="p6345">Myocardial infarction/heart failure</ce:para></ce:list-item><ce:list-item id="u3760"><ce:label>•</ce:label><ce:para id="p6350">Inflammatory bowel disease</ce:para></ce:list-item><ce:list-item id="u3765"><ce:label>•</ce:label><ce:para id="p6355">Malignancy (anti-cancer chemotherapy increases the risk of venous thromboembolism compared with cancer alone)</ce:para></ce:list-item><ce:list-item id="u3770"><ce:label>•</ce:label><ce:para id="p6360">Nephrotic syndrome</ce:para></ce:list-item><ce:list-item id="u3775"><ce:label>•</ce:label><ce:para id="p6365">Chronic obstructive pulmonary disease</ce:para></ce:list-item><ce:list-item id="u3780"><ce:label>•</ce:label><ce:para id="p6370">Pneumonia</ce:para></ce:list-item><ce:list-item id="u3785"><ce:label>•</ce:label><ce:para id="p6375">Neurological conditions associated with immobility, e.g. stroke, paraplegia, Guillain–Barré syndrome</ce:para></ce:list-item><ce:list-item id="u3790"><ce:label>•</ce:label><ce:para id="p6380">Any high-dependency admission</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1755"><ce:section-title id="st1655">Haematological disorders</ce:section-title><ce:para id="p6385"><ce:list id="ulist1230"><ce:list-item id="u3795"><ce:label>•</ce:label><ce:para id="p6390">Polycythaemia rubra vera</ce:para></ce:list-item><ce:list-item id="u3800"><ce:label>•</ce:label><ce:para id="p6395">Essential thrombocythaemia</ce:para></ce:list-item><ce:list-item id="u3805"><ce:label>•</ce:label><ce:para id="p6400">Deficiency of natural anticoagulants: antithrombin, protein C, protein S</ce:para></ce:list-item><ce:list-item id="u3810"><ce:label>•</ce:label><ce:para id="p6405">Paroxysmal nocturnal haemoglobinuria</ce:para></ce:list-item><ce:list-item id="u3815"><ce:label>•</ce:label><ce:para id="p6410">Gain-of-function prothrombotic mutations: factor V Leiden, prothrombin gene <ce:italic>G20210A</ce:italic></ce:para></ce:list-item><ce:list-item id="u3820"><ce:label>•</ce:label><ce:para id="p6415">Myelofibrosis</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p6420">Antiphospholipid syndrome</ce:para></ce:section></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0370" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0570" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0990" role="short">Image 66</ce:alt-text></ce:inline-figure>23.66</ce:label><ce:alt-text id="atte0995" role="short">23.66</ce:alt-text><ce:textbox-head><ce:title id="tit0375">Antithrombotic prophylaxis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p6450"><ce:display><ce:table frame="topbot" id="t0175"><ce:alt-text id="atte1000" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Indications</ce:bold></entry></row><row rowsep="0"><entry namest="col1" nameend="col2" align="left">Patients in the following categories should be considered for specific antithrombotic prophylaxis:</entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Moderate risk of DVT</ce:bold></entry></row><row rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:list id="ulist1235"><ce:list-item id="u3825"><ce:label>•</ce:label><ce:para id="p6455">Major surgery:<ce:list id="ulist1240"><ce:list-item id="u3830"><ce:para id="p6460">In patients &#x003E; 40 years or with other risk factor for VTE</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u3835"><ce:label>•</ce:label><ce:para id="p6465">Major medical illness, e.g.:<ce:list id="ulist1245"><ce:list-item id="u3840"><ce:para id="p6470">Heart failure</ce:para></ce:list-item><ce:list-item id="u3845"><ce:para id="p6475">Myocardial infarction with complications</ce:para></ce:list-item><ce:list-item id="u3850"><ce:para id="p6480">Sepsis</ce:para></ce:list-item><ce:list-item id="u3855"><ce:para id="p6485">Inflammatory conditions, including inflammatory bowel disease</ce:para></ce:list-item><ce:list-item id="u3860"><ce:para id="p6490">Active malignancy</ce:para></ce:list-item><ce:list-item id="u3865"><ce:para id="p6495">Nephrotic syndrome</ce:para></ce:list-item><ce:list-item id="u3870"><ce:para id="p6500">Stroke and other conditions leading to lower limb paralysis</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>High risk of DVT</ce:bold></entry></row><row rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:list id="ulist1250"><ce:list-item id="u3875"><ce:label>•</ce:label><ce:para id="p6505">Major abdominal or pelvic surgery for malignancy or with history of DVT or known thrombophilia (see <ce:cross-ref id="crf1160" refid="b0055">Box 23.4</ce:cross-ref>, p. 923)</ce:para></ce:list-item><ce:list-item id="u3880"><ce:label>•</ce:label><ce:para id="p6510">Major hip or knee surgery</ce:para></ce:list-item><ce:list-item id="u3885"><ce:label>•</ce:label><ce:para id="p6515">Neurosurgery</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Methods of VTE prophylaxis</ce:bold></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Mechanical</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1255"><ce:list-item id="u3890"><ce:label>•</ce:label><ce:para id="p6520">Intermittent pneumatic compression</ce:para></ce:list-item><ce:list-item id="u3895"><ce:label>•</ce:label><ce:para id="p6525">Mechanical foot pumps</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1260"><ce:list-item id="u3900"><ce:label>•</ce:label><ce:para id="p6530">Graduated compression stockings</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Pharmacological</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist1265"><ce:list-item id="u3905"><ce:label>•</ce:label><ce:para id="p6535">LMWHs</ce:para></ce:list-item><ce:list-item id="u3910"><ce:label>•</ce:label><ce:para id="p6540">Unfractionated heparin</ce:para></ce:list-item><ce:list-item id="u3915"><ce:label>•</ce:label><ce:para id="p6545">Fondaparinux</ce:para></ce:list-item><ce:list-item id="u3920"><ce:label>•</ce:label><ce:para id="p6550">Dabigatran</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1270"><ce:list-item id="u3925"><ce:label>•</ce:label><ce:para id="p6555">Rivaroxaban</ce:para></ce:list-item><ce:list-item id="u3930"><ce:label>•</ce:label><ce:para id="p6560">Apixaban</ce:para></ce:list-item><ce:list-item id="u3935"><ce:label>•</ce:label><ce:para id="p6565">Warfarin</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para><ce:para id="p6570">(DVT = deep vein thrombosis; VTE = venous thromboembolism)</ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0375" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0575" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1005" role="short">Image 67</ce:alt-text></ce:inline-figure>23.67</ce:label><ce:alt-text id="atte1010" role="short">23.67</ce:alt-text><ce:textbox-head><ce:title id="tit0380">Antiphospholipid syndrome (APS)</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p6630"><ce:display><ce:table frame="topbot" id="t0180"><ce:alt-text id="atte1015" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Clinical manifestations</ce:bold></entry></row><row rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:list id="ulist1280"><ce:list-item id="u3965"><ce:label>•</ce:label><ce:para id="p6635">Adverse pregnancy outcome<ce:list id="ulist1285"><ce:list-item id="u3970"><ce:para id="p6640">Recurrent first trimester abortion (≥ 3)</ce:para></ce:list-item><ce:list-item id="u3975"><ce:para id="p6645">Unexplained death of morphologically normal fetus after 10 weeks' gestation</ce:para></ce:list-item><ce:list-item id="u3980"><ce:para id="p6650">Severe early pre-eclampsia</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u3985"><ce:label>•</ce:label><ce:para id="p6655">Venous thromboembolism</ce:para></ce:list-item><ce:list-item id="u3990"><ce:label>•</ce:label><ce:para id="p6660">Arterial thromboembolism</ce:para></ce:list-item><ce:list-item id="u3995"><ce:label>•</ce:label><ce:para id="p6665">Livedo reticularis, catastrophic APS, transverse myelitis, skin necrosis, chorea</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Conditions associated with secondary APS</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1290"><ce:list-item id="u4000"><ce:label>•</ce:label><ce:para id="p6670">Systemic lupus erythematosus</ce:para></ce:list-item><ce:list-item id="u4005"><ce:label>•</ce:label><ce:para id="p6675">Rheumatoid arthritis</ce:para></ce:list-item><ce:list-item id="u4010"><ce:label>•</ce:label><ce:para id="p6680">Systemic sclerosis</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1295"><ce:list-item id="u4015"><ce:label>•</ce:label><ce:para id="p6685">Behçet's disease</ce:para></ce:list-item><ce:list-item id="u4020"><ce:label>•</ce:label><ce:para id="p6690">Temporal arteritis</ce:para></ce:list-item><ce:list-item id="u4025"><ce:label>•</ce:label><ce:para id="p6695">Sjögren's syndrome</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Targets for antiphospholipid antibodies</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist1300"><ce:list-item id="u4030"><ce:label>•</ce:label><ce:para id="p6700">β<ce:inf loc="post">2</ce:inf>-glycoprotein 1</ce:para></ce:list-item><ce:list-item id="u4035"><ce:label>•</ce:label><ce:para id="p6705">Protein C</ce:para></ce:list-item><ce:list-item id="u4040"><ce:label>•</ce:label><ce:para id="p6710">Annexin V</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1305"><ce:list-item id="u4045"><ce:label>•</ce:label><ce:para id="p6715">Prothrombin (may result in haemorrhagic presentation)</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0110" role="alt6"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0185" locator="icon06-9780702070280" xlink:href="pii:B9780702070280000238/icon06-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1020" role="short">Image 68</ce:alt-text></ce:inline-figure>23.68</ce:label><ce:alt-text id="atte1025" role="short">23.68</ce:alt-text><ce:textbox-head><ce:title id="tit0115">Disseminated intravascular coagulation (DIC)</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2090"><ce:display><ce:table frame="topbot" id="t0060"><ce:alt-text id="atte1030" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Underlying conditions</ce:bold></entry></row><row rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:list id="ulist0530"><ce:list-item id="u1525"><ce:label>•</ce:label><ce:para id="p2095">Infection/sepsis</ce:para></ce:list-item><ce:list-item id="u1530"><ce:label>•</ce:label><ce:para id="p2100">Trauma</ce:para></ce:list-item><ce:list-item id="u1535"><ce:label>•</ce:label><ce:para id="p2105">Obstetric, e.g. amniotic fluid embolism, placental abruption, pre-eclampsia</ce:para></ce:list-item><ce:list-item id="u1540"><ce:label>•</ce:label><ce:para id="p2110">Severe liver failure</ce:para></ce:list-item><ce:list-item id="u1545"><ce:label>•</ce:label><ce:para id="p2115">Malignancy, e.g. solid tumours and leukaemias</ce:para></ce:list-item><ce:list-item id="u1550"><ce:label>•</ce:label><ce:para id="p2120">Tissue destruction, e.g. pancreatitis, burns</ce:para></ce:list-item><ce:list-item id="u1555"><ce:label>•</ce:label><ce:para id="p2125">Vascular abnormalities, e.g. vascular aneurysms, liver haemangiomas</ce:para></ce:list-item><ce:list-item id="u1560"><ce:label>•</ce:label><ce:para id="p2130">Toxic/immunological, e.g. ABO incompatibility, snake bites, recreational drugs</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>ISTH scoring system for diagnosis of DIC</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:bold>Presence of an associated disorder</ce:bold></entry><entry align="left">Essential</entry></row><row rowsep="0"><entry morerows="2" align="left"><ce:bold>Platelets (× 10<ce:sup loc="post">9</ce:sup>/L)</ce:bold></entry><entry align="left">&#x003E; 100 = 0</entry></row><row rowsep="0"><entry align="left">&#x003C; 100 = 1</entry></row><row rowsep="0"><entry align="left">&#x003C; 50 = 2</entry></row><row rowsep="0"><entry morerows="2" align="left"><ce:bold>Elevated fibrin degradation products</ce:bold></entry><entry align="left">No increase = 0</entry></row><row rowsep="0"><entry align="left">Moderate = 2</entry></row><row rowsep="0"><entry align="left">Strong = 3</entry></row><row rowsep="0"><entry morerows="2" align="left"><ce:bold>Prolonged prothrombin time</ce:bold></entry><entry align="left">&#x003C; 3 secs = 0</entry></row><row rowsep="0"><entry align="left">&#x003E; 3 secs but &#x003C; 6 secs = 1</entry></row><row rowsep="0"><entry align="left">&#x003E; 6 secs = 2</entry></row><row><entry morerows="1" rowsep="1" align="left"><ce:bold>Fibrinogen</ce:bold></entry><entry rowsep="0" align="left">&#x003E; 1 g/L = 0</entry></row><row rowsep="1"><entry align="left">&#x003C; 1 g/L = 1</entry></row><row><entry namest="col1" nameend="col2" align="center"><ce:bold>Total score</ce:bold><ce:br/>≥ 5 = Compatible with overt DIC<ce:br/>&#x003C; 5 = Repeat monitoring over 1–2 days</entry></row></tbody></tgroup></ce:table></ce:display></ce:para><ce:para id="p2135">(ISTH = International Society for Thrombosis and Haemostasis)</ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0380" role="alt2"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0580" locator="icon02-9780702070280" xlink:href="pii:B9780702070280000238/icon02-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1035" role="short">Image 69</ce:alt-text></ce:inline-figure>23.69</ce:label><ce:alt-text id="atte1040" role="short">23.69</ce:alt-text><ce:textbox-head><ce:title id="tit0385">Haemostasis and thrombosis in old age</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p6765"><ce:list id="ulist1315"><ce:list-item id="u4060"><ce:label>•</ce:label><ce:para id="p6770"><ce:bold>Thrombocytopenia</ce:bold>: not uncommon because of the rising prevalence of disorders in which it may be a secondary feature, and also because of the greater use of drugs that can cause it.</ce:para></ce:list-item><ce:list-item id="u4065"><ce:label>•</ce:label><ce:para id="p6775"><ce:bold>‘Senile’ purpura</ce:bold>: presumed to be due to an age-associated loss of subcutaneous fat and the collagenous support of small blood vessels, making them more prone to damage from minor trauma.</ce:para></ce:list-item><ce:list-item id="u4070"><ce:label>•</ce:label><ce:para id="p6780"><ce:bold>Thrombosis</ce:bold>: incidence of thromboembolic disease rises with increasing age. This may be due to stasis and concurrent illness, to which older people are prone; some studies show increased platelet aggregation with age, and others age-associated hyperactivity of the haemostatic system, which could contribute to a prothrombotic state.</ce:para></ce:list-item><ce:list-item id="o9000"><ce:label>•</ce:label><ce:para id="p9000"><ce:bold>Thromboprophylaxis</ce:bold>: should be considered in all older patients who are immobile as a result of acute illness. Prophylaxis is not required in chronic immobility without a medical cause, as there is no associated increase in thromboembolism.</ce:para></ce:list-item><ce:list-item id="o9005"><ce:label>•</ce:label><ce:para id="p9005"><ce:bold>Anticoagulation</ce:bold>: older patients are more sensitive to the anticoagulant effects of warfarin, partly due to the concurrent use of other drugs and the presence of other pathology. Life-threatening or fatal bleeds on warfarin are significantly more common in those over 80 years.</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox></ce:floats><ce:label>23</ce:label><ce:title id="tit0010">Haematology and transfusion medicine</ce:title><ce:author-group id="aug0010"><ce:author author-id="B9780702070280000238-8742cf177bdcd5d76f1bbb025c32031c" id="au0010"><ce:given-name>HG</ce:given-name><ce:surname>Watson</ce:surname></ce:author></ce:author-group><ce:author-group id="aug0015"><ce:author author-id="B9780702070280000238-54d5c9c47ef6b646ecd8ca85dfc72439" id="au0015"><ce:given-name>DJ</ce:given-name><ce:surname>Culligan</ce:surname></ce:author></ce:author-group><ce:author-group id="aug0020"><ce:author author-id="B9780702070280000238-35af8b947823a1193cf62cc2e134af6d" id="au0020"><ce:given-name>LM</ce:given-name><ce:surname>Manson</ce:surname></ce:author></ce:author-group><outline id="out0010"><ce:list id="ulist0010"><ce:list-item id="u0010"><ce:para id="p0010"><ce:bold>Clinical examination in blood disease</ce:bold> <ce:cross-ref id="crf0010" refid="s0010"><ce:bold>912</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0015"><ce:para id="p0015"><ce:bold>Functional anatomy and physiology</ce:bold> <ce:cross-ref id="crf0015" refid="s0060"><ce:bold>914</ce:bold></ce:cross-ref><ce:list id="ulist0015"><ce:list-item id="u0020"><ce:para id="p0020">Haematopoiesis <ce:cross-ref id="crf0020" refid="s0065">914</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0025"><ce:para id="p0025">Blood cells and their functions <ce:cross-ref id="crf0025" refid="s0075">915</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0030"><ce:para id="p0030">Haemostasis <ce:cross-ref id="crf0030" refid="s0125">917</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0035"><ce:para id="p0035"><ce:bold>Investigation of diseases of the blood</ce:bold> <ce:cross-ref id="crf0035" refid="s0140"><ce:bold>919</ce:bold></ce:cross-ref><ce:list id="ulist0020"><ce:list-item id="u0040"><ce:para id="p0040">The full blood count <ce:cross-ref id="crf0040" refid="s0145">919</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0045"><ce:para id="p0045">Blood film examination <ce:cross-ref id="crf0045" refid="s0150">920</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0050"><ce:para id="p0050">Bone marrow examination <ce:cross-ref id="crf0050" refid="s0155">920</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0055"><ce:para id="p0055">Investigation of coagulation <ce:cross-ref id="crf0055" refid="s0160">920</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0060"><ce:para id="p0060"><ce:bold>Presenting problems in blood disease</ce:bold> <ce:cross-ref id="crf0060" refid="s0200"><ce:bold>923</ce:bold></ce:cross-ref><ce:list id="ulist0025"><ce:list-item id="u0065"><ce:para id="p0065">Anaemia <ce:cross-ref id="crf0065" refid="s0205">923</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0070"><ce:para id="p0070">High haemoglobin <ce:cross-ref id="crf0070" refid="s0225">925</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0075"><ce:para id="p0075">Leucopenia (low white cell count) <ce:cross-ref id="crf0075" refid="s0240">925</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0080"><ce:para id="p0080">Leucocytosis (high white cell count) <ce:cross-ref id="crf0080" refid="s0315">926</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0085"><ce:para id="p0085">Lymphadenopathy <ce:cross-ref id="crf0085" refid="s0335">927</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0090"><ce:para id="p0090">Splenomegaly <ce:cross-ref id="crf0090" refid="s0365">927</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0095"><ce:para id="p0095">Bleeding <ce:cross-ref id="crf0095" refid="s0370">927</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0100"><ce:para id="p0100">Thrombocytopenia (low platelet count) <ce:cross-ref id="crf0100" refid="s0390">929</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0105"><ce:para id="p0105">Thrombocytosis (high platelet count) <ce:cross-ref id="crf0105" refid="s0395">929</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0110"><ce:para id="p0110">Pancytopenia <ce:cross-ref id="crf0110" refid="s0400">930</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0115"><ce:para id="p0115">Infection <ce:cross-ref id="crf0115" refid="s0425">930</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0120"><ce:para id="p0120"><ce:bold>Principles of management of haematological disease</ce:bold> <ce:cross-ref id="crf0120" refid="s0430"><ce:bold>930</ce:bold></ce:cross-ref><ce:list id="ulist0030"><ce:list-item id="u0125"><ce:para id="p0125">Blood products and transfusion <ce:cross-ref id="crf0125" refid="s0435">930</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0130"><ce:para id="p0130">Chemotherapy <ce:cross-ref id="crf0130" refid="s0505">936</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0135"><ce:para id="p0135">Haematopoietic stem cell transplantation <ce:cross-ref id="crf0135" refid="s0535">936</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0140"><ce:para id="p0140">Anticoagulant and antithrombotic therapy <ce:cross-ref id="crf0140" refid="s0560">938</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0145"><ce:para id="p0145"><ce:bold>Anaemias</ce:bold> <ce:cross-ref id="crf0145" refid="s0610"><ce:bold>940</ce:bold></ce:cross-ref><ce:list id="ulist0035"><ce:list-item id="u0150"><ce:para id="p0150">Iron deficiency anaemia <ce:cross-ref id="crf0150" refid="s0615">940</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0155"><ce:para id="p0155">Anaemia of chronic disease <ce:cross-ref id="crf0155" refid="s0665">943</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0160"><ce:para id="p0160">Megaloblastic anaemia <ce:cross-ref id="crf0160" refid="s0685">943</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0165"><ce:para id="p0165">Haemolytic anaemia <ce:cross-ref id="crf0165" refid="s0805">945</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0170"><ce:para id="p0170"><ce:bold>Haemoglobinopathies</ce:bold> <ce:cross-ref id="crf0170" refid="s0965"><ce:bold>951</ce:bold></ce:cross-ref><ce:list id="ulist0040"><ce:list-item id="u0175"><ce:para id="p0175">Sickle-cell anaemia <ce:cross-ref id="crf0175" refid="s0990">951</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0180"><ce:para id="p0180">Other abnormal haemoglobins <ce:cross-ref id="crf0180" refid="s1030">953</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0185"><ce:para id="p0185">Thalassaemias <ce:cross-ref id="crf0185" refid="s1035">953</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0190"><ce:para id="p0190"><ce:bold>Haematological malignancies</ce:bold> <ce:cross-ref id="crf0190" refid="s1065"><ce:bold>954</ce:bold></ce:cross-ref><ce:list id="ulist0045"><ce:list-item id="u0195"><ce:para id="p0195">Leukaemias <ce:cross-ref id="crf0195" refid="s1070">954</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0200"><ce:para id="p0200">Lymphomas <ce:cross-ref id="crf0200" refid="s1305">961</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0205"><ce:para id="p0205">Paraproteinaemias <ce:cross-ref id="crf0205" refid="s1410">966</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0210"><ce:para id="p0210"><ce:bold>Aplastic anaemias</ce:bold> <ce:cross-ref id="crf0210" refid="s1480"><ce:bold>968</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0215"><ce:para id="p0215"><ce:bold>Myeloproliferative neoplasms</ce:bold> <ce:cross-ref id="crf0215" refid="s1525"><ce:bold>969</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0220"><ce:para id="p0220"><ce:bold>Bleeding disorders</ce:bold> <ce:cross-ref id="crf0220" refid="s1560"><ce:bold>970</ce:bold></ce:cross-ref><ce:list id="ulist0050"><ce:list-item id="u0225"><ce:para id="p0225">Disorders of primary haemostasis <ce:cross-ref id="crf0225" refid="s1565">970</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0230"><ce:para id="p0230">Coagulation disorders <ce:cross-ref id="crf0230" refid="s1615">971</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0235"><ce:para id="p0235"><ce:bold>Thrombotic disorders</ce:bold> <ce:cross-ref id="crf0235" refid="s1725"><ce:bold>975</ce:bold></ce:cross-ref><ce:list id="ulist0055"><ce:list-item id="u0240"><ce:para id="p0240">Venous thromboembolic disease (venous thromboembolism) <ce:cross-ref id="crf9000" refid="s1730">975</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0245"><ce:para id="p0245">Inherited and acquired thrombophilia and prothrombotic states <ce:cross-ref id="crf0240" refid="s1775">977</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></outline><ce:sections><ce:section id="s0010"><ce:section-title id="st0010">Clinical examination in blood disease</ce:section-title><ce:para id="p0250"><ce:display><ce:figure id="f0010"><ce:alt-text id="atte1045" role="short">Unlabelled image</ce:alt-text><ce:source><ce:italic>Insets (Glossitis)</ce:italic> From Hoffbrand VA, John E, Pettit JE, Vyas P. Color atlas of clinical hematology, 4th edn. Philadelphia: Mosby, Elsevier Inc.; 2010; <ce:italic>(Petechiae)</ce:italic> Young NS, Gerson SL, High KA (eds). Clinical hematology. St Louis: Mosby, Elsevier Inc.; 2006.</ce:source><ce:link id="ln0010" locator="u023-001-9780702070280" xlink:href="pii:B9780702070280000238/u023-001-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure></ce:display></ce:para><ce:para id="p0255">Abnormalities detected in the blood are caused not only by primary diseases of the blood and lymphoreticular systems but also by diseases affecting other systems of the body. The clinical assessment of patients with haematological abnormalities must include a general history and examination, as well as a search for symptoms and signs of abnormalities of red cells, white cells, platelets, haemostatic systems, lymph nodes and lymphoreticular tissues.</ce:para><ce:para id="p0260"><ce:display><ce:textbox id="b0010" role="alt7"><ce:label>6</ce:label><ce:alt-text id="atte1050" role="short">6</ce:alt-text><ce:textbox-head><ce:title id="tit0015">Lymphadenopathy</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0265">Lymphadenopathy can be caused by benign or malignant disease. The clinical points to clarify are shown in the box.<ce:display><ce:figure id="f0015"><ce:alt-text id="atte1055" role="short">Unlabelled image</ce:alt-text><ce:link id="ln0015" locator="u023-002-9780702070280" xlink:href="pii:B9780702070280000238/u023-002-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox></ce:display><ce:display><ce:textbox id="b0015" role="alt1"><ce:alt-text id="atte1060" role="short">Unlabelled box</ce:alt-text><ce:textbox-head><ce:title id="tit0020"><ce:inline-figure baseline="0.0"><ce:link id="ln9000" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1065" role="short">Image 70</ce:alt-text></ce:inline-figure>Lymphadenopathy</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0015"><ce:section-title id="st0015">History</ce:section-title><ce:para id="p0270"><ce:list id="ulist0060"><ce:list-item id="u0250"><ce:label>•</ce:label><ce:para id="p0275">Speed of onset, rate of enlargement</ce:para></ce:list-item><ce:list-item id="u0255"><ce:label>•</ce:label><ce:para id="p0280">Painful or painless</ce:para></ce:list-item><ce:list-item id="u0260"><ce:label>•</ce:label><ce:para id="p0285">Associated symptoms: weight loss, night sweats, itch</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0020"><ce:section-title id="st0020">Examination</ce:section-title><ce:para id="p0290"><ce:list id="ulist0065"><ce:list-item id="u0265"><ce:label>•</ce:label><ce:para id="p0295">Sites: localised, generalised</ce:para></ce:list-item><ce:list-item id="u0270"><ce:label>•</ce:label><ce:para id="p0300">Size (cm)</ce:para></ce:list-item><ce:list-item id="u0275"><ce:label>•</ce:label><ce:para id="p0305">Character: hard, soft, rubbery</ce:para></ce:list-item><ce:list-item id="u0280"><ce:label>•</ce:label><ce:para id="p0310">Fixed, mobile</ce:para></ce:list-item><ce:list-item id="u0285"><ce:label>•</ce:label><ce:para id="p0315">Search area that node drains for abnormalities (e.g. dental abscess)</ce:para></ce:list-item><ce:list-item id="u0290"><ce:label>•</ce:label><ce:para id="p0320">Other general examination (e.g. joints, rashes, finger clubbing)</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox></ce:display><ce:display><ce:textbox id="b0020" role="alt7"><ce:label>8</ce:label><ce:alt-text id="atte1070" role="short">8</ce:alt-text><ce:textbox-head><ce:title id="tit0025">Examination of the spleen</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0325"><ce:list id="ulist0070"><ce:list-item id="u0295"><ce:label>•</ce:label><ce:para id="p0330">Move your hand up from the right iliac fossa, towards the left upper quadrant on expiration.</ce:para></ce:list-item><ce:list-item id="u0300"><ce:label>•</ce:label><ce:para id="p0335">Keep your hand still and ask the patient to take a deep breath through the mouth to feel the spleen edge being displaced downwards.</ce:para></ce:list-item><ce:list-item id="u0305"><ce:label>•</ce:label><ce:para id="p0340">Place your left hand around the patient's lower ribs and approach the costal margin to pull the spleen forwards.</ce:para></ce:list-item><ce:list-item id="u0310"><ce:label>•</ce:label><ce:para id="p0345">To help palpate small spleens, roll the patient on to the right side and examine as before.</ce:para></ce:list-item></ce:list><ce:display><ce:figure id="f0020"><ce:alt-text id="atte1075" role="short">Unlabelled image</ce:alt-text><ce:link id="ln0020" locator="u023-003-9780702070280" xlink:href="pii:B9780702070280000238/u023-003-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox></ce:display><ce:display><ce:textbox id="b0025" role="alt1"><ce:alt-text id="atte1080" role="short">Unlabelled box</ce:alt-text><ce:textbox-head><ce:title id="tit0030"><ce:inline-figure baseline="0.0"><ce:link id="ln9005" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1085" role="short">Image 71</ce:alt-text></ce:inline-figure>Characteristics of the spleen</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0350"><ce:list id="ulist0075"><ce:list-item id="u0315"><ce:label>•</ce:label><ce:para id="p0355">Notch</ce:para></ce:list-item><ce:list-item id="u0320"><ce:label>•</ce:label><ce:para id="p0360">Superficial</ce:para></ce:list-item><ce:list-item id="u0325"><ce:label>•</ce:label><ce:para id="p0365">Dull to percussion</ce:para></ce:list-item><ce:list-item id="u0330"><ce:label>•</ce:label><ce:para id="p0370">Cannot get examining hand between ribs and spleen</ce:para></ce:list-item><ce:list-item id="u0335"><ce:label>•</ce:label><ce:para id="p0375">Moves well with respiration</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox></ce:display></ce:para><ce:section id="s0025"><ce:section id="s0030"><ce:section-title id="st0025">Anaemia</ce:section-title><ce:para id="p0380">Symptoms and signs help to indicate the clinical severity of anaemia. A full history and examination is needed to identify the underlying cause.<ce:display><ce:textbox id="b0030" role="alt1"><ce:alt-text id="atte1090" role="short">Unlabelled box</ce:alt-text><ce:textbox-head><ce:title id="tit0035"><ce:inline-figure baseline="0.0"><ce:link id="ln9010" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1095" role="short">Image 72</ce:alt-text></ce:inline-figure>Anaemia</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0035"><ce:section-title id="st0030">Non-specific symptoms</ce:section-title><ce:para id="p0385"><ce:list id="ulist0080"><ce:list-item id="u0340"><ce:label>•</ce:label><ce:para id="p0390">Tiredness</ce:para></ce:list-item><ce:list-item id="u0345"><ce:label>•</ce:label><ce:para id="p0395">Lightheadedness</ce:para></ce:list-item><ce:list-item id="u0350"><ce:label>•</ce:label><ce:para id="p0400">Breathlessness</ce:para></ce:list-item><ce:list-item id="u0355"><ce:label>•</ce:label><ce:para id="p0405">Development/worsening of ischaemic symptoms, e.g. angina or claudication</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0040"><ce:section-title id="st0035">Non-specific signs</ce:section-title><ce:para id="p0410"><ce:list id="ulist0085"><ce:list-item id="u0360"><ce:label>•</ce:label><ce:para id="p0415">Mucous membrane pallor</ce:para></ce:list-item><ce:list-item id="u0365"><ce:label>•</ce:label><ce:para id="p0420">Tachypnoea</ce:para></ce:list-item><ce:list-item id="u0370"><ce:label>•</ce:label><ce:para id="p0425">Raised jugular venous pressure</ce:para></ce:list-item><ce:list-item id="u0375"><ce:label>•</ce:label><ce:para id="p0430">Tachycardia</ce:para></ce:list-item><ce:list-item id="u0380"><ce:label>•</ce:label><ce:para id="p0435">Flow murmurs</ce:para></ce:list-item><ce:list-item id="u0385"><ce:label>•</ce:label><ce:para id="p0440">Ankle oedema</ce:para></ce:list-item><ce:list-item id="u0390"><ce:label>•</ce:label><ce:para id="p0445">Postural hypotension</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox></ce:display></ce:para></ce:section><ce:section id="s0045"><ce:section-title id="st0040">Bleeding</ce:section-title><ce:para id="p0450">Bleeding can be due to congenital or acquired abnormalities in the clotting system. History and examination help to clarify the severity and the underlying cause of the bleeding problem.<ce:display><ce:textbox id="b0035" role="alt1"><ce:alt-text id="atte1100" role="short">Unlabelled box</ce:alt-text><ce:textbox-head><ce:title id="tit0040"><ce:inline-figure baseline="0.0"><ce:link id="ln9015" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000238/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1105" role="short">Image 73</ce:alt-text></ce:inline-figure>Bleeding</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0050"><ce:section-title id="st0045">History</ce:section-title><ce:para id="p0455"><ce:list id="ulist0090"><ce:list-item id="u0395"><ce:label>•</ce:label><ce:para id="p0460">Site of bleed</ce:para></ce:list-item><ce:list-item id="u0400"><ce:label>•</ce:label><ce:para id="p0465">Duration of bleed</ce:para></ce:list-item><ce:list-item id="u0405"><ce:label>•</ce:label><ce:para id="p0470">Precipitating causes, including previous surgery or trauma</ce:para></ce:list-item><ce:list-item id="u0410"><ce:label>•</ce:label><ce:para id="p0475">Family history</ce:para></ce:list-item><ce:list-item id="u0415"><ce:label>•</ce:label><ce:para id="p0480">Drug history</ce:para></ce:list-item><ce:list-item id="u0420"><ce:label>•</ce:label><ce:para id="p0485">Age at presentation</ce:para></ce:list-item><ce:list-item id="u0425"><ce:label>•</ce:label><ce:para id="p0490">Other medical conditions, e.g. liver disease</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0055"><ce:section-title id="st0050">Examination</ce:section-title><ce:para id="p0495">There are two main patterns of bleeding:<ce:list id="olist0095"><ce:list-item id="o0430"><ce:label>1</ce:label><ce:para id="p0500">Mucosal bleeding</ce:para><ce:para id="p0505">Reduced number or function of platelets (e.g. bone marrow failure or aspirin) or von Willebrand factor (e.g. von Willebrand disease)<ce:list id="ulist0100"><ce:list-item id="u0435"><ce:para id="p0510">Skin: petechiae, bruises</ce:para></ce:list-item><ce:list-item id="u0440"><ce:para id="p0515">Gum and mucous membrane bleeding</ce:para></ce:list-item><ce:list-item id="u0445"><ce:para id="p0520">Fundal haemorrhage</ce:para></ce:list-item><ce:list-item id="u0450"><ce:para id="p0525">Post-surgical bleeding</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="o0455"><ce:label>2</ce:label><ce:para id="p0530">Coagulation factor deficiency</ce:para><ce:para id="p0535">(e.g. haemophilia or warfarin/anticoagulant)<ce:list id="ulist0105"><ce:list-item id="u0460"><ce:para id="p0540">Bleeding into joints (haemarthrosis) or muscles</ce:para></ce:list-item><ce:list-item id="u0465"><ce:para id="p0545">Bleeding into soft tissues</ce:para></ce:list-item><ce:list-item id="u0470"><ce:para id="p0550">Retroperitoneal haemorrhage</ce:para></ce:list-item><ce:list-item id="u0475"><ce:para id="p0555">Intracranial haemorrhage</ce:para></ce:list-item><ce:list-item id="u0480"><ce:para id="p0560">Post-surgical bleeding</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox></ce:display>Disorders of the blood cover a wide spectrum of illnesses, ranging from some of the most common disorders affecting humans (anaemias) to relatively rare conditions such as leukaemias and congenital coagulation disorders. Although the latter are uncommon, advances in cellular and molecular biology have had major impacts on their diagnosis, treatment and prognosis. Haematological changes occur as a consequence of diseases affecting any system and give important information in the diagnosis and monitoring of many conditions.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0060"><ce:section-title id="st0055">Functional anatomy and physiology</ce:section-title><ce:para id="p0565">Blood flows throughout the body in the vascular system, and consists of:<ce:list id="ulist0110"><ce:list-item id="u0485"><ce:label>•</ce:label><ce:para id="p0570">red cells, which transport oxygen from the lungs to the tissues</ce:para></ce:list-item><ce:list-item id="u0490"><ce:label>•</ce:label><ce:para id="p0575">white cells, which defend against infection</ce:para></ce:list-item><ce:list-item id="u0495"><ce:label>•</ce:label><ce:para id="p0580">platelets, which interact with blood vessels and clotting factors to maintain vascular integrity and prevent bleeding</ce:para></ce:list-item><ce:list-item id="u0500"><ce:label>•</ce:label><ce:para id="p0585">plasma, which contains proteins with many functions, including antibodies and coagulation factors.</ce:para></ce:list-item></ce:list></ce:para><ce:section id="s0065"><ce:section-title id="st0060">Haematopoiesis</ce:section-title><ce:para id="p0590">Haematopoiesis describes the formation of blood cells, an active process that must maintain normal numbers of circulating cells and be able to respond rapidly to increased demands such as bleeding or infection. During development, haematopoiesis occurs in the yolk sac, liver and spleen, and subsequently in red bone marrow in the medullary cavity of all bones. In childhood, red marrow is progressively replaced by fat (yellow marrow) so that, in adults, normal haematopoiesis is restricted to the vertebrae, pelvis, sternum, ribs, clavicles, skull, upper humeri and proximal femora. However, red marrow can expand in response to increased demands for blood cells.</ce:para><ce:para id="p0595">Bone marrow contains a range of immature haematopoietic precursor cells and a storage pool of mature cells for release at times of increased demand. Haematopoietic cells interact closely with surrounding connective tissue stroma, made up of reticular cells, macrophages, fat cells, blood vessels and nerve fibres (<ce:cross-ref id="crf0245" refid="f0025">Fig. 23.1</ce:cross-ref><ce:float-anchor refid="f0025"/>). In normal marrow, nests of red cell precursors cluster around a central macrophage, which provides iron and also phagocytoses nuclei from red cells prior to their release into the circulation. Megakaryocytes are large cells that produce and release platelets into vascular sinuses. White cell precursors are clustered next to the bone trabeculae; maturing cells migrate into the marrow spaces towards the vascular sinuses. Plasma cells are antibody-secreting mature B cells that normally represent less than 5% of the marrow population and are scattered throughout the intertrabecular spaces.</ce:para><ce:section id="s0070"><ce:section-title id="st0065">Stem cells</ce:section-title><ce:para id="p0600">All blood cells are derived from pluripotent haematopoietic stem cells. These comprise only 0.01% of the total marrow cells, but they can self-renew (i.e. make more stem cells) or differentiate to produce a hierarchy of lineage-committed progenitor cells. The resulting primitive progenitor cells cannot be identified morphologically, so they are named according to the types of cell (or colony) they form during cell culture experiments. CFU–GM (colony-forming unit – granulocyte, monocyte) is a progenitor cell that produces granulocytic and monocytic lines, CFU–E produce erythroid cells, and CFU–Meg produce megakaryocytes and ultimately platelets (<ce:cross-ref id="crf0250" refid="f0030">Fig. 23.2</ce:cross-ref><ce:float-anchor refid="f0030"/>).</ce:para><ce:para id="p0605">Growth factors, produced in bone marrow stromal cells and elsewhere, control the survival, proliferation, differentiation and function of stem cells and their progeny. Some, such as, interleukin-3 (IL-3), stem cell factor (SCF) and granulocyte, macrophage–colony-stimulating factor (GM–CSF), act on a wide number of cell types at various stages of differentiation. Others, such as erythropoietin, granulocyte–colony-stimulating factor (G–CSF) and thrombopoietin (Tpo), are lineage-specific. Many of these growth factors are now synthesised by recombinant DNA technology and used as treatments: for example, erythropoietin to correct renal anaemia and G–CSF to hasten neutrophil recovery after chemotherapy.</ce:para><ce:para id="p0610">The bone marrow also contains stem cells that can differentiate into non-haematological cells. Mesenchymal stem cells differentiate into skeletal muscle, cartilage, cardiac muscle, and fat cells while others differentiate into nerves, liver and blood vessel endothelium. This is termed stem cell plasticity and may have exciting clinical applications in the future (<ce:intra-ref id="ii0010" xlink:href="pii:B978-0-7020-7028-0.00003-2#c00003">Ch. 3</ce:intra-ref>).</ce:para></ce:section></ce:section><ce:section id="s0075"><ce:section-title id="st0070">Blood cells and their functions</ce:section-title><ce:section id="s0080"><ce:section-title id="st0075">Red cells</ce:section-title><ce:para id="p0615">Red cell precursors formed in the bone marrow from the erythroid (CFU–E) progenitor cells are called erythroblasts or normoblasts (<ce:cross-ref id="crf0255" refid="f0035">Fig. 23.3</ce:cross-ref><ce:float-anchor refid="f0035"/>). These divide and acquire haemoglobin, which turns the cytoplasm pink; the nucleus condenses and is extruded from the cell. The first non-nucleated red cell is a reticulocyte, which still contains ribosomal material in the cytoplasm, giving these large cells a faint blue tinge (‘polychromasia’). Reticulocytes lose their ribosomal material and mature over 3 days, during which time they are released into the circulation. Increased numbers of circulating reticulocytes (reticulocytosis) reflect increased erythropoiesis. Proliferation and differentiation of red cell precursors is stimulated by erythropoietin, a polypeptide hormone produced by renal interstitial peritubular cells in response to hypoxia. Failure of erythropoietin production in patients with renal failure (<ce:intra-ref id="ii0015" xlink:href="pii:B978-0-7020-7028-0.00015-9#s0025">p. 384</ce:intra-ref>) causes anaemia, which can be treated with exogenous recombinant erythropoietin or similar pharmacological agents called erythropoiesis-stimulating agents, e.g. darbepoetin.</ce:para><ce:para id="p0620">Normal mature red cells circulate for about 120 days. They are 8 µm biconcave discs lacking a nucleus but filled with haemoglobin, which delivers oxygen to the tissues. In order to pass through the smallest capillaries, the red cell membrane is deformable, with a lipid bilayer to which a ‘skeleton’ of filamentous proteins is attached via special linkage proteins (<ce:cross-ref id="crf0260" refid="f0040">Fig. 23.4</ce:cross-ref><ce:float-anchor refid="f0040"/>). Inherited abnormalities of any of these proteins result in loss of membrane as cells pass through the spleen, and the formation of abnormally shaped red cells called spherocytes or elliptocytes (see <ce:cross-ref id="crf0265" refid="f0060">Fig. 23.8D</ce:cross-ref>). Red cells are exposed to osmotic stress in the pulmonary and renal circulation; in order to maintain homeostasis, the membrane contains ion pumps, which control intracellular levels of sodium, potassium, chloride and bicarbonate. In the absence of mitochondria, the energy for these functions is provided by anaerobic glycolysis and the pentose phosphate pathway in the cytosol. Membrane glycoproteins inserted into the lipid bilayer also form the antigens recognised by blood grouping (see <ce:cross-ref id="crf0270" refid="f0040">Fig. 23.4</ce:cross-ref>). The ABO and Rhesus systems are the most commonly recognised (p. 931) but over 400 blood group antigens have been described.</ce:para><ce:section id="s0085"><ce:section-title id="st0080">Haemoglobin</ce:section-title><ce:para id="p0625">Haemoglobin is a protein specially adapted for oxygen transport. It is composed of four globin chains, each surrounding an iron-containing porphyrin pigment molecule termed haem. Globin chains are a combination of two alpha and two non-alpha chains; haemoglobin A (αα/ββ) represents over 90% of adult haemoglobin, whereas haemoglobin F (αα/γγ) is the predominant type in the fetus. Each haem molecule contains a ferrous ion (Fe<ce:sup loc="post">2+</ce:sup>), to which oxygen reversibly binds; the affinity for oxygen increases as successive oxygen molecules bind. When oxygen is bound, the beta chains ‘swing’ closer together; they move apart as oxygen is lost. In the ‘open’ deoxygenated state, 2,3-bisphosphoglycerate (2,3-BPG), a product of red cell metabolism, binds to the haemoglobin molecule and lowers its oxygen affinity. These complex interactions produce the sigmoid shape of the oxygen dissociation curve (<ce:cross-ref id="crf0275" refid="f0045">Fig. 23.5</ce:cross-ref><ce:float-anchor refid="f0045"/>). The position of this curve depends on the concentrations of 2,3-BPG, H<ce:sup loc="post">+</ce:sup> ions and CO<ce:inf loc="post">2</ce:inf>; increased levels shift the curve to the right and cause oxygen to be released more readily, e.g. when red cells reach hypoxic tissues. Haemoglobin F is unable to bind 2,3-BPG and has a left-shifted oxygen dissociation curve, which, together with the low pH of fetal blood, ensures fetal oxygenation. Strong oxidising agents, such as dapsone, can convert ferrous iron in haemoglobin to its ferric state (Fe<ce:sup loc="post">3+</ce:sup>). The resultant methaemoglobin also has a left-shifted oxygen dissociation curve, which can result in tissue hypoxia (<ce:intra-ref id="ii0030" xlink:href="pii:B978-0-7020-7028-0.00007-X#s0040">p. 135</ce:intra-ref>).</ce:para><ce:para id="p0630">Genetic mutations affecting the haem-binding pockets of globin chains or the ‘hinge’ interactions between globin chains result in haemoglobinopathies or unstable haemoglobins. Alpha globin chains are produced by two genes on chromosome 16, and beta globin chains by a single gene on chromosome 11; imbalance in the production of globin chains results in the thalassaemias (p. 951). Defects in haem synthesis cause the porphyrias (<ce:intra-ref id="ii0040" xlink:href="pii:B978-0-7020-7028-0.00014-7#s0735">p. 378</ce:intra-ref>).</ce:para></ce:section><ce:section id="s0090"><ce:section-title id="st0085">Destruction</ce:section-title><ce:para id="p0635">Red cells at the end of their lifespan of approximately 120 days are phagocytosed by the reticulo-endothelial system. Amino acids from globin chains are recycled and iron is removed from haem for reuse in haemoglobin synthesis. The remnant haem structure is degraded to bilirubin and conjugated with glucuronic acid before being excreted in bile. In the small bowel, bilirubin is converted to stercobilin; most of this is excreted, but a small amount is reabsorbed and excreted by the kidney as urobilinogen. Increased red cell destruction due to haemolysis or ineffective haematopoiesis results in jaundice and increased urinary urobilinogen. Free intravascular haemoglobin is toxic and is normally bound by haptoglobins, which are plasma proteins produced by the liver.</ce:para></ce:section></ce:section><ce:section id="s0095"><ce:section-title id="st0090">White cells</ce:section-title><ce:para id="p0640">White cells or leucocytes in the blood consist of granulocytes (neutrophils, eosinophils and basophils), monocytes and lymphocytes (see <ce:cross-ref id="crf0280" refid="f0080">Fig. 23.12</ce:cross-ref>). Granulocytes and monocytes are formed from bone marrow CFU–GM progenitor cells during myelopoiesis. The first recognisable granulocyte in the marrow is the myeloblast, a large cell with a small amount of basophilic cytoplasm and a primitive nucleus with open chromatin and nucleoli. As the cells divide and mature, the nucleus segments and the cytoplasm acquires specific neutrophilic, eosinophilic or basophilic granules (see <ce:cross-ref id="crf0285" refid="f0035">Fig. 23.3</ce:cross-ref>). This takes about 14 days. The cytokines G–CSF, GM–CSF and M–CSF are involved in the production of myeloid cells, and G–CSF can be used clinically to hasten recovery of blood neutrophil counts after chemotherapy.</ce:para><ce:para id="p0645">Myelocytes or metamyelocytes are normally found only in the marrow but may appear in the circulation in infection or toxic states. The appearance of more primitive myeloid precursors in the blood is often associated with the presence of nucleated red cells and is termed a ‘leucoerythroblastic’ picture; this indicates a serious disturbance of marrow function.</ce:para><ce:section id="s0100"><ce:section-title id="st0095">Neutrophils</ce:section-title><ce:para id="p0650">Neutrophils, the most common white blood cells in the blood of adults, are 10–14 µm in diameter, with a multilobular nucleus containing 2–5 segments and granules in their cytoplasm. Their main function is to recognise, ingest and destroy foreign particles and microorganisms (<ce:intra-ref id="ii0045" xlink:href="pii:B978-0-7020-7028-0.00004-4#p0290">p. 64</ce:intra-ref>). A large storage pool of mature neutrophils exists in the bone marrow. Every day, some 10<ce:sup loc="post">11</ce:sup> neutrophils enter the circulation, where cells may be circulating freely or attached to endothelium in the marginating pool. These two pools are equal in size; factors such as exercise or catecholamines increase the number of cells flowing in the blood. Neutrophils spend 6–10 hours in the circulation before being removed, principally by the spleen. Alternatively, they pass into the tissues and either are consumed in the inflammatory process or undergo apoptotic cell death and phagocytosis by macrophages.</ce:para></ce:section><ce:section id="s0105"><ce:section-title id="st0100">Eosinophils</ce:section-title><ce:para id="p0655">Eosinophils represent 1–6% of the circulating white cells. They are a similar size to neutrophils but have a bilobed nucleus and prominent orange granules on Romanowsky staining. Eosinophils are phagocytic and their granules contain a peroxidase capable of generating reactive oxygen species and proteins involved in the intracellular killing of protozoa and helminths (<ce:intra-ref id="ii0050" xlink:href="pii:B978-0-7020-7028-0.00011-1#p2750">p. 233</ce:intra-ref>). They are also involved in allergic reactions (e.g. atopic asthma, <ce:intra-ref id="ii0055" xlink:href="pii:B978-0-7020-7028-0.00017-2#p1730">p. 567</ce:intra-ref>; see also <ce:intra-ref id="ii0060" xlink:href="pii:B978-0-7020-7028-0.00004-4#s0565">p. 84</ce:intra-ref>).</ce:para></ce:section><ce:section id="s0110"><ce:section-title id="st0105">Basophils</ce:section-title><ce:para id="p0660">These cells are less common than eosinophils, representing less than 1% of circulating white cells. They contain dense black granules that obscure the nucleus. Mast cells resemble basophils but are found only in the tissues. These cells are involved in hypersensitivity reactions (<ce:intra-ref id="ii0065" xlink:href="pii:B978-0-7020-7028-0.00004-4#s0070">p. 66</ce:intra-ref>).</ce:para></ce:section><ce:section id="s0115"><ce:section-title id="st0110">Monocytes</ce:section-title><ce:para id="p0665">Monocytes are the largest of the white cells, with a diameter of 12–20 µm and an irregular nucleus in abundant pale blue cytoplasm containing occasional cytoplasmic vacuoles. These cells circulate for a few hours and then migrate into tissue, where they become macrophages, Kupffer cells or antigen-presenting dendritic cells. The former phagocytose debris, apoptotic cells and microorganisms (see <ce:intra-ref id="ii0070" xlink:href="pii:B978-0-7020-7028-0.00004-4#b0010">Box 4.1</ce:intra-ref>, <ce:intra-ref id="ii0075" xlink:href="pii:B978-0-7020-7028-0.00004-4#p0290">p. 64</ce:intra-ref>).</ce:para></ce:section><ce:section id="s0120"><ce:section-title id="st0115">Lymphocytes</ce:section-title><ce:para id="p0670">Lymphocytes are derived from pluripotent haematopoietic stem cells in the bone marrow. There are two main types: T cells (which mediate cellular immunity) and B cells (which mediate humoral immunity) (<ce:intra-ref id="ii0080" xlink:href="pii:B978-0-7020-7028-0.00004-4#s0125">p. 68</ce:intra-ref>). Lymphoid cells that migrate to the thymus develop into T cells, whereas B cells develop in the bone marrow.</ce:para><ce:para id="p0675">The majority (about 80%) of lymphocytes in the circulation are T cells. Lymphocytes are heterogeneous, the smallest being the size of red cells and the largest the size of neutrophils. Small lymphocytes are circular with scanty cytoplasm but the larger cells are more irregular with abundant blue cytoplasm. Lymphocyte subpopulations have specific functions and lifespan can vary from a few days to many years. Cell surface antigens (‘cluster of differentiation’ (CD) antigens), which appear at different points of lymphocyte maturation and indicate the lineage and maturity of the cell, are used to classify lymphomas and lymphoid leukaemias.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0125"><ce:section-title id="st0120">Haemostasis</ce:section-title><ce:para id="p0680">Blood must be maintained in a fluid state in order to function as a transport system, but must be able to solidify to form a clot following vascular injury in order to prevent excessive bleeding, a process known as haemostasis. Successful haemostasis is localised to the area of tissue damage and is followed by removal of the clot and tissue repair. This is achieved by complex interactions between the vascular endothelium, platelets, von Willebrand factor, coagulation factors, natural anticoagulants and fibrinolytic enzymes (<ce:cross-ref id="crf0290" refid="f0050">Fig. 23.6</ce:cross-ref><ce:float-anchor refid="f0050"/>). Dysfunction of any of these components may result in haemorrhage or thrombosis.</ce:para><ce:section id="s0130"><ce:section-title id="st0125">Platelets</ce:section-title><ce:para id="p0685">Platelets are formed in the bone marrow from megakaryocytes. Megakaryocytic progenitor cells (CFU–Meg) divide to form megakaryoblasts, which undergo a process called ‘endomitotic reduplication’, in which there is division of the nucleus but not the cell. This creates mature megakaryocytes, large cells with several nuclei and cytoplasm containing platelet granules. Large numbers of platelets then fragment off from each megakaryocyte into the circulation. The formation and maturation of megakaryocytes is stimulated by thrombopoietin produced in the liver. Platelets circulate for 8–10 days before they are destroyed in the reticulo-endothelial system. Some 30% of peripheral platelets are normally pooled in the spleen and do not circulate.</ce:para><ce:para id="p0690">Under normal conditions, platelets are discoid, with a diameter of 2–4 µm (<ce:cross-ref id="crf0300" refid="f0055">Fig. 23.7</ce:cross-ref><ce:float-anchor refid="f0055"/>). The surface membrane invaginates to form a tubular network, the canalicular system, which provides a conduit for the discharge of the granule content following platelet activation. Drugs that inhibit platelet function and thrombosis include aspirin (cyclo-oxygenase inhibitor), clopidogrel, prasugrel and ticagrelor (adenosine diphosphate (ADP)-mediated activation inhibitors), dipyridamole (phosphodiesterase inhibitor), and the glycoprotein IIb/IIIa inhibitors abciximab, tirofiban and eptifibatide (which prevent fibrinogen binding; <ce:intra-ref id="ii0085" xlink:href="pii:B978-0-7020-7028-0.00016-0#s1485">p. 500</ce:intra-ref>).</ce:para></ce:section><ce:section id="s0135"><ce:section-title id="st0130">Clotting factors</ce:section-title><ce:para id="p0695">The coagulation system consists of a cascade of soluble inactive zymogen proteins designated by Roman numerals. When proteolytically cleaved and activated, each is capable of activating one or more components of the cascade. Activated factors are designated by the suffix ‘a’. Some of these reactions require phospholipid and calcium. Coagulation occurs by two pathways: it is initiated by the extrinsic (or tissue factor) pathway and amplified by the ‘intrinsic pathway’ (see <ce:cross-ref id="crf0305" refid="f0050">Fig. 23.6D</ce:cross-ref>).</ce:para><ce:para id="p0700">Clotting factors are synthesised by the liver, although factor V is also produced by platelets and endothelial cells. Factors II, VII, IX and X require post-translational carboxylation to allow them to participate in coagulation. The carboxylase enzyme responsible for this in the liver is vitamin K-dependent. Vitamin K is converted to an epoxide in this reaction and must be reduced to its active form by a reductase enzyme. This reductase is inhibited by warfarin, and this is the basis of the anticoagulant effect of coumarins (p. 939). Congenital (e.g. haemophilia) and acquired (e.g. liver failure) causes of coagulation factor deficiency are associated with bleeding.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0140"><ce:section-title id="st0135">Investigation of diseases of the blood</ce:section-title><ce:section id="s0145"><ce:section-title id="st0140">The full blood count</ce:section-title><ce:para id="p0705">To obtain a full blood count (FBC), anticoagulated blood is processed through automated blood analysers that use a variety of technologies (particle-sizing, radiofrequency and laser instrumentation) to measure the haematological parameters. These include numbers of circulating cells, the proportion of whole blood volume occupied by red cells (the haematocrit, Hct), and the red cell indices that give information about the size of red cells (mean cell volume, MCV) and the amount of haemoglobin present in the red cells (mean cell haemoglobin, MCH). Blood analysers can differentiate types of white blood cell and give automated counts of neutrophils, lymphocytes, monocytes, eosinophils and basophils. It is important to appreciate, however, that a number of conditions can lead to spurious results (<ce:cross-ref id="crf0310" refid="b0040">Box 23.1</ce:cross-ref><ce:float-anchor refid="b0040"/>). The reference ranges for a number of common haematological parameters in adults are given in <ce:intra-ref id="ii0095" xlink:href="pii:B978-0-7020-7028-0.00035-4#c00035">Chapter 35</ce:intra-ref>.</ce:para></ce:section><ce:section id="s0150"><ce:section-title id="st0145">Blood film examination</ce:section-title><ce:para id="p0715">Although technical advances in full blood count analysers have resulted in fewer blood samples requiring manual examination, scrutiny of blood components prepared on a microscope slide (the ‘blood film’) can often yield valuable information (<ce:cross-ref id="crf0315" refid="b0045">Box 23.2</ce:cross-ref><ce:float-anchor refid="b0045"/> and <ce:cross-ref id="crf0320" refid="f0060">Fig. 23.8</ce:cross-ref>). Analysers cannot identify abnormalities of red cell shape and content (e.g. Howell–Jolly bodies, basophilic stippling, malaria parasites) or fully define abnormal white cells such as blasts.</ce:para></ce:section><ce:section id="s0155"><ce:section-title id="st0150">Bone marrow examination</ce:section-title><ce:para id="p0865">In adults, bone marrow for examination is usually obtained from the posterior iliac crest. After a local anaesthetic, marrow can be sucked out from the medullary space, stained and examined under the microscope (bone marrow aspirate). In addition, a core of bone may be removed (trephine biopsy), fixed and decalcified before sections are cut for staining (<ce:cross-ref id="crf0325" refid="f0065">Fig. 23.9</ce:cross-ref><ce:float-anchor refid="f0065"/>). A bone marrow aspirate is used to assess the composition and morphology of haematopoietic cells or abnormal infiltrates. Further investigations may be performed, such as cell surface marker analysis (immunophenotyping), chromosome and molecular studies to assess malignant disease, or marrow culture for suspected tuberculosis. A trephine biopsy is superior for assessing marrow cellularity, marrow fibrosis, and infiltration by abnormal cells such as metastatic carcinoma.</ce:para></ce:section><ce:section id="s0160"><ce:section-title id="st0155">Investigation of coagulation</ce:section-title><ce:section id="s0165"><ce:section-title id="st0160">Bleeding disorders</ce:section-title><ce:para id="p0870">In patients with clinical evidence of a bleeding disorder (p. 913), there are recommended screening tests (<ce:cross-ref id="crf0330" refid="b0050">Box 23.3</ce:cross-ref><ce:float-anchor refid="b0050"/>). Physiological activation of coagulation is predominantly by tissue factor, with amplification of the process by the small amounts of thrombin formed as a result. For ease of description, the terms extrinsic, intrinsic and common pathways are still used (see <ce:cross-ref id="crf0340" refid="f0050">Fig. 23.6D</ce:cross-ref>).</ce:para><ce:para id="p0880">Coagulation tests measure the time to clot formation in vitro in a plasma sample after the clotting process is initiated by activators and calcium. The result of the test sample is compared with normal controls. The tissue factor (‘extrinsic’) pathway (see <ce:cross-ref id="crf0345" refid="f0050">Fig. 23.6D</ce:cross-ref>) is assessed by the prothrombin time (PT), and the ‘intrinsic’ pathway by the activated partial thromboplastin time (APTT), sometimes known as the partial thromboplastin time with kaolin (PTTK). Coagulation is delayed by deficiencies of coagulation factors and by the presence of inhibitors of coagulation, such as heparin. The approximate reference ranges and causes of abnormalities are shown in <ce:cross-ref id="crf0350" refid="b0050">Box 23.3</ce:cross-ref>. If both the PT and APTT are prolonged, this indicates either deficiency or inhibition of the final common pathway (which includes factors X, V, prothrombin and fibrinogen) or global coagulation factor deficiency involving more than one factor, as occurs in disseminated intravascular coagulation (DIC, <ce:intra-ref id="ii0105" xlink:href="pii:B978-0-7020-7028-0.00010-X#s0475">pp. 196</ce:intra-ref> and 978). Further specific tests may be performed based on interpretation of the clinical scenario and results of these screening tests. A mixing test with normal plasma allows differentiation between a coagulation factor deficiency (the prolonged time corrects) and the presence of an inhibitor of coagulation (the prolonged time does not correct); the latter may be a chemical (heparins) or an antibody (most often a lupus anticoagulant but occasionally a specific inhibitor of one of the coagulation factors, typically factor VIII). Von Willebrand disease may present with a normal APTT; further investigation of suspected cases is detailed on page 974.</ce:para><ce:para id="p0885">Platelet function has historically been assessed by the bleeding time, measured as the time to stop bleeding after a standardised incision. However, most centres have abandoned the use of this test. Platelet function can be assessed in vitro by measuring aggregation in response to various agonists, such as adrenaline (epinephrine), collagen, thrombin, arachidonic acid and ADP, agglutination in response to ristocetin or by measuring the constituents of the intracellular granules, e.g. adenosine triphosphate, adenosine diphosphate and their ratio to each other (ATP/ADP).</ce:para><ce:para id="p0890">Coagulation screening tests are also performed in patients with suspected DIC, when clotting factors and platelets are consumed, resulting in thrombocytopenia and prolonged PT and APTT. In addition, there is evidence of active coagulation with consumption of fibrinogen and generation of fibrin degradation products (D-dimers). Note, however, that fibrinogen is an acute phase protein that may also be elevated in inflammatory disease (<ce:intra-ref id="ii0115" xlink:href="pii:B978-0-7020-7028-0.00004-4#p0470">p. 70</ce:intra-ref>).</ce:para></ce:section><ce:section id="s0170"><ce:section-title id="st0165">Monitoring anticoagulant therapy</ce:section-title><ce:para id="p0895">The international normalised ratio (INR) is validated only to assess the therapeutic effect of coumarin anticoagulants, including warfarin. INR is the ratio of the patient's PT to that of a normal control, raised to the power of the international sensitivity index of the thromboplastin used in the test (ISI, derived by comparison with an international reference standard material). Concentrations of the direct oral anticoagulants (DOACs) cannot be accurately assessed from the PT or the APTT, with which they have a variable and generally poor correlation.</ce:para><ce:para id="p0900">Monitoring of heparin therapy is, on the whole, required only with unfractionated heparins. Therapeutic anticoagulation prolongs the APTT relative to a control sample by a ratio of approximately 1.5–2.5. Low-molecular-weight heparins have such a predictable dose response that monitoring of the anticoagulant effect is not required, except in patients with renal impairment (glomerular filtration rate less than 30 mL/min). When monitoring is indicated, an anti-Xa activity assay rather than APTT should be used.</ce:para></ce:section><ce:section id="s0175"><ce:section-title id="st0170">Thrombotic disorders</ce:section-title><ce:para id="p0905">Measurement of plasma levels of D-dimers derived from fibrin degradation is useful in excluding the diagnosis of active venous thrombosis in some patients (see <ce:intra-ref id="ii0120" xlink:href="pii:B978-0-7020-7028-0.00010-X#f0050">Fig. 10.6</ce:intra-ref>, <ce:intra-ref id="ii0125" xlink:href="pii:B978-0-7020-7028-0.00010-X#p1345">p. 187</ce:intra-ref>).</ce:para><ce:para id="p0910">A variety of tests exist that may help to explain an underlying propensity to thrombosis, especially venous thromboembolism (thrombophilia) (<ce:cross-ref id="crf0355" refid="b0055">Box 23.4</ce:cross-ref><ce:float-anchor refid="b0055"/>). Examples of possible indications for testing are given in <ce:cross-ref id="crf0360" refid="b0060">Box 23.5</ce:cross-ref><ce:float-anchor refid="b0060"/>. In most patients, the results do not affect clinical management (p. 975) but they may influence the duration of anticoagulation (e.g. antiphospholipid antibodies, p. 977), justify family screening in inherited thrombophilias (p. 975), or suggest additional management strategies to reduce thrombosis risk (e.g. in myeloproliferative disease and paroxysmal nocturnal haemoglobinuria; p. 950). Anticoagulants can interfere with some of these assays; for example, warfarin reduces protein C and S levels and affects measurement of lupus anticoagulant, while heparin interferes with antithrombin and lupus anticoagulant assays. Therefore these tests, when required, should be performed when the patient is not taking anticoagulants.</ce:para><ce:para id="p1035"><ce:float-anchor refid="b0065"/></ce:para></ce:section></ce:section></ce:section><ce:section id="s0200"><ce:section-title id="st0190">Presenting problems in blood disease</ce:section-title><ce:section id="s0205"><ce:section-title id="st0195">Anaemia</ce:section-title><ce:para id="p1075">Anaemia refers to a state in which the level of haemoglobin in the blood is below the reference range appropriate for age and sex. Other factors, including pregnancy and altitude, also affect haemoglobin levels and must be taken into account when considering whether an individual is anaemic. The clinical features of anaemia reflect diminished oxygen supply to the tissues (p. 912). A rapid onset of anaemia (e.g. due to blood loss) causes more profound symptoms than a gradually developing anaemia. Individuals with cardiorespiratory disease are more susceptible to symptoms of anaemia.</ce:para><ce:para id="p1080">The clinical assessment and investigation of anaemia should gauge its severity and define the underlying cause (<ce:cross-ref id="crf0370" refid="b0070">Box 23.7</ce:cross-ref><ce:float-anchor refid="b0070"/>).</ce:para><ce:section id="s0210"><ce:section id="s0215"><ce:section-title id="st0200">Clinical assessment</ce:section-title><ce:para id="p1130"><ce:list id="ulist0260"><ce:list-item id="u0800"><ce:label>•</ce:label><ce:para id="p1135"><ce:italic>Iron deficiency anaemia</ce:italic> (p. 940) is the most common type of anaemia worldwide. A thorough gastrointestinal history is important, looking in particular for symptoms of blood loss. Menorrhagia is a common cause of anaemia in pre-menopausal females, so women should always be asked about their periods.</ce:para></ce:list-item><ce:list-item id="u0805"><ce:label>•</ce:label><ce:para id="p1140"><ce:italic>A dietary history</ce:italic> should assess the intake of iron and folate, which may become deficient in comparison to needs (e.g. in pregnancy or during periods of rapid growth; <ce:intra-ref id="ii0165" xlink:href="pii:B978-0-7020-7028-0.00019-6#p1945">pp. 712</ce:intra-ref>, 945 and <ce:intra-ref id="ii9000" xlink:href="pii:B978-0-7020-7028-0.00030-5#s0390">1284</ce:intra-ref>).</ce:para></ce:list-item><ce:list-item id="u0810"><ce:label>•</ce:label><ce:para id="p1145"><ce:italic>Past medical history</ce:italic> may reveal a disease that is known to be associated with anaemia, such as rheumatoid arthritis (anaemia of chronic disease), or previous surgery (e.g. resection of the stomach or small bowel, which may lead to malabsorption of iron and/or vitamin B<ce:inf loc="post">12</ce:inf>).</ce:para></ce:list-item><ce:list-item id="u0815"><ce:label>•</ce:label><ce:para id="p1150"><ce:italic>Family history and ethnic background</ce:italic> may raise suspicion of haemolytic anaemias, such as the haemoglobinopathies and hereditary spherocytosis. Pernicious anaemia may also run in families but is not associated with a clear Mendelian pattern of inheritance.</ce:para></ce:list-item><ce:list-item id="u0820"><ce:label>•</ce:label><ce:para id="p1155"><ce:italic>A drug history</ce:italic> may reveal the ingestion of drugs that cause blood loss (e.g. aspirin and anti-inflammatory drugs), haemolysis (e.g. sulphonamides) or aplasia (e.g. chloramphenicol).</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p1160">On examination, as well as the general physical findings of anaemia shown on page 912, there may be specific findings related to the aetiology of the anaemia; for example, a patient may be found to have a right iliac fossa mass due to an underlying caecal carcinoma. Haemolytic anaemias can cause jaundice. Vitamin B<ce:inf loc="post">12</ce:inf> deficiency may be associated with neurological signs, including peripheral neuropathy, dementia and signs of subacute combined degeneration of the cord (<ce:intra-ref id="ii0175" xlink:href="pii:B978-0-7020-7028-0.00025-1#s2035">p. 1138</ce:intra-ref>). Sickle-cell anaemia (p. 951) may result in leg ulcers, stroke or features of pulmonary hypertension. Anaemia may be multifactorial and the lack of specific symptoms and signs does not rule out silent pathology.</ce:para></ce:section><ce:section id="s0220"><ce:section-title id="st0205">Investigations</ce:section-title><ce:para id="p1165">Schemes for the investigation of anaemias are often based on the size of the red cells, which is most accurately indicated by the MCV in the FBC. Commonly, in the presence of anaemia:<ce:list id="ulist0265"><ce:list-item id="u0825"><ce:label>•</ce:label><ce:para id="p1170">A normal MCV (normocytic anaemia) suggests either acute blood loss or the anaemia of chronic disease, also known as the anaemia of inflammation (ACD/AI) (<ce:cross-ref id="crf0375" refid="f0070">Fig. 23.10</ce:cross-ref><ce:float-anchor refid="f0070"/>).</ce:para></ce:list-item><ce:list-item id="u0830"><ce:label>•</ce:label><ce:para id="p1175">A low MCV (microcytic anaemia) suggests iron deficiency or thalassaemia or sometimes ACD/AI (<ce:cross-ref id="crf0380" refid="f0070">Fig. 23.10</ce:cross-ref>).</ce:para></ce:list-item><ce:list-item id="u0835"><ce:label>•</ce:label><ce:para id="p1180">A high MCV (macrocytic anaemia) suggests vitamin B<ce:inf loc="post">12</ce:inf> or folate deficiency or myelodysplasia (<ce:cross-ref id="crf0385" refid="f0075">Fig. 23.11</ce:cross-ref><ce:float-anchor refid="f0075"/>).</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p1185">Specific types of anaemia and their management are described later in this chapter (p. 940).</ce:para></ce:section></ce:section></ce:section><ce:section id="s0225"><ce:section-title id="st0210">High haemoglobin</ce:section-title><ce:para id="p1190">Patients with a persistently raised haematocrit (Hct) (&#x003E; 0.52 males, &#x003E; 0.48 females) for more than 2 months should be investigated. ‘True’ polycythaemia (or absolute erythrocytosis) indicates an excess of red cells, while ‘relative’, ‘apparent’ or ‘low-volume’ polycythaemia is due to a decreased plasma volume. Causes of polycythaemia are shown in <ce:cross-ref id="crf0390" refid="b0075">Box 23.8</ce:cross-ref><ce:float-anchor refid="b0075"/>. These involve increased erythropoiesis in the bone marrow, either due to a primary increase in marrow activity, or in response to increased erythropoietin (Epo) levels in chronic hypoxaemia, or due to inappropriate secretion of Epo. Athletes who seek to benefit from increased oxygen-carrying capacity have been known to use Epo to achieve this.</ce:para><ce:para id="p1295">Apparent erythrocytosis with a raised Hct, normal red cell mass (RCM) and reduced plasma volume may be associated with hypertension, smoking, alcohol and diuretic use (Gaisböck's syndrome).</ce:para><ce:section id="s0230"><ce:section id="s0235"><ce:section-title id="st0215">Clinical assessment and investigations</ce:section-title><ce:para id="p1300">Males and females with Hct values of over 0.60 and over 0.56, respectively, can be assumed to have an absolute erythrocytosis. A clinical history and examination will identify most patients with polycythaemia secondary to hypoxia. The presence of hypertension, smoking, excess alcohol consumption and/or diuretic use is consistent with low-volume polycythaemia (Gaisböck's syndrome). In polycythaemia rubra vera (PRV), a mutation in a kinase, <ce:italic>JAK-2 V617F</ce:italic>, is found in over 90% of cases (p. 970). Patients with PRV have an increased risk of arterial thromboses, particularly stroke, and venous thromboembolism. They may also have aquagenic pruritus (itching after exposure to water), hepatosplenomegaly and gout (due to high red cell turnover).</ce:para><ce:para id="p1305">If the <ce:italic>JAK-2</ce:italic> mutation is absent and there is no obvious secondary cause, a measurement of red cell mass is required to confirm an absolute erythrocytosis, followed by further investigations to exclude hypoxia, and causes of inappropriate erythropoietin secretion.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0240"><ce:section-title id="st0220">Leucopenia (low white cell count)</ce:section-title><ce:para id="p1310">A reduction in the total numbers of circulating white cells is called leucopenia. This may be due to a reduction in all types of white cell or in individual cell types (usually neutrophils or lymphocytes). Leucopenia may occur in isolation or as part of a reduction in all three haematological lineages (pancytopenia; p. 930).</ce:para><ce:section id="s0245"><ce:section-title id="st0225">Neutropenia</ce:section-title><ce:para id="p1315">A reduction in neutrophil count (usually &#x003C; 1.5 × 10<ce:sup loc="post">9</ce:sup>/L but dependent on age and race) is called neutropenia. The main causes are listed in <ce:cross-ref id="crf0395" refid="b0080">Box 23.9</ce:cross-ref><ce:float-anchor refid="b0080"/> and <ce:cross-ref id="crf0405" refid="f0080">Figure 23.12</ce:cross-ref>. Drug-induced neutropenia is not uncommon (<ce:cross-ref id="crf0410" refid="b0085">Box 23.10</ce:cross-ref><ce:float-anchor refid="b0085"/>). Clinical manifestations range from no symptoms to overwhelming sepsis. The risk of bacterial infection is related to the degree of neutropenia, with counts lower than 0.5 × 10<ce:sup loc="post">9</ce:sup>/L considered to be critically low. Fever is the first and often only manifestation of infection. A sore throat, perianal pain or skin inflammation may be present. The lack of neutrophils allows the patient to become septicaemic and shocked within hours if immediate antibiotic therapy is not commenced. Management is discussed on <ce:intra-ref id="ii0200" xlink:href="pii:B978-0-7020-7028-0.00011-1#p1470">page 224</ce:intra-ref>.</ce:para></ce:section><ce:section id="s0310"><ce:section-title id="st0290">Lymphopenia</ce:section-title><ce:para id="p1545">This is an absolute lymphocyte count of less than 1 × 10<ce:sup loc="post">9</ce:sup>/L. The causes are shown in <ce:cross-ref id="crf0420" refid="b0080">Box 23.9</ce:cross-ref>. Although minor reductions may be asymptomatic, deficiencies in cell-mediated immunity may result in infections (with organisms such as fungi, viruses and mycobacteria) and a propensity to lymphoid and other malignancies (particularly those associated with viral infections such as Epstein–Barr virus (EBV), human papillomavirus (HPV) and human herpesvirus 8 (HHV-8)). Lymphopenia without any obvious cause is common with advancing age.</ce:para></ce:section></ce:section><ce:section id="s0315"><ce:section-title id="st0295">Leucocytosis (high white cell count)</ce:section-title><ce:para id="p1550">An increase in the total numbers of circulating white cells is called leucocytosis. This is usually due to an increase in a specific type of cell (see <ce:cross-ref id="crf0425" refid="b0080">Box 23.9</ce:cross-ref>). It is important to realise that an increase in a single type of white cell (e.g. eosinophils or monocytes) may not increase the total white cell count (WCC) above the upper limit of normal and will be apparent only if the ‘differential’ of the white count is examined.</ce:para><ce:section id="s0320"><ce:section-title id="st0300">Neutrophilia</ce:section-title><ce:para id="p1555">An increase in the number of circulating neutrophils is called a neutrophilia or a neutrophil leucocytosis. It can result from an increased production of cells from the bone marrow or redistribution from the marginated pool. The normal neutrophil count depends on age, race and certain physiological parameters. During pregnancy, not only is there an increase in neutrophils but also earlier forms, such as metamyelocytes, can be found in the blood. The causes of a neutrophilia are shown in <ce:cross-ref id="crf0430" refid="b0080">Box 23.9</ce:cross-ref>.</ce:para></ce:section><ce:section id="s0325"><ce:section-title id="st0305">Eosinophilia</ce:section-title><ce:para id="p1560">A high eosinophil count of more than 0.5 × 10<ce:sup loc="post">9</ce:sup>/L is usually secondary to infection (especially parasites; <ce:intra-ref id="ii0205" xlink:href="pii:B978-0-7020-7028-0.00011-1#p2750">p. 233</ce:intra-ref>), allergy (e.g. eczema, asthma, reactions to drugs; <ce:intra-ref id="ii0210" xlink:href="pii:B978-0-7020-7028-0.00004-4#s0565">p. 84</ce:intra-ref>), immunological disorders (e.g. polyarteritis, sarcoidosis) or malignancy (e.g. lymphomas) (see <ce:cross-ref id="crf0435" refid="b0080">Box 23.9</ce:cross-ref>). Usually, such eosinophilia is short-lived.</ce:para><ce:para id="p1565">In the rarer primary disorders, there is a persistently raised, often clonal, eosinophilia, e.g. in myeloproliferative disorders, subtypes of acute myeloid leukaemia and idiopathic hypereosinophilic syndrome (HES). Recently, specific mutations in receptor tyrosine kinase genes have been found in some primary eosinophilias (e.g. causing rearrangements of platelet-derived growth factor receptors α and β or c-kit), which allow diagnosis and, in some cases, specific therapy with tyrosine kinase inhibitors such as imatinib.</ce:para><ce:para id="p1570">Eosinophil infiltration can damage many organs (e.g. heart, lungs, gastrointestinal tract, skin, musculoskeletal system); evaluation of eosinophilia therefore includes not only the identification of any underlying cause and its appropriate treatment but also assessment of any related organ damage.</ce:para></ce:section><ce:section id="s0330"><ce:section-title id="st0310">Lymphocytosis</ce:section-title><ce:para id="p1575">A lymphocytosis is an increase in circulating lymphocytes above that expected for the patient's age. In adults, this is greater than 3.5 × 10<ce:sup loc="post">9</ce:sup>/L. Infants and children have higher counts; age-related reference ranges should be consulted. Causes are shown in <ce:cross-ref id="crf0440" refid="b0080">Box 23.9</ce:cross-ref>; the most common is viral infection.</ce:para></ce:section></ce:section><ce:section id="s0335"><ce:section-title id="st0315">Lymphadenopathy</ce:section-title><ce:para id="p1580">Enlarged lymph glands may be an important indicator of haematological disease but they are not uncommon in reaction to infection or inflammation (<ce:cross-ref id="crf0445" refid="b0090">Box 23.11</ce:cross-ref><ce:float-anchor refid="b0090"/>). The sites of lymph node groups, and symptoms and signs that may help elucidate the underlying cause are shown on page 913. Nodes that enlarge in response to local infection or inflammation (‘reactive nodes’) usually expand rapidly and are painful, whereas those due to haematological disease are more frequently painless. Localised lymphadenopathy should elicit a search for a source of inflammation or primary malignancy in the appropriate drainage area:<ce:list id="ulist0350"><ce:list-item id="u1165"><ce:label>•</ce:label><ce:para id="p1660">the scalp, ear, mouth and throat, face, teeth or thyroid for neck nodes</ce:para></ce:list-item><ce:list-item id="u1170"><ce:label>•</ce:label><ce:para id="p1665">the breast for axillary nodes</ce:para></ce:list-item><ce:list-item id="u1175"><ce:label>•</ce:label><ce:para id="p1670">the perineum or external genitalia for inguinal nodes.</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p1675">Generalised lymphadenopathy may be secondary to infection, often viral, connective tissue disease or extensive skin disease (dermatopathic lymphadenopathy) but is more likely to signify underlying haematological malignancy. Weight loss and drenching night sweats that may require a change of nightclothes are associated with haematological malignancies, particularly lymphoma.</ce:para><ce:para id="p1680">Initial investigations in lymphadenopathy include an FBC (to detect neutrophilia in infection or evidence of haematological disease), measurement of erythrocyte sedimentation rate (ESR) and a chest X-ray (to detect mediastinal lymphadenopathy). If the findings suggest malignancy, a formal cutting needle or excision biopsy of a representative node is indicated to obtain a histological diagnosis.</ce:para></ce:section><ce:section id="s0365"><ce:section-title id="st0340">Splenomegaly</ce:section-title><ce:para id="p1685">The spleen may be enlarged due to involvement by lymphoproliferative disease, the resumption of extramedullary haematopoiesis in myeloproliferative disease, enhanced reticulo-endothelial activity in autoimmune haemolysis, expansion of the lymphoid tissue in response to infections, or vascular congestion as a result of portal hypertension (<ce:cross-ref id="crf0450" refid="b0095">Box 23.12</ce:cross-ref><ce:float-anchor refid="b0095"/>). Hepatosplenomegaly is suggestive of lympho- or myeloproliferative disease, liver disease or infiltration (e.g. with amyloid). Associated lymphadenopathy is suggestive of lymphoproliferative disease. An enlarged spleen may cause abdominal discomfort, accompanied by back pain and abdominal bloating and early satiety due to stomach compression. Splenic infarction produces severe abdominal pain radiating to the left shoulder tip, associated with a splenic rub on auscultation. Rarely, spontaneous or traumatic rupture and bleeding may occur.</ce:para><ce:para id="p1865">Investigation should focus on the suspected cause. Imaging of the spleen by ultrasound or computed tomography (CT) will detect variations in density in the spleen, which may be a feature of lymphoproliferative disease; it also allows imaging of the liver and abdominal lymph nodes. Biopsy of enlarged abdominal or superficial lymph nodes may provide the diagnosis, as might a bone marrow biopsy in splenic lymphomas. A chest X-ray or CT of the thorax will detect mediastinal lymphadenopathy. An FBC may show pancytopenia secondary to hypersplenism, when the enlarged spleen has become overactive, destroying blood cells prematurely. If other abnormalities are present, such as abnormal lymphocytes or a leucoerythroblastic blood film, a bone marrow examination is indicated. Screening for infectious or liver disease (<ce:intra-ref id="ii0220" xlink:href="pii:B978-0-7020-7028-0.00022-6#s0135">p. 852</ce:intra-ref>) may be appropriate. If all investigations are unhelpful, splenectomy may be diagnostic but is rarely carried out in these circumstances.</ce:para></ce:section><ce:section id="s0370"><ce:section-title id="st0345">Bleeding</ce:section-title><ce:para id="p1870">Normal bleeding is seen following surgery and trauma. Pathological bleeding occurs when structurally abnormal vessels rupture or when a vessel is breached in the presence of a defect in haemostasis. This may be due to a deficiency or dysfunction of platelets, the coagulation factors or von Willebrand factor, or occasionally to excessive fibrinolysis, which is most commonly observed following therapeutic thrombolysis (<ce:intra-ref id="ii0225" xlink:href="pii:B978-0-7020-7028-0.00016-0#s1485">p. 500</ce:intra-ref>).</ce:para><ce:section id="s0375"><ce:section id="s0380"><ce:section-title id="st0350">Clinical assessment</ce:section-title><ce:para id="p1875">‘Screening’ blood tests (see <ce:cross-ref id="crf0480" refid="b0050">Box 23.3</ce:cross-ref>) do not reliably detect all causes of pathological bleeding (e.g. von Willebrand disease, scurvy, certain anticoagulant drugs and the causes of purpura listed in <ce:cross-ref id="crf0485" refid="b0100">Box 23.13</ce:cross-ref><ce:float-anchor refid="b0100"/>) and should not be used indiscriminately. A careful clinical evaluation is the key to diagnosis of bleeding disorders (<ce:cross-ref id="crf9035" refid="p5845">p. 970</ce:cross-ref>). It is important to consider the following:<ce:list id="ulist0480"><ce:list-item id="u1380"><ce:label>•</ce:label><ce:para id="p1915"><ce:italic>Site of bleeding.</ce:italic> Bleeding into muscle and joints, along with retroperitoneal and intracranial haemorrhage, indicates a likely defect in coagulation factors. Purpura, prolonged bleeding from superficial cuts, epistaxis, gastrointestinal haemorrhage or menorrhagia is more likely to be due to thrombocytopenia, a platelet function disorder or von Willebrand disease. Recurrent bleeds at a single site suggest a local structural abnormality rather than coagulopathic bleeding.</ce:para></ce:list-item><ce:list-item id="u1385"><ce:label>•</ce:label><ce:para id="p1920"><ce:italic>Duration of history.</ce:italic> It may be possible to assess whether the disorder is congenital or acquired.</ce:para></ce:list-item><ce:list-item id="u1390"><ce:label>•</ce:label><ce:para id="p1925"><ce:italic>Precipitating causes.</ce:italic> Bleeding arising spontaneously indicates a more severe defect than bleeding that occurs only after trauma.</ce:para></ce:list-item><ce:list-item id="u1395"><ce:label>•</ce:label><ce:para id="p1930"><ce:italic>Surgery.</ce:italic> Ask about operations. Dental extractions, tonsillectomy and circumcision are stressful tests of the haemostatic system. Immediate post-surgical bleeding suggests defective platelet plug formation and primary haemostasis; delayed haemorrhage is more suggestive of a coagulation defect. However, in post-surgical patients, persistent bleeding from a single site is more likely to indicate surgical bleeding than a bleeding disorder.</ce:para></ce:list-item><ce:list-item id="u1400"><ce:label>•</ce:label><ce:para id="p1935"><ce:italic>Family history.</ce:italic> While a positive family history may be present in patients with inherited disorders, the absence of affected relatives does not exclude a hereditary bleeding diathesis; about one-third of cases of haemophilia arise in individuals without a family history, and deficiencies of factor VII, X and XIII are recessively inherited. Recessive disorders are more common in cultures where there is consanguineous marriage.</ce:para></ce:list-item><ce:list-item id="u1405"><ce:label>•</ce:label><ce:para id="p1940"><ce:italic>Drugs.</ce:italic> Use of antithrombotic, anticoagulant and fibrinolytic drugs must be elicited. Drug interactions with warfarin and drug-induced thrombocytopenia should be considered. Some ‘herbal’ remedies may result in a bleeding diathesis.</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p1945">Clinical examination may reveal different patterns of skin bleeding. Petechial purpura is minor bleeding into the dermis that is flat and non-blanching (<ce:cross-ref id="crf0490" refid="f0085">Fig. 23.13</ce:cross-ref><ce:float-anchor refid="f0085"/>). Petechiae are typically found in patients with thrombocytopenia or platelet dysfunction. Palpable purpura occurs in vasculitis. Ecchymosis, or bruising, is more extensive bleeding into deeper layers of the skin. The lesions are initially dark red or purple but become yellow as haemoglobin is degraded. Retroperitoneal bleeding presents with a flank or peri-umbilical haematoma. Telangiectasia of lips and tongue points to hereditary haemorrhagic telangiectasia (<ce:cross-ref id="crf9040" refid="p5845">p. 970</ce:cross-ref>). Joints should be examined for evidence of haemarthroses. A full examination is important, as it may give clues to an underlying associated systemic illness such as a haematological or other malignancy, liver disease, renal failure, connective tissue disease and possible causes of splenomegaly.</ce:para></ce:section><ce:section id="s0385"><ce:section-title id="st0355">Investigations</ce:section-title><ce:para id="p1950">Screening investigations and their interpretation are described on <ce:cross-ref id="crf9045" refid="s0150">page 920</ce:cross-ref>. If the patient has a history that is strongly suggestive of a bleeding disorder and all the preliminary screening tests give normal results, further investigations, such as measurement of von Willebrand factor and assessment of platelet function, should be performed (<ce:cross-ref id="crf9050" refid="p0885">p. 921</ce:cross-ref>).</ce:para></ce:section></ce:section></ce:section><ce:section id="s0390"><ce:section-title id="st0360">Thrombocytopenia (low platelet count)</ce:section-title><ce:para id="p1955">A reduced platelet count may arise by one of two mechanisms:<ce:list id="ulist0485"><ce:list-item id="u1410"><ce:label>•</ce:label><ce:para id="p1960">decreased or abnormal production (bone marrow failure and hereditary thrombocytopathies)</ce:para></ce:list-item><ce:list-item id="u1415"><ce:label>•</ce:label><ce:para id="p1965">increased consumption following release into the circulation (immune-mediated, DIC or sequestration).</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p1970">Spontaneous bleeding does not usually occur until the platelet count falls below 20 × 10<ce:sup loc="post">9</ce:sup>/L, unless their function is also compromised. Purpura and spontaneous bruising are characteristic but there may also be oral, nasal, gastrointestinal or genitourinary bleeding. Severe thrombocytopenia (&#x003C; 10 × 10<ce:sup loc="post">9</ce:sup>/L) may result in retinal haemorrhage and potentially fatal intracranial bleeding, but this is rare.</ce:para><ce:para id="p1975">Investigations are directed at the possible causes listed in <ce:cross-ref id="crf0495" refid="b0105">Box 23.14</ce:cross-ref><ce:float-anchor refid="b0105"/>. A blood film is the single most useful initial investigation. Examination of the bone marrow may reveal increased megakaryocytes in consumptive causes of thrombocytopenia, or the underlying cause of bone marrow failure in leukaemia, hypoplastic anaemia or myelodysplasia.</ce:para><ce:para id="p2175">Treatment (if required) depends on the underlying cause. Platelet transfusion is rarely required and is usually confined to patients with bone marrow failure and platelet counts below 10 × 10<ce:sup loc="post">9</ce:sup>/L, or to clinical situations with actual or predicted serious haemorrhage.</ce:para></ce:section><ce:section id="s0395"><ce:section-title id="st0365">Thrombocytosis (high platelet count)</ce:section-title><ce:para id="p2180">The most common reason for a raised platelet count is that it is reactive to another process, such as infection, inflammation, connective tissue disease, malignancy, iron deficiency, acute haemolysis or gastrointestinal bleeding (<ce:cross-ref id="crf0510" refid="b0115">Box 23.15</ce:cross-ref><ce:float-anchor refid="b0115"/>). The presenting clinical features are usually those of the underlying disorder and haemostasis is rarely affected. Reactive thrombocytosis is distinguished from the myeloproliferative disorders by the presence of uniform small platelets, lack of splenomegaly, and the presence of an associated disorder. The key to diagnosis is the clinical history and examination, combined with observation of the platelet count over time (reactive thrombocytosis gets better with resolution of the underlying cause).</ce:para><ce:para id="p2250">The platelets are a product of an abnormally expanding clone of cells in the myeloproliferative disorders, chronic myeloid leukaemia and some forms of myelodysplasia. As with PRV, patients with essential thrombocythaemia may present with thrombosis or, rarely, bleeding. Stroke, transient ischaemic attacks, amaurosis fugax, digital ischaemia or gangrene, aquagenic pruritus, splenomegaly and systemic upset are also features. Patients with myeloproliferative disorders may also present with features such as aquagenic pruritus, splenomegaly and systemic upset.</ce:para></ce:section><ce:section id="s0400"><ce:section-title id="st0370">Pancytopenia</ce:section-title><ce:para id="p2255">Pancytopenia refers to the combination of anaemia, leucopenia and thrombocytopenia. It may be due to reduced production of blood cells as a consequence of bone marrow suppression or infiltration, or there may be peripheral destruction or splenic pooling of mature cells. Causes are shown in <ce:cross-ref id="crf0515" refid="b0120">Box 23.16</ce:cross-ref><ce:float-anchor refid="b0120"/>. A bone marrow aspirate and trephine are usually required to establish the diagnosis.</ce:para></ce:section><ce:section id="s0425"><ce:section-title id="st0395">Infection</ce:section-title><ce:para id="p2335">Infection is a major complication of haematological disorders. It relates to the immunological deficit caused by the disease itself, or its treatment with chemotherapy and/or immunotherapy (<ce:intra-ref id="ii0270" xlink:href="pii:B978-0-7020-7028-0.00011-1#p1470">pp. 224</ce:intra-ref> and 925).</ce:para></ce:section></ce:section><ce:section id="s0430"><ce:section-title id="st0400">Principles of management of haematological disease</ce:section-title><ce:section id="s0435"><ce:section-title id="st0405">Blood products and transfusion</ce:section-title><ce:para id="p2340">Blood transfusion from an unrelated donor to a recipient inevitably carries some risk, including adverse immunological interactions between the host and infused blood (p. 931), and transmission of infectious agents. Although there are many compelling clinical indications for blood component transfusion, there are also many clinical circumstances in which transfusion is conventional but the evidence for its effectiveness is limited. In these settings, allogeneic transfusion may be avoided by following protocols that recommend the use of low haemoglobin thresholds for red cell transfusion, perioperative blood salvage and antifibrinolytic drugs.</ce:para><ce:section id="s0440"><ce:section-title id="st0410">Blood products</ce:section-title><ce:para id="p2345">Blood components are prepared from whole blood or specific blood constituents collected from individual donors and include red cells, platelets, plasma and cryoprecipitate (<ce:cross-ref id="crf0520" refid="b0125">Box 23.17</ce:cross-ref><ce:float-anchor refid="b0125"/>).</ce:para><ce:para id="p2385">Plasma derivatives are licensed pharmaceutical products produced on a factory scale from large volumes of human plasma obtained from many people and treated to remove transmissible infection. Examples include:<ce:list id="ulist0605"><ce:list-item id="u1745"><ce:label>•</ce:label><ce:para id="p2390"><ce:italic>Coagulation factors.</ce:italic> Concentrates of factors VIII and IX are used for the treatment of conditions such as haemophilia A, haemophilia B and von Willebrand disease. Coagulation factors made by recombinant DNA technology are now preferred due to perceived lack of infection risk but plasma-derived products are still used in many countries.</ce:para></ce:list-item><ce:list-item id="u1750"><ce:label>•</ce:label><ce:para id="p2395"><ce:italic>Immunoglobulins.</ce:italic> Intravenous immunoglobulin G (IVIgG) is administered as regular replacement therapy to reduce infective complications in patients with primary and secondary immunodeficiency. A short, high-dose course of IVIgG may also be effective in some immunological disorders, including immune thrombocytopenia (p. 971) and Guillain–Barré syndrome (<ce:intra-ref id="ii0285" xlink:href="pii:B978-0-7020-7028-0.00025-1#s2070">p. 1140</ce:intra-ref>). IVIgG can cause acute reactions and must be infused strictly according to the manufacturer's product information. There is a risk of renal dysfunction in susceptible patients and, in these circumstances, immunoglobulin products containing low or no sucrose are preferred. Anti-zoster immunoglobulin has a role in the prophylaxis of varicella zoster (<ce:intra-ref id="ii0290" xlink:href="pii:B978-0-7020-7028-0.00011-1#s0615">p. 239</ce:intra-ref>). Anti-Rhesus D immunoglobulin is used in pregnancy to prevent haemolytic disease of the newborn (see <ce:cross-ref id="crf0540" refid="b0135">Box 23.19</ce:cross-ref> below).</ce:para></ce:list-item><ce:list-item id="u1755"><ce:label>•</ce:label><ce:para id="p2400"><ce:italic>Human albumin.</ce:italic> This is available in two strengths. The 5% solution can be used as a colloid resuscitation fluid but it is no more effective and is more expensive than crystalloid solutions. Human albumin 20% solution is used in the management of hypoproteinaemic oedema in nephrotic syndrome (<ce:intra-ref id="ii0295" xlink:href="pii:B978-0-7020-7028-0.00015-9#s0220">p. 395</ce:intra-ref>) and ascites in chronic liver disease (<ce:intra-ref id="ii0300" xlink:href="pii:B978-0-7020-7028-0.00022-6#s0370">p. 864</ce:intra-ref>). It is hyperoncotic and expands plasma volume by more than the amount infused.</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p2405">Blood components and their use are summarised in <ce:cross-ref id="crf0545" refid="b0125">Box 23.17</ce:cross-ref>.</ce:para><ce:section id="s0445"><ce:section-title id="st0415">Blood donation</ce:section-title><ce:para id="p2410">A safe supply of blood components depends on a well-organised system with regular donation by healthy individuals who have no excess risk of infections transmissible in blood (<ce:cross-ref id="crf0550" refid="f0090">Fig. 23.14</ce:cross-ref><ce:float-anchor refid="f0090"/>). Blood donations are obtained by either venesection of a unit of whole blood or collection of a specific component, such as platelets, by apheresis. During apheresis, the donor's blood is drawn via a closed system into a machine that separates the components by centrifugation and collects the desired fraction into a bag, returning the rest of the blood to the donor. Each donation must be tested for hepatitis B virus (HBV), hepatitis C virus (HCV), HIV and human T-cell lymphotropic virus (HTLV) nucleic acid and/or antibodies. Platelet concentrates may be tested for bacterial contamination. The need for other microbiological tests depends on local epidemiology. For example, testing for <ce:italic>Trypanosoma cruzi</ce:italic> (Chagas' disease; <ce:intra-ref id="ii0305" xlink:href="pii:B978-0-7020-7028-0.00011-1#s2110">p. 279</ce:intra-ref>) is necessary in areas of South America and the USA where infection is prevalent. Tests for West Nile virus have been required in the USA since this agent became prevalent. Components for use in specific patient groups are prepared from hepatitis E virus-negative donors in the UK, and plasma donated in the UK is not used at present for producing pooled plasma derivatives in view of concerns about transmission of variant Creutzfeldt–Jakob disease (vCJD; <ce:intra-ref id="ii0310" xlink:href="pii:B978-0-7020-7028-0.00025-1#p8080">p. 1127</ce:intra-ref>).</ce:para></ce:section></ce:section><ce:section id="s0450"><ce:section-title id="st0420">Adverse effects of transfusion</ce:section-title><ce:para id="p2415">Death directly attributable to transfusion is rare, at less than 0.3 per 100 000 transfusions. Relatively minor symptoms of transfusion reactions (fever, itch or urticaria) occur in up to 3% of transfusions, and usually in patients who have had repeated transfusions. Any symptoms or signs that arise during a transfusion must be taken seriously, as they may be the first warnings of a serious reaction. <ce:cross-ref id="crf0555" refid="f0100">Figure 23.16</ce:cross-ref> below outlines the symptoms and signs, management and investigation of acute reactions to blood components.</ce:para><ce:section id="s0455"><ce:section-title id="st0425">Red cell incompatibility</ce:section-title><ce:para id="p2420">Red blood cell membranes contain numerous cell surface molecules that are potentially antigenic (see <ce:cross-ref id="crf0560" refid="f0040">Fig. 23.4</ce:cross-ref>). The ABO and Rhesus D antigens are the most important in routine transfusion and antenatal practice.</ce:para><ce:section id="s0460"><ce:section-title id="st0430">ABO blood groups</ce:section-title><ce:para id="p2425">The frequency of the ABO antigens varies among different populations. The ABO blood group antigens are oligosaccharide chains that project from the red cell surface. These chains are attached to proteins and lipids that lie in the red cell membrane. The <ce:italic>ABO</ce:italic> gene encodes a glycosyltransferase that catalyses the final step in the synthesis of the chain, which has three common alleles: A, B and O. The O allele encodes an inactive enzyme, leaving the ABO antigen precursor (called the H antigen) unmodified. The A and B alleles encode enzymes that differ by four amino acids and hence attach different sugars to the end of the chain. Individuals are tolerant to their own ABO antigens, but do not suppress B-cell clones producing antibodies against ABO antigens that they do not carry themselves (<ce:cross-ref id="crf0565" refid="b0130">Box 23.18</ce:cross-ref><ce:float-anchor refid="b0130"/>). They are, therefore, capable of mounting a humoral immune response to these ‘foreign’ antigens.</ce:para></ce:section><ce:section id="s0465"><ce:section-title id="st0435">ABO-incompatible red cell transfusion</ce:section-title><ce:para id="p2435">If red cells of an incompatible ABO group are transfused (especially if a group O recipient is transfused with group A, B or AB red cells), the <ce:italic>recipient</ce:italic>'s IgM anti-A, anti-B or anti-AB binds to the <ce:italic>transfused</ce:italic> red cells. This activates the full complement pathway (<ce:intra-ref id="ii0315" xlink:href="pii:B978-0-7020-7028-0.00004-4#s0070">p. 66</ce:intra-ref>), creating pores in the red cell membrane and destroying the transfused red cells in the circulation (intravascular haemolysis). The anaphylatoxins C3a and C5a, released by complement activation, liberate cytokines such as tumour necrosis factor (TNF), interleukin 1 (IL-1) and IL-8, and stimulate degranulation of mast cells with release of vasoactive mediators. All these substances may lead to inflammation, increased vascular permeability and hypotension, which may, in turn, cause shock and renal failure. Inflammatory mediators can also cause platelet aggregation, lung peribronchial oedema and smooth muscle contraction. About 20–30% of ABO-incompatible transfusions cause some degree of morbidity, and 5–10% cause or contribute to a patient's death. The main reason for this relatively low morbidity is the lack of potency of ABO antibodies in group A or B subjects; even if the recipient is group O, those who are very young or very old usually have weaker antibodies that do not lead to the activation of large amounts of complement.</ce:para></ce:section><ce:section id="s0470"><ce:section-title id="st0440">The Rhesus D blood group and haemolytic disease of the newborn</ce:section-title><ce:para id="p2440">About 15% of Caucasians are Rhesus-negative: that is, they lack the Rhesus D (RhD) red cell surface antigen (see <ce:cross-ref id="crf0570" refid="f0040">Fig. 23.4</ce:cross-ref>). In other populations (e.g. in Chinese and Bengalis), only 1–5% are Rhesus-negative. RhD-negative individuals do not normally produce substantial amounts of anti-RhD antibodies. However, if RhD-positive red cells enter the circulation of an RhD-negative individual, IgG antibodies are produced. This can occur during pregnancy if the mother is exposed to fetal cells via fetomaternal haemorrhage, or following transfusion. If a woman is so sensitised, during a subsequent pregnancy anti-RhD antibodies can cross the placenta; if the fetus is RhD-positive, haemolysis with severe fetal anaemia and hyperbilirubinaemia can result. This can cause severe neurological damage or death due to haemolytic disease of the newborn (HDN). Therefore, an RhD-negative female who may subsequently become pregnant should never be transfused with RhD-positive blood.</ce:para><ce:para id="p2445">In RhD-negative women, administration of anti-RhD immunoglobulin (anti-D) perinatally can block the immune response to RhD antigen on fetal cells and is the only effective product for preventing the development of Rhesus antibodies (<ce:cross-ref id="crf0575" refid="b0135">Box 23.19</ce:cross-ref><ce:float-anchor refid="b0135"/>).</ce:para><ce:para id="p2470">HDN can also be caused by other alloantibodies against red cell antigens, usually after previous pregnancies or transfusions. These antigens include Rhc, RhC, RhE, Rhe, and the Kell, Kidd and Duffy antigen systems. HDN can also occur if there is fetomaternal ABO incompatibility, most commonly seen in a group O mother with a group A fetus. The fetus is generally less severely affected by ABO incompatibility than by RhD, Rhc or Kell antigen mismatch, and the incompatibility is often picked up coincidentally after birth.</ce:para></ce:section></ce:section><ce:section id="s0475"><ce:section-title id="st0445">Other immunological complications of transfusion</ce:section-title><ce:para id="p2475">Rare but serious complications include transfusion-associated lung injury (TRALI) and transfusion-associated graft-versus-host disease (TA GVHD). The latter occurs when there is sharing of a human leucocyte antigen (HLA) haplotype between donor and recipient, which allows transfused lymphocytes to engraft, proliferate and recognise the recipient as foreign, resulting in acute GVHD (p. 937). Prevention is by gamma- or X-ray irradiation of blood components before their administration to prevent lymphocyte proliferation. Those at risk of TA GVHD, who must receive irradiated blood components, include patients with congenital T-cell immunodeficiencies or Hodgkin lymphoma, patients with aplastic anaemia receiving immunosuppressive therapy with antithymocyte globulin (ATG), recipients of haematopoietic stem cell transplants or of blood from a family member, neonates who have received an intrauterine transfusion, and patients taking T-lymphocyte-suppressing drugs, such as fludarabine and other purine analogues.</ce:para></ce:section><ce:section id="s0480"><ce:section-title id="st0450">Transfusion-transmitted infection</ce:section-title><ce:para id="p2480">Over the past 30 years, HBV, HIV-1 and HCV have been identified and effective tests introduced to detect and exclude infected donations. Where blood is from ‘safe’ donors and correctly tested, the current risk of a donated unit being infectious is very small. By 2013 in the UK, the estimated chance that a unit of blood from a ‘safe’ donor might transmit one of the viruses for which blood is tested was 1 in 6.6 million units for HIV-1, 1 in 51.5 million for HCV and 1 in 2.6 million for HBV. However, some patients who received transfusions before these tests were available suffered serious consequences from infection; this serves as a reminder to avoid non-essential transfusion, since it is impossible to exclude the emergence of new or currently unrecognised transfusion-transmissible infection. Licensed plasma derivatives that have been virus-inactivated do not transmit HIV, HTLV, HBV, HCV, cytomegalovirus or other lipid-enveloped viruses.</ce:para><ce:para id="p2485">Variant CJD is a human prion disease linked to bovine spongiform encephalitis (BSE; <ce:intra-ref id="ii0325" xlink:href="pii:B978-0-7020-7028-0.00025-1#p8080">p. 1127</ce:intra-ref>). The risk of a recipient acquiring the agent of vCJD from a transfusion is uncertain, but of 16 recipients of blood from donors who later developed the disease, 3 have died with clinical vCJD and 1 other had postmortem immunohistological features of infection.</ce:para><ce:para id="p2490">Bacterial contamination of a blood component – usually platelets – is extremely rare (1 proven case in the UK in 2015) but can result in severe bacteraemia/sepsis in the recipient.</ce:para></ce:section></ce:section><ce:section id="s0485"><ce:section-title id="st0455">Safe transfusion procedures</ce:section-title><ce:para id="p2495">The proposed transfusion and any alternatives should be discussed with the patient or, if that is not possible, with a relative, and this should be documented in the case record. Some patients, e.g. Jehovah's Witnesses, may refuse transfusion and require specialised management to survive profound anaemia following blood loss.</ce:para><ce:section id="s0490"><ce:section-title id="st0460">Pre-transfusion testing</ce:section-title><ce:para id="p2500">To ensure that red cells supplied for transfusion are compatible with the intended recipient, the transfusion laboratory will perform either a ‘group and screen’ procedure or a ‘cross-match’. In the group and screen procedure, the red cells from the patient's blood sample are tested to determine the ABO and RhD type, and the patient's serum is also tested against an array of red cells expressing the most important antigens to detect any red cell antibodies. Any antibody detected can be identified by further testing, so that red cell units that lack the corresponding antigen can be selected. The patient's sample can be held in the laboratory for up to a week, so that the hospital blood bank can quickly prepare compatible blood without the need for a further patient sample. Conventional cross-matching consists of the group and antibody screen, followed by direct confirmation of the compatibility of individual units of red cells with the patient's serum. Full cross-matching takes about 45 minutes if no red cell antibodies are present, but may require hours if a patient has multiple antibodies.</ce:para><ce:para id="p2505">Blood can be supplied by ‘electronic issue’, without the need for compatibility cross-matching, if the laboratory's computer system shows that the patient's ABO and RhD groups have been identified and confirmed on two separate occasions and their antibody screen is negative. This allows group-specific units to be issued quickly and safely, for elective and emergency transfusion.</ce:para></ce:section><ce:section id="s0495"><ce:section-title id="st0465">Bedside procedures for safe transfusion</ce:section-title><ce:para id="p2510">Errors leading to patients receiving the wrong blood are an important avoidable cause of mortality and morbidity. Most incompatible transfusions result from failure to adhere to standard procedures for taking correctly labelled blood samples from the patient and ensuring that the correct pack of blood component is transfused into the intended patient. In the UK in 2015, there were 280 reports of transfusion of an incorrect blood component (11 per 100 000 units transfused). Every hospital where blood is transfused should have a written transfusion policy used by all staff who order, check or administer blood products (<ce:cross-ref id="crf0580" refid="f0095">Fig. 23.15</ce:cross-ref><ce:float-anchor refid="f0095"/>). Management of suspected transfusion reactions is shown in <ce:cross-ref id="crf0585" refid="f0100">Figure 23.16</ce:cross-ref><ce:float-anchor refid="f0100"/>.</ce:para></ce:section></ce:section><ce:section id="s0500"><ce:section-title id="st0470">Transfusion in major haemorrhage</ce:section-title><ce:para id="p2515">The successful management of a patient with major haemorrhage requires frontline clinical staff to be trained to recognise significant blood loss early and to intervene before shock is established. Hospitals should have local major haemorrhage protocols and all clinical staff must be familiar with their content. Good team working and communication are essential to prevent poor clinical outcome, suboptimal or inappropriate transfusion practice and component wastage. Fresh frozen plasma (FFP) should be given as part of initial resuscitation in (at least) a 1 : 2 ratio with red cell concentrate (RCC) until coagulation results are available. If the patient is bleeding, a ratio of FFP to RCC of 1 : 1 should be given until laboratory results are available and use of cryoprecipitate should be considered. Once the bleeding is under control, further FFP transfusion should be guided by laboratory results with transfusion triggers of PT and/or APTT above 1⋅5 times normal for a standard dose of FFP (15–20 mL/kg). Cryoprecipitate should be given if the fibrinogen level falls below 1.5 g/L. Platelets should be kept above 50 × 10<ce:sup loc="post">9</ce:sup>/L; to allow for delivery time, platelets should be requested if there is ongoing bleeding and the platelet count has fallen below 100 × 10<ce:sup loc="post">9</ce:sup>/L. Blood component use in major haemorrhage is summarised in <ce:cross-ref id="crf0590" refid="b0125">Box 23.17</ce:cross-ref> and key points in transfusion medicine in <ce:cross-ref id="crf0595" refid="b0140">Box 23.20</ce:cross-ref><ce:float-anchor refid="b0140"/>.</ce:para></ce:section></ce:section><ce:section id="s0505"><ce:section-title id="st0475">Chemotherapy</ce:section-title><ce:para id="p2555">Chemotherapy refers to the use of drugs to treat cancer (<ce:cross-ref id="crf0600" refid="b0145">Box 23.21</ce:cross-ref><ce:float-anchor refid="b0145"/>; see also <ce:intra-ref id="ii0330" xlink:href="pii:B978-0-7020-7028-0.00033-0#f0030">Fig. 33.2</ce:intra-ref>, <ce:intra-ref id="ii0335" xlink:href="pii:B978-0-7020-7028-0.00033-0#s0045">p. 1317</ce:intra-ref>). Many haematological malignancies are sensitive to the effects of chemotherapy drugs and, as such, chemotherapy is the mainstay of treatment for most haematological cancers. There is a wide range of drugs available that work by damaging DNA or disrupting cellular metabolism, in such a way that natural apoptosis mechanisms, such as <ce:italic>TP53</ce:italic>, are activated and the cell dies. Despite cancer cells being more sensitive, chemotherapy is largely non-specific and kills some normal cells as well as cancer cells. This leads to common side-effects of treatment, such as transient bone marrow failure, mucositis and infertility. The supportive care of patients undergoing chemotherapy is critical in overcoming these side-effects. It is this supportive care, including blood product support, antibiotics, antifungal drugs, growth factors and antiemetics, that has allowed specialist haematology units to achieve the best possible results from intensive chemotherapy: for example, when treating acute leukaemia.</ce:para><ce:para id="p2615">The basic principles of chemotherapy include combining several non-cross-reacting drugs in a regimen that kills a fixed proportion of cancer cells with a given dose. Several cycles of the combination are given to achieve gradual reduction of the tumour burden, to induce remission and, in some instances, to produce a cure (<ce:intra-ref id="ii0340" xlink:href="pii:B978-0-7020-7028-0.00033-0#u0660">p. 1330</ce:intra-ref>).</ce:para><ce:para id="p2620">In recent years, chemotherapy has been improved by the addition of treatments that are more targeted to the cancer cell, particularly monoclonal antibodies; for example, rituximab (anti-CD20) has been added to CHOP (cyclophosphamide doxorubicin, vincristine, prednisolone) and other regimens, significantly improving the outcome in a range of CD20-positive B-cell lymphomas, including diffuse large B-cell lymphoma, follicular lymphoma and mantle cell lymphoma. Chemotherapy drugs can also be linked to a monoclonal antibody to allow targeting of the chemotherapy drug to the specific cancer cell. Examples of such antibody–drug conjugates (ADCs) include the linking of the intercalating antibiotic calicheamicin to anti-CD33 (gemtuzumab ozogamicin) to treat acute myeloid leukaemia, and to anti-CD22 (inotuzumab ozogamicin) to treat acute lymphoblastic leukaemia. Small molecules targeted at the mechanisms causing cancer are replacing chemotherapy in some disease situations, such as tyrosine kinase inhibitors in chronic myeloid leukaemia and inhibitors of B-cell signalling in relapsed chronic lymphocytic leukaemia and lymphomas. More details of specific chemotherapies are given later in the chapter.</ce:para></ce:section><ce:section id="s0535"><ce:section-title id="st0505">Haematopoietic stem cell transplantation</ce:section-title><ce:para id="p2625">Transplantation of haematopoietic stem cells (HSCT) has offered the only hope of ‘cure’ in a variety of haematological and non-haematological disorders (<ce:cross-ref id="crf0605" refid="b0150">Box 23.22</ce:cross-ref><ce:float-anchor refid="b0150"/>). As standard treatment improves, the indications for HSCT are being refined and extended, although its use remains most common in haematological malignancies. The type of HSCT is defined according to the donor and source of stem cells:<ce:list id="ulist0650"><ce:list-item id="u1845"><ce:label>•</ce:label><ce:para id="p2655">In <ce:italic>allogeneic</ce:italic> HSCT, the stem cells come from a <ce:italic>donor –</ce:italic> either a related donor (usually an HLA-identical sibling) or a closely HLA-matched volunteer unrelated donor (VUD).</ce:para></ce:list-item><ce:list-item id="u1850"><ce:label>•</ce:label><ce:para id="p2660">In an <ce:italic>autologous</ce:italic> transplant, the stem cells are harvested from the <ce:italic>patient</ce:italic> and stored in the vapour phase of liquid nitrogen until required. Stem cells can be harvested from the bone marrow or from the blood.</ce:para></ce:list-item></ce:list></ce:para><ce:section id="s0540"><ce:section-title id="st0510">Allogeneic HSCT</ce:section-title><ce:para id="p2665">Healthy bone marrow or blood stem cells from a donor are infused intravenously into the recipient, who has been suitably ‘conditioned’. The conditioning treatment (chemotherapy with or without radiotherapy) is ‘myeloablative’ or, increasingly, ‘non-myeloablative’. Myeloablative conditioning destroys malignant cells and immunosuppresses the recipient, as well as ablating the recipient's haematopoietic tissues. Reduced intensity conditioning (non-myeloablative) relies on intense immunosuppression to provide ‘immunological space’ for transplanted stem cells. The infused donor cells ‘home’ to the marrow, engraft and produce enough erythrocytes, granulocytes and platelets for the patient's needs after about 3–4 weeks. During this period of aplasia, patients are at risk of infection and bleeding, and require intensive supportive care as described on page 957. It may take several years to regain normal immunological function and patients remain at risk from opportunistic infections, particularly in the first year.</ce:para><ce:para id="p2670">An advantage of receiving allogeneic donor stem cells is that the donor's immune system can recognise residual recipient malignant cells and destroy them. This immunological ‘graft-versus-disease’ effect is a powerful tool against many haematological tumours and can be boosted post-transplantation by the infusion of T cells taken from the donor: so-called donor lymphocyte infusion (DLI).</ce:para><ce:para id="p2675">Considerable morbidity and mortality are associated with HSCT. The best results are obtained in patients with minimal residual disease, and in those under 20 years of age who have an HLA-identical sibling donor. Reduced-intensity conditioning has enabled treatment of older or less fit patients. In this form of transplantation, rather than using very intensive myeloablative conditioning, which causes morbidity from organ damage, relatively low doses of chemotherapy drugs, such as fludarabine and cyclophosphamide or busulfan, are used in combination with antibodies such as alemtuzumab (which targets CD52 on mature lymphoid cells) or anti-thymocyte globulin (ATG) to immunosuppress the recipient and allow donor stem cells to engraft. The emerging donor immune system then eliminates malignant cells via the ‘graft-versus-disease’ effect, which may be boosted by the elective use of donor T-cell infusions post-transplant. Such transplants have produced long-term remissions in some patients with acute leukaemia and myelodysplastic syndromes aged 40–65 years, who would not previously have been considered for a myeloablative allograft.</ce:para><ce:section id="s0545"><ce:section-title id="st0515">Complications</ce:section-title><ce:para id="p2680">These are outlined in <ce:cross-ref id="crf0610" refid="b0155">Boxes 23.23</ce:cross-ref><ce:float-anchor refid="b0155"/> and <ce:cross-ref id="crf0615" refid="b0160">23.24</ce:cross-ref><ce:float-anchor refid="b0160"/>. The risks and outcomes of transplantation depend upon several patient- and disease-related factors. In general, 25% die from procedure-related complications, such as infection and GVHD, and there remains a significant risk of the haematological malignancy relapsing. The long-term survival for patients undergoing allogeneic HSCT in acute leukaemia is around 50%.</ce:para><ce:section id="s0550"><ce:section-title id="st0520">Graft-versus-host disease</ce:section-title><ce:para id="p2750">GVHD is caused by the cytotoxic activity of donor T lymphocytes that become sensitised to their new host, regarding it as foreign. This may cause either an acute or a chronic form of GVHD.</ce:para><ce:para id="p2755">Acute GVHD occurs in the first 100 days after transplant in about one-third of patients. It can affect the skin, causing rashes, the liver, causing jaundice, and the gut, causing diarrhoea, and may vary from mild to lethal. Prevention includes HLA-matching of the donor, immunosuppressant drugs, including methotrexate, ciclosporin, alemtuzumab or ATG. Severe presentations are very difficult to control and, despite high-dose glucocorticoids, may result in death.</ce:para><ce:para id="p2760">Chronic GVHD may follow acute GVHD or arise independently; it occurs later than acute GVHD. It often resembles a connective tissue disorder, although in mild cases a rash may be the only manifestation. Chronic GVHD is usually treated with glucocorticoids and prolonged immunosuppression with, for example, ciclosporin. Chronic GVHD results in an increased infection risk. However, associated with chronic GVHD are the graft-versus-disease effect and a lower relapse rate of the underlying malignancy.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0555"><ce:section-title id="st0525">Autologous HSCT</ce:section-title><ce:para id="p2765">This procedure can also be used in haematological malignancies. The patient's own stem cells from blood or marrow are first harvested and frozen. After conditioning myeloablative therapy, the autologous stem cells are reinfused into the blood stream in order to rescue the patient from the marrow damage and aplasia caused by chemotherapy. Autologous HSCT may be used for disorders that do not primarily involve the haematopoietic tissues, or for patients in whom very good remissions have been achieved. The most common indications are lymphomas and myeloma. The preferred source of stem cells for autologous transplants is peripheral blood (PBSCT). These stem cells engraft more quickly, marrow recovery occurring within 2–3 weeks. There is no risk of GVHD and no immunosuppression is required. Thus autologous stem cell transplantation carries a lower procedure-related mortality rate than allogeneic HSCT at around 5%, but there is a higher rate of recurrence of malignancy because the anti-malignancy effect is solely dependent on the conditioning chemotherapy with no ‘graft-versus-disease’ effect.</ce:para></ce:section></ce:section><ce:section id="s0560"><ce:section-title id="st0530">Anticoagulant and antithrombotic therapy</ce:section-title><ce:para id="p2770">There are numerous indications for anticoagulant and antithrombotic medications (<ce:cross-ref id="crf0620" refid="b0165">Box 23.25</ce:cross-ref><ce:float-anchor refid="b0165"/>). The guiding principles are outlined here but management in specific indications is discussed elsewhere in the book. Broadly speaking, antiplatelet medications are of greater efficacy in the prevention of arterial thrombosis and of less value in the prevention of venous thromboembolism (VTE). Thus, antiplatelet agents, such as aspirin, clopidogrel and, increasingly, ticagrelor, are the drugs of choice in acute coronary events (<ce:intra-ref id="ii0375" xlink:href="pii:B978-0-7020-7028-0.00016-0#s1460">p. 498</ce:intra-ref>) and in ischaemic cerebrovascular disease, while warfarin and other anticoagulants are favoured in VTE (p. 975) and management of atrial fibrillation (<ce:intra-ref id="ii0385" xlink:href="pii:B978-0-7020-7028-0.00016-0#s0755">p. 471</ce:intra-ref>). In some extremely prothrombotic situations, such as coronary artery stenting, a combination of anticoagulant and antiplatelet drugs is used (<ce:intra-ref id="ii0390" xlink:href="pii:B978-0-7020-7028-0.00016-0#s1315">p. 491</ce:intra-ref>).</ce:para><ce:para id="p2785">A wide range of anticoagulant and antithrombotic drugs is used in clinical practice. These drugs and their modes of action are given in <ce:cross-ref id="crf0625" refid="b0170">Box 23.26</ce:cross-ref><ce:float-anchor refid="b0170"/>. Newer agents allow predictable anticoagulation without the need for frequent monitoring and dose titration. Although warfarin remains the mainstay for oral anticoagulation, newer oral anticoagulants (dabigatran, rivaroxaban, edoxaban and apixaban), which can be given at fixed doses with predictable effects and no need for monitoring, have now been approved for the prevention of perioperative VTE, the treatment of established VTE and the prevention of cardioembolic stroke in patients with atrial fibrillation.</ce:para><ce:section id="s0565"><ce:section-title id="st0535">Heparins</ce:section-title><ce:para id="p2795">Unfractionated heparin (UFH) and low-molecular-weight heparins (LMWHs) act by binding via a specific pentasaccharide in the heparin molecule to antithrombin. Fondaparinux is a synthetic pentasaccharide, which also binds antithrombin and has similar properties to LMWH. These agents enhance the natural anticoagulant activity of antithrombin (see <ce:cross-ref id="crf0630" refid="f0050">Fig. 23.6E</ce:cross-ref>). Increased cleavage of activated proteases, particularly factor Xa and thrombin (IIa), accounts for the anticoagulant effect. LMWHs preferentially augment antithrombin activity against factor Xa. For the licensed indications, LMWHs are at least as efficacious as UFH but have several advantages:<ce:list id="ulist0675"><ce:list-item id="u1905"><ce:label>•</ce:label><ce:para id="p2800">LMWHs are nearly 100% bioavailable and so produce reliable dose-dependent anticoagulation.</ce:para></ce:list-item><ce:list-item id="u1910"><ce:label>•</ce:label><ce:para id="p2805">LMWHs do not require monitoring of their anticoagulant effect (except possibly in patients with very low body weight and with a glomerular filtration rate below 30 mL/min).</ce:para></ce:list-item><ce:list-item id="u1915"><ce:label>•</ce:label><ce:para id="p2810">LMWHs have a half-life of around 4 hours when given subcutaneously, compared with 1 hour for UFH. This permits once-daily dosing by the subcutaneous route, rather than the therapeutic continuous intravenous infusion or twice-daily subcutaneous administration required for UFH.</ce:para></ce:list-item><ce:list-item id="u1920"><ce:label>•</ce:label><ce:para id="p2815">While rates of bleeding are similar between products, the risk of osteoporosis and heparin-induced thrombocytopenia is much lower for LMWH.</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p2820">UFH is, however, more completely reversed by protamine sulphate in the event of bleeding and at the end of cardiopulmonary bypass, for which UFH remains the drug of choice (<ce:cross-ref id="crf0635" refid="b0175">Box 23.27</ce:cross-ref><ce:float-anchor refid="b0175"/>).</ce:para><ce:para id="p2880">LMWHs are widely used for the prevention and treatment of VTE, the management of acute coronary syndromes and for most other scenarios listed in <ce:cross-ref id="crf0640" refid="b0165">Box 23.25</ce:cross-ref>. In some situations, UFH is still favoured by some clinicians, though there is little evidence that it is advantageous, except when rapid reversibility is required. UFH is useful in patients with a high risk of bleeding, e.g. those who have peptic ulceration or who may require urgent surgery. It is also favoured in the treatment of life-threatening thromboembolism, e.g. major pulmonary embolism with significant hypoxaemia, hypotension and right-sided heart strain. In this situation, UFH is started with a loading intravenous dose of 80 U/kg, followed by a continuous infusion of 18 U/kg/hr initially. The level of anticoagulation should be assessed by the APTT after 6 hours and, if satisfactory, twice daily thereafter. It is usual to aim for a patient APTT that is 1.5–2.5 times the control time of the test. Monitoring of UFH treatment by APTT is not without difficulties and other assays, such as the specific anti-Xa assay, may provide more accurate guidance.</ce:para><ce:section id="s0570"><ce:section-title id="st0540">Heparin-induced thrombocytopenia</ce:section-title><ce:para id="p2885">Heparin-induced thrombocytopenia (HIT) is a rare complication of heparin therapy, caused by induction of anti-heparin/PF4 antibodies that bind to and activate platelets via an Fc receptor. This results in platelet activation and a prothrombotic state, with a paradoxical thrombocytopenia. HIT is more common in surgical than medical patients (especially cardiac and orthopaedic patients), with use of UFH rather than LMWH, and with higher doses of heparin.</ce:para><ce:section id="s0575"><ce:section-title id="st0545">Clinical features</ce:section-title><ce:para id="p2890">Patients present, typically 5–14 days after starting heparin treatment, with a fall in platelet count of more than 30% from baseline. The count may still be in the reference range. The patient may be asymptomatic, or develop venous or arterial thrombosis and skin lesions, including overt skin necrosis. Affected patients may complain of pain or itch at injection sites and of systemic symptoms, such as shivering, following heparin injections. Patients who have received heparin in the preceding 100 days and who have preformed antibodies may develop acute systemic symptoms and an abrupt fall in platelet count in the first 24 hours after re-exposure.</ce:para></ce:section><ce:section id="s0580"><ce:section-title id="st0550">Investigations</ce:section-title><ce:para id="p2895">The pre-test probability of the diagnosis is assessed using the 4Ts scoring system. This assigns a score based on:<ce:list id="ulist0690"><ce:list-item id="u1975"><ce:label>•</ce:label><ce:para id="p2900">the <ce:bold><ce:underline>t</ce:underline></ce:bold>hrombocytopenia</ce:para></ce:list-item><ce:list-item id="u1980"><ce:label>•</ce:label><ce:para id="p2905">the <ce:bold><ce:underline>t</ce:underline></ce:bold>iming of the fall in platelet count</ce:para></ce:list-item><ce:list-item id="u1985"><ce:label>•</ce:label><ce:para id="p2910">the presence of new <ce:bold><ce:underline>t</ce:underline></ce:bold>hrombosis</ce:para></ce:list-item><ce:list-item id="u1990"><ce:label>•</ce:label><ce:para id="p2915">the likelihood of ano<ce:bold><ce:underline>t</ce:underline></ce:bold>her cause for the thrombocytopenia.</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p2920">Individuals at low risk need no further test. Those with intermediate and high likelihood scores should have the diagnosis confirmed or refuted using an anti-PF4 enzyme-linked immunosorbent assay (ELISA).</ce:para></ce:section><ce:section id="s0585"><ce:section-title id="st0555">Management</ce:section-title><ce:para id="p2925">Heparin should be discontinued as soon as HIT is diagnosed and an alternative anticoagulant that does not cross-react with the antibody should be substituted. Argatroban (a direct thrombin inhibitor) and danaparoid (a heparin analogue) are licensed for use in the UK. In asymptomatic patients with HIT who do not receive an alternative anticoagulant, around 50% will sustain a thrombosis in the subsequent 30 days. Patients with established thrombosis have a poorer prognosis.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0590"><ce:section-title id="st0560">Coumarins</ce:section-title><ce:para id="p2930">Although several coumarin anticoagulants are used around the world, warfarin is the most common.</ce:para><ce:para id="p2935">Coumarins inhibit the vitamin K-dependent post-translational carboxylation of factors II (prothrombin), VII, IX and X in the liver (see <ce:cross-ref id="crf0645" refid="f0050">Fig. 23.6D</ce:cross-ref>). This results in anticoagulation due to an effective deficiency of these factors. This is monitored by the INR, a standardised test based on measurement of the prothrombin time (p. 922). Recommended target INR values for specific indications are given in <ce:cross-ref id="crf0650" refid="b0165">Box 23.25</ce:cross-ref>.</ce:para><ce:para id="p2940">Warfarin anticoagulation typically takes more than 3–5 days to become established, even using loading doses. Patients who require rapid initiation of therapy may receive higher initiation doses of warfarin. A typical regime in this situation is to give 10 mg warfarin on the first and second days, with 5 mg on the third day; subsequent doses are titrated against the INR. Patients without an urgent need for anticoagulation (e.g. atrial fibrillation) can have warfarin introduced slowly using lower doses. Low-dose regimens are associated with a lower risk of the patient developing a supratherapeutic INR, and hence a lower bleeding risk. The duration of warfarin therapy depends on the clinical indication, and while treatment of deep vein thrombosis (DVT) or preparation for cardioversion may require a limited duration, anticoagulation to prevent cardioembolic stroke in atrial fibrillation or from heart valve disease is long-term.</ce:para><ce:para id="p2945">The major problems with warfarin are:<ce:list id="ulist0695"><ce:list-item id="u1995"><ce:label>•</ce:label><ce:para id="p2950">a narrow therapeutic window</ce:para></ce:list-item><ce:list-item id="u2000"><ce:label>•</ce:label><ce:para id="p2955">metabolism that is affected by many factors</ce:para></ce:list-item><ce:list-item id="u2005"><ce:label>•</ce:label><ce:para id="p2960">numerous drug interactions.</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p2965">Drug interactions are common through protein binding and metabolism by the cytochrome P450 system. Inter-individual differences in warfarin doses required to achieve a therapeutic INR are mostly accounted for by naturally occurring polymorphisms in the <ce:italic>CYP2C9</ce:italic> and the <ce:italic>VKORC1</ce:italic> genes (which predict the metabolism and function of warfarin, respectively) and dietary intake of vitamin K.</ce:para><ce:para id="p2970">Major bleeding is the most common serious side-effect of warfarin and occurs in 1–2% of patients each year. Fatal haemorrhage, which is most commonly intracranial, occurs in about 0.25% per annum. There are scoring systems that predict the annual bleeding risk and these can be used to help compare the risks and benefits of warfarin for an individual patient (<ce:cross-ref id="crf0655" refid="b0180">Box 23.28</ce:cross-ref><ce:float-anchor refid="b0180"/>). There are also some specific contraindications to anticoagulation (<ce:cross-ref id="crf0660" refid="b0180">Box 23.28</ce:cross-ref>). Management of warfarin includes strategies for over-anticoagulation and for bleeding:<ce:list id="ulist0710"><ce:list-item id="u2070"><ce:label>•</ce:label><ce:para id="p3045">If the INR is above the therapeutic level, warfarin should be withheld or the dose reduced. If the patient is not bleeding, it may be appropriate to give a small dose of vitamin K either orally or intravenously (1–2.5 mg), especially if the INR is greater than 8.</ce:para></ce:list-item><ce:list-item id="u2075"><ce:label>•</ce:label><ce:para id="p3050">In the event of bleeding, withhold further warfarin. Minor bleeding can be treated with 1–2.5 mg of vitamin K IV. Major haemorrhage should be treated as an emergency with vitamin K 5–10 mg slowly IV, combined with coagulation factor replacement (see <ce:cross-ref id="crf0665" refid="b0175">Box 23.27</ce:cross-ref>). This should optimally be a prothrombin complex concentrate (30–50 U/kg) that contains factors II, VII, IX and X; if that is not available, fresh frozen plasma (15–30 mL/kg) should be given.</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0605"><ce:section-title id="st0575">Direct oral anticoagulants</ce:section-title><ce:para id="p3055">The direct oral anticoagulants (DOACs) offer an alternative to coumarins in the management of VTE and the prevention of stroke and systemic embolism in patients with atrial fibrillation. The DOACs are direct specific inhibitors of key proteases in the common pathway. Dabigatran inhibits thrombin while rivaroxaban, apixaban and edoxaban inhibit Xa. The key features of these drugs include the fact that they are efficacious in fixed oral doses, have a short half-life of around 10 hours, achieve peak plasma levels 2–4 hours after oral intake, have very few drug interactions and are all moderately dependent on renal function for their excretion. An initial perceived drawback was the lack of specific reversal agents for these drugs but idarucizumab is a monoclonal antibody now available for the reversal of dabigatran, and andexanet alfa, a site-inactivated Xa molecule, is close to licensing for the reversal of apixaban and rivaroxaban (see <ce:cross-ref id="crf0670" refid="b0175">Box 23.27</ce:cross-ref>).</ce:para><ce:para id="p3060">DOACs are now licensed for the prevention of VTE following high-risk orthopaedic surgery (except edoxaban), the acute management and prevention of recurrence of VTE, and the prevention of stroke and systemic embolism in patients with atrial fibrillation with risk factors. The general perception at present is that in these indications they are at least as efficacious as dose-adjusted coumarin and probably associated with less clinically significant bleeding.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0610"><ce:section-title id="st0580">Anaemias</ce:section-title><ce:para id="p3065">Around 30% of the total world population is anaemic and half of these, some 600 million people, have iron deficiency. The classification of anaemia by the size of the red cells (MCV) indicates the likely cause (see <ce:cross-ref id="crf0675" refid="f0070">Figs 23.10</ce:cross-ref> and <ce:cross-ref id="crf0680" refid="f0075">23.11</ce:cross-ref>).</ce:para><ce:para id="p3070">Red cells in the bone marrow must acquire a minimum level of haemoglobin before being released into the blood stream (<ce:cross-ref id="crf0685" refid="f0110">Fig. 23.17</ce:cross-ref><ce:float-anchor refid="f0110"/>). While in the marrow compartment, red cell precursors undergo cell division, driven by erythropoietin. If red cells cannot acquire haemoglobin at a normal rate, they will undergo more divisions than normal and will have a low MCV when finally released into the blood. The MCV is low because component parts of the haemoglobin molecule are not fully available: that is, iron in iron deficiency, globin chains in thalassaemia, haem ring in congenital sideroblastic anaemia and, occasionally, poor iron utilisation in the anaemia of chronic disease/anaemia of inflammation.</ce:para><ce:para id="p3075">In megaloblastic anaemia, the biochemical consequence of vitamin B<ce:inf loc="post">12</ce:inf> or folate deficiency is an inability to synthesise new bases to make DNA. A similar defect of cell division is seen in the presence of cytotoxic drugs or haematological disease in the marrow, such as myelodysplasia. In these states, cells haemoglobinise normally but undergo fewer cell divisions, resulting in circulating red cells with a raised MCV. The red cell membrane is composed of a lipid bilayer that will freely exchange with the plasma pool of lipid. Conditions such as liver disease, hypothyroidism, hyperlipidaemia and pregnancy are associated with raised lipids and may also cause a raised MCV. Reticulocytes are larger than mature red cells, so when the reticulocyte count is raised – e.g. in haemolysis – this may also increase the MCV.</ce:para><ce:section id="s0615"><ce:section-title id="st0585">Iron deficiency anaemia</ce:section-title><ce:para id="p3080">This occurs when iron losses or physiological requirements exceed absorption.</ce:para><ce:section id="s0620"><ce:section id="s0625"><ce:section id="s0630"><ce:section-title id="st0590">Blood loss</ce:section-title><ce:para id="p3085">The most common explanation in men and post-menopausal women is gastrointestinal blood loss (<ce:intra-ref id="ii0400" xlink:href="pii:B978-0-7020-7028-0.00021-4#s0390">p. 780</ce:intra-ref>). This may result from occult gastric or colorectal malignancy, gastritis, peptic ulceration, inflammatory bowel disease, diverticulitis, polyps and angiodysplastic lesions. Worldwide, hookworm and schistosomiasis are the most common causes of gut blood loss (<ce:intra-ref id="ii0405" xlink:href="pii:B978-0-7020-7028-0.00011-1#s2385">pp. 288 and 294</ce:intra-ref>). Gastrointestinal blood loss may be exacerbated by the chronic use of aspirin or non-steroidal anti-inflammatory drugs (NSAIDs), which cause intestinal erosions and impair platelet function. In women of child-bearing age, menstrual blood loss, pregnancy and breastfeeding contribute to iron deficiency by depleting iron stores; in developed countries, one-third of pre-menopausal women have low iron stores but only 3% display iron-deficient haematopoiesis. Very rarely, chronic haemoptysis or haematuria may cause iron deficiency.</ce:para></ce:section><ce:section id="s0635"><ce:section-title id="st0595">Malabsorption</ce:section-title><ce:para id="p3090">A dietary assessment should be made in all patients to ascertain their iron intake (<ce:intra-ref id="ii0410" xlink:href="pii:B978-0-7020-7028-0.00019-6#p2295">p. 716</ce:intra-ref>). Gastric acid is required to release iron from food and helps to keep iron in the soluble ferrous state (<ce:cross-ref id="crf0690" refid="f0115">Fig. 23.18</ce:cross-ref><ce:float-anchor refid="f0115"/>). Achlorhydria in the elderly or that due to drugs such as proton pump inhibitors may contribute to the lack of iron availability from the diet, as may previous gastric surgery. Iron is absorbed actively in the upper small intestine and hence can be affected by coeliac disease (<ce:intra-ref id="ii0415" xlink:href="pii:B978-0-7020-7028-0.00021-4#s1250">p. 805</ce:intra-ref>).</ce:para></ce:section><ce:section id="s0640"><ce:section-title id="st0600">Physiological demands</ce:section-title><ce:para id="p3095">At times of rapid growth, such as infancy and puberty, iron requirements increase and may outstrip absorption. In pregnancy, iron is diverted to the fetus, the placenta and the increased maternal red cell mass, and is lost with bleeding at parturition (<ce:cross-ref id="crf0695" refid="b0185">Box 23.29</ce:cross-ref><ce:float-anchor refid="b0185"/>).</ce:para></ce:section></ce:section><ce:section id="s0645"><ce:section-title id="st0605">Investigations</ce:section-title><ce:section id="s0650"><ce:section-title id="st0610">Confirmation of iron deficiency</ce:section-title><ce:para id="p3135">Serum ferritin is a measure of iron stores in tissues and is the best single test to confirm iron deficiency (<ce:cross-ref id="crf0700" refid="b0190">Box 23.30</ce:cross-ref><ce:float-anchor refid="b0190"/>). It is a very specific test; a subnormal level is due to iron deficiency or, very rarely, hypothyroidism or vitamin C deficiency. Ferritin levels can be raised in liver disease and in the acute phase response; in these conditions, a ferritin level of up to 100 µg/L may still be compatible with low bone marrow iron stores.</ce:para><ce:para id="p3145">Plasma iron and total iron binding capacity (TIBC) are measures of iron availability; hence they are affected by many factors besides iron stores. Plasma iron has a marked diurnal and day-to-day variation and becomes very low during an acute phase response but is raised in liver disease and haemolysis. Levels of transferrin, the binding protein for iron, are lowered by malnutrition, liver disease, the acute phase response and nephrotic syndrome, but raised by pregnancy and the oral contraceptive pill. A transferrin saturation (i.e. iron/TIBC × 100) of less than 16% is consistent with iron deficiency but is less specific than a ferritin measurement.</ce:para><ce:para id="p3150">All proliferating cells express membrane transferrin receptors to acquire iron; a small amount of this receptor is shed into blood, where it can be detected in a free soluble form. At times of poor iron stores, cells up-regulate transferrin receptor expression and the levels of soluble plasma transferrin receptor increase. This can now be measured by immunoassay and used to distinguish storage iron depletion in the presence of an acute phase response or liver disease, when a raised level indicates iron deficiency. In difficult cases, it may still be necessary to examine a bone marrow aspirate for iron stores.</ce:para></ce:section><ce:section id="s0655"><ce:section-title id="st0615">Investigation of the cause</ce:section-title><ce:para id="p3155">This will depend on the age and sex of the patient, as well as the history and clinical findings. In men and in post-menopausal women with a normal diet, the upper and lower gastrointestinal tract should be investigated by endoscopy or radiological studies. Serum anti-transglutaminase antibodies and possibly a duodenal biopsy are indicated (<ce:intra-ref id="ii0430" xlink:href="pii:B978-0-7020-7028-0.00021-4#s1280">p. 806</ce:intra-ref>) to detect coeliac disease. Current guidelines suggest exclusion of coeliac disease by antibody testing at an early stage of investigation. In the tropics, stool and urine should be examined for parasites (<ce:intra-ref id="ii0435" xlink:href="pii:B978-0-7020-7028-0.00011-1#p2750">p. 233</ce:intra-ref>).</ce:para></ce:section></ce:section><ce:section id="s0660"><ce:section-title id="st0620">Management</ce:section-title><ce:para id="p3160">Unless the patient has angina, heart failure or evidence of cerebral hypoxia, transfusion is not necessary and oral iron replacement is appropriate. Ferrous sulphate 200 mg 3 times daily (195 mg of elemental iron per day) is adequate and should be continued for 3–6 months to replete iron stores. Many patients suffer gastrointestinal side-effects with ferrous sulphate, including dyspepsia and altered bowel habit. When this occurs, reduction in dose to 200 mg twice daily or a switch to ferrous gluconate 300 mg twice daily (70 mg of elemental iron per day) or another alternative oral preparation should be tried. Delayed-release preparations are not useful, since they release iron beyond the upper small intestine, where it cannot be absorbed.</ce:para><ce:para id="p3165">The haemoglobin should rise by around 10 g/L every 7–10 days and a reticulocyte response will be evident within a week. A failure to respond adequately may be due to non-adherence, continued blood loss, malabsorption or an incorrect diagnosis. Patients with malabsorption, chronic gut disease or inability to tolerate any oral preparation may need parenteral iron therapy. Previously, iron dextran or iron sucrose was used, but new preparations of iron isomaltose and iron carboxymaltose have fewer allergic effects and are preferred. Doses required can be calculated based on the patient's starting haemoglobin and body weight. Observation for anaphylaxis following an initial test dose is recommended.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0665"><ce:section-title id="st0625">Anaemia of chronic disease</ce:section-title><ce:para id="p3170">Anaemia of chronic disease (ACD), also known as anaemia of inflammation (AI), is a common type of anaemia, particularly in hospital populations. It occurs in the setting of chronic infection, chronic inflammation or neoplasia. The anaemia is not related to bleeding, haemolysis or marrow infiltration, is mild, with haemoglobin in the range of 85–115 g/L, and is usually associated with a normal MCV (normocytic, normochromic), though this may be reduced in long-standing inflammation. The serum iron is low but iron stores are normal or increased, as indicated by the ferritin or stainable marrow iron.</ce:para><ce:section id="s0670"><ce:section id="s0675"><ce:section-title id="st0630">Pathogenesis</ce:section-title><ce:para id="p3175">It has recently become clear that the key regulatory protein that accounts for the findings characteristic of ACD/AI is hepcidin, which is produced by the liver (see <ce:cross-ref id="crf0705" refid="f0115">Fig. 23.18</ce:cross-ref>). Hepcidin production is induced by pro-inflammatory cytokines, especially IL-6. Hepcidin binds to ferroportin on the membrane of iron-exporting cells, such as small intestinal enterocytes and macrophages, internalising the ferroportin and thereby inhibiting the export of iron from these cells into the blood. The iron remains trapped inside the cells in the form of ferritin, levels of which are therefore normal or high in the face of significant anaemia. Inhibition or blockade of hepcidin is a potential target for treatment of this form of anaemia.</ce:para></ce:section><ce:section id="s0680"><ce:section-title id="st0635">Diagnosis and management</ce:section-title><ce:para id="p3180">It is often difficult to distinguish ACD associated with a low MCV from iron deficiency. <ce:cross-ref id="crf0710" refid="b0190">Box 23.30</ce:cross-ref> summarises the investigations and results. Examination of the marrow may ultimately be required to assess iron stores directly. A trial of oral iron can be given in difficult situations. A positive response occurs in true iron deficiency but not in ACD. Measures that reduce the severity of the underlying disorder generally help to improve the ACD. Trials of higher-dose intravenous iron are under way to try to bypass the hepcidin-induced blockade.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0685"><ce:section-title id="st0640">Megaloblastic anaemia</ce:section-title><ce:para id="p3185">This results from a deficiency of vitamin B<ce:inf loc="post">12</ce:inf> or folic acid, or from disturbances in folic acid metabolism. Folate is an important substrate of, and vitamin B<ce:inf loc="post">12</ce:inf> a co-factor for, the generation of the essential amino acid methionine from homocysteine. This reaction produces tetrahydrofolate, which is converted to thymidine monophosphate for incorporation into DNA. Deficiency of either vitamin B<ce:inf loc="post">12</ce:inf> or folate will therefore produce high plasma levels of homocysteine and impaired DNA synthesis.</ce:para><ce:para id="p3190">The end result is cells with arrested nuclear maturation but normal cytoplasmic development: so-called nucleocytoplasmic asynchrony. All proliferating cells will exhibit megaloblastosis; hence changes are evident in the buccal mucosa, tongue, small intestine, cervix, vagina and uterus. The high proliferation rate of bone marrow results in striking changes in the haematopoietic system in megaloblastic anaemia. Cells become arrested in development and die within the marrow; this ineffective erythropoiesis results in an expanded hypercellular marrow. The megaloblastic changes are most evident in the early nucleated red cell precursors, and haemolysis within the marrow results in a raised bilirubin and lactate dehydrogenase (LDH), but without the reticulocytosis characteristic of other forms of haemolysis (p. 945). Iron stores are usually raised. The mature red cells are large and oval, and sometimes contain nuclear remnants. Nuclear changes are seen in the immature granulocyte precursors and a characteristic appearance is that of ‘giant’ metamyelocytes with a large ‘sausage-shaped’ nucleus. The mature neutrophils show hypersegmentation of their nuclei, with cells having six or more nuclear lobes. If severe, a pancytopenia may be present in the peripheral blood.</ce:para><ce:para id="p3195">Vitamin B<ce:inf loc="post">12</ce:inf> deficiency, but not folate deficiency, is associated with neurological disease in up to 40% of cases, although advanced neurological disease due to B<ce:inf loc="post">12</ce:inf> deficiency is now uncommon in the developed world. The main pathological finding is focal demyelination affecting the spinal cord, peripheral nerves, optic nerves and cerebrum. The most common manifestations are sensory, with peripheral paraesthesiae and ataxia of gait. The clinical and diagnostic features of megaloblastic anaemia are summarised in <ce:cross-ref id="crf0715" refid="b0195">Boxes 23.31</ce:cross-ref><ce:float-anchor refid="b0195"/> and <ce:cross-ref id="crf0720" refid="b0200">23.32</ce:cross-ref><ce:float-anchor refid="b0200"/>, and the neurological features of B<ce:inf loc="post">12</ce:inf> deficiency in <ce:cross-ref id="crf0725" refid="b0205">Box 23.33</ce:cross-ref><ce:float-anchor refid="b0205"/>.</ce:para><ce:section id="s0710"><ce:section-title id="st0660">Vitamin B<ce:inf loc="post">12</ce:inf></ce:section-title><ce:section id="s0715"><ce:section-title id="st0665">Vitamin B<ce:inf loc="post">12</ce:inf> absorption</ce:section-title><ce:para id="p3350">The average daily diet contains 5–30 µg of vitamin B<ce:inf loc="post">12</ce:inf>, mainly in meat, fish, eggs and milk – well in excess of the 1 µg daily requirement. In the stomach, gastric enzymes release vitamin B<ce:inf loc="post">12</ce:inf> from food and at gastric pH it binds to a carrier protein termed R protein. The gastric parietal cells produce intrinsic factor, a vitamin B<ce:inf loc="post">12</ce:inf>-binding protein that optimally binds vitamin B<ce:inf loc="post">12</ce:inf> at pH 8. As gastric emptying occurs, pancreatic secretion raises the pH and vitamin B<ce:inf loc="post">12</ce:inf> released from the diet switches from the R protein to intrinsic factor. Bile also contains vitamin B<ce:inf loc="post">12</ce:inf> that is available for reabsorption in the intestine. The vitamin B<ce:inf loc="post">12</ce:inf>–intrinsic factor complex binds to specific receptors in the terminal ileum, and vitamin B<ce:inf loc="post">12</ce:inf> is actively transported by the enterocytes to plasma, where it binds to transcobalamin II, a transport protein produced by the liver, which carries it to the tissues for utilisation. The liver stores enough vitamin B<ce:inf loc="post">12</ce:inf> for 3 years and this, together with the enterohepatic circulation, means that vitamin B<ce:inf loc="post">12</ce:inf> deficiency takes years to become manifest, even if all dietary intake is stopped or severe B<ce:inf loc="post">12</ce:inf> malabsorption supervenes.</ce:para><ce:para id="p3355">Blood levels of vitamin B<ce:inf loc="post">12</ce:inf> (cobalamin) provide a reasonable indication of tissue stores, are usually diagnostic of deficiency and remain the first-line tests for most laboratories. Additional tests have been evaluated, including measurement of methylmalonic acid, holotranscobalamin and plasma homocysteine levels, but do not add much in most clinical situations. Levels of cobalamins fall in normal pregnancy. Reference ranges vary between laboratories but levels below 150 ng/L are common and, in the last trimester, 5–10% of women have levels below 100 ng/L. Spuriously low B<ce:inf loc="post">12</ce:inf> values occur in women using the oral contraceptive pill and in patients with myeloma, in whom paraproteins can interfere with vitamin B<ce:inf loc="post">12</ce:inf> assays.</ce:para></ce:section><ce:section id="s0720"><ce:section-title id="st0670">Causes of vitamin B<ce:inf loc="post">12</ce:inf> deficiency</ce:section-title><ce:section id="s0725"><ce:section-title id="st0675">Dietary deficiency</ce:section-title><ce:para id="p3360">This occurs only in strict vegans but the onset of clinical features can occur at any age between 10 and 80 years. Less strict vegetarians often have slightly low vitamin B<ce:inf loc="post">12</ce:inf> levels but are not tissue vitamin B<ce:inf loc="post">12</ce:inf>-deficient.</ce:para></ce:section><ce:section id="s0730"><ce:section-title id="st0680">Gastric pathology</ce:section-title><ce:para id="p3365">Release of vitamin B<ce:inf loc="post">12</ce:inf> from food requires normal gastric acid and enzyme secretion, and this is impaired by hypochlorhydria in elderly patients or following gastric surgery. Total gastrectomy invariably results in vitamin B<ce:inf loc="post">12</ce:inf> deficiency within 5 years, often combined with iron deficiency; these patients need life-long 3-monthly vitamin B<ce:inf loc="post">12</ce:inf> injections. After partial gastrectomy, vitamin B<ce:inf loc="post">12</ce:inf> deficiency only develops in 10–20% of patients by 5 years; an annual injection of vitamin B<ce:inf loc="post">12</ce:inf> should prevent deficiency in this group.</ce:para></ce:section><ce:section id="s0735"><ce:section-title id="st0685">Pernicious anaemia</ce:section-title><ce:para id="p3370">This is an organ-specific autoimmune disorder in which the gastric mucosa is atrophic, with loss of parietal cells causing intrinsic factor deficiency. In the absence of intrinsic factor, less than 1% of dietary vitamin B<ce:inf loc="post">12</ce:inf> is absorbed. Pernicious anaemia has an incidence of 25/100 000 population over the age of 40 years in developed countries, but an average age of onset of 60 years. It is more common in individuals with other autoimmune disease (Hashimoto's thyroiditis, Graves' disease, vitiligo or Addison's disease; <ce:intra-ref id="ii0445" xlink:href="pii:B978-0-7020-7028-0.00018-4#c00018">Ch. 18</ce:intra-ref>) or a family history of these or pernicious anaemia. The finding of anti-intrinsic factor antibodies in the context of B<ce:inf loc="post">12</ce:inf> deficiency is diagnostic of pernicious anaemia without further investigation. Antiparietal cell antibodies are present in over 90% of cases but are also present in 20% of normal females over the age of 60 years; a negative result makes pernicious anaemia less likely but a positive result is not diagnostic. The Schilling test, involving measurement of absorption of radio-labelled B<ce:inf loc="post">12</ce:inf> after oral administration before and after replacement of intrinsic factor, has fallen out of favour with the availability of autoantibody tests, greater caution in the use of radioactive tracers, and limited availability of intrinsic factor.</ce:para></ce:section><ce:section id="s0740"><ce:section-title id="st0690">Small bowel pathology</ce:section-title><ce:para id="p3375">One-third of patients with pancreatic exocrine insufficiency fail to transfer dietary vitamin B<ce:inf loc="post">12</ce:inf> from R protein to intrinsic factor. This usually results in slightly low vitamin B<ce:inf loc="post">12</ce:inf> values but no tissue evidence of vitamin B<ce:inf loc="post">12</ce:inf> deficiency.</ce:para><ce:para id="p3380">Motility disorders or hypogammaglobulinaemia can result in bacterial overgrowth, and the ensuing competition for free vitamin B<ce:inf loc="post">12</ce:inf> can lead to deficiency. This is corrected to some extent by appropriate antibiotics.</ce:para><ce:para id="p3385">A small number of people heavily infected with the fish tapeworm (<ce:intra-ref id="ii0450" xlink:href="pii:B978-0-7020-7028-0.00011-1#s2740">p. 297</ce:intra-ref>) develop vitamin B<ce:inf loc="post">12</ce:inf> deficiency.</ce:para><ce:para id="p3390">Inflammatory disease of the terminal ileum, such as Crohn's disease, may impair the absorption of vitamin B<ce:inf loc="post">12</ce:inf>–intrinsic factor complex, as may surgery on that part of the bowel.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0745"><ce:section-title id="st0695">Folate</ce:section-title><ce:section id="s0750"><ce:section-title id="st0700">Folate absorption</ce:section-title><ce:para id="p3395">Folates are produced by plants and bacteria; hence dietary leafy vegetables (spinach, broccoli, lettuce), fruits (bananas, melons) and animal protein (liver, kidney) are a rich source. An average Western diet contains more than the minimum daily intake of 50 µg but excess cooking destroys folates. Most dietary folate is present as polyglutamates; these are converted to monoglutamate in the upper small bowel and actively transported into plasma. Plasma folate is loosely bound to plasma proteins such as albumin and there is an enterohepatic circulation. Total body stores of folate are small and deficiency can occur in a matter of weeks.</ce:para></ce:section><ce:section id="s0755"><ce:section-title id="st0705">Folate deficiency</ce:section-title><ce:para id="p3400">The causes and diagnostic features of folate deficiency are shown in <ce:cross-ref id="crf0730" refid="b0210">Boxes 23.34</ce:cross-ref><ce:float-anchor refid="b0210"/> and <ce:cross-ref id="crf0740" refid="b0215">23.35</ce:cross-ref><ce:float-anchor refid="b0215"/>. The edentulous elderly or psychiatric patient is particularly susceptible to dietary deficiency and this is exacerbated in the presence of gut disease or malignancy. Pregnancy-induced folate deficiency is the most common cause of megaloblastosis worldwide and is more likely in the context of twin pregnancies, multiparity and hyperemesis gravidarum. Serum folate measurement is very sensitive to dietary intake; a single folate-rich meal can normalise it in a patient with true folate deficiency, whereas anorexia, alcohol and anticonvulsant therapy can reduce it in the absence of megaloblastosis. For this reason, red cell folate levels are a more accurate indicator of folate stores and tissue folate deficiency.</ce:para></ce:section></ce:section><ce:section id="s0790"><ce:section-title id="st0740">Management of megaloblastic anaemia</ce:section-title><ce:para id="p3490">If a patient with a severe megaloblastic anaemia is very ill and treatment must be started before vitamin B<ce:inf loc="post">12</ce:inf> and red cell folate results are available, that treatment should always include both folic acid and vitamin B<ce:inf loc="post">12</ce:inf>. The use of folic acid alone in the presence of vitamin B<ce:inf loc="post">12</ce:inf> deficiency may result in worsening of neurological features.</ce:para><ce:para id="p3495">Rarely, if severe angina or heart failure is present, transfusion can be used in megaloblastic anaemia. The cardiovascular system is adapted to the chronic anaemia present in megaloblastosis, and the volume load imposed by transfusion may result in decompensation and severe cardiac failure. In such circumstances, exchange transfusion or slow administration of 1 U of red cells with diuretic cover may be given.</ce:para><ce:section id="s0795"><ce:section-title id="st0745">Vitamin B<ce:inf loc="post">12</ce:inf> deficiency</ce:section-title><ce:para id="p3500">Vitamin B<ce:inf loc="post">12</ce:inf> deficiency is treated with hydroxycobalamin. In cases of uncomplicated deficiency, 1000 µg IM for 6 doses 2 or 3 days apart, followed by maintenance therapy of 1000 µg every 3 months for life, is recommended. In the presence of neurological involvement, a dose of 1000 µg on alternate days until there is no further improvement, followed by maintenance as above, is recommended. The reticulocyte count will peak by the 5th–10th day after starting replacement therapy. The haemoglobin will rise by 10 g/L every week until normalised. The response of the marrow is associated with a fall in plasma potassium levels and rapid depletion of iron stores. If an initial response is not maintained and the blood film is dimorphic (i.e. shows a mixture of microcytic and macrocytic cells), the patient may need additional iron therapy. A sensory neuropathy may take 6–12 months to correct; long-standing neurological damage may not improve.</ce:para></ce:section><ce:section id="s0800"><ce:section-title id="st0750">Folate deficiency</ce:section-title><ce:para id="p3505">Oral folic acid (5 mg daily for 3 weeks) will treat acute deficiency and 5 mg once weekly is adequate maintenance therapy. Prophylactic folic acid in pregnancy prevents megaloblastosis in women at risk, and reduces the risk of fetal neural tube defects (<ce:intra-ref id="ii0455" xlink:href="pii:B978-0-7020-7028-0.00019-6#p1945">p. 712</ce:intra-ref>). Prophylactic supplementation is also given in chronic haematological disease associated with reduced red cell lifespan (e.g. haemolytic anaemias). There is some evidence that supraphysiological supplementation (400 µg/day) can reduce the risk of coronary and cerebrovascular disease by lowering plasma homocysteine levels. This has led the US Food and Drug Administration to introduce fortification of bread, flour and rice with folic acid.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0805"><ce:section-title id="st0755">Haemolytic anaemia</ce:section-title><ce:para id="p3510">Haemolysis indicates that there is shortening of the normal red cell lifespan of 120 days. There are many causes, as shown in <ce:cross-ref id="crf0745" refid="f0120">Figure 23.19</ce:cross-ref><ce:float-anchor refid="f0120"/>. To compensate, the bone marrow may increase its output of red cells six- to eightfold by increasing the proportion of red cells produced, expanding the volume of active marrow, and releasing reticulocytes prematurely. Anaemia occurs only if the rate of destruction exceeds this increased production rate.</ce:para><ce:para id="p3515">There are some general features of haemolysis and other specific features that help to identify the reason for haemolysis. Results of investigations that establish the presence of haemolysis are shown in <ce:cross-ref id="crf0750" refid="b0220">Box 23.36</ce:cross-ref><ce:float-anchor refid="b0220"/>. Red cell destruction overloads pathways for haemoglobin breakdown in the liver (<ce:intra-ref id="ii0460" xlink:href="pii:B978-0-7020-7028-0.00022-6#p0550">p. 850</ce:intra-ref>), causing a modest rise in unconjugated bilirubin in the blood and mild jaundice. Increased reabsorption of urobilinogen from the gut results in an increase in urinary urobilinogen (<ce:intra-ref id="ii0465" xlink:href="pii:B978-0-7020-7028-0.00022-6#s0295">pp. 860</ce:intra-ref> and 915). Red cell destruction releases LDH into the serum. The bone marrow compensation results in a reticulocytosis, and sometimes nucleated red cell precursors appear in the blood. Increased proliferation of the bone marrow can result in a thrombocytosis, neutrophilia and, if marked, immature granulocytes in the blood, producing a leucoerythroblastic blood film. The appearances of the red cells may give an indication of the likely cause of the haemolysis:<ce:list id="ulist0790"><ce:list-item id="u2285"><ce:label>•</ce:label><ce:para id="p3520">Spherocytes are small, dark red cells that suggest autoimmune haemolysis or hereditary spherocytosis.</ce:para></ce:list-item><ce:list-item id="u2290"><ce:label>•</ce:label><ce:para id="p3525">Sickle cells suggest sickle-cell disease.</ce:para></ce:list-item><ce:list-item id="u2295"><ce:label>•</ce:label><ce:para id="p3530">Red cell fragments indicate microangiopathic haemolysis.</ce:para></ce:list-item><ce:list-item id="u2300"><ce:label>•</ce:label><ce:para id="p3535">Bite cells (normal-sized red cells that look as if they have been partially eaten) suggest oxidative haemolysis.</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p3540">The compensatory erythroid hyperplasia may give rise to folate deficiency, with megaloblastic blood features.</ce:para><ce:para id="p3545">The differential diagnosis of haemolysis is determined by the clinical scenario in combination with the results of blood film examination and Coombs testing for antibodies directed against red cells (see below and <ce:cross-ref id="crf0755" refid="f0120">Fig. 23.19</ce:cross-ref>).</ce:para><ce:section id="s0810"><ce:section id="s0815"><ce:section id="s0820"><ce:section-title id="st0760">Extravascular haemolysis</ce:section-title><ce:para id="p3550">Physiological red cell destruction occurs in the reticulo-endothelial cells in the liver or spleen, so avoiding free haemoglobin in the plasma. In most haemolytic states, haemolysis is predominantly extravascular.</ce:para><ce:para id="p3555">To confirm the haemolysis, patients' red cells can be labelled with <ce:sup loc="post">51</ce:sup>chromium. When re-injected, they can be used to determine red cell survival; when combined with body surface radioactivity counting, this test may indicate whether the liver or the spleen is the main source of red cell destruction. However, it is seldom performed in clinical practice.</ce:para></ce:section><ce:section id="s0825"><ce:section-title id="st0765">Intravascular haemolysis</ce:section-title><ce:para id="p3560">Less commonly, red cell lysis occurs within the blood stream due to membrane damage by complement (ABO transfusion reactions, paroxysmal nocturnal haemoglobinuria), infections (malaria, <ce:italic>Clostridium perfringens</ce:italic>), mechanical trauma (heart valves, DIC) or oxidative damage (e.g. enzymopathies such as glucose-6-phosphate dehydrogenase deficiency, which may be triggered by drugs such as dapsone and maloprim). When intravascular red cell destruction occurs, free haemoglobin is released into the plasma. Free haemoglobin is toxic to cells and binding proteins have evolved to minimise this risk. Haptoglobin is an α<ce:inf loc="post">2</ce:inf>-globulin produced by the liver, which binds free haemoglobin, resulting in a fall in its levels during active haemolysis. Once haptoglobins are saturated, free haemoglobin is oxidised to form methaemoglobin, which binds to albumin, in turn forming methaemalbumin, which can be detected spectrophotometrically in Schumm's test. Methaemoglobin is degraded and any free haem is bound to a second binding protein called haemopexin. If all the protective mechanisms are saturated, free haemoglobin may appear in the urine (haemoglobinuria). When fulminant, this gives rise to black urine, as in severe <ce:italic>falciparum</ce:italic> malaria infection (<ce:intra-ref id="ii0470" xlink:href="pii:B978-0-7020-7028-0.00011-1#s1905">p. 274</ce:intra-ref>). In smaller amounts, renal tubular cells absorb the haemoglobin, degrade it and store the iron as haemosiderin. When the tubular cells are subsequently sloughed into the urine, they give rise to haemosiderinuria, which is always indicative of intravascular haemolysis (<ce:cross-ref id="crf0760" refid="b0220">Box 23.36</ce:cross-ref>).</ce:para></ce:section></ce:section><ce:section id="s0830"><ce:section-title id="st0770">Causes of haemolytic anaemia</ce:section-title><ce:para id="p3565">These can be classified as inherited or acquired (<ce:cross-ref id="crf0765" refid="f0120">Fig. 23.19</ce:cross-ref>).<ce:list id="ulist0795"><ce:list-item id="u2305"><ce:label>•</ce:label><ce:para id="p3570"><ce:italic>Inherited</ce:italic> red cell abnormalities resulting in chronic haemolytic anaemia may arise from pathologies of the red cell membrane (hereditary spherocytosis or elliptocytosis), haemoglobin (haemoglobinopathies), or protective enzymes that prevent cellular oxidative damage, such as glucose-6-phosphate dehydrogenase (G6PD).</ce:para></ce:list-item><ce:list-item id="u2310"><ce:label>•</ce:label><ce:para id="p3575"><ce:italic>Acquired</ce:italic> causes include auto- and alloantibody-mediated destruction of red blood cells and other mechanical, toxic and infective causes.</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:section><ce:section id="s0835"><ce:section-title id="st0775">Red cell membrane defects</ce:section-title><ce:para id="p3580">The structure of the red cell membrane is shown in <ce:cross-ref id="crf0770" refid="f0040">Figure 23.4</ce:cross-ref>. The basic structure is a cytoskeleton ‘stapled’ on to the lipid bilayer by special protein complexes. This structure ensures great deformability and elasticity; the red cell diameter is 8 µm but the narrowest capillaries in the circulation are in the spleen, measuring just 2 µm in diameter. When the normal red cell structure is disturbed, usually by a quantitative or functional deficiency of one or more proteins in the cytoskeleton, cells lose their elasticity. Each time such cells pass through the spleen, they lose membrane relative to their cell volume. This results in an increase in mean cell haemoglobin concentration (MCHC), abnormal cell shape (see <ce:cross-ref id="crf0775" refid="b0045">Box 23.2</ce:cross-ref>) and reduced red cell survival due to extravascular haemolysis.</ce:para><ce:section id="s0840"><ce:section-title id="st0780">Hereditary spherocytosis</ce:section-title><ce:para id="p3585">This is usually inherited as an autosomal dominant condition, although 25% of cases have no family history and represent new mutations. The incidence is approximately 1 : 5000 in developed countries but this may be an under-estimate, since the disease may present de novo in patients aged over 65 years and is often discovered as a chance finding on a blood count. The most common abnormalities are deficiencies of beta spectrin or ankyrin (see <ce:cross-ref id="crf0780" refid="f0040">Fig. 23.4</ce:cross-ref>). The severity of spontaneous haemolysis varies. Most cases are associated with an asymptomatic compensated chronic haemolytic state with spherocytes present on the blood film, a reticulocytosis and mild hyperbilirubinaemia. Pigment gallstones are present in up to 50% of patients and may cause symptomatic cholecystitis. Occasional cases are associated with more severe haemolysis; these may be due to coincidental polymorphisms in alpha spectrin or co-inheritance of a second defect involving a different protein. These cases tend to present earlier in life with symptomatic, sometimes transfusion-dependent anaemia.</ce:para><ce:para id="p3590">The clinical course may be complicated by crises:<ce:list id="ulist0800"><ce:list-item id="u2315"><ce:label>•</ce:label><ce:para id="p3595"><ce:italic>A haemolytic crisis</ce:italic> occurs when the severity of haemolysis increases; this is rare, and usually associated with infection.</ce:para></ce:list-item><ce:list-item id="u2320"><ce:label>•</ce:label><ce:para id="p3600"><ce:italic>A megaloblastic crisis</ce:italic> follows the development of folate deficiency; this may occur as a first presentation of the disease in pregnancy.</ce:para></ce:list-item><ce:list-item id="u2325"><ce:label>•</ce:label><ce:para id="p3605"><ce:italic>An aplastic crisis</ce:italic> occurs in association with parvovirus (erythrovirus) infection (<ce:intra-ref id="ii0475" xlink:href="pii:B978-0-7020-7028-0.00011-1#s0570">p. 237</ce:intra-ref>). Parvovirus causes a common exanthem in children, but if individuals with chronic haemolysis become infected, the virus directly invades red cell precursors and temporarily switches off red cell production. Patients present with severe anaemia and a low reticulocyte count.</ce:para></ce:list-item></ce:list></ce:para><ce:section id="s0845"><ce:section-title id="st0785">Investigations</ce:section-title><ce:para id="p3610">The patient and other family members should be screened for features of compensated haemolysis (see <ce:cross-ref id="crf0785" refid="b0220">Box 23.36</ce:cross-ref>). This may be all that is required to confirm the diagnosis. Haemoglobin levels are variable, depending on the degree of compensation. The blood film will show spherocytes but the direct Coombs test (<ce:cross-ref id="crf0790" refid="f0125">Fig. 23.20</ce:cross-ref><ce:float-anchor refid="f0125"/>) is negative, excluding immune haemolysis. An osmotic fragility test may show increased sensitivity to lysis in hypotonic saline solutions but is limited by lack of sensitivity and specificity. More specific flow cytometric tests, detecting binding of eosin-5-maleimide to red cells, are recommended in borderline cases.</ce:para></ce:section><ce:section id="s0850"><ce:section-title id="st0790">Management</ce:section-title><ce:para id="p3665">Folic acid prophylaxis, 5 mg daily, should be given for life. In severe cases, consideration may be given to splenectomy, which improves but does not normalise red cell survival. Potential indications for splenectomy include moderate to severe haemolysis with complications (anaemia and gallstones), although splenectomy should be delayed where possible until after 6 years of age in view of the risk of sepsis. Guidelines for the management of patients after splenectomy are presented in <ce:cross-ref id="crf0795" refid="b0225">Box 23.37</ce:cross-ref><ce:float-anchor refid="b0225"/>.</ce:para><ce:para id="p3715">Acute, severe haemolytic crises require transfusion support, but blood must be cross-matched carefully and transfused slowly as haemolytic transfusion reactions may occur (p. 935).</ce:para></ce:section></ce:section><ce:section id="s0855"><ce:section-title id="st0795">Hereditary elliptocytosis</ce:section-title><ce:para id="p3720">This term refers to a heterogeneous group of disorders that produce an increase in elliptocytic red cells on the blood film and a variable degree of haemolysis. This is due to a functional abnormality of one or more anchor proteins in the red cell membrane, e.g. alpha spectrin or protein 4.1 (see <ce:cross-ref id="crf0800" refid="f0040">Fig. 23.4</ce:cross-ref>). Inheritance may be autosomal dominant or recessive. Hereditary elliptocytosis is less common than hereditary spherocytosis in Western countries, with an incidence of 1/10 000, but is more common in equatorial Africa and parts of South-east Asia. The clinical course is variable and depends on the degree of membrane dysfunction caused by the inherited molecular defect(s); most cases present as an asymptomatic blood film abnormality but occasional cases result in neonatal haemolysis or a chronic compensated haemolytic state. Management of the latter is the same as for hereditary spherocytosis.</ce:para><ce:para id="p3725">A characteristic variant of hereditary elliptocytosis occurs in South-east Asia, particularly Malaysia and Papua New Guinea, with stomatocytes and ovalocytes in the blood. This has a prevalence of up to 30% in some communities because it offers relative protection from malaria and thus has sustained a high gene frequency. The blood film is often very abnormal and immediate differential diagnosis is broad.</ce:para></ce:section></ce:section><ce:section id="s0860"><ce:section-title id="st0800">Red cell enzymopathies</ce:section-title><ce:para id="p3730">The mature red cell must produce energy via ATP to maintain a normal internal environment and cell volume while protecting itself from the oxidative stress presented by oxygen carriage. ATP is generated by glycolysis, while the hexose monophosphate shunt produces nicotinamide adenine dinucleotide phosphate (NADPH) and glutathione to protect against oxidative stress. The impact of functional or quantitative defects in the enzymes in these pathways depends on the importance of the steps affected and the presence of alternative pathways. In general, defects in the hexose monophosphate shunt pathway result in periodic haemolysis precipitated by episodic oxidative stress, while those in the glycolysis pathway result in shortened red cell survival and chronic haemolysis.</ce:para><ce:section id="s0865"><ce:section-title id="st0805">Glucose-6-phosphate dehydrogenase deficiency</ce:section-title><ce:para id="p3735">The enzyme glucose-6-phosphate dehydrogenase (G6PD) is pivotal in the hexose monophosphate shunt pathway. Deficiencies result in the most common human enzymopathy, affecting 10% of the world's population, with a geographical distribution that parallels the malaria belt because heterozygotes are protected from malarial parasitisation. The enzyme is a heteromeric structure made of catalytic subunits that are encoded by a gene on the X chromosome. The deficiency therefore affects males and rare homozygous females (<ce:intra-ref id="ii0485" xlink:href="pii:B978-0-7020-7028-0.00003-2#s0125">p. 48</ce:intra-ref>), but it is carried by females. Carrier heterozygous females are usually only affected in the neonatal period or in the presence of skewed X-inactivation (<ce:intra-ref id="ii0490" xlink:href="pii:B978-0-7020-7028-0.00003-2#s0195">p. 49</ce:intra-ref>).</ce:para><ce:para id="p3740">Over 400 subtypes of G6PD are described. The most common types associated with normal activity are the B+ enzyme present in most Caucasians and 70% of Afro-Caribbeans, and the A+ variant present in 20% of Afro-Caribbeans. The two common variants associated with reduced activity are the A<ce:sup loc="post">−</ce:sup> variety in approximately 10% of Afro-Caribbeans, and the Mediterranean or B<ce:sup loc="post">−</ce:sup> variety in Caucasians. In East and West Africa, up to 20% of males and 4% of females (homozygotes) are affected and have enzyme levels of about 15% of normal. The deficiency in Caucasian and East Asian populations is more severe, with enzyme levels as low as 1%.</ce:para><ce:para id="p3745">Clinical features and investigation findings are shown in <ce:cross-ref id="crf0805" refid="b0230">Box 23.38</ce:cross-ref><ce:float-anchor refid="b0230"/>.</ce:para><ce:para id="p3850">Management aims to stop the intake of any precipitant drugs or foods and treat any underlying infection. Favism due to the consumption of fava beans is the classically described precipitant of haemolysis in patients with G6PD deficiency. Acute transfusion support may be life-saving.</ce:para></ce:section><ce:section id="s0890"><ce:section-title id="st0830">Pyruvate kinase deficiency</ce:section-title><ce:para id="p3855">This is the second most common red cell enzyme defect. It results in deficiency of ATP production and a chronic haemolytic anaemia. It is inherited as an autosomal recessive trait. The extent of anaemia is variable; the blood film shows characteristic ‘prickle cells’ that resemble holly leaves. Enzyme activity is only 5–20% of normal. Transfusion support may be necessary during periods of haemolysis.</ce:para></ce:section><ce:section id="s0895"><ce:section-title id="st0835">Pyrimidine 5′ nucleotidase deficiency</ce:section-title><ce:para id="p3860">The pyrimidine 5′ nucleotidase enzyme catalyses the dephosphorylation of nucleoside monophosphates and is important during the degradation of RNA in reticulocytes. It is inherited as an autosomal recessive trait and is as common as pyruvate kinase deficiency in Mediterranean, African and Jewish populations. The accumulation of excess ribonucleoprotein results in coarse basophilic stippling (see <ce:cross-ref id="crf0810" refid="b0045">Box 23.2</ce:cross-ref>), associated with a chronic haemolytic state. The enzyme is very sensitive to inhibition by lead and this is the reason why basophilic stippling is a feature of lead poisoning.</ce:para></ce:section></ce:section><ce:section id="s0900"><ce:section-title id="st0840">Autoimmune haemolytic anaemia</ce:section-title><ce:para id="p3865">This results from increased red cell destruction due to red cell autoantibodies. The antibodies may be IgG or IgM, or more rarely IgE or IgA. If an antibody avidly fixes complement, it will cause intravascular haemolysis, but if complement activation is weak, the haemolysis will be extravascular (in the reticulo-endothelial system). Antibody-coated red cells lose membrane to macrophages in the spleen and hence spherocytes are present in the blood. The optimum temperature at which the antibody is active (thermal specificity) is used to classify immune haemolysis:<ce:list id="ulist0850"><ce:list-item id="u2500"><ce:label>•</ce:label><ce:para id="p3870"><ce:italic>Warm antibodies</ce:italic> bind best at 37°C and account for 80% of cases. The majority are IgG and often react against Rhesus antigens.</ce:para></ce:list-item><ce:list-item id="u2505"><ce:label>•</ce:label><ce:para id="p3875"><ce:italic>Cold antibodies</ce:italic> bind best at 4°C but can bind up to 37°C in some cases. They are usually IgM and bind complement. To be clinically relevant, they must act within the range of normal body temperatures. They account for the other 20% of cases.</ce:para></ce:list-item></ce:list></ce:para><ce:section id="s0905"><ce:section-title id="st0845">Warm autoimmune haemolysis</ce:section-title><ce:para id="p3880">The incidence of warm autoimmune haemolysis is approximately 1/100 000 population per annum; it occurs at all ages but is more common in middle age and in females. No underlying cause is identified in up to 50% of cases. The remainder are secondary to a wide variety of other conditions (see <ce:cross-ref id="crf0815" refid="f0120">Fig. 23.19B</ce:cross-ref>).</ce:para><ce:section id="s0910"><ce:section-title id="st0850">Investigations</ce:section-title><ce:para id="p3885">There is evidence of haemolysis, spherocytes and polychromasia on the blood film. The diagnosis is confirmed by the direct Coombs or antiglobulin test (see <ce:cross-ref id="crf0820" refid="f0125">Fig. 23.20</ce:cross-ref>). The patient's red cells are mixed with Coombs reagent, which contains antibodies against human IgG/IgM/complement. If the red cells have been coated by antibody in vivo, the Coombs reagent will induce their agglutination and this can be detected visually. The relevant antibody can be eluted from the red cell surface and tested against a panel of typed red cells to determine against which red cell antigen it is directed. The most common specificity is for Rhesus antigens and most often anti-e; this is helpful when choosing blood to cross-match. The direct Coombs test can be negative in the presence of brisk haemolysis. A positive test requires about 200 antibody molecules to attach to each red cell; with a very avid complement-fixing antibody, haemolysis may occur at lower levels of antibody-binding. The standard Coombs reagent will miss IgA or IgE antibodies. Around 10% of all warm autoimmune haemolytic anaemias are Coombs test-negative.</ce:para></ce:section><ce:section id="s0915"><ce:section-title id="st0855">Management</ce:section-title><ce:para id="p3890">If the haemolysis is secondary to an underlying cause, this must be treated and any implicated drugs stopped.</ce:para><ce:para id="p3895">It is usual to treat patients initially with prednisolone (1 mg/kg orally). A response is seen in 70–80% of cases but may take up to 3 weeks; a rise in haemoglobin will be matched by a fall in bilirubin, LDH and reticulocyte levels. Once the haemoglobin has normalised and the reticulocytosis resolved, the glucocorticoid dose can be reduced slowly over several weeks. Glucocorticoids probably work by decreasing macrophage destruction of antibody-coated red cells and reducing antibody production.</ce:para><ce:para id="p3900">Transfusion support may be required for life-threatening problems, such as the development of heart failure or rapid unabated falls in haemoglobin. The least incompatible blood should be used but this may still give rise to transfusion reactions or the development of alloantibodies.</ce:para><ce:para id="p3905">If the haemolysis fails to respond to glucocorticoids or can only be stabilised by large doses, then second-line therapies should be considered. These include immunomodulation/suppression and splenectomy. Currently, there are fewer splenectomies than previously and the second-line drug of choice in current UK guidance is the anti-CD20 monoclonal antibody rituximab. Splenectomy is associated with a good response in 50–60% of cases. The operation can be performed laparoscopically with reduced morbidity. If splenectomy is not appropriate, alternative immunosuppressive therapy with azathioprine, ciclosporin, mycophenolate or cyclophosphamide may be considered. There are concerns about all modes of second-line therapy, as long-term immunosuppression carries a risk of malignancy, while splenectomy is associated with an excess of severe infection due to the capsulate organisms pneumococcus and meningococcus (see <ce:cross-ref id="crf0825" refid="b0240">Box 23.40</ce:cross-ref>).</ce:para></ce:section></ce:section><ce:section id="s0920"><ce:section-title id="st0860">Cold agglutinin disease</ce:section-title><ce:para id="p3910">This is mediated by antibodies, usually IgM, which bind to the red cells at low temperatures and cause them to agglutinate. It may cause intravascular haemolysis if complement fixation occurs. This can be chronic when the antibody is monoclonal, or acute or transient when the antibody is polyclonal.</ce:para><ce:section id="s0925"><ce:section-title id="st0865">Chronic cold agglutinin disease</ce:section-title><ce:para id="p3915">This typically affects elderly patients and may be associated with an underlying low-grade B-cell lymphoma. It causes a low-grade intravascular haemolysis with cold, painful and often blue fingers, toes, ears or nose (so-called acrocyanosis). The latter is due to red cell agglutination in the small vessels in these colder, exposed areas. The blood film shows red cell agglutination and the MCV may be spuriously high because the automated analysers detect red cell aggregates as single cells. Monoclonal IgM usually has anti-I or, less often, anti-i specificity. Treatment is primarily by transfusion support but may also be directed at any underlying lymphoma. Patients must keep extremities warm, especially in winter. Some patients respond to glucocorticoid therapy and rituximab. Two considerations for patients requiring blood transfusion is that the cross-match sample must be placed in a transport flask at a temperature of 37°C and blood administered via a blood-warmer. All patients should receive folic acid supplementation.</ce:para></ce:section><ce:section id="s0930"><ce:section-title id="st0870">Other causes of cold agglutination</ce:section-title><ce:para id="p3920">Cold agglutination can occur in association with <ce:italic>Mycoplasma pneumoniae</ce:italic> or with infectious mononucleosis. Paroxysmal cold haemoglobinuria is a very rare cause seen in children, in association with viral or bacterial infection. An IgG antibody binds to red cells in the peripheral circulation but lysis occurs in the central circulation when complement fixation takes place. This antibody is termed the Donath–Landsteiner antibody and has specificity against the P antigen on the red cells.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0935"><ce:section-title id="st0875">Alloimmune haemolytic anaemia</ce:section-title><ce:para id="p3925">Alloimmune haemolytic anaemia is caused by antibodies against non-self red cells. It has two main causes, occurring after:<ce:list id="ulist0855"><ce:list-item id="u2510"><ce:label>•</ce:label><ce:para id="p3930">unmatched blood transfusion (p. 935)</ce:para></ce:list-item><ce:list-item id="u2515"><ce:label>•</ce:label><ce:para id="p3935">maternal sensitisation to paternal antigens on fetal cells (haemolytic disease of the newborn, p. 933).</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0940"><ce:section-title id="st0880">Non-immune haemolytic anaemia</ce:section-title><ce:section id="s0945"><ce:section-title id="st0885">Endothelial damage</ce:section-title><ce:para id="p3940">Disruption of red cell membrane may occur in a number of conditions and is characterised by the presence of red cell fragments on the blood film and markers of intravascular haemolysis:<ce:list id="ulist0860"><ce:list-item id="u2520"><ce:label>•</ce:label><ce:para id="p3945"><ce:italic>Mechanical heart valves.</ce:italic> High flow through incompetent valves or periprosthetic leaks through the suture ring holding a valve in place result in shear stress damage.</ce:para></ce:list-item><ce:list-item id="u2525"><ce:label>•</ce:label><ce:para id="p3950"><ce:italic>March haemoglobinuria.</ce:italic> Vigorous exercise, such as prolonged marching or marathon running, can cause red cell damage in the capillaries in the feet.</ce:para></ce:list-item><ce:list-item id="u2530"><ce:label>•</ce:label><ce:para id="p3955"><ce:italic>Thermal injury.</ce:italic> Severe burns cause thermal damage to red cells, characterised by fragmentation and the presence of microspherocytes in the blood.</ce:para></ce:list-item><ce:list-item id="u2535"><ce:label>•</ce:label><ce:para id="p3960"><ce:italic>Microangiopathic haemolytic anaemia.</ce:italic> Fibrin deposition in capillaries can cause severe red cell disruption. It may occur in a wide variety of conditions: disseminated carcinomatosis, malignant or pregnancy-induced hypertension, haemolytic uraemic syndrome (<ce:intra-ref id="ii0505" xlink:href="pii:B978-0-7020-7028-0.00015-9#s0580">p. 408</ce:intra-ref>), thrombotic thrombocytopenic purpura (p. 979) and disseminated intravascular coagulation (p. 978).</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0950"><ce:section-title id="st0890">Infection</ce:section-title><ce:para id="p3965"><ce:italic>Plasmodium falciparum</ce:italic> malaria (<ce:intra-ref id="ii0520" xlink:href="pii:B978-0-7020-7028-0.00011-1#s1905">p. 274</ce:intra-ref>) may be associated with intravascular haemolysis; when severe, this is termed blackwater fever because of the associated haemoglobinuria. <ce:italic>Clostridium perfringens</ce:italic> sepsis (<ce:intra-ref id="ii0525" xlink:href="pii:B978-0-7020-7028-0.00011-1#p1705">p. 227</ce:intra-ref>), usually in the context of ascending cholangitis or necrotising fasciitis, may cause severe intravascular haemolysis with marked spherocytosis due to bacterial production of a lecithinase that destroys the red cell membrane.</ce:para></ce:section><ce:section id="s0955"><ce:section-title id="st0895">Chemicals or drugs</ce:section-title><ce:para id="p3970">Dapsone and sulfasalazine cause haemolysis by oxidative denaturation of haemoglobin. Denatured haemoglobin forms Heinz bodies in the red cells, visible on supravital staining with brilliant cresyl blue. Arsenic gas, copper, chlorates, nitrites and nitrobenzene derivatives may all cause haemolysis.</ce:para></ce:section></ce:section><ce:section id="s0960"><ce:section-title id="st0900">Paroxysmal nocturnal haemoglobinuria</ce:section-title><ce:para id="p3975">Paroxysmal nocturnal haemoglobinuria (PNH) is a rare acquired, non-malignant clonal expansion of haematopoietic stem cells deficient in glycosylphosphatidylinositol (GPI) anchor protein. GPI anchors several key molecules to cells and its absence results in clinical outcomes that reflect this, causing intravascular haemolysis and anaemia because of increased sensitivity of red cells to lysis by complement. This happens because key defence mechanisms that protect cells from complement-mediated lysis (CD55 and CD59) are GPI-anchored to red cells under normal circumstances. Episodes of intravascular haemolysis result in haemoglobinuria, most noticeable in early morning urine, which has a characteristic red–brown colour. The disease is associated with an increased risk of venous and arterial thrombosis in unusual sites, such as the liver or abdomen. PNH clones are also associated with hypoplastic bone marrow failure, aplastic anaemia and myelodysplastic syndrome (pp. 960 and 969). Management is supportive with transfusion and folate supplements and prophylaxis or treatment of thrombosis. Standard care now includes the anti-complement C5 monoclonal antibody eculizimab. This has been shown to be effective in reducing haemolysis, transfusion requirements and thrombotic risk. Eculizumab carries a risk of infection, particularly for <ce:italic>Neisseria meningitidis</ce:italic>, and all treated patients must be vaccinated against this organism.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0965"><ce:section-title id="st0905">Haemoglobinopathies</ce:section-title><ce:para id="p3980">These diseases are caused by mutations affecting the genes encoding the globin chains of the haemoglobin molecule. Normal haemoglobin is composed of two alpha and two non-alpha globin chains. Alpha globin chains are produced throughout life, including in the fetus, so severe mutations may cause intrauterine death. Production of non-alpha chains varies with age; fetal haemoglobin (HbF-αα/γγ) has two gamma chains, while the predominant adult haemoglobin (HbA-αα/ββ) has two beta chains. Thus, disorders affecting the beta chains do not present until after 6 months of age. A constant small amount of haemoglobin A<ce:inf loc="post">2</ce:inf> (HbA<ce:inf loc="post">2</ce:inf>-αα/δδ, usually less than 2%) is made from birth.</ce:para><ce:para id="p3985">The geographical distribution of the common haemoglobinopathies is shown in <ce:cross-ref id="crf0830" refid="f0130">Figure 23.21</ce:cross-ref><ce:float-anchor refid="f0130"/>. The haemoglobinopathies can be classified into qualitative or quantitative abnormalities.</ce:para><ce:section id="s0970"><ce:section id="s0975"><ce:section id="s0980"><ce:section-title id="st0910">Qualitative abnormalities – abnormal haemoglobins</ce:section-title><ce:para id="p3990">In qualitative abnormalities (called the abnormal haemoglobins), there is a functionally important alteration in the amino acid structure of the polypeptide chains of the globin chains. Several hundred such variants are known; they were originally designated by letters of the alphabet, e.g. S, C, D or E, but the more recently described ones are known by names that usually taken from the town or district in which they were first described. The best-known example is haemoglobin S, found in sickle-cell anaemia. Mutations around the haem-binding pocket cause the haem ring to fall out of the structure and produce an unstable haemoglobin. These substitutions often change the charge of the globin chains, producing different electrophoretic mobility, and this forms the basis for the diagnostic use of haemoglobin electrophoresis to identify haemoglobinopathies.</ce:para></ce:section><ce:section id="s0985"><ce:section-title id="st0915">Quantitative abnormalities – thalassaemias</ce:section-title><ce:para id="p3995">In quantitative abnormalities (the thalassaemias), there are mutations causing a reduced rate of production of one or other of the globin chains, altering the ratio of alpha to non-alpha chains. In alpha-thalassaemia excess beta chains are present, while in beta-thalassaemia excess alpha chains are present. The excess chains precipitate, causing red cell membrane damage and reduced red cell survival due to haemolysis.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0990"><ce:section-title id="st0920">Sickle-cell anaemia</ce:section-title><ce:para id="p4000">Sickle-cell disease results from a single glutamic acid to valine substitution at position 6 of the beta globin polypeptide chain. It is inherited as an autosomal recessive trait (<ce:intra-ref id="ii0535" xlink:href="pii:B978-0-7020-7028-0.00003-2#s0125">p. 48</ce:intra-ref>). Homozygotes only produce abnormal beta chains that make haemoglobin S (HbS, termed SS), and this results in the clinical syndrome of sickle-cell disease. Heterozygotes produce a mixture of normal and abnormal beta chains that make normal HbA and HbS (termed AS), and this results in sickle-cell trait; although this was previously thought of as asymptomatic, it may be associated with an increased risk of sudden and cardiovascular death.</ce:para><ce:section id="s0995"><ce:section id="s1000"><ce:section-title id="st0925">Epidemiology</ce:section-title><ce:para id="p4005">The heterozygote frequency is over 20% in tropical Africa (see <ce:cross-ref id="crf0835" refid="f0130">Fig. 23.21</ce:cross-ref>). In black American populations, sickle-cell trait has a frequency of 8%. Individuals with sickle-cell trait are relatively resistant to the lethal effects of <ce:italic>falciparum</ce:italic> malaria in early childhood; the high prevalence in equatorial Africa can be explained by the survival advantage it confers in areas where <ce:italic>falciparum</ce:italic> malaria is endemic. However, homozygous patients with sickle-cell anaemia do not have correspondingly greater resistance to <ce:italic>falciparum</ce:italic> malaria.</ce:para></ce:section><ce:section id="s1005"><ce:section-title id="st0930">Pathogenesis</ce:section-title><ce:para id="p4010">When haemoglobin S is deoxygenated, the molecules of haemoglobin polymerise to form pseudocrystalline structures known as ‘tactoids’. These distort the red cell membrane and produce characteristic sickle-shaped cells (<ce:cross-ref id="crf0840" refid="f0135">Fig. 23.22</ce:cross-ref><ce:float-anchor refid="f0135"/>). The polymerisation is reversible when re-oxygenation occurs. The distortion of the red cell membrane, however, may become permanent and the red cell ‘irreversibly sickled’. The greater the concentration of sickle-cell haemoglobin in the individual cell, the more easily tactoids are formed, but this process may be enhanced or retarded by the presence of other haemoglobins. Thus the abnormal haemoglobin C variant participates in polymerisation more readily than haemoglobin A, whereas haemoglobin F strongly inhibits polymerisation.</ce:para></ce:section><ce:section id="s1010"><ce:section-title id="st0935">Clinical features</ce:section-title><ce:para id="p4015">Sickling is precipitated by hypoxia, acidosis, dehydration and infection. Irreversibly sickled cells have a shortened survival and plug vessels in the microcirculation. This results in a number of acute syndromes, termed ‘crises’, and chronic organ damage (<ce:cross-ref id="crf0845" refid="f0135">Fig. 23.22</ce:cross-ref>):<ce:list id="ulist0865"><ce:list-item id="u2540"><ce:label>•</ce:label><ce:para id="p4020"><ce:italic>Painful vaso-occlusive crisis</ce:italic>. Plugging of small vessels in the bone produces acute severe bone pain. This affects areas of active marrow: the hands and feet in children (so-called dactylitis) or the femora, humeri, ribs, pelvis and vertebrae in adults. Patients usually have a systemic response with tachycardia, sweating and a fever. This is the most common form of crisis.</ce:para></ce:list-item><ce:list-item id="u2545"><ce:label>•</ce:label><ce:para id="p4025"><ce:italic>Stroke.</ce:italic> The single most devastating consequence of sickle-cell disease is stroke. Stroke or silent stroke occurs in 10–15% of children with sickle-cell disease. Children at risk of stroke can be identified by screening with transcranial Doppler ultrasound, with fast flow associated with increased stroke risk. These children may be offered strategies such as transfusion or treatment with hydroxycarbamide to reduce the risk of stroke.</ce:para></ce:list-item><ce:list-item id="u2550"><ce:label>•</ce:label><ce:para id="p4030"><ce:italic>Sickle chest syndrome</ce:italic>. This may follow a vaso-occlusive crisis and is the most common cause of death in adult sickle-cell disease. Bone marrow infarction results in fat emboli to the lungs, which cause further sickling and infarction, leading to ventilatory failure if not treated.</ce:para></ce:list-item><ce:list-item id="u2555"><ce:label>•</ce:label><ce:para id="p4035"><ce:italic>Sequestration crisis</ce:italic>. Thrombosis of the venous outflow from an organ causes loss of function and acute painful enlargement. In children, the spleen is the most common site. Massive splenic enlargement may result in severe anaemia, circulatory collapse and death. Recurrent sickling in the spleen in childhood results in infarction and adults may have no functional spleen. In adults, the liver may undergo sequestration with severe pain due to capsular stretching. Priapism is a complication seen in affected men.</ce:para></ce:list-item><ce:list-item id="u2560"><ce:label>•</ce:label><ce:para id="p4040"><ce:italic>Aplastic crisis</ce:italic>. Infection of adult sicklers with human parvovirus B19 (erythrovirus) may result in a severe but self-limiting red cell aplasia. This results in profound anaemia, which may cause heart failure. Unlike in all other sickle crises, the reticulocyte count is low.</ce:para></ce:list-item><ce:list-item id="u2565"><ce:label>•</ce:label><ce:para id="p4045"><ce:italic>Pregnancy</ce:italic>. Pregnancy in sickle-cell disease requires planning and multidisciplinary management. Women with sickle-cell disease have increased pregnancy-related morbidity, which includes painful crisis, placental failure and thrombosis (<ce:cross-ref id="crf0850" refid="b0235">Box 23.39</ce:cross-ref><ce:float-anchor refid="b0235"/>).</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1015"><ce:section-title id="st0940">Investigations</ce:section-title><ce:para id="p4105">Patients with sickle-cell disease have a compensated anaemia, usually around 60–80 g/L. The blood film shows sickle cells, target cells and features of hyposplenism from a young age. A reticulocytosis is present. The presence of HbS can be demonstrated by exposing red cells to a reducing agent such as sodium dithionite; HbA gives a clear solution, whereas HbS polymerises to produce a turbid solution. This forms the basis of emergency screening tests before surgery in appropriate ethnic groups but cannot distinguish between sickle-cell trait and disease. The definitive diagnosis requires haemoglobin electrophoresis to demonstrate the absence of HbA, 2–20% HbF and the predominance of HbS. Both parents of the affected individual will have sickle-cell trait.</ce:para></ce:section><ce:section id="s1020"><ce:section-title id="st0945">Management</ce:section-title><ce:para id="p4110">All patients with sickle-cell disease should receive prophylaxis with daily folic acid, and appropriate management of the hyposplenic state that is uniformly found in these patients from an early age (see <ce:cross-ref id="crf0855" refid="b0225">Box 23.37</ce:cross-ref>). Seasonal vaccination against influenza is also advised in these patients.</ce:para><ce:para id="p4115">Vaso-occlusive crises are managed by aggressive rehydration, oxygen therapy, adequate analgesia (which often requires opiates) and antibiotics. Transfusion should be with fully genotyped blood wherever possible. Simple top-up transfusion may be used in a sequestration or aplastic crisis. A regular transfusion programme to suppress HbS production and maintain the HbS level below 30% may be indicated in patients with recurrent severe complications, such as cerebrovascular accidents in children or chest syndromes in adults. Exchange transfusion, in which a patient is simultaneously venesected and transfused to replace HbS with HbA, may be used in life-threatening crises or to prepare patients for surgery.</ce:para><ce:para id="p4120">A high HbF level inhibits polymerisation of HbS and reduces sickling. Patients with sickle-cell disease and high HbF levels have a mild clinical course with few crises. Some agents are able to increase synthesis of HbF and this has been used to reduce the frequency of severe crises. The oral cytotoxic agent hydroxycarbamide has been shown to have clinical benefit with acceptable side-effects in children and adults who have recurrent severe crises.</ce:para><ce:para id="p4125">Relatively few allogeneic stem cell transplants from HLA-matched siblings have been performed but this procedure appears to be potentially curative (p. 937).</ce:para></ce:section><ce:section id="s1025"><ce:section-title id="st0950">Prognosis</ce:section-title><ce:para id="p4130">In Africa, few children with sickle-cell anaemia survive to adult life without medical attention. Even with standard medical care, approximately 15% die by the age of 20 years and 50% by the age of 40 years.</ce:para></ce:section></ce:section></ce:section><ce:section id="s1030"><ce:section-title id="st0955">Other abnormal haemoglobins</ce:section-title><ce:para id="p4135">Another beta-chain haemoglobinopathy, haemoglobin C (HbC) disease, is clinically silent but associated with microcytosis and target cells on the blood film. Compound heterozygotes inheriting one <ce:italic>HbS</ce:italic> gene and one <ce:italic>HbC</ce:italic> gene from their parents have haemoglobin SC disease, which behaves like a mild form of sickle-cell disease. SC disease is associated with a reduced frequency of crises but is not uncommonly associated with complications in pregnancy and retinopathy.</ce:para></ce:section><ce:section id="s1035"><ce:section-title id="st0960">Thalassaemias</ce:section-title><ce:para id="p4140">Thalassaemia is an inherited impairment of haemoglobin production, in which there is partial or complete failure to synthesise a specific type of globin chain. In alpha-thalassaemia, disruption of one or both alleles on chromosome 16 may occur, with production of some or no alpha globin chains. In beta-thalassaemia, defective production usually results from disabling point mutations causing no (β<ce:sup loc="post">0</ce:sup>) or reduced (β<ce:sup loc="post">–</ce:sup>) beta chain production.</ce:para><ce:section id="s1040"><ce:section-title id="st0965">Beta-thalassaemia</ce:section-title><ce:para id="p4145">Failure to synthesise beta chains (beta-thalassaemia) is the most common type of thalassaemia, most prevalent in the Mediterranean area. Heterozygotes have thalassaemia minor, a condition in which there is usually mild microcytic anaemia and little or no clinical disability, which may be detected only when iron therapy for a mild microcytic anaemia fails. Homozygotes (thalassaemia major) either are unable to synthesise haemoglobin A or, at best, produce very little; after the first 4–6 months of life, they develop profound transfusion-dependent hypochromic anaemia. The diagnostic features are summarised in <ce:cross-ref id="crf0860" refid="b0240">Box 23.40</ce:cross-ref><ce:float-anchor refid="b0240"/>. Intermediate grades of severity occur.</ce:para><ce:section id="s1055"><ce:section-title id="st0980">Management and prevention</ce:section-title><ce:para id="p4215">See <ce:cross-ref id="crf0865" refid="b0245">Box 23.41</ce:cross-ref><ce:float-anchor refid="b0245"/>. Cure is now a possibility for selected children, with allogeneic HSCT (p. 937).</ce:para><ce:para id="p4225">It is possible to identify a fetus with homozygous beta-thalassaemia by obtaining chorionic villous material for DNA analysis sufficiently early in pregnancy to allow termination. This examination is appropriate only if both parents are known to be carriers (beta-thalassaemia minor) and will accept a termination.</ce:para></ce:section></ce:section><ce:section id="s1060"><ce:section-title id="st0985">Alpha-thalassaemia</ce:section-title><ce:para id="p4230">Reduced or absent alpha-chain synthesis is common in South-east Asia. There are two alpha gene loci on chromosome 16 and therefore each individual carries four alpha gene alleles.<ce:list id="ulist0885"><ce:list-item id="u2675"><ce:label>•</ce:label><ce:para id="p4235">If one is deleted, there is no clinical effect.</ce:para></ce:list-item><ce:list-item id="u2680"><ce:label>•</ce:label><ce:para id="p4240">If two are deleted, there may be a mild hypochromic anaemia.</ce:para></ce:list-item><ce:list-item id="u2685"><ce:label>•</ce:label><ce:para id="p4245">If three are deleted, the patient has haemoglobin H disease.</ce:para></ce:list-item><ce:list-item id="u2690"><ce:label>•</ce:label><ce:para id="p4250">If all four are deleted, the baby is stillborn (hydrops fetalis).</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p4255">Haemoglobin H is a beta-chain tetramer, formed from the excess of beta chains, which is functionally useless, so that patients rely on their low levels of HbA for oxygen transport. Treatment of haemoglobin H disease is similar to that of beta-thalassaemia of intermediate severity, involving folic acid supplementation, transfusion if required and avoidance of iron therapy.</ce:para><ce:para id="p4260"><ce:float-anchor refid="b0250"/></ce:para></ce:section></ce:section></ce:section><ce:section id="s1065"><ce:section-title id="st0990">Haematological malignancies</ce:section-title><ce:para id="p4315">Haematological malignancies arise when the processes controlling proliferation or apoptosis are corrupted in blood cells because of acquired mutations in key regulatory genes. If mature differentiated cells are involved, the cells will have a low growth fraction and produce indolent neoplasms, such as the low-grade lymphomas or chronic leukaemias, when patients have an expected survival of many years. In contrast, if more primitive stem or progenitor cells are involved, the cells can have the highest growth fractions of all human neoplasms, producing rapidly progressive, life-threatening illnesses such as the acute leukaemias or high-grade lymphomas. Involvement of pluripotent stem cells produces the most aggressive acute leukaemias. In general, haematological neoplasms are diseases of elderly patients, the exceptions being acute lymphoblastic leukaemia, which predominantly affects children, and Hodgkin lymphoma, which affects people aged 20–40 years. Management of young patients with haematological malignancy is particularly challenging (<ce:cross-ref id="crf0875" refid="b0255">Box 23.43</ce:cross-ref><ce:float-anchor refid="b0255"/>).</ce:para><ce:section id="s1070"><ce:section-title id="st0995">Leukaemias</ce:section-title><ce:para id="p4340">Leukaemias are malignant disorders of the haematopoietic stem cell compartment, characteristically associated with increased numbers of white cells in the bone marrow and/or peripheral blood. The course of leukaemia may vary from a few days or weeks to many years, depending on the type.</ce:para><ce:section id="s1075"><ce:section id="s1080"><ce:section-title id="st1000">Epidemiology and aetiology</ce:section-title><ce:para id="p4345">The incidence of leukaemia of all types in the population is approximately 10/100 000 per annum, of which just under half are cases of acute leukaemia. Males are affected more frequently than females, the ratio being about 3 : 2 in acute leukaemia, 2 : 1 in chronic lymphocytic leukaemia and 1.3 : 1 in chronic myeloid leukaemia. Geographical variation in incidence does occur, the most striking being the rarity of chronic lymphocytic leukaemia in Chinese and related races. Acute leukaemia occurs at all ages. Acute lymphoblastic leukaemia shows a peak of incidence in children aged 1–5 years. All forms of acute myeloid leukaemia have their lowest incidence in young adult life and there is a striking rise over the age of 50. Chronic leukaemias occur mainly in middle and old age.</ce:para><ce:para id="p4350">The cause of the leukaemia is unknown in the majority of patients. Several risk factors have been identified (<ce:cross-ref id="crf0880" refid="b0260">Box 23.44</ce:cross-ref><ce:float-anchor refid="b0260"/>).</ce:para></ce:section><ce:section id="s1110"><ce:section-title id="st1030">Terminology and classification</ce:section-title><ce:para id="p4425">Leukaemias are traditionally classified into four main groups:<ce:list id="ulist0925"><ce:list-item id="u2800"><ce:label>•</ce:label><ce:para id="p4430">acute lymphoblastic leukaemia (ALL)</ce:para></ce:list-item><ce:list-item id="u2805"><ce:label>•</ce:label><ce:para id="p4435">acute myeloid leukaemia (AML)</ce:para></ce:list-item><ce:list-item id="u2810"><ce:label>•</ce:label><ce:para id="p4440">chronic lymphocytic leukaemia (CLL)</ce:para></ce:list-item><ce:list-item id="u2815"><ce:label>•</ce:label><ce:para id="p4445">chronic myeloid leukaemia (CML).</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p4450">In acute leukaemia, there is proliferation of primitive stem cells, with limited accompanying differentiation, leading to an accumulation of blasts, predominantly in the bone marrow, which causes bone marrow failure. In chronic leukaemia, the malignant clone is able to differentiate, resulting in an accumulation of more mature cells. Lymphocytic and lymphoblastic cells are those derived from the lymphoid stem cell (B cells and T cells). Myeloid refers to the other lineages: that is, precursors of red cells, granulocytes, monocytes and platelets (see <ce:cross-ref id="crf0885" refid="f0030">Fig. 23.2</ce:cross-ref>).</ce:para><ce:para id="p4455">The diagnosis of leukaemia is usually suspected from an abnormal blood count, often a raised white count, and is confirmed by examination of the bone marrow. This includes the morphology of the abnormal cells, analysis of cell surface markers (immunophenotyping), clone-specific chromosome abnormalities and molecular changes. These results are incorporated in the World Health Organisation (WHO) classification of tumours of haematopoietic and lymphoid tissues; the subclassification of acute leukaemias is shown in <ce:cross-ref id="crf0890" refid="b0265">Box 23.45</ce:cross-ref><ce:float-anchor refid="b0265"/>. The features in the bone marrow not only provide an accurate diagnosis but also give valuable prognostic information, increasingly allowing therapy to be tailored to the patient's disease.</ce:para></ce:section></ce:section><ce:section id="s1145"><ce:section-title id="st1060">Acute leukaemia</ce:section-title><ce:para id="p4550">There is a failure of cell maturation in acute leukaemia. Proliferation of cells that do not mature leads to an accumulation of primitive cells that take up more and more marrow space at the expense of the normal haematopoietic elements. Eventually, this proliferation spills into the blood. Acute myeloid leukaemia (AML) is about four times more common than acute lymphoblastic leukaemia (ALL) in adults. In children, the proportions are reversed, the lymphoblastic variety being more common. The clinical features are usually those of bone marrow failure (anaemia, bleeding or infection; pp. 923, 927 and 930).</ce:para><ce:section id="s1150"><ce:section-title id="st1065">Investigations</ce:section-title><ce:para id="p4555">Blood examination usually shows anaemia with a normal or raised MCV. The leucocyte count may vary from as low as 1 × 10<ce:sup loc="post">9</ce:sup>/L to as high as 500 × 10<ce:sup loc="post">9</ce:sup>/L or more. In the majority of patients, the count is below 100 × 10<ce:sup loc="post">9</ce:sup>/L. Severe thrombocytopenia is usual but not invariable. Frequently, blast cells are seen in the blood film but sometimes the blast cells may be infrequent or absent. A bone marrow examination will confirm the diagnosis. The bone marrow is usually hypercellular, with replacement of normal elements by leukaemic blast cells in varying degrees (but more than 20% of the cells) (<ce:cross-ref id="crf0895" refid="f0140">Fig. 23.23</ce:cross-ref><ce:float-anchor refid="f0140"/>). The presence of Auer rods in the cytoplasm of blast cells indicates a myeloblastic type of leukaemia. Classification and prognosis are determined by immunophenotyping and chromosome and molecular analysis, as shown in <ce:cross-ref id="crf0900" refid="f0145">Figure 23.24</ce:cross-ref><ce:float-anchor refid="f0145"/>.</ce:para></ce:section><ce:section id="s1155"><ce:section-title id="st1070">Management</ce:section-title><ce:para id="p4560">The first decision must be whether or not to give specific treatment to attempt to achieve remission. This is generally aggressive, has numerous side-effects, and may not be appropriate for the very elderly or patients with serious comorbidities (<ce:intra-ref id="ii0555" xlink:href="pii:B978-0-7020-7028-0.00032-9#c00032">Chs 32</ce:intra-ref> and <ce:intra-ref id="ii0560" xlink:href="pii:B978-0-7020-7028-0.00033-0#c00033">33</ce:intra-ref>). In these patients, supportive treatment can effect considerable improvement in well-being. Low-intensity chemotherapy, such as low-dose cytosine arabinoside or, recently, azacitidine, is frequently used in elderly and more frail patients but only induces remission in less than 20% of patients.</ce:para><ce:section id="s1160"><ce:section-title id="st1075">Specific therapy</ce:section-title><ce:para id="p4565">Ideally, whenever possible, patients with acute leukaemia should be treated within a clinical trial. If a decision to embark on specific therapy has been taken, the patient should be prepared as recommended in <ce:cross-ref id="crf0905" refid="b0270">Box 23.46</ce:cross-ref><ce:float-anchor refid="b0270"/>. It is unwise to attempt aggressive management of acute leukaemia unless adequate services are available for the provision of supportive therapy.</ce:para><ce:para id="p4610">The aim of treatment is to destroy the leukaemic clone of cells without destroying the residual normal stem cell compartment from which repopulation of the haematopoietic tissues will occur. There are three phases:<ce:list id="ulist0960"><ce:list-item id="u2910"><ce:label>•</ce:label><ce:para id="p4615"><ce:italic>Remission induction.</ce:italic> In this phase, a fraction of the tumour is destroyed by combination chemotherapy. The patient goes through a period of severe bone marrow hypoplasia lasting 3–4 weeks and requires intensive support and inpatient care from a specially trained multidisciplinary team. The aim is to achieve remission, a state in which the blood counts return to normal and the marrow blast count is less than 5%. Quality of life is highly dependent on achieving remission.</ce:para></ce:list-item><ce:list-item id="u2915"><ce:label>•</ce:label><ce:para id="p4620"><ce:italic>Remission consolidation.</ce:italic> If remission has been achieved, residual disease is attacked by therapy during the consolidation phase. This consists of a number of courses of chemotherapy, again resulting in periods of marrow hypoplasia. In poor-prognosis leukaemia, this may include allogeneic HSCT.</ce:para></ce:list-item><ce:list-item id="u2920"><ce:label>•</ce:label><ce:para id="p4625"><ce:italic>Remission maintenance.</ce:italic> If the patient is still in remission after the consolidation phase for ALL, a period of maintenance therapy is given, with the individual as an outpatient and treatment consisting of a repeating cycle of drug administration. This may extend for up to 3 years if relapse does not occur.</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p4630">In patients with ALL, it is necessary to give prophylactic treatment to the central nervous system, as this is a sanctuary site where standard therapy does not penetrate. This usually consists of a combination of cranial irradiation, intrathecal chemotherapy and high-dose methotrexate, which crosses the blood–brain barrier.</ce:para><ce:para id="p4635">Thereafter, specific therapy is discontinued and the patient observed.</ce:para><ce:para id="p4640">The detail of the schedules for these treatments can be found in specialist texts. The drugs most commonly employed are listed in <ce:cross-ref id="crf0910" refid="b0275">Box 23.47</ce:cross-ref><ce:float-anchor refid="b0275"/>. Generally, if a patient fails to go into remission with induction treatment, alternative drug combinations may be tried, but the outlook is poor unless remission can be achieved. Disease that relapses during treatment or soon after the end of treatment carries a poor prognosis and is difficult to treat. The longer after the end of treatment that relapse occurs, the more likely it is that further treatment will be effective.</ce:para><ce:para id="p4800">In some patients, alternative palliative chemotherapy, not designed to achieve remission, may be used to curb excessive leucocyte proliferation. Drugs used for this purpose include hydroxycarbamide and mercaptopurine. The aim is to reduce the blast count without inducing bone marrow failure.</ce:para></ce:section><ce:section id="s1165"><ce:section-title id="st1080">Supportive therapy</ce:section-title><ce:para id="p4805">Aggressive and potentially curative therapy, which involves periods of severe bone marrow failure, would not be possible without appropriate supportive care. The following problems commonly arise.</ce:para><ce:section id="s1170"><ce:section-title id="st1085">Anaemia</ce:section-title><ce:para id="p4810">Anaemia is treated with red cell concentrate transfusions.</ce:para></ce:section><ce:section id="s1175"><ce:section-title id="st1090">Bleeding</ce:section-title><ce:para id="p4815">Thrombocytopenic bleeding requires platelet transfusions, unless the bleeding is trivial. Recent trials have confirmed that in acute leukaemia prophylactic platelet transfusion should be given to maintain the platelet count above 10 × 10<ce:sup loc="post">9</ce:sup>/L. Coagulation abnormalities occur and need accurate diagnosis and treatment (<ce:cross-ref id="crf9055" refid="p5920">p. 971</ce:cross-ref>).</ce:para></ce:section><ce:section id="s1180"><ce:section-title id="st1095">Infection</ce:section-title><ce:para id="p4820">Fever (&#x003E; 38°C) lasting over 1 hour in a neutropenic patient indicates possible sepsis (see also <ce:intra-ref id="ii0570" xlink:href="pii:B978-0-7020-7028-0.00011-1#s0115">p. 218</ce:intra-ref>). Parenteral broad-spectrum antibiotic therapy is essential. Empirical therapy is given according to local bacteriological resistance patterns, such as with a combination of an aminoglycoside (e.g. gentamicin) and a broad-spectrum penicillin (e.g. piperacillin/tazobactam) or a single-agent beta-lactam (e.g. meropenem). The organisms most commonly associated with severe neutropenic sepsis are Gram-positive bacteria, such as <ce:italic>Staphylococcus aureus</ce:italic> and <ce:italic>Staphylococcus epidermidis</ce:italic>, which are present on the skin and gain entry via cannulae and central lines. Gram-negative infections often originate from the gastrointestinal tract, which is affected by chemotherapy-induced mucositis; organisms such as <ce:italic>Escherichia coli</ce:italic>, <ce:italic>Pseudomonas</ce:italic> and <ce:italic>Klebsiella</ce:italic> spp. are likely to cause rapid clinical deterioration and must be covered with initially empirical antibiotic therapy. Gram-positive infection may require vancomycin or teicoplanin therapy. If fever has not resolved after 3–5 days and there is evidence on CT scanning or sensitive blood tests for a disseminated fungal infection, empirical antifungal therapy (e.g. a liposomal amphotericin B preparation, voriconazole or caspofungin) is added.</ce:para><ce:para id="p4825">Patients with ALL are susceptible to infection with <ce:italic>Pneumocystis jirovecii</ce:italic> (<ce:intra-ref id="ii0575" xlink:href="pii:B978-0-7020-7028-0.00012-3#s0220">p. 318</ce:intra-ref>), which causes a severe pneumonia. Prophylaxis with co-trimoxazole is given during chemotherapy. Diagnosis may require either induced sputum, bronchoalveolar lavage or open lung biopsy. Treatment is with high-dose co-trimoxazole, initially intravenously, changing to oral treatment as soon as possible.</ce:para><ce:para id="p4830">Oral and pharyngeal <ce:italic>Candida</ce:italic> infection is common. Fluconazole is effective for the treatment of established local infection and for prophylaxis against systemic candidaemia. Prophylaxis against other systemic fungal infections, including <ce:italic>Aspergillus</ce:italic>, using itraconazole or posaconazole, for example, is usual practice during high-risk intensive chemotherapy. This is often used along with sensitive markers of early fungal infection to guide treatment initiation (a ‘pre-emptive approach’).</ce:para><ce:para id="p4835">For systemic fungal infection with <ce:italic>Candida</ce:italic> or aspergillosis, intravenous liposomal amphotericin, caspofungin or voriconazole is required for at least 3 weeks. In systemic <ce:italic>Candida</ce:italic> infection intravenous catheters should be removed.</ce:para><ce:para id="p4840">Reactivation of herpes simplex infection (<ce:intra-ref id="ii0580" xlink:href="pii:B978-0-7020-7028-0.00011-1#s0895">p. 247</ce:intra-ref>) occurs frequently around the lips and nose during ablative therapy for acute leukaemia, and is treated with aciclovir. This may also be prescribed prophylactically to patients with a history of cold sores or elevated antibody titres to herpes simplex. Herpes zoster manifesting as chickenpox or, after reactivation, as shingles (<ce:intra-ref id="ii0585" xlink:href="pii:B978-0-7020-7028-0.00011-1#s0615">p. 239</ce:intra-ref>) should be treated in the early stage with high-dose aciclovir, as it can be fatal in immunocompromised patients.</ce:para><ce:para id="p4845">The value of isolation facilities, such as laminar flow rooms, is debatable but may contribute to staff awareness of careful reverse barrier nursing practice. The isolation can be psychologically stressful for the patient.</ce:para></ce:section><ce:section id="s1185"><ce:section-title id="st1100">Metabolic problems</ce:section-title><ce:para id="p4850">Frequent monitoring of fluid balance and renal, hepatic and haemostatic function is necessary. Patients are often severely anorexic and diarrhoea is common as a consequence of the side-effects of therapy; they may find drinking difficult and hence require intravenous fluids and electrolytes. Renal toxicity occurs with some antibiotics (e.g. aminoglycosides) and antifungal agents (amphotericin). Cellular breakdown during induction therapy (tumour lysis syndrome; <ce:intra-ref id="ii0590" xlink:href="pii:B978-0-7020-7028-0.00033-0#s0285">p. 1328</ce:intra-ref>) releases intracellular ions and nucleic acid breakdown products, causing hyperkalaemia, hyperuricaemia, hyperphosphataemia and hypocalcaemia. This may lead to renal failure. Allopurinol and intravenous hydration are given to try to prevent this. In patients at high risk of tumour lysis syndrome, prophylactic rasburicase (a recombinant urate oxidase enzyme) is used. Occasionally, dialysis may be required.</ce:para></ce:section><ce:section id="s1190"><ce:section-title id="st1105">Psychological problems</ce:section-title><ce:para id="p4855">Psychological support is a key aspect of care. Patients should be kept informed, and their questions answered and fears allayed as far as possible. A multidisciplinary approach to patient care involves input from many services, including psychology. Key members of the team include haematology specialist nurses, who are often the central point of contact for patients and families throughout the illness.</ce:para></ce:section></ce:section><ce:section id="s1195"><ce:section-title id="st1110">Haematopoietic stem cell transplantation</ce:section-title><ce:para id="p4860">This is described on page 936. In patients with high-risk acute leukaemia, allogeneic HSCT can improve 5-year survival from 20% to around 50%. Reduced-intensity conditioning has allowed HSCT to be delivered to a higher proportion of patients with acute leukaemias, up to the age of about 65 years.</ce:para></ce:section></ce:section><ce:section id="s1200"><ce:section-title id="st1115">Prognosis</ce:section-title><ce:para id="p4865">Without treatment, the median survival of patients with acute leukaemia is about 5 weeks. This may be extended to a number of months with supportive treatment. Patients who achieve remission with specific therapy have a better outlook. Around 80% of adult patients under 60 years of age with ALL or AML achieve remission, although remission rates are lower for older patients. However, the relapse rate continues to be high. <ce:cross-ref id="crf0930" refid="b0280">Box 23.48</ce:cross-ref><ce:float-anchor refid="b0280"/> shows the survival in ALL and AML and the influence of prognostic features. The level of detectable leukaemia cells, called minimal residual disease (MRD), measured after induction therapy in ALL by sensitive laboratory techniques, has been shown to be a powerful prognostic tool that is now used routinely to direct subsequent consolidation therapy.</ce:para><ce:para id="p4875">Advances in treatment have led to steady improvement in survival from leukaemia. They include the introduction of drugs such as all-<ce:italic>trans</ce:italic> retinoic acid (ATRA) and arsenic trioxide (ATO) in acute promyelocytic leukaemia, which has greatly reduced induction deaths from bleeding in this good-risk leukaemia. A chemotherapy-free schedule of ATRA and ATO has recently produced cure rates of 90% in patients with low-risk acute promyelocytic leukaemia. Current trials aim to improve survival, especially in standard and poor-risk disease, with strategies that include better use of allogeneic HSCT and targeted therapies such as anti-CD33 monoclonal antibodies (Mylotarg) and FLT3 inhibitors. FLT3 is a cytokine receptor often expressed on AML blast cells and whose expression is associated with a poorer prognosis.</ce:para></ce:section></ce:section><ce:section id="s1205"><ce:section-title id="st1120">Chronic myeloid leukaemia</ce:section-title><ce:para id="p4880">Chronic myeloid leukaemia (CML) is a myeloproliferative stem cell disorder resulting in proliferation of all haematopoietic lineages but manifesting predominantly in the granulocytic series. Maturation of cells proceeds fairly normally. The disease occurs chiefly between the ages of 30 and 80 years, with a peak incidence at 55 years. It is rare, with an annual incidence in the UK of 1.8/100 000, and accounts for 20% of all leukaemias. It is found in all races.</ce:para><ce:para id="p4885">The defining characteristic of CML is the chromosome abnormality known as the Philadelphia (Ph) chromosome. This is a shortened chromosome 22 resulting from a reciprocal translocation of material with chromosome 9. The break on chromosome 22 occurs in the breakpoint cluster region (BCR). The fragment from chromosome 9 that joins the BCR carries the <ce:italic>abl</ce:italic> oncogene, which forms a fusion gene with the remains of the BCR. This <ce:italic>BCR ABL</ce:italic> fusion gene codes for a 210 kDa protein with tyrosine kinase activity, which plays a causative role in the disease as an oncogene (<ce:intra-ref id="ii0600" xlink:href="pii:B978-0-7020-7028-0.00033-0#s0065">p. 1318</ce:intra-ref>), influencing cellular proliferation, differentiation and survival. In some patients in whom conventional chromosomal analysis does not detect a Ph chromosome, the BCR ABL gene product is detectable by molecular techniques.</ce:para><ce:section id="s1210"><ce:section-title id="st1125">Natural history</ce:section-title><ce:para id="p4890">The disease has three phases:<ce:list id="ulist1010"><ce:list-item id="u3075"><ce:label>•</ce:label><ce:para id="p4895"><ce:italic>A chronic phase</ce:italic>, in which the disease is responsive to treatment and is easily controlled, which used to last 3–5 years. With the introduction of imatinib therapy, this phase has been prolonged to encompass a normal life expectancy in many patients.</ce:para></ce:list-item><ce:list-item id="u3080"><ce:label>•</ce:label><ce:para id="p4900"><ce:italic>An accelerated phase</ce:italic> (not always seen), in which disease control becomes more difficult.</ce:para></ce:list-item><ce:list-item id="u3085"><ce:label>•</ce:label><ce:para id="p4905"><ce:italic>Blast crisis</ce:italic>, in which the disease transforms into an acute leukaemia, either myeloblastic (70%) or lymphoblastic (30%), which is relatively refractory to treatment. This is the cause of death in the majority of patients; survival is therefore dictated by the timing of blast crisis, which cannot be predicted. Prior to imatinib therapy (see below), approximately 10% of patients per year would transform. In those treated with imatinib for up to 10 years, only between 0.5 and 2.5% have transformed each year.</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1215"><ce:section-title id="st1130">Clinical features</ce:section-title><ce:para id="p4910">Symptoms at presentation may include lethargy, weight loss, abdominal discomfort, gout and sweating, but about 25% of patients are asymptomatic at diagnosis. Splenomegaly is present in 90%; in about 10%, the enlargement is massive, extending to over 15 cm below the costal margin. A friction rub may be heard in cases of splenic infarction. Hepatomegaly occurs in about 50%. Lymphadenopathy is unusual.</ce:para></ce:section><ce:section id="s1220"><ce:section-title id="st1135">Investigations</ce:section-title><ce:para id="p4915">FBC results are variable between patients. There is usually a normocytic, normochromic anaemia. The leucocyte count can vary from 10 to 600 × 10<ce:sup loc="post">9</ce:sup>/L. In about one-third of patients, there is a very high platelet count, sometimes as high as 2000 × 10<ce:sup loc="post">9</ce:sup>/L. In the blood film, the full range of granulocyte precursors, from myeloblasts to mature neutrophils, is seen but the predominant cells are neutrophils and myelocytes (see <ce:cross-ref id="crf0935" refid="f0035">Fig. 23.3</ce:cross-ref>). Myeloblasts usually constitute less than 10% of all white cells. There is often an absolute increase in eosinophils and basophils, and nucleated red cells are common. If the disease progresses through an accelerated phase, the percentage of more primitive cells increases. Blast transformation is characterised by a dramatic increase in the number of circulating blasts. In patients with thrombocytosis, very high platelet counts may persist during treatment, in both chronic and accelerated phases, but usually drop dramatically at blast transformation. Basophilia tends to increase as the disease progresses.</ce:para><ce:para id="p4920">Bone marrow should be obtained to confirm the diagnosis and phase of disease by morphology, chromosome analysis to demonstrate the presence of the Ph chromosome, and RNA analysis to demonstrate the presence of the BCR ABL gene product. Blood LDH levels are elevated and the uric acid level may be high due to increased cell breakdown.</ce:para></ce:section><ce:section id="s1225"><ce:section-title id="st1140">Management</ce:section-title><ce:section id="s1230"><ce:section-title id="st1145">Chronic phase</ce:section-title><ce:para id="p4925">There are now five available tyrosine kinase inhibitors (TKIs) for the treatment of CML (<ce:cross-ref id="crf0940" refid="b0285">Box 23.49</ce:cross-ref><ce:float-anchor refid="b0285"/>). These specifically inhibit BCR ABL tyrosine kinase activity. Imatinib, nilotinib and dasatinib are recommended as first-line therapy in chronic phase CML; they usually normalise the blood count within a month and within 3–6 months produce complete cytogenetic response (disappearance of the Ph chromosome) in some 90% of patients. A sample of bone marrow is taken at 6 months to confirm complete cytogenetic response, and patients are subsequently monitored by 3-monthly real-time quantitative polymerase chain reaction (PCR) for BCR ABL mRNA transcripts in blood. The aim is to reduce the BCR ABL transcript levels by 3–5 logs from baseline and this is called major molecular response (MR3–MR5). A proportion of patients achieve a complete molecular response where the transcripts are not detectable by PCR. It may be possible for patients with a complete or major molecular response to stop TKI therapy and this is being investigated in clinical trials. For those failing to respond or who lose their response and progress on first-line therapy, options include switching to a different TKI (<ce:cross-ref id="crf0950" refid="b0285">Box 23.49</ce:cross-ref>). Some patients develop detectable mutations in the <ce:italic>BCR ABL</ce:italic> gene, which renders them resistant to one or more of the TKIs. The T315I mutation has been particularly problematic, as this provides wide-ranging resistance. The third-generation TKI ponatinib is effective, however. Allogeneic HSCT (<ce:cross-ref id="crf9060" refid="s0540">p. 937</ce:cross-ref>) is now reserved for patients who fail TKI therapy. Hydroxycarbamide and interferon were previously used for control of disease. Hydroxycarbamide is still useful in palliative situations and interferon is used in women planning pregnancy.</ce:para></ce:section><ce:section id="s1235"><ce:section-title id="st1150">Accelerated phase and blast crisis</ce:section-title><ce:para id="p4935">Management is more difficult. For patients in accelerated phase, TKI therapy is indicated, most commonly with nilotinib or dasatinib. When blast transformation occurs, the type of blast cell should be determined. Response to appropriate acute leukaemia treatment (see <ce:cross-ref id="crf0955" refid="b0285">Box 23.49</ce:cross-ref>) is better if disease is lymphoblastic than if myeloblastic. Second- or third-generation TKIs such as dasatinib are used in combination with chemotherapy to try and achieve remission. In younger and fitter patients an allogeneic HSCT is appropriate therapy if a return to chronic phase is achieved. Hydroxycarbamide can be an effective single agent and low-dose cytarabine can also be used palliatively in older patients.</ce:para></ce:section></ce:section></ce:section><ce:section id="s1240"><ce:section-title id="st1155">Chronic lymphocytic leukaemia</ce:section-title><ce:para id="p4940">Chronic lymphocytic leukaemia (CLL) is the most common variety of leukaemia, accounting for 30% of cases. The male-to-female ratio is 2 : 1 and the median age at presentation is 65–70 years. In this disease, B lymphocytes, which would normally respond to antigens by transformation and antibody formation, fail to do so. An ever-increasing mass of immuno-incompetent cells accumulates, to the detriment of immune function and normal bone marrow haematopoiesis.</ce:para><ce:section id="s1245"><ce:section-title id="st1160">Clinical features</ce:section-title><ce:para id="p4945">The onset is usually insidious. Indeed, in around 70% of patients, the diagnosis is made incidentally on a routine FBC. Presenting problems may be anaemia, infections, painless lymphadenopathy, and systemic symptoms such as night sweats or weight loss; these more often occur later in the course of the disease.</ce:para></ce:section><ce:section id="s1250"><ce:section-title id="st1165">Investigations</ce:section-title><ce:para id="p4950">The diagnosis is based on the peripheral blood findings of a mature lymphocytosis (&#x003E; 5 × 10<ce:sup loc="post">9</ce:sup>/L) with characteristic morphology and cell surface markers. Immunophenotyping reveals the lymphocytes to be monoclonal B cells expressing the B-cell antigens CD19 and CD23, with either kappa or lambda immunoglobulin light chains and, characteristically, an aberrant T-cell antigen CD5. On flow cytometry, some people are shown to have circulating CLL cells at a level less than 5 × 10<ce:sup loc="post">9</ce:sup>/L. This is known as monoclonal B lymphocytosis of uncertain significance.</ce:para><ce:para id="p4955">Other useful investigations in CLL include a reticulocyte count and a direct Coombs test, as autoimmune haemolytic anaemia may occur (<ce:cross-ref id="crf9065" refid="s0890">p. 949</ce:cross-ref>). Serum immunoglobulin levels should be estimated to establish the degree of hypogammaglobulinaemia, which is common and progressive. Bone marrow examination by aspirate and trephine is not essential for the diagnosis of CLL, but may be helpful in difficult cases, for prognosis (patients with diffuse marrow involvement have a poorer prognosis) and to monitor response to therapy. The main prognostic factor is stage of disease (<ce:cross-ref id="crf0960" refid="b0290">Box 23.50</ce:cross-ref><ce:float-anchor refid="b0290"/>); however, loss of chromosome 17p or mutation in the <ce:italic>TP53</ce:italic> gene, which resides at this genetic locus, is a powerful prognostic marker and predictor of response to therapy. A mutation in <ce:italic>TP53</ce:italic> is present in &#x003C; 10% of patients at presentation but rises to 30% of cases at relapse. This test should be performed in all patients prior to the initiation of therapy.</ce:para></ce:section><ce:section id="s1270"><ce:section-title id="st1185">Management</ce:section-title><ce:para id="p4990">No specific treatment is required for most clinical stage A patients, unless progression occurs. Life expectancy is usually normal in older patients. The patient should be offered clear information about CLL and be reassured about the indolent nature of the disease, as the diagnosis of leukaemia inevitably causes anxiety.</ce:para><ce:para id="p4995">Treatment is required only if there is evidence of bone marrow failure, massive or progressive lymphadenopathy or splenomegaly, systemic symptoms such as weight loss or night sweats, a rapidly increasing lymphocyte count, autoimmune haemolytic anaemia or thrombocytopenia. Initial therapy for those requiring treatment (progressive stage A and stages B and C) is based on the age and fitness of the patient and the <ce:italic>TP53</ce:italic> mutation status. For patients who are under 70 years, fit and <ce:italic>TP53</ce:italic> mutation-negative, fludarabine in combination with the alkylating agent cyclophosphamide and the anti-CD20 monoclonal antibody rituximab (FCR) is standard care. For older, less fit patients, rituximab is combined with gentler chemotherapy: bendamustine or oral chlorambucil. Recently, a more potent type 2 anti-CD20 antibody, obinutuzumab, has become available and produces better responses in combination with chlorambucil than rituximab.</ce:para><ce:para id="p5000">CLL cells are dependent on abnormal and persistent signalling through the B-cell receptor (BCR) pathway. Drugs that can inhibit this pathway are now available and show great promise. Ibrutinib inhibits Bruton's tyrosine kinase and idelalisib inhibits PI3 kinase, both components of the BCR pathway. Ibrutinib and idelalisib are licensed for relapsed CLL but crucially are licensed and effective in <ce:italic>TP53</ce:italic>-mutated disease at all stages and are quickly becoming standard care in <ce:italic>TP53</ce:italic>-mutated CLL. Bone marrow failure or autoimmune cytopenias may respond to glucocorticoid treatment.</ce:para><ce:para id="p5005">Supportive care is increasingly required in progressive disease, such as transfusions for symptomatic anaemia or thrombocytopenia, prompt treatment of infections and, for some patients with hypogammaglobulinaemia, immunoglobulin replacement. Radiotherapy may be used for lymphadenopathy that is causing discomfort or local obstruction, and for symptomatic splenomegaly. Splenectomy may be required to improve low blood counts due to autoimmune destruction or to hypersplenism, and can relieve massive splenomegaly.</ce:para></ce:section><ce:section id="s1275"><ce:section-title id="st1190">Prognosis</ce:section-title><ce:para id="p5010">The majority of clinical stage A patients have a normal life expectancy but patients with advanced CLL are more likely to die from their disease or infectious complications. Survival is influenced by prognostic features of the leukaemia, particularly <ce:italic>TP53</ce:italic> mutation status, and whether patients can tolerate and respond to fludarabine-based treatment. In those able to be treated with chemotherapy and rituximab, 90% are alive 4 years later. Rarely, CLL transforms to an aggressive high-grade lymphoma, called Richter's transformation.</ce:para></ce:section></ce:section><ce:section id="s1280"><ce:section-title id="st1195">Prolymphocytic leukaemia</ce:section-title><ce:para id="p5015">Prolymphocytic leukaemia (PLL) is a variant of chronic lymphocytic leukaemia found mainly in males over the age of 60 years; 25% of cases are of the T-cell variety. There is typically massive splenomegaly with little lymphadenopathy and a very high leucocyte count, often in excess of 400 × 10<ce:sup loc="post">9</ce:sup>/L. The characteristic cell is a large lymphocyte with a prominent nucleolus. Treatment is generally unsuccessful and the prognosis very poor. Leukapharesis, splenectomy and chemotherapy may be tried. The anti-CD52 antibody alemtuzumab, when given intravenously, has produced responses in some 90% of patients with T-PLL.</ce:para></ce:section><ce:section id="s1285"><ce:section-title id="st1200">Hairy cell leukaemia</ce:section-title><ce:para id="p5020">This is a rare chronic B-cell lymphoproliferative disorder. The male-to-female ratio is 6 : 1 and the median age at diagnosis is 50 years. Presenting symptoms are general ill health and recurrent infections. Splenomegaly occurs in 90% but lymph node enlargement is unusual.</ce:para><ce:para id="p5025">Severe neutropenia, monocytopenia and the characteristic hairy cells in the blood and bone marrow are typical. These cells usually have a B-lymphocyte immunotype but they also characteristically express CD25 and CD103. Recently, all patients with hairy cell leukaemia have been found to have a mutation in the <ce:italic>BRAF</ce:italic> gene.</ce:para><ce:para id="p5030">Over recent years, a number of treatments, including cladribine and deoxycoformycin, have been shown to produce long-lasting remissions.</ce:para></ce:section><ce:section id="s1290"><ce:section-title id="st1205">Myelodysplastic syndromes</ce:section-title><ce:para id="p5035">Myelodysplastic syndromes (MDSs) constitute a group of clonal haematopoietic disorders with the common features of ineffective blood cell production and a tendency to progress to AML. As such, they are pre-leukaemic and represent genetic steps in the development of leukaemia. These genetic abnormalities have been identified and are present as a manifestation of clonal haematopoiesis in about 3% of patients over the age of 80, at a time when their blood counts are normal (clonal haematopoiesis of indeterminate potential, CHIP). MDS presents with consequences of bone marrow failure (anaemia, recurrent infections or bleeding), usually in older people (median age at diagnosis is 73 years). The overall incidence is 4/100 000 in the population, rising to more than 30/100 000 in the over-seventies. The blood film is characterised by cytopenias and abnormal-looking (dysplastic) blood cells, including macrocytic red cells and hypogranular neutrophils with nuclear hyper- or hyposegmentation. The bone marrow is hypercellular, with dysplastic changes in at least 10% of cells of one or more cell lines. Blast cells may be increased but do not reach the 20% level that indicates acute leukaemia. Chromosome analysis frequently reveals abnormalities, particularly of chromosome 5 or 7. The WHO classification of MDS is shown in <ce:cross-ref id="crf0965" refid="b0295">Box 23.51</ce:cross-ref><ce:float-anchor refid="b0295"/>.</ce:para><ce:section id="s1295"><ce:section-title id="st1210">Prognosis</ce:section-title><ce:para id="p5045">The natural history of MDS is progressive worsening of dysplasia leading to fatal bone marrow failure or progression to AML in 30% of cases. The time to progression varies (from months to years) with the subtype of MDS, being slowest in MDS with ring sideroblasts and single-lineage dysplasia and most rapid in MDS with excess blasts. The revised International Prognostic Scoring System (IPSS-R) predicts clinical outcome based on karyotype and cytopenias in blood, as well as percentage of bone marrow blasts (<ce:cross-ref id="crf0970" refid="b0300">Box 23.52</ce:cross-ref><ce:float-anchor refid="b0300"/>). There are five prognostic groups. The median survival for low-risk patients (IPSS-R very low and low) is 5–9 years, that for the intermediate group is 3 years and that for high-risk patients (IPSS-R high and very high) is 1–1.5 years.</ce:para></ce:section><ce:section id="s1300"><ce:section-title id="st1215">Management</ce:section-title><ce:para id="p5055">For the vast majority of patients who are elderly, the disease is incurable, and supportive care with red cell and platelet transfusions is the mainstay of treatment. A trial of erythropoiesis stimulating agents (ESA) and granulocyte–colony-stimulating factor (G–CSF) is recommended in some patients with low-risk MDS (IPSS-R very low, low and intermediate) to improve haemoglobin or neutrophil counts. A rare subtype called MDS with isolated del(5q) responds well to the immunomodulatory drug lenalidomide, with two-thirds of anaemic patients becoming transfusion-independent for up to 2 years. Allogeneic stem cell transplantation may afford a cure in patients with a good performance status and is considered in high-risk patients (IPSS-R high and very high) and some low-risk patients. More recently, the hypomethylating agent azacytidine has improved survival by a median of 9 months for high-risk patients, and in the UK is a recommended standard of care for those not eligible for transplantation.</ce:para></ce:section></ce:section></ce:section><ce:section id="s1305"><ce:section-title id="st1220">Lymphomas</ce:section-title><ce:para id="p5060">These neoplasms arise from lymphoid tissues, and are diagnosed from the pathological findings on biopsy as Hodgkin or non-Hodgkin lymphoma. The majority are of B-cell origin. Non-Hodgkin lymphomas are classified as low- or high-grade tumours on the basis of their proliferation rate. The normal architecture of the lymph node is outlined in <ce:cross-ref id="crf0980" refid="f0150">Figure 23.25</ce:cross-ref><ce:float-anchor refid="f0150"/>.<ce:list id="ulist1030"><ce:list-item id="u3105"><ce:label>•</ce:label><ce:para id="p5065"><ce:italic>High-grade tumours</ce:italic> divide rapidly, are typically present for a matter of weeks before diagnosis, and may be life-threatening with frequent risk of extranodal involvement.</ce:para></ce:list-item><ce:list-item id="u3110"><ce:label>•</ce:label><ce:para id="p5070"><ce:italic>Low-grade tumours</ce:italic> divide slowly, may be present for many months before diagnosis, and typically behave in an indolent fashion.</ce:para></ce:list-item></ce:list></ce:para><ce:section id="s1310"><ce:section-title id="st1225">Hodgkin lymphoma</ce:section-title><ce:para id="p5075">The histological hallmark of Hodgkin lymphoma (HL) is the presence of Reed–Sternberg cells: large, malignant lymphoid cells of B-cell origin (<ce:cross-ref id="crf0985" refid="f0155">Fig. 23.26</ce:cross-ref><ce:float-anchor refid="f0155"/>). They are often present only in small numbers but are surrounded by large numbers of reactive non-malignant T cells, plasma cells and eosinophils.</ce:para><ce:para id="p5080">The epidemiology of HL is shown in <ce:cross-ref id="crf0990" refid="b0305">Box 23.53</ce:cross-ref><ce:float-anchor refid="b0305"/> and its histological WHO classification in <ce:cross-ref id="crf0995" refid="b0310">Box 23.54</ce:cross-ref><ce:float-anchor refid="b0310"/>.</ce:para><ce:para id="p5140">Nodular lymphocyte-predominant HL is slow-growing, localised and rarely fatal. It has biological features, such as CD20-positive Hodgkin cells, and clinical features that make it more akin to a low-grade B-cell non-Hodgkin lymphoma. Classical HL is divided into four histological subtypes from the appearance of the Reed–Sternberg cells and surrounding reactive cells. The nodular sclerosing type is more common in young patients and in women. Mixed cellularity is more common in the elderly. Lymphocyte-rich HL usually presents in men. Lymphocyte-depleted HL is rare and probably represents large-cell or anaplastic non-Hodgkin lymphoma.</ce:para><ce:section id="s1335"><ce:section-title id="st1250">Clinical features</ce:section-title><ce:para id="p5145">There is painless, rubbery lymphadenopathy, usually in the neck or supraclavicular fossae; the lymph nodes may fluctuate in size. Young patients with nodular sclerosing disease may have large mediastinal masses that are surprisingly asymptomatic but may cause dry cough and some breathlessness. Isolated subdiaphragmatic nodes occur in fewer than 10% at diagnosis. Hepatosplenomegaly may be present but does not always indicate disease in those organs. Spread is contiguous from one node to the next, and extranodal disease, such as bone, brain or skin involvement, is rare.</ce:para></ce:section><ce:section id="s1340"><ce:section-title id="st1255">Investigations</ce:section-title><ce:para id="p5150">Treatment of HL depends on the stage at presentation; investigations therefore aim not only to diagnose lymphoma but also to determine the extent of disease (<ce:cross-ref id="crf1000" refid="b0315">Box 23.55</ce:cross-ref><ce:float-anchor refid="b0315"/>).<ce:list id="ulist1055"><ce:list-item id="u3145"><ce:label>•</ce:label><ce:para id="p5160"><ce:italic>FBC</ce:italic> may be normal. If a normochromic, normocytic anaemia or lymphopenia is present, this is a poor prognostic factor. An eosinophilia or a neutrophilia may be present.</ce:para></ce:list-item><ce:list-item id="u3150"><ce:label>•</ce:label><ce:para id="p5165"><ce:italic>ESR</ce:italic> may be raised.</ce:para></ce:list-item><ce:list-item id="u3155"><ce:label>•</ce:label><ce:para id="p5170"><ce:italic>Renal function tests</ce:italic> are required to ensure function is normal prior to treatment.</ce:para></ce:list-item><ce:list-item id="u3160"><ce:label>•</ce:label><ce:para id="p5175"><ce:italic>Liver function</ce:italic> may be abnormal in the absence of disease or may reflect hepatic infiltration. An obstructive pattern may be caused by nodes at the porta hepatis.</ce:para></ce:list-item><ce:list-item id="u3165"><ce:label>•</ce:label><ce:para id="p5180"><ce:italic>LDH measurements</ce:italic> showing raised levels are an adverse prognostic factor.</ce:para></ce:list-item><ce:list-item id="u3170"><ce:label>•</ce:label><ce:para id="p5185"><ce:italic>Chest X-ray</ce:italic> may show a mediastinal mass.</ce:para></ce:list-item><ce:list-item id="u3175"><ce:label>•</ce:label><ce:para id="p5190"><ce:italic>CT scan</ce:italic> of chest, abdomen and pelvis permits staging. Bulky disease (&#x003E; 10 cm in a single node mass) is an adverse prognostic feature.</ce:para></ce:list-item><ce:list-item id="u3180"><ce:label>•</ce:label><ce:para id="p5195"><ce:italic>Positron emission tomography (PET) scanning</ce:italic> identifies nodes involved with HL, which are <ce:sup loc="post">18</ce:sup>fluorodeoxyglucose (FDG)-avid, and this allows more accurate staging and monitoring of response (<ce:cross-ref id="crf1010" refid="f0160">Fig. 23.27</ce:cross-ref><ce:float-anchor refid="f0160"/>).</ce:para></ce:list-item><ce:list-item id="u3185"><ce:label>•</ce:label><ce:para id="p5200"><ce:italic>Lymph node biopsy</ce:italic> may be undertaken surgically or by percutaneous needle biopsy under radiological guidance (<ce:cross-ref id="crf1015" refid="f0165">Fig. 23.28</ce:cross-ref><ce:float-anchor refid="f0165"/>).</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1345"><ce:section-title id="st1260">Management</ce:section-title><ce:para id="p5205">Clinical trials have shown that patients with early-stage disease (stages IA and IIA) have better outcomes if limited cycles of chemotherapy are combined with radiotherapy, rather than using radiotherapy alone.</ce:para><ce:para id="p5210">The ABVD regimen (doxorubicin, bleomycin, vinblastine and dacarbazine) is widely used in the UK. Standard therapy for early-stage patients without additional risk factors, such as bulk disease or high ESR, is two cycles of ABVD combined with 20 Gy radiotherapy to the involved sites of disease. Standard therapy for early-stage patients with additional risk factors is four cycles of ABVD combined with 30 Gy radiotherapy. Careful planning of radiotherapy is required to limit the doses delivered to normal tissues and new planning techniques continue to improve targeting of radiotherapy. Nevertheless, the long-term risks of second cancers and heart and lung disease within the radiation fields remain a concern, especially for young people with a high cure rate and decades of life ahead of them. Recent randomised trial data from the UK RAPID study have suggested that early-stage patients without bulk disease who have a negative PET scan after three cycles of ABVD can safely omit radiotherapy. Young women receiving breast irradiation during the treatment of chest disease have an increased risk of breast cancer and should participate in a screening programme. Patients continuing to smoke after lung irradiation are at particular risk of lung cancer.</ce:para><ce:para id="p5215">ABVD chemotherapy can cause cardiac and pulmonary toxicity, due to doxorubicin and bleomycin, respectively. The incidence of infertility and secondary myelodysplasia/AML is low with this regimen.</ce:para><ce:para id="p5220">Patients with advanced-stage disease are most commonly managed with chemotherapy alone. Standard treatment in the UK is 6–8 cycles of ABVD, followed by an assessment of response. The recent UK RATHL trial has confirmed previous data showing that achieving a PET-negative response after two cycles of ABVD (interim PET-2 response) predicts a very good outcome from continuing with up to six cycles of ABVD. Indeed, the same outcome can be achieved by omitting the bleomycin from the last four cycles and using just AVD, thus reducing the risk of lung toxicity. Patients who are PET-positive after two cycles, however, have a very high relapse risk if they continue with ABVD, only 13% being relapse-free at 2 years. The RATHL and other studies have demonstrated that changing to a more intensive regimen, BEACOPP (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine (oncovin), procarbazine, prednisolone), in these patients improves the relapse-free survival to approximately 65%.</ce:para><ce:para id="p5225">Patients with relapsed disease that responds to salvage chemotherapy and ideally becomes PET-negative should be considered for autologous stem cell transplantation (<ce:cross-ref id="crf9070" refid="s0540">p. 937</ce:cross-ref>). Those with resistant disease might benefit from an allogeneic stem cell transplant. Brentuximab vedotin is an antibody–drug conjugate directed against CD30 on the Reed–Sternberg cell surface. This antibody delivers the antimitotic toxin monomethyl auristatin E to the Hodgkin cells and, as a single agent, can produce good responses in patients who have failed, or are not suitable for, an autologous transplant and can be a ‘bridge’ to an allogeneic transplant.</ce:para></ce:section><ce:section id="s1350"><ce:section-title id="st1265">Prognosis</ce:section-title><ce:para id="p5230">Over 90% of patients with early-stage HL achieve complete remission when treated with chemotherapy followed by involved field radiotherapy, and the great majority are cured. The major challenge is how to reduce treatment intensity, and hence long-term toxicity, without reducing the excellent cure rates in this group. Omitting radiotherapy in the majority of PET-negative patients is one major step forward in this regard.</ce:para><ce:para id="p5235">Historically, between 50 and 70% of those with advanced-stage HL were cured. The Hasenclever index (<ce:cross-ref id="crf1020" refid="b0320">Box 23.56</ce:cross-ref><ce:float-anchor refid="b0320"/>) can be helpful in assigning approximate chances of cure when discussing treatment plans with patients. More recent data using the PET scanner to direct therapy suggests that long-term survival is improving to beyond 80%. Patients who fail to respond to initial chemotherapy or relapse within a year of initial therapy have a poor prognosis but some may achieve long-term survival after autologous HSCT. Patients relapsing after 1 year may obtain long-term survival with further chemotherapy alone, but fit patients frequently proceed to autologous HSCT.</ce:para></ce:section></ce:section><ce:section id="s1355"><ce:section-title id="st1270">Non-Hodgkin lymphoma</ce:section-title><ce:para id="p5280">Non-Hodgkin lymphoma (NHL) represents a monoclonal proliferation of lymphoid cells of B-cell (90%) or T-cell (10%) origin. The incidence of these tumours increases with age, to 62.8/million population per annum at age 75 years, and the overall rate is increasing at about 3% per year.</ce:para><ce:para id="p5285">The epidemiology of NHL is shown in <ce:cross-ref id="crf1025" refid="b0325">Box 23.57</ce:cross-ref><ce:float-anchor refid="b0325"/>. Previous classifications were based principally on histological appearances. The current WHO classification stratifies according to cell lineage (T or B cells) and incorporates clinical features, histology, chromosomal abnormalities and concepts related to the biology of the lymphoma. Clinically, the most important factor is grade, which is a reflection of proliferation rate. High-grade NHL has high proliferation rates, rapidly produces symptoms, is fatal if untreated, but is potentially curable. Low-grade NHL has low proliferation rates, may be asymptomatic for many months or even years before presentation, runs an indolent course, but is not curable by conventional therapy. Of all cases of NHL in the developed world, over two-thirds are either diffuse large B-cell NHL (high-grade) or follicular NHL (low-grade) (<ce:cross-ref id="crf1030" refid="f0170">Fig. 23.29</ce:cross-ref><ce:float-anchor refid="f0170"/>). Other forms of NHL, including Burkitt lymphoma, mantle cell lymphoma, mucosa-associated lymphoid tissue (MALT) lymphomas and T-cell lymphomas, are less common.</ce:para><ce:section id="s1380"><ce:section-title id="st1295">Clinical features</ce:section-title><ce:para id="p5365">Unlike Hodgkin lymphoma, NHL is often widely disseminated at presentation, including in extranodal sites. Patients present with lymph node enlargement (<ce:cross-ref id="crf1035" refid="f0175">Fig. 23.30</ce:cross-ref><ce:float-anchor refid="f0175"/>), which may be associated with systemic upset: weight loss, sweats, fever and itching. Hepatosplenomegaly may be present. Sites of extranodal involvement include the bone marrow, gut, thyroid, lung, skin, testis, brain and, more rarely, bone. Bone marrow involvement is more common in low-grade (50–60%) than high-grade (10%) disease. Compression syndromes may occur, including gut obstruction, ascites, superior vena cava obstruction and spinal cord compression.</ce:para><ce:para id="p5370">The same staging system (see <ce:cross-ref id="crf1040" refid="b0315">Box 23.55</ce:cross-ref>) is used for both HL and NHL, but NHL is more likely to be stage III or IV at presentation.</ce:para></ce:section><ce:section id="s1385"><ce:section-title id="st1300">Investigations</ce:section-title><ce:para id="p5375">These are as for HL, but in addition the following should be performed:<ce:list id="ulist1090"><ce:list-item id="u3280"><ce:label>•</ce:label><ce:para id="p5380"><ce:italic>Bone marrow aspiration and trephine</ce:italic> to identify bone marrow involvement.</ce:para></ce:list-item><ce:list-item id="u3285"><ce:label>•</ce:label><ce:para id="p5385"><ce:italic>Immunophenotyping of surface antigens to distinguish T-cell from B-cell tumours</ce:italic>. This may be done on blood, marrow or nodal material.</ce:para></ce:list-item><ce:list-item id="u3290"><ce:label>•</ce:label><ce:para id="p5390"><ce:italic>Cytogenetic analysis to detect chromosomal translocations</ce:italic> and molecular testing for T-cell receptor or immunoglobulin gene rearrangements.</ce:para></ce:list-item><ce:list-item id="u3295"><ce:label>•</ce:label><ce:para id="p5395"><ce:italic>Immunoglobulin determination</ce:italic>. Some lymphomas are associated with IgG or IgM paraproteins, which serve as markers for treatment response.</ce:para></ce:list-item><ce:list-item id="u3300"><ce:label>•</ce:label><ce:para id="p5400"><ce:italic>Measurement of uric acid levels</ce:italic>. Some very aggressive high-grade NHLs are associated with very high urate levels, which can precipitate renal failure when treatment is started.</ce:para></ce:list-item><ce:list-item id="u3305"><ce:label>•</ce:label><ce:para id="p5405"><ce:italic>HIV testing</ce:italic>. HIV is a risk factor for some lymphomas and affects treatment decisions<ce:italic>.</ce:italic></ce:para></ce:list-item><ce:list-item id="u3310"><ce:label>•</ce:label><ce:para id="p5410"><ce:italic>Hepatitis B and C testing.</ce:italic> This should be done prior to therapy with rituximab.</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1390"><ce:section-title id="st1305">Management</ce:section-title><ce:section id="s1395"><ce:section-title id="st1310">Low-grade NHL</ce:section-title><ce:para id="p5415">The majority of patients (80%) present with advanced stage disease and will run a relapsing and remitting course over several years. Asymptomatic patients may not require therapy and are managed by ‘watching and waiting’. Indications for treatment include marked systemic symptoms, lymphadenopathy causing discomfort or disfigurement, bone marrow failure or compression syndromes. In follicular lymphoma, the options are:<ce:list id="ulist1095"><ce:list-item id="u3315"><ce:label>•</ce:label><ce:para id="p5420"><ce:italic>Radiotherapy</ce:italic>. This can be used for localised stage I disease, which is rare.</ce:para></ce:list-item><ce:list-item id="u3320"><ce:label>•</ce:label><ce:para id="p5425"><ce:italic>Chemotherapy</ce:italic>. Most patients will respond to oral therapy with chlorambucil, which is well tolerated but not curative. More intensive intravenous chemotherapy in younger patients produces better quality of life but no survival benefit.</ce:para></ce:list-item><ce:list-item id="u3325"><ce:label>•</ce:label><ce:para id="p5430"><ce:italic>Monoclonal antibody therapy</ce:italic>. Humanised monoclonal antibodies (‘biological therapy’; p. 960) can be used to target surface antigens on tumour cells and to induce tumour cell apoptosis directly. The anti-CD20 antibody rituximab has been shown to induce durable clinical responses in up to 60% of patients when given alone, and acts synergistically when given with chemotherapy. Rituximab (R) in combination with cyclophosphamide, vincristine and prednisolone (R-CVP), cyclophosphamide, doxorubicin, vincristine, prednisolone (R-CHOP) or bendamustine (R-bendamustine) is commonly used as first-line therapy. Randomised trials have also confirmed that 2 years of maintenance therapy with single-agent rituximab, following achievement of first or second response, delays relapse and the time to next treatment. As yet, however, rituximab maintenance has not shown a survival benefit. New and more potent monoclonal antibodies are also in development and trials of obinutuzumab (p. 960) have been completed.</ce:para></ce:list-item><ce:list-item id="u3330"><ce:label>•</ce:label><ce:para id="p5435"><ce:italic>Kinase inhibitors</ce:italic>. Idelalisib is approved for relapsed follicular lymphoma and ibrutinib (p. 960) is approved for relapsed mantle cell lymphoma, a poor-prognosis lymphoma with low-grade histology but aggressive clinical behaviour. These targeted therapies are likely to become more widely used in low-grade lymphomas in the near future.</ce:para></ce:list-item><ce:list-item id="u3335"><ce:label>•</ce:label><ce:para id="p5440"><ce:italic>Transplantation</ce:italic>. High-dose chemotherapy and autologous HSCT can produce long remissions in patients with relapsed disease. Decisions on the timing of such treatment are complex in the context of rituximab maintenance and newer targeted therapies. However, younger patients with short first or second remissions or who relapse during rituximab maintenance should be considered.</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1400"><ce:section-title id="st1315">High-grade NHL</ce:section-title><ce:para id="p5445">Patients with diffuse large B-cell NHL need treatment at initial presentation:<ce:list id="ulist1100"><ce:list-item id="u3340"><ce:label>•</ce:label><ce:para id="p5450"><ce:italic>Chemotherapy.</ce:italic> The majority (&#x003E; 90%) are treated with intravenous combination chemotherapy, typically with the CHOP regimen (cyclophosphamide, doxorubicin, vincristine and prednisolone).</ce:para></ce:list-item><ce:list-item id="u3345"><ce:label>•</ce:label><ce:para id="p5455"><ce:italic>Monoclonal antibody therapy</ce:italic>. When combined with CHOP chemotherapy, rituximab (R) increases the complete response rates and improves overall survival. R-CHOP is currently recommended as first-line therapy for those with stage II or higher diffuse large B-cell lymphoma.</ce:para></ce:list-item><ce:list-item id="u3350"><ce:label>•</ce:label><ce:para id="p5460"><ce:italic>Radiotherapy.</ce:italic> Stage I patients without bulky disease are treated with four cycles of CHOP or R-CHOP, followed by involved site radiotherapy. Radiotherapy is also indicated for a residual localised site of bulk disease after chemotherapy, and for spinal cord and other compression syndromes.</ce:para></ce:list-item><ce:list-item id="u3355"><ce:label>•</ce:label><ce:para id="p5465"><ce:italic>HSCT.</ce:italic> Autologous HSCT (p. 937) benefits patients with relapsed disease that is sensitive to salvage immunochemotherapy. As with HL, achieving PET negativity prior to autologous transplantation is desirable.</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:section><ce:section id="s1405"><ce:section-title id="st1320">Prognosis</ce:section-title><ce:para id="p5470">Low-grade NHL runs an indolent remitting and relapsing course, with an overall median survival of 12 years. Transformation to a high-grade NHL occurs in 3% per annum and is associated with poor survival.</ce:para><ce:para id="p5475">In diffuse large B-cell NHL treated with R-CHOP, some 75% of patients overall respond initially to therapy and 50% will have disease-free survival at 5 years. The prognosis for patients with NHL is further refined according to the international prognostic index (IPI). For high-grade NHL, 5-year survival ranges from over 75% in those with low-risk scores (age &#x003C; 60 years, stage I or II, one or fewer extranodal sites, normal LDH and good performance status) to 25% in those with high-risk scores (increasing age, advanced stage, concomitant disease and a raised LDH).</ce:para><ce:para id="p5480">Relapse is associated with a poor response to further chemotherapy (&#x003C; 10% 5-year survival), but in patients under 65 years HSCT improves survival.</ce:para></ce:section></ce:section></ce:section><ce:section id="s1410"><ce:section-title id="st1325">Paraproteinaemias</ce:section-title><ce:para id="p5485">A gammopathy refers to over-production of one or more classes of immunoglobulin. It may be polyclonal in association with acute or chronic inflammation, such as infection, sarcoidosis, autoimmune disorders or some malignancies. Alternatively, a monoclonal increase in a single immunoglobulin class may occur in association with normal or reduced levels of the other immunoglobulins. Such monoclonal proteins (also called M-proteins, paraproteins or monoclonal gammopathies) occur as a feature of myeloma, lymphoma and amyloidosis, in connective tissue disease such as rheumatoid arthritis or polymyalgia rheumatica, in infection such as HIV, and in solid tumours. In addition, they may be present with no underlying disease. Gammopathies are detected by plasma immunoelectrophoresis.</ce:para><ce:section id="s1415"><ce:section-title id="st1330">Monoclonal gammopathy of uncertain significance</ce:section-title><ce:para id="p5490">In monoclonal gammopathy of uncertain significance (MGUS, also known as benign monoclonal gammopathy), a paraprotein is present in the blood but there are no other features of myeloma, Waldenström macroglobulinaemia (see below), lymphoma or related disease. It is a common condition associated with increasing age; a paraprotein can be found in 1% of the population aged over 50 years, increasing to 5% over 80 years.</ce:para><ce:section id="s1420"><ce:section-title id="st1335">Clinical features and investigations</ce:section-title><ce:para id="p5495">Patients are usually asymptomatic, and the paraprotein is found on blood testing for other reasons. The routine blood count and biochemistry are normal, the paraprotein is usually present in small amounts with no associated immune paresis, and there are no lytic bone lesions. The bone marrow may have increased plasma cells but these usually constitute less than 10% of nucleated cells.</ce:para></ce:section><ce:section id="s1425"><ce:section-title id="st1340">Prognosis</ce:section-title><ce:para id="p5500">After follow-up of 20 years, only one-quarter of cases will progress to myeloma or a related disorder (i.e. around 1% per annum). There is no certain way of predicting progression in an individual patient. However, an abnormal ratio of kappa to lambda light chains (serum free light chain ratio, SFLR) increases the risk of progression. Patients with an abnormal ratio should be monitored for progression on an annual basis.</ce:para></ce:section></ce:section><ce:section id="s1430"><ce:section-title id="st1345">Waldenström macroglobulinaemia</ce:section-title><ce:para id="p5505">This is a low-grade lymphoplasmacytic lymphoma associated with an IgM paraprotein, causing clinical features of hyperviscosity syndrome. It is a rare tumour occurring in the elderly and more commonly affects males.</ce:para><ce:para id="p5510">Patients classically present with features of hyperviscosity, such as nosebleeds, bruising, delirium and visual disturbance. However, presentation may be with anaemia, systemic symptoms, splenomegaly or lymphadenopathy, or may be asymptomatic, with an IgM paraprotein detected on routine screening. Patients are found on investigation to have an IgM paraprotein associated with a raised plasma viscosity. The bone marrow has a characteristic appearance, with infiltration of lymphoid cells, plasma cells and sometimes prominent mast cells. A high proportion of patients have a mutation in the <ce:italic>MYD88</ce:italic> gene.</ce:para><ce:section id="s1435"><ce:section-title id="st1350">Management</ce:section-title><ce:para id="p5515">If patients show symptoms of hyperviscosity and anaemia, plasmapheresis is required to remove IgM and make blood transfusion possible. Chemotherapy with alkylating agents, such as chlorambucil, has been the mainstay of treatment, controlling disease in over 50%. Fludarabine may be more effective in this disease but has more side-effects. Rituximab in combination with chemotherapy is most commonly used; ibrutinib is very effective and has recently been licensed for use. Rituximab alone can cause a rapid release of IgM and increase in viscosity. The median survival is 5 years.</ce:para></ce:section></ce:section><ce:section id="s1440"><ce:section-title id="st1355">Multiple myeloma</ce:section-title><ce:para id="p5520">This is a malignant proliferation of plasma cells. Normal plasma cells are derived from B cells and produce immunoglobulins that contain heavy and light chains. Normal immunoglobulins are polyclonal, which means that a variety of heavy chains are produced and each may be of kappa or lambda light chain type (<ce:intra-ref id="ii0645" xlink:href="pii:B978-0-7020-7028-0.00004-4#s0125">p. 68</ce:intra-ref>). In myeloma, plasma cells produce immunoglobulin of a single heavy and light chain, a monoclonal protein commonly referred to as a paraprotein. In most cases an excess of light chain is produced, and in some cases only light chain is produced; this appears in the urine as Bence Jones proteinuria and can be measured in the urine or serum as free light chain. The frequency of different isotypes of monoclonal protein in myeloma is shown in <ce:cross-ref id="crf1045" refid="b0330">Box 23.58</ce:cross-ref><ce:float-anchor refid="b0330"/>.</ce:para><ce:para id="p5530">Although a small number of malignant plasma cells are present in the circulation, the majority are present in the bone marrow. The malignant plasma cells produce cytokines, which stimulate osteoclasts and result in net bone reabsorption. The resulting lytic lesions cause bone pain, fractures and hypercalcaemia. Marrow involvement can result in anaemia or pancytopenia.</ce:para><ce:section id="s1445"><ce:section-title id="st1360">Clinical features and investigations</ce:section-title><ce:para id="p5535">The incidence of myeloma is 4/100 000 new cases per annum, with a male-to-female ratio of 2 : 1. The median age at diagnosis is 60–70 years and the disease is more common in Afro-Caribbeans. The clinical features are demonstrated in <ce:cross-ref id="crf1050" refid="f0180">Figure 23.31</ce:cross-ref><ce:float-anchor refid="f0180"/>.</ce:para><ce:para id="p5540">Diagnosis of myeloma requires two of the following criteria to be fulfilled:<ce:list id="ulist1105"><ce:list-item id="u3360"><ce:label>•</ce:label><ce:para id="p5545">increased malignant plasma cells in the bone marrow</ce:para></ce:list-item><ce:list-item id="u3365"><ce:label>•</ce:label><ce:para id="p5550">serum and/or urinary M-protein</ce:para></ce:list-item><ce:list-item id="u3370"><ce:label>•</ce:label><ce:para id="p5555">skeletal lytic lesions.</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p5560">Bone marrow aspiration, plasma and urine electrophoresis, and a skeletal survey are thus required. Normal immunoglobulin levels, i.e. the absence of immunoparesis, should cast doubt on the diagnosis. Paraproteinaemia can cause an elevated ESR but this is a non-specific test; only approximately 5% of patients with a persistently elevated ESR above 100 mm/hr have underlying myeloma.</ce:para></ce:section><ce:section id="s1450"><ce:section-title id="st1365">Management</ce:section-title><ce:para id="p5565">If patients are asymptomatic with no evidence of end-organ damage (e.g. to kidneys, bone marrow or bone), treatment may not be required. So-called asymptomatic myeloma should be monitored closely for the development of end-organ damage.</ce:para><ce:section id="s1455"><ce:section-title id="st1370">Immediate support</ce:section-title><ce:para id="p5570"><ce:list id="ulist1110"><ce:list-item id="u3375"><ce:label>•</ce:label><ce:para id="p5575">High fluid intake to treat renal impairment and hypercalcaemia (<ce:intra-ref id="ii0655" xlink:href="pii:B978-0-7020-7028-0.00018-4#s0780">p. 661</ce:intra-ref>).</ce:para></ce:list-item><ce:list-item id="u3380"><ce:label>•</ce:label><ce:para id="p5580">Analgesia for bone pain.</ce:para></ce:list-item><ce:list-item id="u3385"><ce:label>•</ce:label><ce:para id="p5585">Bisphosphonates for hypercalcaemia and to delay other skeletal related events (<ce:intra-ref id="ii0660" xlink:href="pii:B978-0-7020-7028-0.00024-X#s1660">p. 1047</ce:intra-ref>).</ce:para></ce:list-item><ce:list-item id="u3390"><ce:label>•</ce:label><ce:para id="p5590">Allopurinol to prevent urate nephropathy.</ce:para></ce:list-item><ce:list-item id="u3395"><ce:label>•</ce:label><ce:para id="p5595">Plasmapheresis, if necessary, for hyperviscosity.</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1460"><ce:section-title id="st1375">Chemotherapy with or without HSCT</ce:section-title><ce:para id="p5600">Myeloma therapy has improved with the addition of novel agents, initially thalidomide and more recently the proteasome inhibitor bortezomib and the second-generation immunomodulatory drug lenalidomide. For first-line therapy in older patients, thalidomide combined with the alkylating agent melphalan and prednisolone (MPT) has increased the median overall survival to more than 4 years. Lenalidomide is approved first-line treatment for patients not eligible for transplantation and who are intolerant of, or unsuitable for, thalidomide. Thalidomide and lenalidomide both have anti-angiogenic effects against tumour blood vessels and immunomodulatory effects. Both can cause somnolence, constipation, peripheral neuropathy and thrombosis, though lenalidomide has a better side-effect profile. It is vital that females of child-bearing age use adequate contraception, as thalidomide and lenalidomide are teratogenic. Treatment is administered until paraprotein levels have stopped falling. This is termed ‘plateau phase’ and can last for weeks or years.</ce:para><ce:para id="p5605"><ce:float-anchor refid="b0335"/></ce:para><ce:para id="p5645">In younger, fitter patients, standard treatment includes first-line therapies, such as cyclophosphamide, thalidomide and dexamethasone (CTD) or bortezomib (Velcade), thalidomide and dexamethasone (VTD) to maximum response, and then autologous HSCT, which improves quality of life and prolongs survival but does not cure myeloma. In all patients who have achieved maximal response, lenalidomide maintenance has been shown to prolong the response.</ce:para><ce:para id="p5650">When myeloma progresses, treatment is given to induce a further plateau phase. In the UK, the proteosome inhibitor bortezomib and lenalidomide have been used as second- and third-line therapy, as appropriate. As they have been used more frequently in the first or second line with prognostic benefit, however, subsequent relapses are more difficult to treat. A second-generation proteasome inhibitor, carfilzomib, and the anti-CD38 antibody daratumumab show promise in relapsed/refractory disease. Responding patients may benefit from a second autologous HSCT.</ce:para></ce:section><ce:section id="s1465"><ce:section-title id="st1380">Radiotherapy</ce:section-title><ce:para id="p5655">This is effective for localised bone pain not responding to simple analgesia and for pathological fractures. It is also useful for the emergency treatment of spinal cord compression complicating extradural plasmacytomas.</ce:para></ce:section><ce:section id="s1470"><ce:section-title id="st1385">Bisphosphonates</ce:section-title><ce:para id="p5660">Long-term bisphosphonate therapy reduces bone pain and skeletal events. These drugs protect bone (<ce:intra-ref id="ii0665" xlink:href="pii:B978-0-7020-7028-0.00024-X#s1660">p. 1047</ce:intra-ref>) and may cause apoptosis of malignant plasma cells. There is evidence that intravenous zoledronate in combination with anti-myeloma therapy confers a survival advantage over oral bisphosphonates. Osteonecrosis of the jaw may be associated with long-term use or poor oral hygiene and gum sepsis; regular dental review, including a check before starting therapy, is therefore important.</ce:para></ce:section></ce:section><ce:section id="s1475"><ce:section-title id="st1390">Prognosis</ce:section-title><ce:para id="p5665">The international staging system (ISS) identifies poor prognostic features, including a high β<ce:inf loc="post">2</ce:inf>-microglobulin and low albumin at diagnosis (ISS stage 3, median survival 29 months). Those with a normal albumin and a low β<ce:inf loc="post">2</ce:inf>-microglobulin (ISS stage 1) have a median survival of 62 months. Increasingly, cytogenetic analysis is used to identify poor-risk patients, e.g. t(4;14), del(17/17p), t(14;16), t(14;20), non-hyperdiploidy and gain(1q). Use of autologous HSCT and advances in drug therapy with the newer agents have increased survival. Over one-third of patients are now surviving for 5 years, compared with only one-quarter 10 years ago. The outlook may improve further with new drugs and combinations of treatments.</ce:para></ce:section></ce:section></ce:section></ce:section><ce:section id="s1480"><ce:section-title id="st1395">Aplastic anaemias</ce:section-title><ce:section id="s1485"><ce:section id="s1490"><ce:section-title id="st1400">Primary idiopathic acquired aplastic anaemia</ce:section-title><ce:para id="p5670">This is a rare disorder in Europe and North America, with 2–4 new cases per million population per annum. The disease is much more common in certain other parts of the world, e.g. east Asia. The basic problem is failure of the pluripotent stem cells because of an autoimmune attack, producing hypoplasia of the bone marrow with a pancytopenia in the blood. The diagnosis rests on exclusion of other causes of secondary aplastic anaemia (see below) and rare congenital causes, such as Fanconi's anaemia.</ce:para><ce:section id="s1495"><ce:section-title id="st1405">Clinical features and investigations</ce:section-title><ce:para id="p5675">Patients present with symptoms of bone marrow failure, usually anaemia or bleeding, and less commonly, infections. An FBC demonstrates pancytopenia, low reticulocytes and often macrocytosis. Bone marrow aspiration and trephine reveal hypocellularity. The severity of aplastic anaemia is graded according to the Camitta criteria (<ce:cross-ref id="crf1055" refid="b0340">Box 23.60</ce:cross-ref><ce:float-anchor refid="b0340"/>).</ce:para></ce:section><ce:section id="s1515"><ce:section-title id="st1425">Management</ce:section-title><ce:para id="p5725">All patients will require blood product support and aggressive management of infection. The prognosis of severe aplastic anaemia managed with supportive therapy only is poor and more than 50% of patients die, usually in the first year. The curative treatment for patients under 35 years of age with severe idiopathic aplastic anaemia is allogeneic HSCT if there is an available sibling donor (p. 937). Older patients (35–50) may be candidates if they have no comorbidities (p. 937). Those with a compatible sibling donor should proceed to transplantation as soon as possible; they have a 75–90% chance of long-term cure. In older patients and those without a suitable donor, immunosuppressive therapy (IST) with anti-thymocyte globulin (ATG) and ciclosporin is the treatment of choice and gives 5-year survival rates of 75%. Unrelated donor allografts are considered for suitable patients who fail IST. The thrombopoietin receptor agonist eltrombopag (p. 971) has produced trilineage responses in patients who fail IST and is licensed for this indication. Non-transplanted patients may relapse or other clonal disorders of haematopoiesis may evolve, such as paroxysmal nocturnal haemoglobinuria (p. 950), myelodysplastic syndrome (p. 960) and AML (p. 955). Patients with aplastic anaemia must be followed up long-term.</ce:para></ce:section></ce:section><ce:section id="s1520"><ce:section-title id="st1430">Secondary aplastic anaemia</ce:section-title><ce:para id="p5730">Causes of this condition are listed in <ce:cross-ref id="crf1060" refid="b0345">Box 23.61</ce:cross-ref><ce:float-anchor refid="b0345"/>. It is not practical to list all the drugs that have been suspected of causing aplasia. It is important to check the reported side-effects of all drugs taken over the preceding months. In some instances, the cytopenia is more selective and affects only one cell line, most often the neutrophils. Frequently, this is an incidental finding, with no ill health. It probably has an immune basis but this is difficult to prove.</ce:para><ce:para id="p5810">The clinical features and methods of diagnosis are the same as for primary idiopathic aplastic anaemia. An underlying cause should be treated or removed, but otherwise management is as for the idiopathic form.</ce:para></ce:section></ce:section></ce:section><ce:section id="s1525"><ce:section-title id="st1435">Myeloproliferative neoplasms</ce:section-title><ce:para id="p5815">These make up a group of chronic conditions characterised by clonal proliferation of marrow precursor cells. Polycythaemia rubra vera (PRV), essential thrombocythaemia and myelofibrosis are the non-leukaemic myeloproliferative neoplasms. Although the majority of patients are classifiable as having one of these disorders, some have overlapping features and there is often progression from one to another, e.g. PRV to myelofibrosis. The recent discovery of the molecular basis of these disorders will lead to changes in classification and treatment; a mutation in the gene on chromosome 9 encoding the signal transduction molecule <ce:italic>JAK-2</ce:italic> has been found in more than 90% of PRV cases and 50% of those with essential thrombocythaemia and myelofibrosis. Mutations in the calreticulin gene (<ce:italic>CALR</ce:italic>), which produces a chaperone protein that protects proteins moving from the endoplasmic reticulin to the cytoplasm, have been found in a further 25% of patients with essential thrombocythaemia. Less commonly, mutations can be detected in the thrombopoietin receptor gene <ce:italic>MPL</ce:italic>.</ce:para><ce:section id="s1530"><ce:section id="s1535"><ce:section-title id="st1440">Myelofibrosis</ce:section-title><ce:para id="p5820">In myelofibrosis, the marrow is initially hypercellular, with an excess of abnormal megakaryocytes that release growth factors, such as platelet-derived growth factor, to the marrow microenvironment, resulting in a reactive proliferation of fibroblasts. As the disease progresses, the marrow becomes fibrosed.</ce:para><ce:para id="p5825">Most patients present over the age of 50 years, with lassitude, weight loss and night sweats. The spleen can be massively enlarged due to extramedullary haematopoiesis (blood cell formation outside the bone marrow), and painful splenic infarcts may occur.</ce:para><ce:para id="p5830">The characteristic blood picture is leucoerythroblastic anaemia, with circulating immature red blood cells (increased reticulocytes and nucleated red blood cells) and granulocyte precursors (myelocytes). The red cells are shaped like teardrops (teardrop poikilocytes), and giant platelets may be seen in the blood. The white count varies from low to moderately high and the platelet count may be high, normal or low. Urate levels may be high due to increased cell breakdown, and folate deficiency is common. The marrow is often difficult to aspirate and a trephine biopsy shows an excess of megakaryocytes, increased reticulin and fibrous tissue replacement. The presence of a <ce:italic>JAK-2</ce:italic> mutation supports the diagnosis.</ce:para><ce:section id="s1540"><ce:section-title id="st1445">Management and prognosis</ce:section-title><ce:para id="p5835">Median survival is 4 years from diagnosis, but ranges from 1 year to over 20 years. Treatment is directed at control of symptoms, e.g. red cell transfusions for anaemia. Folic acid should be given to prevent deficiency. Cytotoxic therapy with hydroxycarbamide may help control spleen size, the white cell count or systemic symptoms. Splenectomy may be required for a grossly enlarged spleen or symptomatic pancytopenia secondary to splenic pooling of cells and hypersplenism. HSCT may be considered for younger patients. Ruxolitinib, an inhibitor of <ce:italic>JAK-2</ce:italic>, is now licensed in myelofibrosis and is effective at reducing systemic symptoms and splenomegaly.</ce:para></ce:section></ce:section><ce:section id="s1545"><ce:section-title id="st1450">Essential thrombocythaemia</ce:section-title><ce:para id="p5840">Uncontrolled proliferation of megakaryocytes results in a raised level of circulating platelets that are often dysfunctional. Prior to a diagnosis of essential thrombocythaemia being made, reactive causes of thrombocytosis must be excluded (see <ce:cross-ref id="crf1065" refid="b0115">Box 23.15</ce:cross-ref>). The presence of a <ce:italic>JAK-2, CALR</ce:italic> or, rarely, <ce:italic>MPL</ce:italic> mutation supports the diagnosis but is not universal. Patients present at a median age of 60 years with vascular occlusion or bleeding, or with an asymptomatic isolated raised platelet count. A small percentage (around 5%) will transform to acute leukaemia and others to myelofibrosis.</ce:para><ce:para id="p5845">It is likely that most patients with essential thrombocythaemia benefit from low-dose aspirin to reduce the risk of occlusive vascular events. Low-risk patients (age &#x003C; 40 years, platelet count &#x003C; 1500 × 10<ce:sup loc="post">9</ce:sup>/L and no bleeding or thrombosis) may not require treatment to reduce the platelet count. For those with a platelet count above 1500 × 10<ce:sup loc="post">9</ce:sup>/L, with symptoms, or with other risk factors for thrombosis such as diabetes or hypertension, treatment to control platelet counts should be given. Agents include oral hydroxycarbamide or anagrelide, an inhibitor of megakaryocyte maturation. Intravenous radioactive phosphorus (<ce:sup loc="post">32</ce:sup>P) may be useful in old age and interferon-alfa has a role in younger patients.</ce:para></ce:section><ce:section id="s1550"><ce:section-title id="st1455">Polycythaemia rubra vera</ce:section-title><ce:para id="p5850">PRV occurs mainly in patients over the age of 40 years and presents either as an incidental finding of a high haemoglobin, or with symptoms of hyperviscosity, such as lassitude, loss of concentration, headaches, dizziness, blackouts, pruritus and epistaxis. Some patients present with manifestations of peripheral arterial or cerebrovascular disease. Venous thromboembolism may also occur. Peptic ulceration is common, sometimes complicated by bleeding. Patients are often plethoric and many have a palpable spleen at diagnosis.</ce:para><ce:para id="p5855">Investigation of polycythaemia is discussed on page 925. The diagnosis of PRV now rests on the demonstration of a high haematocrit and the presence of the <ce:italic>JAK-2 V617F</ce:italic> mutation (positive in 95% of cases). In the occasional <ce:italic>JAK</ce:italic>-<ce:italic>2</ce:italic>-negative cases, a raised red cell mass and absence of causes of a secondary erythrocytosis must be established. The spleen may be enlarged and neutrophil and platelet counts are frequently raised, an abnormal karyotype may be found in the marrow, and in vitro culture of the marrow can be used to demonstrate autonomous growth in the absence of added growth factors.</ce:para><ce:section id="s1555"><ce:section-title id="st1460">Management and prognosis</ce:section-title><ce:para id="p5860">Aspirin reduces the risk of thrombosis. Venesection gives prompt relief of hyperviscosity symptoms. Between 400 and 500 mL of blood (less if the patient is elderly) are removed and the venesection is repeated every 5–7 days until the haematocrit is reduced to below 45%. Less frequent but regular venesection will maintain this level until the haemoglobin remains reduced because of iron deficiency.</ce:para><ce:para id="p5865">Suppression of marrow proliferation with hydroxycarbamide or interferon-alfa may reduce the risk of vascular occlusion, control spleen size and reduce transformation to myelofibrosis. Intravenous <ce:sup loc="post">32</ce:sup>P, which is reserved for older patients as it increases the risk of transformation to acute leukaemia by 6–10-fold, is rarely used now in Europe and North America.</ce:para><ce:para id="p5870">Median survival after diagnosis in treated patients exceeds 10 years. Some patients survive more than 20 years; however, cerebrovascular or coronary events occur in up to 60% of patients. The disease may convert to another myeloproliferative disorder, with about 15% developing acute leukaemia or myelofibrosis.</ce:para></ce:section></ce:section></ce:section></ce:section><ce:section id="s1560"><ce:section-title id="st1465">Bleeding disorders</ce:section-title><ce:section id="s1565"><ce:section-title id="st1470">Disorders of primary haemostasis</ce:section-title><ce:para id="p5875">The initial formation of the platelet plug (see <ce:cross-ref id="crf1070" refid="f0050">Fig. 23.6A</ce:cross-ref>, p. 918; also known as ‘primary haemostasis’) may fail in thrombocytopenia (p. 929), von Willebrand disease (p. 974), and also in platelet function disorders and diseases affecting the vessel wall.</ce:para><ce:section id="s1570"><ce:section-title id="st1475">Vessel wall abnormalities</ce:section-title><ce:para id="p5880">Vessel wall abnormalities may be:<ce:list id="ulist1155"><ce:list-item id="u3530"><ce:label>•</ce:label><ce:para id="p5885">congenital, such as hereditary haemorrhagic telangiectasia</ce:para></ce:list-item><ce:list-item id="u3535"><ce:label>•</ce:label><ce:para id="p5890">acquired, as in a vasculitis (<ce:intra-ref id="ii0725" xlink:href="pii:B978-0-7020-7028-0.00024-X#p5220">p. 1040</ce:intra-ref>) or scurvy.</ce:para></ce:list-item></ce:list></ce:para><ce:section id="s1575"><ce:section-title id="st1480">Hereditary haemorrhagic telangiectasia</ce:section-title><ce:para id="p5895">Hereditary haemorrhagic telangiectasia (HHT) is a dominantly inherited condition caused by mutations in the genes encoding endoglin and activin receptor-like kinase, which are endothelial cell receptors for transforming growth factor-beta (TGF-β), a potent angiogenic cytokine. Telangiectasia and small aneurysms are found on the fingertips, face and tongue, and in the nasal passages, lung and gastrointestinal tract. A significant proportion of these patients develop larger pulmonary arteriovenous malformations (PAVMs) that cause arterial hypoxaemia due to a right-to-left shunt. These predispose to paradoxical embolism, resulting in stroke or cerebral abscess. All patients with HHT should be screened for PAVMs; if these are found, ablation by percutaneous embolisation should be considered.</ce:para><ce:para id="p5900">Patients present either with recurrent bleeds, particularly epistaxis, or with iron deficiency due to occult gastrointestinal bleeding. Treatment can be difficult because of the multiple bleeding points but regular iron therapy often allows the marrow to compensate for blood loss. Local cautery or laser therapy may prevent single lesions from bleeding. A variety of medical therapies have been tried but none has been found to be universally effective.</ce:para></ce:section><ce:section id="s1580"><ce:section-title id="st1485">Ehlers–Danlos disease</ce:section-title><ce:para id="p5905">Vascular Ehlers–Danlos syndrome (type 4) is a rare autosomal dominant disorder (1/100 000) caused by a defect in type 3 collagen that results in fragile blood vessels and organ membranes, leading to bleeding and organ rupture. Classical joint hypermobility (<ce:intra-ref id="ii0730" xlink:href="pii:B978-0-7020-7028-0.00024-X#s2005">p. 1059</ce:intra-ref>) is often limited in this form of the disease but skin changes and facial appearance are typical. The diagnosis should be considered when there is a history of bleeding with normal laboratory tests.</ce:para></ce:section><ce:section id="s1585"><ce:section-title id="st1490">Scurvy</ce:section-title><ce:para id="p5910">Vitamin C deficiency affects the normal synthesis of collagen and results in a bleeding disorder characterised by perifollicular and petechial haemorrhage, bruising and subperiosteal bleeding. The key to diagnosis is the dietary history (<ce:intra-ref id="ii0735" xlink:href="pii:B978-0-7020-7028-0.00019-6#s0500">p. 715</ce:intra-ref>).</ce:para></ce:section></ce:section><ce:section id="s1590"><ce:section-title id="st1495">Platelet function disorders</ce:section-title><ce:para id="p5915">Bleeding may result from thrombocytopenia (see <ce:cross-ref id="crf1075" refid="b0105">Box 23.14</ce:cross-ref>, p. 929) or from congenital or acquired abnormalities of platelet function. The most common acquired disorders are iatrogenic, resulting from the use of aspirin, clopidogrel, ticagrelor, dipyridamole and the glycoprotein IIb/IIIa inhibitors to prevent arterial thrombosis (see <ce:cross-ref id="crf1080" refid="b0170">Box 23.26</ce:cross-ref>, p. 938). Inherited platelet function abnormalities are relatively rare. Congenital abnormalities may be due to deficiency of the membrane glycoproteins, e.g. Glanzmann's thrombasthenia (IIb/IIIa) or Bernard–Soulier syndrome (Ib), or due to the presence of defective platelet granules, e.g. a deficiency of dense (delta) granules (see <ce:cross-ref id="crf1085" refid="f0055">Fig. 23.7</ce:cross-ref>, p. 920) giving rise to storage pool disorders. The congenital macrothrombocytopathies that are due to mutations in the myosin heavy chain gene <ce:italic>MYH-9</ce:italic> are characterised by large platelets, inclusion bodies in the neutrophils (Döhle bodies) and a variety of other features, including sensorineural deafness and renal abnormalities. Other familial thrombocytopathies are important, as they can be associated with somatic features, and some are associated with a propensity for development of bone marrow failure or dysplasia (e.g. <ce:italic>RUNX-1</ce:italic>-associated thrombocytopenia).</ce:para><ce:para id="p5920">Apart from Glanzmann's thrombasthenia, these conditions are mild disorders, with bleeding typically occurring after trauma or surgery, but rarely spontaneous. Glanzmann's thrombasthenia is an autosomal recessive condition associated with a variable but often severe bleeding disorder. These conditions are usually managed by local mechanical measures, but antifibrinolytics, such as tranexamic acid, may be useful and, in severe bleeding, platelet transfusion may be required. Recombinant VIIa is licensed for the treatment of resistant bleeding in Glanzmann's thrombasthenia.</ce:para></ce:section><ce:section id="s1595"><ce:section-title id="st1500">Thrombocytopenia</ce:section-title><ce:para id="p5925">Thrombocytopenia occurs in many disease processes, as listed in <ce:cross-ref id="crf1090" refid="b0105">Box 23.14</ce:cross-ref> (p. 929), many of which are discussed elsewhere in this chapter.</ce:para><ce:section id="s1600"><ce:section-title id="st1505">Idiopathic thrombocytopenic purpura</ce:section-title><ce:para id="p5930">Idiopathic thrombocytopenic purpura (ITP) is immune-mediated with involvement of autoantibodies, most often directed against the platelet membrane glycoprotein IIb/IIIa, which sensitise the platelet, resulting in premature removal from the circulation by cells of the reticulo-endothelial system. It is not a single disorder; some cases occur in isolation while others are associated with underlying immune dysregulation in conditions such as connective tissue diseases, HIV infection, B-cell malignancies, pregnancy and certain drug therapies. The clinical presentation and pathogenesis are similar, however, whatever the cause of ITP.</ce:para><ce:section id="s1605"><ce:section-title id="st1510">Clinical features and investigations</ce:section-title><ce:para id="p5935">The presentation depends on the degree of thrombocytopenia. Spontaneous bleeding typically occurs only when the platelet count is below 20 × 10<ce:sup loc="post">9</ce:sup>/L. At higher counts, the patient may complain of easy bruising or sometimes epistaxis or menorrhagia. Many cases with counts of more than 50 × 10<ce:sup loc="post">9</ce:sup>/L are discovered by chance.</ce:para><ce:para id="p5940">In adults, ITP more commonly affects females and may have an insidious onset. Unlike ITP in children, it is unusual for there to be a history of a preceding viral infection. Symptoms or signs of a connective tissue disease may be apparent at presentation or emerge several years later. Patients aged over 65 years should be considered for a bone marrow examination to look for an accompanying B-cell malignancy, and appropriate autoantibody testing performed if a diagnosis of connective tissue disease is likely. HIV testing should be considered because a positive result will have major implications for appropriate therapy. The peripheral blood film is normal, apart from a greatly reduced platelet number, while the bone marrow reveals an obvious increase in megakaryocytes.</ce:para></ce:section><ce:section id="s1610"><ce:section-title id="st1515">Management</ce:section-title><ce:para id="p5945">Many patients with stable compensated ITP and a platelet count of more than 30 × 10<ce:sup loc="post">9</ce:sup>/L do not require treatment to raise the platelet count, except at times of increased bleeding risk, such as surgery and biopsy. First-line therapy for patients with spontaneous bleeding is with high doses of glucocorticoids, either prednisolone (1 mg/kg daily) or dexamethasone (40 mg daily for 4 days), to suppress antibody production and inhibit phagocytosis of sensitised platelets by reticulo-endothelial cells. Administration of intravenous immunoglobulin can raise the platelet count by blocking antibody receptors on reticulo-endothelial cells, and is combined with glucocorticoid therapy if there is severe haemostatic failure, especially with evidence of significant mucosal bleeding or a slow response to glucocorticoids alone. Persistent or potentially life-threatening bleeding should be treated with platelet transfusion in addition to the other therapies.</ce:para><ce:para id="p5950">The condition may become chronic, with remissions and relapses. Relapses should be treated by re-introducing glucocorticoids. If a patient has two relapses or primary refractory disease, second-line therapies are considered. The options for second-line therapy include the thrombopoietin receptor agonists (TPO-RA) eltrombopag and romiplostim, splenectomy and immunosuppression. Where splenectomy is considered, the precautions shown in <ce:cross-ref id="crf1095" refid="b0240">Box 23.40</ce:cross-ref> need to be in place. Splenectomy produces complete remission in about 70% of patients and improvement in a further 20–25% in favourable cases. The TPO-RAs induce response in around 75% of cases, usually within 10–14 days. Low-dose glucocorticoid therapy and immunosuppressants such as rituximab, ciclosporin, mycophenolate and tacrolimus may also produce remissions. The order in which therapies should be used is not entirely clear, although the TPO-RAs are licensed for this indication while the immunosuppressive agents are not.</ce:para></ce:section></ce:section></ce:section></ce:section><ce:section id="s1615"><ce:section-title id="st1520">Coagulation disorders</ce:section-title><ce:para id="p5955">Normal coagulation is explained in <ce:cross-ref id="crf1100" refid="f0050">Figure 23.6</ce:cross-ref> (p. 918). Coagulation factor deficiency may be congenital or acquired, and may affect one or several of the coagulation factors (<ce:cross-ref id="crf1105" refid="b0350">Box 23.62</ce:cross-ref><ce:float-anchor refid="b0350"/>). Inherited disorders are almost uniformly related to decreased synthesis, as a result of mutation in the gene encoding a key protein in coagulation. Von Willebrand disease is the most common inherited bleeding disorder. Haemophilia A and B are the most common single coagulation factor deficiencies but inherited deficiencies of all the other coagulation factors are seen. Acquired disorders may be due to under-production (e.g. in liver failure), increased consumption (e.g. in DIC) or inhibition of function of coagulation factors (such as heparin therapy or immune inhibitors of coagulation, e.g. acquired haemophilia A).</ce:para><ce:section id="s1655"><ce:section-title id="st1560">Haemophilia A</ce:section-title><ce:para id="p6125">Factor VIII deficiency resulting in haemophilia A affects 1/10 000 individuals. It is the most common congenital coagulation factor deficiency. Factor VIII is primarily synthesised by the liver and endothelial cells and has a half-life of about 12 hours. It is protected from proteolysis in the circulation by binding to von Willebrand factor (vWF).</ce:para><ce:section id="s1660"><ce:section-title id="st1565">Genetics</ce:section-title><ce:para id="p6130">The factor VIII gene is located on the X chromosome. Haemophilia is associated with a range of mutations in the factor VIII gene; these include major inversions, large deletions and missense, nonsense and splice site abnormalities. As the factor VIII gene is on the X chromosome, haemophilia A is a sex-linked disorder (<ce:intra-ref id="ii0765" xlink:href="pii:B978-0-7020-7028-0.00003-2#s0125">p. 48</ce:intra-ref>). Thus all daughters of a patient with haemophilia are obligate carriers and they, in turn, have a 1 in 4 chance of each pregnancy resulting in the birth of an affected male baby, a normal male baby, a carrier female or a normal female. Antenatal diagnosis by chorionic villous sampling is possible in families with a known mutation.</ce:para><ce:para id="p6135">Haemophilia ‘breeds true’ within a family; all members have the same factor VIII gene mutation and a similarly severe or mild phenotype. Female carriers of haemophilia may have reduced factor VIII levels because of random inactivation of their normal X chromosome in the developing fetus (<ce:intra-ref id="ii0770" xlink:href="pii:B978-0-7020-7028-0.00003-2#s0195">p. 49</ce:intra-ref>). This can result in a mild bleeding disorder; thus all known or suspected carriers of haemophilia A should have their factor VIII level measured.</ce:para></ce:section><ce:section id="s1665"><ce:section-title id="st1570">Clinical features</ce:section-title><ce:para id="p6140">The extent and patterns of bleeding are closely related to residual factor VIII levels (<ce:cross-ref id="crf1110" refid="b0355">Box 23.63</ce:cross-ref><ce:float-anchor refid="b0355"/>). Patients with severe haemophilia (factor VIII levels &#x003C; 0.01 U/mL) present with spontaneous bleeding into skin, muscle and joints. Retroperitoneal and intracranial bleeding is also a feature. Babies with severe haemophilia have an increased risk of intracranial haemorrhage and, although there is insufficient evidence to recommend routine caesarean section for these births, it is appropriate to avoid head trauma and to perform imaging of the newborn within the first 24 hours of life. Individuals with moderate and mild haemophilia (factor VIII levels 0.01–0.4 U/mL) present with the same pattern of bleeding but usually after trauma or surgery, when bleeding is disproportionate to the severity of the insult.</ce:para><ce:para id="p6150">The major morbidity of recurrent bleeding in severe haemophilia is musculoskeletal. Bleeding is typically into large joints, especially knees, elbows, ankles and hips. Muscle haematomas are also characteristic, most commonly in the calf and psoas muscles. If early treatment is not given to arrest bleeding, a hot, swollen and very painful joint or muscle haematoma develops. Recurrent bleeding into joints leads to synovial hypertrophy, destruction of the cartilage and chronic haemophilic arthropathy (<ce:cross-ref id="crf1115" refid="f0185">Fig. 23.32</ce:cross-ref><ce:float-anchor refid="f0185"/>). Complications of muscle haematomas depend on their location. A large psoas bleed may extend to compress the femoral nerve; calf haematomas may increase pressure within the inflexible fascial sheath, causing a compartment syndrome with ischaemia, necrosis, fibrosis, and subsequent contraction and shortening of the Achilles tendon.</ce:para></ce:section><ce:section id="s1670"><ce:section-title id="st1575">Management</ce:section-title><ce:para id="p6155">The key to the management of severe haemophilia A (and B; p. 974) in more affluent countries is prophylactic coagulation factor replacement. The aim of this treatment is to maintain trough levels of factor VIII (or IX in the case of haemophilia B) above 0.02 U/mL. Doing this substantially reduces the number of bleeding episodes for men with severe haemophilia and so reduces the rate of deterioration of joints, which is the major long-term morbidity. Prophylaxis can be provided in many different ways: daily, on alternate days, or on information from pharmacokinetic studies that inform on the best way of scheduling prophylaxis. Practice in haemophilia A and B is in the process of changing somewhat due to the introduction of a variety of recombinant factor concentrates that have been manipulated to alter their half-life. In addition to standard half-life recombinant factor VIII, there are new products produced by Fc fusion and pegylation/glycopegylation that extend the half-life of factor VIII to the degree that it can be used to alter dosing schedules for prophylaxis.</ce:para><ce:para id="p6160">The alternative approach, which still needs to be used in less affluent countries, is to treat on demand. In severe haemophilia A, bleeding episodes should be treated by raising the factor VIII level, usually by intravenous infusion of factor VIII concentrate. Factor VIII concentrates are freeze-dried and stable at 4°C and can therefore be stored in domestic refrigerators, allowing patients to treat themselves at home at the earliest indication of bleeding. Factor VIII concentrate prepared from blood donor plasma is now screened for HBV, HCV and HIV, and undergoes two separate virus inactivation processes during manufacture; these preparations have a good safety record. However, factor VIII concentrates prepared by recombinant technology are now widely available and, although more expensive, are perceived as being safer than those derived from human plasma in relation to infection risk. In addition to raising factor VIII concentrations, resting of the bleeding site with either bed rest or a splint reduces continuing haemorrhage. Once bleeding has settled, the patient should be mobilised and physiotherapy used to restore strength to the surrounding muscles. All non-immune potential recipients of pooled blood products should be offered hepatitis A and B immunisation.</ce:para><ce:para id="p6165">The vasopressin receptor agonist desmopressin (<ce:intra-ref id="ii0775" xlink:href="pii:B978-0-7020-7028-0.00018-4#p5315">p. 688</ce:intra-ref>) raises the vWF and factor VIII levels 3–4-fold, which is useful in arresting bleeding in patients with mild or moderate haemophilia A. The dose required for this purpose is higher than that used in diabetes insipidus, usually 0.3 µg/kg, and is given intravenously or subcutaneously. Alternatively, the same effect can be achieved by intranasal administration of 300 µg. Following repeated administration of desmopressin, patients need to be monitored for evidence of water retention, which can result in significant hyponatraemia. Desmopressin is contraindicated in patients with a history of severe arterial disease because of a propensity to provoke a thrombotic event, and in young children where hyponatraemia can result in fits.</ce:para></ce:section><ce:section id="s1675"><ce:section-title id="st1580">Complications of coagulation factor therapy</ce:section-title><ce:para id="p6170">Before 1986, coagulation factor concentrates from human plasma were not virally inactivated and many patients became infected with HIV and HBV/HCV. In patients with haemophilia treated with pooled concentrates that were not virally inactivated before 1988, infection with HCV is almost universal, 80–90% have evidence of HBV exposure, and 60% became HIV-positive. Management is described in <ce:intra-ref id="ii0780" xlink:href="pii:B978-0-7020-7028-0.00022-6#c00022">Chapters 22</ce:intra-ref> and <ce:intra-ref id="ii0785" xlink:href="pii:B978-0-7020-7028-0.00012-3#c00012">12</ce:intra-ref>.</ce:para><ce:para id="p6175">Concern that the infectious agent that causes vCJD (<ce:intra-ref id="ii0790" xlink:href="pii:B978-0-7020-7028-0.00025-1#p8080">p. 1127</ce:intra-ref>) might be transmissible by blood and blood products has been confirmed in recipients of red cell transfusion (p. 931), and in one recipient of factor VIII. Pooled plasma products, including factor VIII concentrate, are now manufactured from plasma collected in countries with a low incidence of bovine spongiform encephalopathy.</ce:para><ce:para id="p6180">Another serious complication of factor VIII infusion is the development of anti-factor VIII antibodies, which arise in about 20% of those with severe haemophilia. Such antibodies rapidly neutralise therapeutic infusions, making treatment relatively ineffective. Infusions of activated clotting factors, e.g. VIIa or factor VIII inhibitor bypass activity (FEIBA), may stop bleeding.</ce:para></ce:section></ce:section><ce:section id="s1680"><ce:section-title id="st1585">Haemophilia B (Christmas disease)</ce:section-title><ce:para id="p6185">Aberrations of the factor IX gene, which is also present on the X chromosome, result in a reduction of the plasma factor IX level, giving rise to haemophilia B. This disorder is clinically indistinguishable from haemophilia A but is less common. The frequency of bleeding episodes is related to the severity of the deficiency of the plasma factor IX level. Treatment is with a factor IX concentrate, used in much the same way as factor VIII for haemophilia A. The new extended half-life recombinant factor IX products made by Fc fusion, albumin fusion and pegylation offer the possibility of prophylaxis on a once-weekly or even two-weekly schedule. Although factor IX concentrates shared the problems of virus transmission seen with factor VIII, they do not commonly induce inhibitor antibodies (&#x003C; 1% patients); when this does occur, however, it may be heralded by the development of a severe allergic-type reaction.</ce:para></ce:section><ce:section id="s1685"><ce:section-title id="st1590">Von Willebrand disease</ce:section-title><ce:para id="p6190">Von Willebrand disease is a common but usually mild bleeding disorder caused by a quantitative (types 1 and 3) or qualitative (type 2) deficiency of von Willebrand factor (vWF). This protein is synthesised by endothelial cells and megakaryocytes, and is involved in both platelet function and coagulation. It normally forms a multimeric structure that is essential for its interaction with subendothelial collagen and platelets (see <ce:cross-ref id="crf1120" refid="f0055">Fig. 23.7</ce:cross-ref>, p. 920). vWF acts as a carrier protein for factor VIII, to which it is non-covalently bound; deficiency of vWF lowers the plasma factor VIII level. vWF also forms bridges between platelets and subendothelial components (e.g. collagen; see <ce:cross-ref id="crf1125" refid="f0050">Fig. 23.6B</ce:cross-ref>, p. 918), allowing platelets to adhere to damaged vessel walls; deficiency of vWF therefore leads to impaired platelet plug formation. Blood group antigens (A and B) are expressed on vWF, reducing its susceptibility to proteolysis; as a result, people with blood group O have lower circulating vWF levels than individuals with non-O groups. This needs to be borne in mind when making a diagnosis of von Willebrand disease.</ce:para><ce:para id="p6195">Most patients with von Willebrand disease have a type 1 disorder, characterised by a quantitative decrease in a normal functional protein. Patients with type 2 disorders inherit vWF molecules that are functionally abnormal. The type of abnormality depends on the site of the mutation in the <ce:italic>vWD</ce:italic> gene and how it affects binding to platelets, collagen and factor VIII. Patients with type 2A disease have abnormalities in vWF-dependent platelet adhesion; those with mutations in the platelet glycoprotein Ib binding site, resulting in increased affinity for glycoprotein 1b, have type 2B disease; those with mutations in the factor VIII binding site have type 2N disease; and those with other abnormalities in platelet binding but with normal vWF multimeric structure have type 2M disease. The patterns of laboratory abnormality accompanying these types are described in <ce:cross-ref id="crf1130" refid="b0360">Box 23.64</ce:cross-ref><ce:float-anchor refid="b0360"/>. The gene for vWF is located on chromosome 12 and the disease is usually autosomal dominantly inherited, except in type 2N and type 3, where inheritance is autosomal recessive.</ce:para><ce:section id="s1690"><ce:section-title id="st1595">Clinical features</ce:section-title><ce:para id="p6205">Patients present with haemorrhagic manifestations similar to those in individuals with reduced platelet function. Superficial bruising, epistaxis, menorrhagia and gastrointestinal haemorrhage are common. Bleeding episodes are usually much less frequent than in severe haemophilia, and excessive haemorrhage may be observed only after trauma or surgery. Within a single family, the disease has variable penetrance, so that some members may have quite severe and frequent bleeds, whereas others are relatively asymptomatic.</ce:para></ce:section><ce:section id="s1695"><ce:section-title id="st1600">Investigations</ce:section-title><ce:para id="p6210">The disorder is characterised by reduced activity of vWF and factor VIII. The disease can be classified using a combination of assays that include functional and antigenic measures of vWF, multimeric analysis of the protein, and specific tests of function to determine binding to platelet glycoprotein Ib (RIPA) and factor VIII (<ce:cross-ref id="crf1135" refid="b0360">Box 23.64</ce:cross-ref>). In addition, analysis for mutations in the <ce:italic>vWF</ce:italic> gene is informative in most cases.</ce:para></ce:section><ce:section id="s1700"><ce:section-title id="st1605">Management</ce:section-title><ce:para id="p6215">Many episodes of mild haemorrhage can be successfully treated by local means or with desmopressin, which raises the vWF level, resulting in a secondary increase in factor VIII. Tranexamic acid may be useful in mucosal bleeding. For more serious or persistent bleeds, haemostasis can be achieved with selected factor VIII concentrates, which contain considerable quantities of vWF in addition to factor VIII. Young children and patients with severe arterial disease should not receive desmopressin, and patients with type 2B disease develop thrombocytopenia that may be troublesome following desmopressin. Bleeding in type 3 patients responds only to factor VIII/vWF concentrate.</ce:para></ce:section></ce:section><ce:section id="s1705"><ce:section-title id="st1610">Rare inherited bleeding disorders</ce:section-title><ce:para id="p6220">Severe deficiencies of factor VII, X and XIII occur as autosomal recessive disorders. They are rare but are associated with severe bleeding. Typical features include haemorrhage from the umbilical stump and intracranial haemorrhage. Factor XIII deficiency in women is typically associated with recurrent fetal loss.</ce:para><ce:para id="p6225">Factor XI deficiency may occur in heterozygous or homozygous individuals. Bleeding is very variable and is not accurately predicted by coagulation factor levels. In general, severe bleeding is confined to patients with levels below 15% of normal.</ce:para></ce:section><ce:section id="s1710"><ce:section-title id="st1615">Acquired bleeding disorders</ce:section-title><ce:para id="p6230">DIC is an important cause of bleeding that begins with exaggerated and inappropriate intravascular coagulation. It is discussed under thrombotic disease on page 978.</ce:para><ce:section id="s1715"><ce:section-title id="st1620">Liver disease</ce:section-title><ce:para id="p6235">Although, traditionally, severe parenchymal liver disease (<ce:intra-ref id="ii0815" xlink:href="pii:B978-0-7020-7028-0.00022-6#c00022">Ch. 22</ce:intra-ref>) has been described as a state associated with an excess of bleeding, it is now clear that these patients also have an increased risk of venous thrombosis. Although there is reduced hepatic synthesis of procoagulant factors, this is balanced to a degree by the reduced production of natural anticoagulant proteins and reduced fibrinolytic activity in patients with advanced liver disease. In severe parenchymal liver disease, bleeding may arise from many different causes. Pathological sources of potential major bleeding, such as oesophageal varices or peptic ulcer, are common. There is reduced hepatic synthesis, for example, of factors V, VII, VIII, IX, X, XI, prothrombin and fibrinogen. Clearance of plasminogen activator is reduced. Thrombocytopenia may occur secondary to hypersplenism in portal hypertension. In cholestatic jaundice, there is reduced vitamin K absorption, leading to deficiency of factors II, VII, IX and X, but also of proteins C and S. Treatment with plasma products or platelet transfusion should be reserved for acute bleeds or to cover interventional procedures such as liver biopsy. Vitamin K deficiency can be readily corrected with parenteral administration of vitamin K.</ce:para></ce:section><ce:section id="s1720"><ce:section-title id="st1625">Renal failure</ce:section-title><ce:para id="p6240">The severity of the haemorrhagic state in renal failure is proportional to the plasma urea concentration. Bleeding manifestations are those of platelet dysfunction, with gastrointestinal haemorrhage being particularly common. The causes are multifactorial and include anaemia, mild thrombocytopenia and the accumulation of low-molecular-weight waste products, normally excreted by the kidney, that inhibit platelet function. Treatment is by dialysis to reduce the urea concentration. Rarely, in severe or persistent bleeding, platelet concentrate infusions and red cell transfusions are indicated. Increasing the concentration of vWF, either by cryoprecipitate or by desmopressin, may promote haemostasis.</ce:para></ce:section></ce:section></ce:section></ce:section><ce:section id="s1725"><ce:section-title id="st1630">Thrombotic disorders</ce:section-title><ce:section id="s1730"><ce:section-title id="st1635">Venous thromboembolic disease (venous thromboembolism)</ce:section-title><ce:para id="p6245">While the most common presentations of venous thromboembolism (VTE) are deep vein thrombosis (DVT) of the leg (<ce:intra-ref id="ii0825" xlink:href="pii:B978-0-7020-7028-0.00010-X#s0230">p. 186</ce:intra-ref>) and/or pulmonary embolism (PE; see also <ce:intra-ref id="ii0830" xlink:href="pii:B978-0-7020-7028-0.00017-2#s1880">p. 619</ce:intra-ref>), similar management principles apply to rarer manifestations such as jugular vein thrombosis, upper limb DVT, cerebral sinus thrombosis (<ce:intra-ref id="ii0835" xlink:href="pii:B978-0-7020-7028-0.00025-1#p8225">p. 1128</ce:intra-ref>) and intra-abdominal venous thrombosis (e.g. Budd–Chiari syndrome; <ce:intra-ref id="ii0840" xlink:href="pii:B978-0-7020-7028-0.00022-6#s1375">p. 898</ce:intra-ref>).</ce:para><ce:para id="p6250">VTE has an annual incidence of approximately 1 : 1000 in Western populations. The relative incidence of DVT:PE is approximately 2 : 1. Mortality 30 days after DVT is approximately 10%, compared to 15% for PE. All forms of VTE are increasingly common with age and many of the deaths are related to coexisting medical conditions, such as active cancer or inflammatory disease, which predispose the patient to thrombosis in the first place. Risk factors for VTE are often present (<ce:cross-ref id="crf1140" refid="b0365">Box 23.65</ce:cross-ref><ce:float-anchor refid="b0365"/>) and it is appropriate to seek evidence of these risk factors in determining the long-term management strategy. <ce:cross-ref id="crf1145" refid="f0190">Figure 23.33</ce:cross-ref><ce:float-anchor refid="f0190"/> illustrates some of the causes and consequences of VTE. The diagnosis of DVT and PE are discussed on <ce:intra-ref id="ii0845" xlink:href="pii:B978-0-7020-7028-0.00010-X#p1345">pages 187 and 619</ce:intra-ref>, respectively.</ce:para><ce:section id="s1760"><ce:section id="s1765"><ce:section-title id="st1660">Management of VTE</ce:section-title><ce:para id="p6425">The mainstay of treatment for all forms of VTE is anticoagulation. This can be achieved in several ways. One option is to use LMWH followed by a coumarin anticoagulant, such as warfarin. Treatment of acute VTE with LMWH should continue for a minimum of 5 days. Patients treated with warfarin should achieve a target INR of 2.5 (range 2–3; pp. 922 and 938) with LMWH continuing until the INR is above 2. Alternatively, patients may be treated with a DOAC. Rivaroxaban and apixaban may be used immediately from diagnosis without the need for LMWH, while the licences for dabigatran and edoxaban include initial treatment with LMWH for a minimum of 5 days before commencing the DOAC. In patients with active cancer and VTE, there is evidence that maintenance anticoagulation with LMWH is associated with a lower recurrence rate than warfarin. Patients who have had VTE and have a strong contraindication to anticoagulation and those who continue to have new pulmonary emboli despite therapeutic anticoagulation should have an inferior vena cava (IVC) filter inserted to prevent life-threatening PE (<ce:intra-ref id="ii0855" xlink:href="pii:B978-0-7020-7028-0.00017-2#s1880">p. 619</ce:intra-ref>).</ce:para><ce:para id="p6430">The optimal <ce:italic>initial</ce:italic> period of anticoagulation is between 6 weeks and 6 months. Patients with a provoked VTE in the presence of a temporary risk factor, which is then removed, can usually be treated for short periods (e.g. 3 months), and indeed anticoagulation for more than 6 months does not alter the rate of recurrence following discontinuation of therapy. If there are ongoing risk factors that cannot be alleviated, such as active cancer, long-term anticoagulation is usually recommended, provided that the risk of bleeding is not deemed excessive.</ce:para><ce:para id="p6435">For patients with unprovoked VTE, the optimum duration of anticoagulation can be difficult to establish. Recurrence of VTE is about 2–3% per annum in patients who have a temporary medical risk factor at presentation and about 7–10% per annum in those with apparently unprovoked VTE. This plateaus at around 30–40% recurrence at 5 years. As such, many patients who have had unprovoked episodes of VTE will benefit from long-term anticoagulation. Several factors predict risk of recurrence following an episode of unprovoked VTE. The strongest predictors of recurrence are male sex and a positive D-dimer assay measured 1 month after stopping anticoagulant therapy. These factors are incorporated into scoring systems to predict recurrence such as the DASH score and the Vienna prediction model.</ce:para><ce:para id="p6440">The management of DVT of the leg should also include elevation and analgesia; in limb-threatening DVT, thrombolysis may also be considered. Thrombolysis for PE is discussed on <ce:intra-ref id="ii0860" xlink:href="pii:B978-0-7020-7028-0.00017-2#s1915">page 621</ce:intra-ref>. Post-thrombotic syndrome is due to damage of venous valves by the thrombus. It occurs in around 30% of patients who sustain a proximal lower limb DVT and results in persistent leg swelling, heaviness and discoloration. The most severe complication of this syndrome is ulceration around the medial malleolus (<ce:cross-ref id="crf1150" refid="f0190">Fig. 23.33</ce:cross-ref>). Recent trial evidence suggests that use of elastic compression stockings following a DVT does not reduce the incidence of post-thrombotic syndrome.</ce:para></ce:section><ce:section id="s1770"><ce:section-title id="st1665">Prophylaxis of VTE</ce:section-title><ce:para id="p6445">All patients admitted to hospital should be assessed for their risk of developing VTE and appropriate prophylactic measures should be put in place. Both medical and surgical patients are at increased risk. A summary of the risk categories is given in <ce:cross-ref id="crf1155" refid="b0370">Box 23.66</ce:cross-ref><ce:float-anchor refid="b0370"/>. Early mobilisation of patients is important to prevent DVT, and those at medium or high risk require additional antithrombotic measures; these may be pharmacological or mechanical. There is increasing evidence in high-risk groups, such as patients who have had major lower limb orthopaedic surgery and abdominal or pelvic cancer surgery, for protracted thromboprophylaxis for as long as 30 days or so after the procedure. Particular care should be taken with the use of pharmacological prophylaxis in patients with a high risk of bleeding or with specific risks of haemorrhage related to the site of surgery or the use of spinal or epidural anaesthesia.</ce:para></ce:section></ce:section></ce:section><ce:section id="s1775"><ce:section-title id="st1670">Inherited and acquired thrombophilia and prothrombotic states</ce:section-title><ce:para id="p6575">Several inherited conditions predispose to VTE (see <ce:cross-ref id="crf1165" refid="b0365">Box 23.65</ce:cross-ref>), and have several points in common that are worth noting:<ce:list id="ulist1275"><ce:list-item id="u3940"><ce:label>•</ce:label><ce:para id="p6580">None of them is strongly associated with arterial thrombosis.</ce:para></ce:list-item><ce:list-item id="u3945"><ce:label>•</ce:label><ce:para id="p6585">All are associated with a slightly increased incidence of adverse outcome of pregnancy, including recurrent early fetal loss, but there are no data to indicate that any specific intervention changes that outcome.</ce:para></ce:list-item><ce:list-item id="u3950"><ce:label>•</ce:label><ce:para id="p6590">Apart from in antithrombin deficiency and homozygous factor V Leiden, most carriers of these genes will never have an episode of VTE; if they do, it will be associated with the presence of an additional temporary risk factor.</ce:para></ce:list-item><ce:list-item id="u3955"><ce:label>•</ce:label><ce:para id="p6595">There is little evidence that detection of these abnormalities predicts recurrence of VTE.</ce:para></ce:list-item><ce:list-item id="u3960"><ce:label>•</ce:label><ce:para id="p6600">None of these conditions per se requires treatment with anticoagulants. Patients with thrombosis should receive anticoagulation, as discussed on page 975. Patients who are deemed to be at high risk of thrombosis, e.g. those with antithrombin deficiency in pregnancy, should receive treatment or prophylactic doses of heparin to cover the period of risk only.</ce:para></ce:list-item></ce:list></ce:para><ce:section id="s1780"><ce:section id="s1785"><ce:section-title id="st1675">Antithrombin deficiency</ce:section-title><ce:para id="p6605">Antithrombin (AT) is a serine protease inhibitor (SERPIN) that inactivates the activated coagulation factors IIa, IXa, Xa and XIa. Heparins and fondaparinux achieve their therapeutic effect by potentiating the activity of AT. Familial deficiency of AT is inherited in an autosomal dominant manner; homozygosity for mutant alleles is not compatible with life. Around 70% of affected individuals will have an episode of VTE before the age of 60 years and the relative risk for thrombosis compared with the background population is 10–20. Pregnancy is a high-risk period for VTE and this requires fairly aggressive management with doses of LMWH that are greater than the usual prophylactic doses (≥ 100 U/kg/day). AT concentrate (either plasma-derived or recombinant) is available; this is required for cardiopulmonary bypass and may be used as an adjunct to heparin in surgical prophylaxis and in the peripartum period.</ce:para></ce:section><ce:section id="s1790"><ce:section-title id="st1680">Protein C and S deficiencies</ce:section-title><ce:para id="p6610">Protein C and its co-factor protein S are vitamin K-dependent natural anticoagulants involved in switching off coagulation factor activation (factors Va and VIIIa) and thrombin generation (see <ce:cross-ref id="crf1170" refid="f0050">Fig. 23.6F</ce:cross-ref>, p. 919). Inherited deficiency of either protein C or S results in a prothrombotic state with a fivefold relative risk of VTE compared with the background population.</ce:para></ce:section><ce:section id="s1795"><ce:section-title id="st1685">Factor V Leiden</ce:section-title><ce:para id="p6615">Factor V Leiden results from a gain-of-function, single-base-pair mutation which prevents the cleavage and hence inactivation of activated factor V. This results in a relative risk of venous thrombosis of 5 in heterozygotes and 50 or more in rare homozygotes. The mutation is found in about 5% of Northern Europeans, 2% of Hispanics, 1.2% of African–Americans, 0.5% of Asian–Americans and 1.25% of Native Americans, and is rare in Chinese and Malay people.</ce:para></ce:section><ce:section id="s1800"><ce:section-title id="st1690">Prothrombin G20210A</ce:section-title><ce:para id="p6620">This gain-of-function mutation in the non-coding 3′ end of the prothrombin gene is associated with an increased plasma level of prothrombin. It is present in about 2% of Northern Europeans but is rare in native populations of Korea, China, India and Africa. In the heterozygous state, it is associated with a 2–3-fold increase in risk of VTE compared with the background population.</ce:para></ce:section></ce:section><ce:section id="s1805"><ce:section-title id="st1695">Antiphospholipid syndrome</ce:section-title><ce:para id="p6625">Antiphospholipid syndrome (APS) is a clinicopathological entity in which a constellation of clinical conditions, alone or in combination, is found in association with a persistently positive test for an antiphospholipid antibody. The antiphospholipid antibodies are heterogeneous and typically are directed against proteins that bind to phospholipids (<ce:cross-ref id="crf1175" refid="b0375">Box 23.67</ce:cross-ref><ce:float-anchor refid="b0375"/>). Although causal roles for these antibodies have been proposed, the mechanisms underlying the clinical features of APS are not clear. In clinical practice, two types of test are used, which detect:<ce:list id="ulist1310"><ce:list-item id="u4050"><ce:label>•</ce:label><ce:para id="p6720">antibodies that bind to negatively charged phospholipid on an ELISA plate (called an anticardiolipin antibody test). These assays usually contain β<ce:inf loc="post">2</ce:inf>-glycoprotein 1 (β<ce:inf loc="post">2</ce:inf>-GP1)</ce:para></ce:list-item><ce:list-item id="u4055"><ce:label>•</ce:label><ce:para id="p6725">those that interfere with phospholipid-dependent coagulation tests like the APTT or the dilute Russell viper venom time (DRVVT; called a lupus anticoagulant test).</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p6730">The term antiphospholipid antibody encompasses both a lupus anticoagulant and an anticardiolipin antibody/ anti-β<ce:inf loc="post">2</ce:inf>-GP1; individuals may be positive for one, two or all three of these activities. It has been shown that patients who are ‘triple-positive’ have an increased likelihood of thrombotic events.</ce:para><ce:section id="s1810"><ce:section-title id="st1700">Clinical features and management</ce:section-title><ce:para id="p6735">APS may present in isolation (primary APS) or in association with one of the conditions shown in <ce:cross-ref id="crf1180" refid="b0375">Box 23.67</ce:cross-ref>, most typically systemic lupus erythematosus (secondary APS). Most patients present with a single manifestation and APS is now most frequently diagnosed in women with adverse outcomes of pregnancy. It is extremely important to make the diagnosis in patients with APS, whatever the manifestation, because it affects the prognosis and management of arterial thrombosis, VTE and pregnancy.</ce:para><ce:para id="p6740">Arterial thrombosis, typically stroke, associated with APS should probably be treated with warfarin, as opposed to aspirin. APS-associated VTE is one of the situations in which the predicted recurrence rate is high enough to indicate long-term anticoagulation after a first event. In women with obstetric presentations of APS, intervention with heparin and aspirin is almost routinely prescribed, although there is little evidence from clinical trials that it is an effective therapy in increasing the chance of a successful pregnancy outcome.</ce:para></ce:section></ce:section><ce:section id="s1815"><ce:section-title id="st1705">Disseminated intravascular coagulation</ce:section-title><ce:para id="p6745">Disseminated intravascular coagulation (DIC) may complicate a range of illnesses (<ce:cross-ref id="crf1185" refid="b0110">Box 23.68</ce:cross-ref><ce:float-anchor refid="b0110"/>). It is characterised by systemic activation of the pathways involved in coagulation and its regulation. This may result in the generation of intravascular fibrin clots causing multi-organ failure, with simultaneous coagulation factor and platelet consumption, causing bleeding. The systemic coagulation activation is induced either through cytokine pathways, which are activated as part of a systemic inflammatory response, or by the release of procoagulant substances such as tissue factor. In addition, suboptimal function of the natural anticoagulant pathways and dysregulated fibrinolysis contribute to DIC. There is consumption of platelets, coagulation factors (notably factors V and VIII) and fibrinogen. The lysis of fibrin clot results in production of fibrin degradation products (FDPs), including D-dimers.</ce:para><ce:section id="s1820"><ce:section-title id="st1710">Investigations</ce:section-title><ce:para id="p6750">DIC should be suspected when any of the conditions listed in <ce:cross-ref id="crf1190" refid="b0110">Box 23.68</ce:cross-ref> are met. Measurement of coagulation times (APTT and PT; p. 920), along with fibrinogen, platelet count and FDPs, helps in the assessment of prognosis and aids clinical decision-making with regard to both bleeding and thrombotic complications.</ce:para></ce:section><ce:section id="s1825"><ce:section-title id="st1715">Management</ce:section-title><ce:para id="p6755">Therapy is primarily aimed at the underlying cause. These patients will often require intensive care to deal with concomitant issues, such as acidosis, dehydration, renal failure and hypoxia. Blood component therapy, such as fresh frozen plasma, cryoprecipitate and platelets, should be given if the patient is bleeding or to cover interventions with a high bleeding risk, but should not be prescribed routinely based on coagulation tests and platelet counts alone. Prophylactic doses of heparin should be given, unless there is a clear contraindication. Established thrombosis should be treated cautiously with therapeutic doses of unfractionated heparin, unless clearly contraindicated. Patients with DIC should not, in general, be treated with antifibrinolytic therapy, e.g. tranexamic acid.</ce:para><ce:para id="p6760"><ce:float-anchor refid="b0380"/></ce:para></ce:section></ce:section><ce:section id="s1830"><ce:section-title id="st1720">Thrombotic thrombocytopenic purpura</ce:section-title><ce:para id="p6785">Like DIC and also heparin-induced thrombocytopenia (p. 938), thrombotic thrombocytopenic purpura (TTP) is a disorder in which thrombosis is accompanied by paradoxical thrombocytopenia. TTP is characterised by a pentad of findings, although few patients have all five components:<ce:list id="ulist1320"><ce:list-item id="u4075"><ce:label>•</ce:label><ce:para id="p6790">thrombocytopenia</ce:para></ce:list-item><ce:list-item id="u4080"><ce:label>•</ce:label><ce:para id="p6795">microangiopathic haemolytic anaemia</ce:para></ce:list-item><ce:list-item id="u4085"><ce:label>•</ce:label><ce:para id="p6800">neurological sequelae</ce:para></ce:list-item><ce:list-item id="u4090"><ce:label>•</ce:label><ce:para id="p6805">fever</ce:para></ce:list-item><ce:list-item id="u4095"><ce:label>•</ce:label><ce:para id="p6810">renal impairment.</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p6815">It is an acute autoimmune disorder mediated by antibodies against ADAMTS-13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif).</ce:para><ce:para id="p6820">This enzyme normally cleaves vWF multimers to produce normal functional units, and its deficiency results in large vWF multimers that cross-link platelets. The features are of microvascular occlusion by platelet thrombi affecting key organs, principally brain and kidneys. It is a rare disorder (1 in 750 000 per annum), which may occur alone or in association with drugs (ticlopidine, ciclosporin), HIV, shiga toxins (<ce:intra-ref id="ii9005" xlink:href="pii:B978-0-7020-7028-0.00011-1#p5450">p. 263</ce:intra-ref>) and malignancy. It should be treated by emergency plasma exchange. Glucocorticoids, aspirin and rituximab also have a role in management. Untreated mortality rates are 90% in the first 10 days, and even with appropriate therapy, the mortality rate is 20–30% at 6 months.</ce:para></ce:section></ce:section></ce:section></ce:sections><ce:further-reading id="fr0010"><ce:section-title id="st1725">Further information</ce:section-title><ce:further-reading-sec id="fs0010"><ce:section-title id="st1730">Websites</ce:section-title><ce:bib-reference id="bib1"><ce:label>,</ce:label><sb:reference id="sr0010"><sb:host><sb:e-host><ce:inter-ref id="iw0010" xlink:href="http://bcshguidelines.com">bcshguidelines.com</ce:inter-ref></sb:e-host></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib2"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp0340"><ce:italic>British Committee for Standards in Haematology guidelines.</ce:italic></ce:simple-para></ce:note></ce:bib-reference><ce:bib-reference id="bib4"><ce:label>,</ce:label><sb:reference id="sr0015"><sb:host><sb:e-host><ce:inter-ref id="iw0015" xlink:href="http://cibmtr.org">cibmtr.org</ce:inter-ref></sb:e-host></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib5"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp0345"><ce:italic>International Bone Marrow Transplant Registry.</ce:italic></ce:simple-para></ce:note></ce:bib-reference><ce:bib-reference id="bib7"><ce:label>,</ce:label><sb:reference id="sr0020"><sb:host><sb:e-host><ce:inter-ref id="iw0020" xlink:href="http://transfusionguidelines.org.uk">transfusionguidelines.org.uk</ce:inter-ref></sb:e-host></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib8"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp0350"><ce:italic>Contains the UK Transfusion Services'</ce:italic> Handbook of Transfusion Medicine <ce:italic>and links to other relevant sites.</ce:italic></ce:simple-para></ce:note></ce:bib-reference><ce:bib-reference id="bib10"><ce:label>,</ce:label><sb:reference id="sr0025"><sb:host><sb:e-host><ce:inter-ref id="iw0025" xlink:href="http://ukhcdo.org">ukhcdo.org</ce:inter-ref></sb:e-host></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib11"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp0355"><ce:italic>UK Haemophilia Centre Doctors' Organisation.</ce:italic></ce:simple-para></ce:note></ce:bib-reference></ce:further-reading-sec></ce:further-reading></chapter>